ANTI-CCR8 ANTIBODIES AND USES THEREOF

Abstract

The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.

Description

FIELD OF THE INVENTION

The present invention relates to the field of oncology. The present invention relates to anti-CCR8 antibodies having ADCC activity, and treatment of cancer patients with said antibodies. Anti-CCR8 antibodies of the present invention bind a unique epitope, and do not block ligand binding to CCR8. The present invention also relates to methods of treatment with a Treg depleting antibody and one or more of a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway.

BACKGROUND OF THE INVENTION

The C—C chemokine receptor type 8 (CCR8) is a member of the beta chemokine receptor family, and is a seven transmembrane G-protein-coupled receptor with a 35 amino acid extracellular N-terminus. CCL1 is a ligand for CCR8, ccr8 and CCL1-induced CCR8 signaling occurs via G proteins. CCL1 binding CCR8 results in intracellular calcium flux that can be inhibited by pertussis toxin. Downstream activation of the RAS/ERK1/2 MAP kinase pathway has been demonstrated in a CCR8 expressing cell line (see e.g., Louahed et al. (2003) “CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/CCL1 and vMIP-I”, European J. of Immunology; 33(2): 494-501).

Chemokines and their receptors are important for the migration of various cell types into the inflammatory sites. Previous studies of CCR8 and its ligands suggest a role in the proper positioning of activated T cells within antigenic challenge sites and specialized areas of peripheral and lymphoid tissues. CCR8 may also contribute to regulation of monocyte chemotaxis and thymic cell apoptosis (Tiffany et al. (1997) “Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309”, J Exp Med; July 7; 186(1):165-70).

Recent data in multiple tumor types have demonstrated CCR8 expression is a marker for tumor specific T regulatory (Treg) cells (see e.g., Plitas et al. (2016) “Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer”, Immunity; 45(5):1122-1134; Villarreal et al. (September 2018) “Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer” Tumor Biol. And Immun.). CCR8 is expressed with much higher prevalence and at higher levels on the surface of tumor-resident Tregs compared to circulating or normal tissue Tregs and conventional T effector (Teff) cells. Treg cell infiltration in solid tumors is associated with poor clinical outcome, and Tregs suppress the anti-cancer immune response through inhibition of Teff cell cytotoxicity.

Some data suggest that Treg suppression of the immune response in the tumor can be reduced by blocking CCR8 function, thereby promoting an inflammatory response and reduced tumor volume. Another therapeutic strategy is to deplete tumor Treg cells via anti-CCR8 antibody dependent cell killing (such as ADCC). For ADCC, anti-CCR8 antibodies may induce redirected T cell lysis of tumor-resident CCR8+ Tregs while sparing normal tissue Tregs that have little to no CCR8 expression by preferentially binding to CCR8 on tumor-resident Tregs and depleting these tumor-resident Tregs via ADCC (e.g., Tanaka et al. (2019) “Targeting Treg cells in cancer immunotherapy” European J. of Immun.; 49(8)1140-1146).

Treg depleting antibodies such as anti-CCR8 antibodies are known in the art. For example, PCT publication No. WO 2018/181425 describes an antibody against CCR8 having ADCC activity for use in treating cancer, and it discloses the commercially available rat anti-mouse CCR8 antibody (SA214G2).

There exists a need for alternative anti-CCR8 antibodies that 1) are able to bind human and cynomolgus monkey CCR8 on tumor-resident Treg cells; 2) lead to specific depletion of tumor-resident Treg cells; 3) demonstrate an acceptable pharmacokinetic profile (compared to anti-CCR8 antibodies that bind a different epitope), and/or 4) display sufficient potency for the treatment of cancer.

There also exists a need for anti-CCR8 antibodies that do not block binding of ligand (such as CCL1) to CCR8, and/or that bind an epitope on CCR8 wherein the epitope comprises at least one residue at positions 1-12 of SEQ ID NO. 31.

SUMMARY OF THE INVENTION

The present invention provides an antibody that binds to human C—C chemokine receptor type 8 (CCR8), or an antigen-binding fragment thereof, wherein said antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain complementarity-determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 1; (b) an HCDR2 amino acid sequence of SEQ ID NO: 2; (c) an HCDR3 amino acid sequence of SEQ ID NO: 3; (d) a light chain complementarity-determining region (LCDR) 1 amino acid sequence of KSSQSVLYSSNNX₁NYLA (SEQ ID NO: 1235), wherein X₁ is K or R, (e) an LCDR2 amino acid sequence of SEQ ID NO: 5, and (f) an LCDR3 amino acid sequence of SEQ ID NO: 6. In some embodiments, the antibody or antigen-binding fragment comprises an LCDR1 amino acid sequence of SEQ ID NO: 4. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 13, and a light chain variable region (LCVR) comprising the amino acid sequence: DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNX₁NYLA WYX₂QKPGQX₃PKLLISWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQ YYSIPITFGGGTKVEIKR (SEQ ID NO: 1236), wherein X₁ is K or R, X₂ is H or Q, and/or X₃ is S or P. In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 13 and a light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 363. In some embodiments, the antibody or antigen-binding fragment comprises a heavy chain (HC) amino acid sequence of SEQ ID NO: 15 and a light chain (LC) amino acid sequence of SEQ ID NO: 16 or SEQ ID NO: 365. In other embodiments, the antibody or antigen-binding fragment comprises two HCs and two LCs, wherein both HCs comprise an amino acid sequence of SEQ ID NO: 15, and both LCs comprise an amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody or antigen-binding fragment comprises two HCs and two LCs, and wherein both HCs comprise an amino acid sequence of SEQ ID NO: 15, and both LCs comprise an amino acid sequence of SEQ ID NO: 365. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody that binds to human CCR8, or an antigen-binding fragment thereof, comprising a heavy chain (HC) and a light chain (LC), wherein the HC comprises a heavy chain variable region (HCVR) and wherein the LC comprises a light chain variable region (LCVR), wherein the HCVR comprises HCDR1, HCDR2, and HCDR3 and the LCVR comprises LCDR1, LCDR2, and LCDR3, and wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 1; HCDR2 comprises an amino acid sequence of SEQ ID NO: 2; HCDR3 comprises an amino acid sequence of SEQ ID NO: 3; LCDR1 comprises an amino acid sequence of SEQ ID NO: 4; LCDR2 comprises an amino acid sequence of SEQ ID NO: 5; and LCDR3 comprises an amino acid sequence of SEQ ID NO: 6. In an embodiment, the HCVR comprises an amino acid sequence of SEQ ID NO: 13, and the LCVR comprises an amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 365. In an embodiment, the LCVR comprises an amino acid sequence of SEQ ID NO: 14. In an embodiment, the LCVR comprises an amino acid sequence of SEQ ID NO: 365. In an embodiment, the HC has an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 573, and the LC has an amino acid sequence given by SEQ ID NO: 16. In another embodiment, the antibody comprises two HCs and two LCs, wherein each HC has an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 573, and each LC has an amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention also provides an antibody that binds to human CCR8, or an antigen-binding fragment thereof, which comprises an HCDR1 amino acid sequence of SEQ ID NO: 839; an HCDR2 amino acid sequence of SEQ ID NO: 840; an HCDR3 amino acid sequence of SEQ ID NO: 841; an LCDR1 amino acid sequence of SEQ ID NO: 842; an LCDR2 amino acid sequence of SEQ ID NO: 843; and an LCDR3 amino acid sequence of SEQ ID NO: 844. In some embodiments, the antibody or antigen-binding fragment comprises an HCVR amino acid sequence of SEQ ID NO: 1017 and an LCVR amino acid sequence of SEQ ID NO: 1018. In some embodiments, the antibody comprises an HC amino acid sequence of SEQ ID NO: 1125 or SEQ ID NO: 1237 and an LC amino acid sequence of SEQ ID NO: 1126. In some embodiments, the antibody comprises an HC amino acid sequence of SEQ ID NO: 1125 and an LC amino acid sequence of SEQ ID NO: 1126. In some embodiments, the antibody comprises an HC amino acid sequence of SEQ ID NO: 1237 and an LC amino acid sequence of SEQ ID NO: 1126. For example, the antibody may comprise two HCs and two LCs, wherein both HCs comprise an amino acid sequence of SEQ ID NO: 1125 or SEQ ID NO: 1237, and both LCs comprise an amino acid sequence of SEQ ID NO: 1126. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention also provides an antibody that binds to human CCR8, or an antigen-binding fragment thereof, which comprises an HCDR1 amino acid sequence of SEQ ID NO: 845; an HCDR2 amino acid sequence of SEQ ID NO: 846; an HCDR3 amino acid sequence of SEQ ID NO: 847; an LCDR1 amino acid sequence of SEQ ID NO: 848; an LCDR2 amino acid sequence of SEQ ID NO: 849; and an LCDR3 amino acid sequence of SEQ ID NO: 850. In some embodiments, the antibody or antigen-binding fragment comprises an HCVR amino acid sequence of SEQ ID NO: 1019 and an LCVR amino acid sequence of SEQ ID NO: 1020. In some embodiments, the antibody comprises an HC amino acid sequence of SEQ ID NO: 1127 or SEQ ID NO: 1238 and an LC amino acid sequence of SEQ ID NO: 1128.

The present invention further provides an antibody that binds to human CCR8, or an antigen-binding fragment thereof, which comprises: (a) an HCDR1 amino acid sequence of X₁X₂GX₄H, (SEQ ID NO: 1233), wherein (i) X₁ is N, S, D, G, T, or R, (ii) X₂ is C, N, Y, S, or F, and (iii) X₄ is M or F; (b) an HCDR2 amino acid sequence of SEQ ID NOs: 648, 654, 660, 666, 672, 678, 684, 690, 696, 702, 708, 714, 720, 726, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 852, 858, 867, 873, 879, 885, 891, 897, 903, 909, 915, 921, 927, 933, 939, or 945, or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any one of the foregoing HCDR2 amino acid sequences; (c) an HCDR3 amino acid sequence of SEQ ID NOs: 649, 655, 661, 667, 673, 679, 685, 691, 697, 703, 709, 715, 721, 727, 733, 739, 745, 751, 757, 763, 769, 775, 781, 787, 793, 799, 805, 811, 817, 823, 829, 835, 847, 853, 859, 868, 874, 880, 886, 892, 898, 904, 910, 916, 922, 928, 934, 940, or 946 or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any one of the foregoing HCDR3 amino acid sequences; (d) an LCDR1 amino acid sequence of SEQ ID NOs: 650, 656, 662, 668, 674, 680, 686, 692, 698, 704, 710, 716, 722, 728, 734, 740, 746, 752, 758, 764, 770, 776, 782, 788, 794, 800, 806, 812, 818, 824, 830, 836, 848, 854, 860, 863, 869, 875, 881, 887, 893, 899, 905, 911, 917, 923, 929, 935, or 941 or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any one of the foregoing LCDR1 amino acid sequences; (e) an LCDR2 amino acid sequence of RX₂X₃X₄RPS (SEQ ID NO: 1234), wherein (i) X₂ is A, N, D, S, or Q, (ii) X₃ is S, T, N, I, F, or A, and (iii) X₄ is N or V; and (f) an LCDR3 amino acid sequence of SEQ ID NOs: 652, 658, 664, 670, 676, 682, 688, 694, 700, 706, 712, 718, 724, 730, 736, 742, 748, 754, 760, 766, 772, 778, 784, 790, 796, 802, 808, 814, 820, 826, 832, 838, 850, 856, 862, 865, 871, 877, 883, 889, 895, 901, 907, 913, 919, 925, 931, 937, or 943 or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any one of the foregoing LCDR3 amino acid sequences. In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NOs: 647, 653, 659, 665, 671, 677, 683, 689, 695, 701, 707, 713, 719, 725, 731, 737, 743, 749, 755, 761, 767, 773, 779, 785, 791, 797, 803, 809, 815, 821, 827, 833, 845, 851, 857, 866, 872, 878, 884, 890, 896, 902, 908, 914, 920, 926, 932, 938, or 944. In some embodiments, the LCDR2 comprises an amino acid sequence of SEQ ID NOs: 651, 657, 663, 669, 675, 681, 687, 693, 699, 705, 711, 717, 723, 729, 735, 741, 747, 753, 759, 765, 771, 777, 783, 789, 795, 801, 807, 813, 819, 825, 831, 837 849, 855, 861, 864, 870, 876, 882, 888, 894, 900, 906, 912, 918, 924, 930, 936, or 942. In some embodiments, the HCVR comprises an amino acid sequence of SEQ ID NOs: 953, 955, 957, 959, 961, 963, 965, 967, 969, 971, 973, 975, 977, 979, 981, 983, 985, 987, 989, 991, 993, 995, 997, 999, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1019, 1021, 1023, 1026, 1028, 1030, 1032, 1034, 1036, 1038, 1040, 1042, 1044, 1046, 1048, 1050, or 1052. In some embodiments, the LCVR comprises an amino acid sequence of SEQ ID NOs: 964, 966, 968, 970, 972, 974, 976, 978, 980, 982, 984, 986, 988, 990, 992, 994, 996, 998, 1000, 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1020, 1022, 1024, 1025, 1027, 1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043, 1045, 1047, 1049, or 1051. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the antibody of or antigen-binding fragment comprises: (a) a HCVR comprising an amino acid sequence of SEQ ID NO: 1019 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1020; (b) a HCVR comprising an amino acid sequence of SEQ ID NO: 1021 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1022; (c) a HCVR comprising an amino acid sequence of SEQ ID NO: 1023 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1024; (d) a HCVR comprising an amino acid sequence of SEQ ID NO: 1026 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1025; (e) a HCVR comprising an amino acid sequence of SEQ ID NO: 1028 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1027; (f) a HCVR comprising an amino acid sequence of SEQ ID NO: 1030 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1029; (g) a HCVR comprising an amino acid sequence of SEQ ID NO: 1032 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1031; (h) a HCVR comprising an amino acid sequence of SEQ ID NO: 1034 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1033; (i) a HCVR comprising an amino acid sequence of SEQ ID NO: 1036 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1035; (j) a HCVR comprising an amino acid sequence of SEQ ID NO: 1038 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1037; (k) a HCVR comprising an amino acid sequence of SEQ ID NO: 1040 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1039; (1) a HCVR comprising an amino acid sequence of SEQ ID NO: 1042 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1041; (m) a HCVR comprising an amino acid sequence of SEQ ID NO: 1044 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1043; (n) a HCVR comprising an amino acid sequence of SEQ ID NO: 1046 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1045; (o) a HCVR comprising an amino acid sequence of SEQ ID NO: 1048 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1047; (p) a HCVR comprising an amino acid sequence of SEQ ID NO: 1050 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1049; or (q) a HCVR comprising an amino acid sequence of SEQ ID NO: 1052 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1051. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the antibody comprises an HC amino acid sequence of SEQ ID NOs: 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, 1160, or 1238-1254; and an LC amino acid sequence of SEQ ID NOs: 1128, 1130, 1132, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, or 1159. For example, in some embodiments, the antibody comprises: (a) an HC amino acid sequence of SEQ ID NO: 1127 or SEQ ID NO: 1238 and a LC amino acid sequence of SEQ ID NO: 1128; (b) an HC amino acid sequence of SEQ ID NO: 1129 or SEQ ID NO: 1239 and a LC amino acid sequence of SEQ ID NO: 1130; (c) an HC amino acid sequence of SEQ ID NO: 1131 or SEQ ID NO: 1240 and a LC amino acid sequence of SEQ ID NO: 1132; (d) an HC amino acid sequence of SEQ ID NO: 1134 or SEQ ID NO: 1241 and a LC amino acid sequence of SEQ ID NO: 1133; (e) an HC amino acid sequence of SEQ ID NO: 1136 or SEQ ID NO: 1242 and a LC amino acid sequence of SEQ ID NO: 1135; (0 an HC amino acid sequence of SEQ ID NO: 1138 or SEQ ID NO: 1243 and a LC amino acid sequence of SEQ ID NO: 1137; (g) an HC amino acid sequence of SEQ ID NO: 1140 or SEQ ID NO: 1244 and a LC amino acid sequence of SEQ ID NO: 1139; (h) an HC amino acid sequence of SEQ ID NO: 1142 or SEQ ID NO: 1245 and a LC amino acid sequence of SEQ ID NO: 1141; (i) an HC amino acid sequence of SEQ ID NO: 1144 or SEQ ID NO: 1246 and a LC amino acid sequence of SEQ ID NO: 1143; (j) an HC amino acid sequence of SEQ ID NO: 1146 or SEQ ID NO: 1247 and a LC amino acid sequence of SEQ ID NO: 1145; (k) an HC amino acid sequence of SEQ ID NO: 1148 or SEQ ID NO: 1248 and a LC amino acid sequence of SEQ ID NO: 1147; (1) an HC amino acid sequence of SEQ ID NO: 1150 or SEQ ID NO: 1249 and a LC amino acid sequence of SEQ ID NO: 1149; (m) an HC amino acid sequence of SEQ ID NO: 1152 or SEQ ID NO: 1250 and a LC amino acid sequence of SEQ ID NO: 1151; (n) an HC amino acid sequence of SEQ ID NO: 1154 or SEQ ID NO: 1251 and a LC amino acid sequence of SEQ ID NO: 1153; (o) an HC amino acid sequence of SEQ ID NO: 1156 or SEQ ID NO: 1252 and a LC amino acid sequence of SEQ ID NO: 1155; (p) an HC amino acid sequence of SEQ ID NO: 1158 or SEQ ID NO: 1253 and a LC amino acid sequence of SEQ ID NO: 1157; or (q) an HC amino acid sequence of SEQ ID NO: 1160 or SEQ ID NO: 1254 and a LC amino acid sequence of SEQ ID NO: 1159. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the antibody or antigen-binding fragment thereof is an antibody. In some embodiments, the antibody or antigen-binding fragment thereof is an antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment is a single chain variable fragment (scFv). In some embodiments, the antibody or antigen-binding fragment is a Fab. In particular embodiments, the antibody or antigen-binding fragment is a single chain Fab (scFab). In some embodiments, the antigen-binding fragment comprises an amino acid sequence of any one of the anti-CCR8 antibodies or antigen-binding fragments thereof of the present invention.

The present invention also provides an antibody or antigen-binding fragment thereof, that binds to human CCR8, comprising a heavy chain (HC) and a light chain (LC), wherein the HC comprises a heavy chain variable region (HCVR) and wherein the LC comprises a light chain variable region (LCVR), wherein the HCVR comprises HCDR1, HCDR2, and HCDR3 and the LCVR comprises LCDR1, LCDR2, and LCDR3, and wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 7; HCDR2 comprises an amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 367, or SEQ ID NO: 377; HCDR3 comprises an amino acid sequence of SEQ ID NO: 9; LCDR1 comprises an amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 369, or SEQ ID NO: 379; LCDR2 comprises an amino acid sequence of SEQ ID NO: 11; and LCDR3 comprises an amino acid sequence of SEQ ID NO: 12. In an embodiment, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 8. In an embodiment, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 367. In an embodiment, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 377. In an embodiment, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 10. In an embodiment, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 369. In an embodiment, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 379. In an embodiment, the HCVR comprises an amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 372, or SEQ ID NO: 382, and the LCVR comprises an amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 373, or SEQ ID NO: 383. In an embodiment, the HCVR comprises an amino acid sequence of SEQ ID NO: 17. In an embodiment, the HCVR comprises an amino acid sequence of SEQ ID NO: 372. In an embodiment, the HCVR comprises an amino acid sequence of SEQ ID NO: 382. In an embodiment, the LCVR comprises an amino acid sequence of SEQ ID NO: 18. In an embodiment, the LCVR comprises an amino acid sequence of SEQ ID NO: 373. In an embodiment, the LCVR comprises an amino acid sequence of SEQ ID NO: 383. In an embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 374, or SEQ ID NO: 384, and the LC comprises an amino acid sequence of SEQ ID NO: 20, SEQ ID NO: 375, or SEQ ID NO: 385. In an embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 19. In an embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 374. In an embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 384. In an embodiment, the LC comprises an amino acid sequence of SEQ ID NO: 20. In an embodiment, the LC comprises an amino acid sequence of SEQ ID NO: 375. In an embodiment, the LC comprises an amino acid sequence of SEQ ID NO: 385. In another embodiment, the antibody comprises two HCs and two LCs, wherein each HC comprises an amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 374, or SEQ ID NO: 384, and each LC comprises an amino acid sequence of SEQ ID NO: 20, SEQ ID NO: 375, or SEQ ID NO: 385. In an embodiment, each HC comprises an amino acid sequence of SEQ ID NO: 19. In an embodiment, each HC comprises an amino acid sequence of SEQ ID NO: 374. In an embodiment, each HC comprises an amino acid sequence of SEQ ID NO: 384. In an embodiment, each LC comprises an amino acid sequence of SEQ ID NO: 20. In an embodiment, each LC comprises an amino acid sequence of SEQ ID NO: 375. In an embodiment, each LC comprises an amino acid sequence of SEQ ID NO: 385. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment thereof, that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; and SEQ ID NO: 6, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 352 and SEQ ID NO: 353, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 354 and 355, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 573 and 355, respectively. In an embodiment, the antibody is Antibody 1 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment thereof, that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; and SEQ ID NO: 6, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 362 and SEQ ID NO: 363, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 364 and 365, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 574 and 365, respectively. In an embodiment, the antibody is Antibody 1.1 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment thereof that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 366; SEQ ID NO: 367; SEQ ID NO: 368; SEQ ID NO: 369; SEQ ID NO: 370; and SEQ ID NO: 371, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 372 and SEQ ID NO: 373, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 374 and 375, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 575 and 375, respectively. In an embodiment, the antibody is Antibody 2.1 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 376; SEQ ID NO: 377; SEQ ID NO: 378; SEQ ID NO: 379; SEQ ID NO: 380; and SEQ ID NO: 381, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 382 and SEQ ID NO: 383, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 384 and 385, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 576 and 385, respectively. In an embodiment, the antibody is Antibody 2.2 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 386; SEQ ID NO: 387; SEQ ID NO: 388; SEQ ID NO: 389; SEQ ID NO: 390; and SEQ ID NO: 391, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and an LCVR comprising amino acid sequences of SEQ ID NO: 392 and SEQ ID NO: 393, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 394 and 395, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 577 and 395, respectively. In an embodiment, the antibody is Antibody 3.0 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 396; SEQ ID NO: 397; SEQ ID NO: 398; SEQ ID NO: 399; SEQ ID NO: 400; and SEQ ID NO: 401; respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 402 and SEQ ID NO: 403, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 404 and 405, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 578 and 405, respectively. In an embodiment, the antibody is Antibody 4.0 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 406; SEQ ID NO: 407; SEQ ID NO: 408; SEQ ID NO: 409; SEQ ID NO: 410; and SEQ ID NO: 411; respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 412 and SEQ ID NO: 413, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 414 and 415, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 579 and 415, respectively. In an embodiment, the antibody is Antibody 4.1 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 416; SEQ ID NO: 417; SEQ ID NO: 418; SEQ ID NO: 419; SEQ ID NO: 420; and SEQ ID NO: 421, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 422 and SEQ ID NO: 423, respectively. In another embodiment, the antibody comprises HC and LC comprising amino acid sequences of SEQ ID NO: 424 and 425, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 580 and 425, respectively. In an embodiment, the antibody is Antibody 4.2 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, and SEQ ID NO: 431, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 432 and SEQ ID NO: 433, respectively. In another embodiment, the antibody comprises an HC and LC comprising amino acid sequences of SEQ ID NO: 434 and 435, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 581 and 435, respectively. In an embodiment, the antibody is Antibody 5.0 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, and SEQ ID NO: 441, respectively. In an embodiment, the antibody or antigen-binding fragment comprises HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 442 and SEQ ID NO: 443, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 444 and 445, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 582 and 445, respectively. In an embodiment, the antibody is Antibody 5.1 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 446; SEQ ID NO: 447; SEQ ID NO: 448; SEQ ID NO: 449; SEQ ID NO: 450; and SEQ ID NO: 451, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 452 and SEQ ID NO: 453, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 454 and 455, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 583 and 455, respectively. In an embodiment, the antibody is Antibody 5.2 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 456, SEQ ID NO: 457, SEQ ID NO: 458, SEQ ID NO: 459, SEQ ID NO: 460, and SEQ ID NO: 461, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising the amino acid sequences of SEQ ID NO: 462 and SEQ ID NO: 463, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 464 and 465, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 584 and 465, respectively. In an embodiment, the antibody is Antibody 5.3 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 466, SEQ ID NO: 467, SEQ ID NO: 468, SEQ ID NO: 469, SEQ ID NO: 470, and SEQ ID NO: 471, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising the amino acid sequences of SEQ ID NO: 472 and SEQ ID NO: 473, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 474 and 475, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 585 and 475, respectively. In an embodiment, the antibody is Antibody 5.4 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 476, SEQ ID NO: 477, SEQ ID NO: 478, SEQ ID NO: 479, SEQ ID NO: 480, and SEQ ID NO: 481, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 482 and SEQ ID NO: 483, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 484 and 485, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 586 and 485, respectively. In an embodiment, the antibody is Antibody 5.5 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 486; SEQ ID NO: 487; SEQ ID NO: 488; SEQ ID NO: 489; SEQ ID NO: 490; and SEQ ID NO: 491, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 492 and SEQ ID NO: 493, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 494 and 495, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 587 and 495, respectively. In an embodiment, the antibody is Antibody 5.6 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 496; SEQ ID NO: 497; SEQ ID NO: 498; SEQ ID NO: 499; SEQ ID NO: 500; and SEQ ID NO: 501, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 502 and SEQ ID NO: 503, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 504 and 505, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 588 and 505, respectively. In an embodiment, the antibody is Antibody 5.7 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 506; SEQ ID NO: 507; SEQ ID NO: 508; SEQ ID NO: 509; SEQ ID NO: 510; and SEQ ID NO: 511; respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 512 and SEQ ID NO: 513, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 514 and 515, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 589 and 515, respectively. In an embodiment, the antibody is Antibody 5.8 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 516; SEQ ID NO: 517; SEQ ID NO: 518; SEQ ID NO: 519; SEQ ID NO: 520; and SEQ ID NO: 521, respectively. In an embodiment, the antibody or antigen-binding fragment comprises HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 522 and SEQ ID NO: 523, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 524 and 525, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 590 and 525, respectively. In an embodiment, the antibody is Antibody 5.9 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 526; SEQ ID NO: 527; SEQ ID NO: 528; SEQ ID NO: 529; SEQ ID NO: 530; and SEQ ID NO: 531; respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 532 and SEQ ID NO: 533, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 534 and 535, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 591 and 535, respectively. In an embodiment, the antibody is Antibody 6.0 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 536; SEQ ID NO: 537; SEQ ID NO: 538; SEQ ID NO: 539; SEQ ID NO: 540; and SEQ ID NO: 541, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising the amino acid sequences of SEQ ID NO: 542 and SEQ ID NO: 543, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 544 and 545, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 592 and 545, respectively. In an embodiment, the antibody is Antibody 6.1 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an antibody or antigen-binding fragment that binds CCR8, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising amino acid sequences of SEQ ID NO: 546; SEQ ID NO: 547; SEQ ID NO: 548; SEQ ID NO: 549; SEQ ID NO: 550; and SEQ ID NO: 551, respectively. In an embodiment, the antibody or antigen-binding fragment comprises an HCVR and LCVR comprising amino acid sequences of SEQ ID NO: 552 and SEQ ID NO: 553, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 554 and 555, respectively. In another embodiment, the antibody comprises an HC and LC comprising the amino acid sequences of SEQ ID NO: 593 and 555, respectively. In an embodiment, the antibody is Antibody 6.2 IgG1. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the anti-CCR8 antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, HCVR, LCVR, HC, and/or LC amino acid residues as disclosed in Table 16, Table 17, Table 19, and/or Table 20.

In another embodiment, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and/or LCDR3 of an antibody or antigen-binding fragment of the present invention comprises a sequence of amino acids that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and/or LCDR3 sequence of an anti-CCR8 antibody or antigen-binding fragment of the present invention listed herein. In an embodiment, the sequence of amino acids is at least 70% identical. In an embodiment, the sequence of amino acids is at least 80% identical. In an embodiment, the sequence of amino acids is at least 90% identical. In another embodiment, the sequence of amino acids is at least 95% identical. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In another embodiment, the HCVR and/or LCVR comprises a sequence of amino acids that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of a HCVR and/or LCVR sequence of an anti-CCR8 antibody or antigen-binding fragment of the present invention listed herein. In an embodiment, the sequence of amino acids is at least 70% identical. In an embodiment, the sequence of amino acids is at least 80% identical. In an embodiment, the sequence of amino acids is at least 90% identical. In another embodiment, the sequence of amino acids is at least 95% identical. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In another embodiment, the HC and/or LC comprises a sequence of amino acids that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of a HC and/or LC sequence of an anti-CCR8 antibody or antigen-binding fragment of the present invention listed herein. In an embodiment, the sequence of amino acids is at least 70% identical. In an embodiment, the sequence of amino acids is at least 80% identical. In an embodiment, the sequence of amino acids is at least 90% identical. In another embodiment, the sequence of amino acids is at least 95% identical. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In an embodiment, the present invention provides an afucosylated antibody of the present invention. In an embodiment, an anti-CCR8 antibody of the present invention is human or humanized.

In some embodiments, an anti-CCR8 antibody or antigen-binding fragment of the present invention can be administered concurrently with, before, or after a variety of drugs and treatments widely employed in cancer treatment such as, for example, chemotherapeutic agents, non-chemotherapeutic agents (e.g., checkpoint inhibitors including anti-PD-1 or anti-PD-L1 inhibitors, such as antagonist antibodies), anti-neoplastic agents, and/or radiation. For example, administration can occur before, during, and/or after any of the treatments described herein. Examples of chemotherapeutic agents are discussed herein and include, but are not limited to, cisplatin, taxol, etoposide, mitoxantrone (Novantrone®), actinomycin D, cycloheximide, camptothecin (or water soluble derivatives thereof), methotrexate, mitomycin (e.g., mitomycin C), dacarbazine (DTIC), anti-neoplastic antibiotics such as adriamycin (doxorubicin) and daunomycin, and all the chemotherapeutic agents mentioned herein. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, an anti-CCR8 antibody or antigen-binding fragment of the present invention may be administered concurrently with, before, or after a checkpoint inhibitor such as a PD-1 antagonist antibody or a PD-L1 antagonist antibody. The term “PD-1 antagonist antibody” refers to an antibody that specifically binds to PD-1 and decreases, blocks, inhibits, abrogates, or interferes with signal transduction resulting from the interaction of PD-1 and one or more of its ligands, such as PD-L1 and PD-L2. In some embodiments, a PD-1 antagonist antibody inhibits the binding of PD-1 to PD-L1 and/or PD-L2. The term “PD-L1 antagonist antibody” refers to an antibody that specifically binds to PD-L1 and decreases, blocks, inhibits, abrogates, or interferes with signal transduction resulting from the interaction of PD-L1 with the PD-1 receptor. In some embodiments, a PD-L1 antagonist antibody inhibits the binding of PD-L1 to PD-1. In some embodiments, the PD-1 antagonist antibody is any one of Antibody 20C1.006 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 72-77, respectively; VL and VH amino acid sequences of SEQ ID NOs 78 and 79, respectively; and LC and HC amino acid sequences of SEQ ID NOs 80 and 81, respectively); zeluvalimab (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 32-37, respectively; VL and VH amino acid sequences of SEQ ID NOs 38 and 39 respectively; LC amino acid sequence of SEQ ID NO: 40; and HC amino acid sequences of SEQ ID NOs 41 or 636); Antibody 20A2.003 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 42-47, respectively; VL and VH amino acid sequences of SEQ ID NOs 48 and 49, respectively; and LC and HC amino acid sequences of SEQ ID NOs 50 and 51, respectively); Antibody 22D4.006 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 52-57, respectively; VL and VH amino acid sequences of SEQ ID NOs 58 and 59, respectively; and LC and HC amino acid sequences of SEQ ID NOs 60 and 61, respectively); or Antibody 22D4.017 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 62-67, respectively; VL and VH amino acid sequences of SEQ ID NOs 68 and 69, respectively; and LC and HC amino acid sequences of SEQ ID NOs 70 and 71, respectively). In one embodiment, the PD-1 antagonist antibody is pembrolizumab. In another embodiment, the PD-1 antagonist antibody is nivolumab. In yet another embodiment, the PD-1 antagonist antibody is cemiplimab. In a particular embodiment, the PD-1 antagonist antibody is zeluvalimab. Zeluvalimab is also known as AMG 404 and is also known as 20C1.009. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody or antigen-binding fragment, wherein the anti-CCR8 antibody or antigen-binding fragment does not block ligand binding to CCR8. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody, wherein the anti-CCR8 antibody has ADCC.

The present invention provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody, wherein the anti-CCR8 antibody does not block ligand binding to CCR8 and wherein the anti-CCR8 antibody has ADCC. In an embodiment, the anti-CCR8 antibody further has an acceptable PK. In an embodiment, the anti-CCR8 antibody binds an epitope wherein the epitope comprises at least one residue at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least two residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least three residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least four residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least five residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises six or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises seven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises eight or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises nine or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises ten or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises eleven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises all twelve amino acid residues at positions 1-12 of SEQ ID NO: 31. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 31. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. The amino acid sequence of amino acid residues 1-12 of SEQ ID NO: 31 is SEQ ID NO: 82. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey cells CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556.

The present invention provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody, wherein the anti-CCR8 antibody does not block ligand binding to CCR8 and wherein the anti-CCR8 antibody has ADCC. In an embodiment, the anti-CCR8 antibody further has an acceptable PK. In an embodiment, the anti-CCR8 antibody binds an epitope wherein the epitope consists of at least one residue at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least two residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least three residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least four residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comp consists of rises at least five residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of six or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of seven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of eight or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of nine or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of ten or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of eleven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of all twelve amino acid residues at positions 1-12 of SEQ ID NO: 31. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 31. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 22. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556.

The present invention provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody, wherein the anti-CCR8 antibody does not block ligand binding to CCR8 and wherein the anti-CCR8 antibody has ADCC. In an embodiment, the anti-CCR8 antibody further has an acceptable PK. In an embodiment, the anti-CCR8 antibody binds an epitope wherein the epitope comprises at least one residue of SEQ ID NO: 82. In an embodiment, the epitope comprises at least two residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least three residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least four residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least five residues of SEQ ID NO: 82. In an embodiment, the epitope comprises six or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises seven or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises eight or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises nine or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises ten or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises eleven or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises all twelve amino acid residues of SEQ ID NO: 82. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. In some embodiments, the epitope is determined by anti-CCR8 antibody binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556.

The present invention provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody, wherein the anti-CCR8 antibody does not block ligand binding to CCR8 and wherein the anti-CCR8 antibody has ADCC. In an embodiment, the anti-CCR8 antibody further has an acceptable PK. In an embodiment, the anti-CCR8 antibody binds an epitope wherein the epitope consists of at least one residue of SEQ ID NO: 82. In an embodiment, the epitope consists of at least two residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least three residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least four residues of SEQ ID NO: 82. In an embodiment, the epitope consists of rises at least five residues of SEQ ID NO: 82. In an embodiment, the epitope consists of six or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of seven or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of eight or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of nine or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of ten or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of eleven or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of all twelve amino acid residues of SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 22. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556.

The present invention also provides a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody or antigen-binding fragment of the present invention to the patient. In an embodiment, the cancer is a solid tumor. In a more particular embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer, pancreatic cancer, or metastatic castrate-resistant prostate cancer. In an embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, or triple-negative breast cancer. In an embodiment, the cancer is non-small cell lung cancer. In an embodiment, the cancer is colorectal cancer. In an embodiment, the cancer is head and neck squamous cell carcinoma. In some embodiments, the method further comprises administering to the patient a PD-1 antagonist antibody or a PD-L1 antagonist antibody. In some such embodiments, the PD-1 antagonist antibody or PD-L1 antagonist antibody is administered prior to, concurrently with, and/or after administration of the anti-CCR8 antibody or antigen-binding fragment. In particular embodiments, the PD-1 antagonist antibody is pembrolizumab, nivolumab, cemiplimab, or zeluvalimab. In other particular embodiments, the PD-L1 antagonist antibody is atezolizumab, avelumab, or durvalumab. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the method further comprises administering to the patient a chemotherapeutic agent. In some embodiments, the method comprises administering to the patient an anti-CCR8 antibody or antigen-binding fragment of the present invention and a chemotherapeutic agent. In some such embodiments, the chemotherapeutic agent may be administered prior to, concurrently with, or after administration of the anti-CCR8 antibody or antigen-binding fragment of the present invention. In some embodiments, the method comprises administering to the patient an anti-CCR8 antibody of the present invention, a PD-1 or PD-L1 antagonist antibody, and a chemotherapeutic agent. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering to the patient an effective amount of a Treg depleting antibody, a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and/or an antagonist of the PD-1/PD-L1 pathway. In some embodiments, the patient is administered two of a Treg depleting antibody, a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway. In some embodiments, the patient is administered three of a Treg depleting antibody, a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway. In some embodiments, the patient is administered each of a Treg depleting antibody, a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway. In some embodiments, the patient is administered a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway.

The present invention also provides a method of treating cancer in a patient comprising administering to the patient an effective amount of a Treg depleting antibody and one or more of a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway. In an embodiment, the method comprises administering to the patient an effective amount of a Treg depleting antibody and a bispecific T-cell engager molecule. In an embodiment, the method comprises administering to the patient an effective amount of a Treg depleting antibody and an antagonist of the PD-1/PD-L1 pathway. In an embodiment, the method comprises administering to the patient an effective amount of a Treg depleting antibody and an agonist of a T cell co-stimulatory receptor. In an embodiment, the method comprises administering to the patient an effective amount of a Treg depleting antibody, a bispecific T-cell engager molecule, and an antagonist of the PD-1/PD-L1 pathway. In an embodiment, the method comprises administering to the patient an effective amount of a Treg depleting antibody, a bispecific T-cell engager molecule, an antagonist of the PD-1/PD-L1 pathway, and an agonist of a T cell co-stimulatory receptor.

In some embodiments, the Treg depleting antibody is an anti-CCR8 antibody. In some embodiments, the Treg depleting antibody is an anti-CTLA4 antibody. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody and a bispecific T-cell engager molecule. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody of the present invention and a bispecific T-cell engager molecule. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CTLA-4 antibody and a bispecific T-cell engager molecule. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody and an antagonist of the PD-1/PD-L1 pathway. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody of the present invention and an antagonist of the PD-1/PD-L1 pathway. In some such embodiments, the antagonist of the PD-1/PD-L1 pathway is an PD-1 antagonist antibody. Antibody 20C1.006 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 72-77, respectively; VL and VH amino acid sequences of SEQ ID NOs 78 and 79, respectively; and LC and HC amino acid sequences of SEQ ID NOs 80 and 81, respectively), zeluvalimab (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 32-37, respectively; VL and VH amino acid sequences of SEQ ID NOs 38 and 39 respectively; LC amino acid sequence of SEQ ID NO: 40; and HC amino acid sequences of SEQ ID NOs 41 or 636), Antibody 20A2.003 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 42-47, respectively; VL and VH amino acid sequences of SEQ ID NOs 48 and 49, respectively; and LC and HC amino acid sequences of SEQ ID NOs 50 and 51, respectively), Antibody 22D4.006 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 52-57, respectively; VL and VH amino acid sequences of SEQ ID NOs 58 and 59, respectively; and LC and HC amino acid sequences of SEQ ID NOs 60 and 61, respectively), or Antibody 22D4.017 (comprising LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3 amino acid sequences of SEQ ID NOs 62-67, respectively; VL and VH amino acid sequences of SEQ ID NOs 68 and 69, respectively; and LC and HC amino acid sequences of SEQ ID NOs 70 and 71, respectively). In one embodiment, the PD-1 antagonist antibody is pembrolizumab. In another embodiment, the PD-1 antagonist antibody is nivolumab. In yet another embodiment, the PD-1 antagonist antibody is cemiplimab. In a particular embodiment, the PD-1 antagonist antibody is zeluvalimab.

In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody, a bispecific T-cell engager molecule, and an PD-1 antagonist antibody. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody of the present invention, a bispecific T-cell engager molecule, and an PD-1 antagonist antibody. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CTLA-4 antibody, a bispecific T-cell engager molecule, and an PD-1 antagonist antibody.

In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody, a bispecific T-cell engager molecule, an PD-1 antagonist antibody, and an agonist of a T cell co-stimulatory receptor. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CCR8 antibody of the present invention, a bispecific T-cell engager molecule, an PD-1 antagonist antibody, and an agonist of a T cell co-stimulatory receptor. In an embodiment, the method comprises administering to the patient an effective amount of an anti-CTLA-4 antibody, a bispecific T-cell engager molecule, an PD-1 antagonist antibody, and an agonist of a T cell co-stimulatory receptor.

In some embodiments, the agonist of a T cell co-stimulatory receptor is an agonist of 4-1BB.

In some embodiments, the bispecific T-cell engager molecule comprises an amino acid sequence of any one of SEQ ID NOs. 87-345 in Table 15.

In some embodiments, the Treg depleting antibody is an antibody against CTLA-4, CCR8, CD25, TIGIT, CCR4, CD27, CD28, CD39, CD40, CD73, ICOS, OX40, 4-1BB, GITR, LAYN, IL1R2, or IL21R.

In some embodiments, the Treg depleting antibody is an anti-CTLA-4 antibody.

In some embodiments, the Treg depleting antibody is an anti-CCR8 antibody. In some such embodiments, the anti-CCR8 antibody is capable of depleting Treg cells. In some embodiments, the anti-CCR8 antibody is an anti-CCR8 antibody that has ADCC activity. In some embodiments, the anti-CCR8 antibody does not block ligand binding to CCR8. In some embodiments, the anti-CCR8 antibody binds human and cynomolgus monkey CCR8 on tumor-resident Treg cells. In some embodiments, the anti-CCR8 antibody binds an epitope on CCR8 wherein the epitope comprises at least one residue at positions 1-12 of SEQ ID NO. 31. In some embodiments, the anti-CCR8 antibody binds an epitope on CCR8 wherein the epitope consists of at least one residue at positions 1-12 of SEQ ID NO. 31. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. The amino acid sequence of amino acid residues 1-12 of SEQ ID NO: 31 is SEQ ID NO: 82. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556. In some embodiments, the anti-CCR8 antibody demonstrates an acceptable pharmacokinetic profile. In a particular embodiment, the anti-CCR8 antibody is an anti-CCR8 antibody of the present invention.

In an embodiment, the agonist of an immune cell co-stimulatory receptor is an agonist of CD2, TNFRSF4 (OX40), TNFRSF5 (CD40), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB), TNFRSF14 (HVEM), TNFRSF18 (GITR), TNFR2, or ICOS. In a particular embodiment, the agonist of an immune cell co-stimulatory receptor is a 4-1BB agonist antibody.

In an embodiment, the antagonist of the PD-1/PD-L1 pathway is a PD-1 antagonist antibody or a PD-L1 antagonist antibody as described herein. In some embodiments, the PD-1 antagonist antibody is any one of Antibody 20C1.006, zeluvalimab, Antibody 20A2.003, Antibody 22D4.006, or Antibody 22D4.017. In one embodiment, the PD-1 antagonist antibody is pembrolizumab. In another embodiment, the PD-1 antagonist antibody is nivolumab. In yet another embodiment, the PD-1 antagonist antibody is cemiplimab. In a particular embodiment, the PD-1 antagonist antibody is zeluvalimab.

In an embodiment, the Treg depleting antibody is administered at the same time as the bispecific T-cell engager molecule, agonist of an immune cell co-stimulatory receptor, and/or an antagonist of the PD-1/PD-L1 pathway. In an embodiment, the Treg depleting antibody, bispecific T-cell engager molecule, agonist of an immune cell co-stimulatory receptor, and/or an antagonist of the PD-1/PD-L1 pathway are administered at different times. In a particular embodiment, the patient is administered a Treg depleting antibody, a bispecific T-cell engager molecule, an agonist of an immune cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway. In another particular embodiment, the patient is administered an anti-CCR8 antibody, a bispecific T-cell engager molecule, a 4-1BB agonist antibody, and an antagonist of the PD-1/PD-L1 pathway. In a particular embodiment, the anti-CCR8 antibody is an anti-CCR8 antibody of the present invention.

In an embodiment, the cancer is a solid tumor. In a more particular embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer, pancreatic cancer, or metastatic castrate-resistant prostate cancer. In an embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, or triple-negative breast cancer. In an embodiment, the cancer is non-small cell lung cancer. In an embodiment, the cancer is colorectal cancer. In an embodiment, the cancer is head and neck squamous cell carcinoma.

The present invention provides an anti-CCR8 antibody or antigen-binding fragment of the present invention for use in therapy. The present invention also provides an anti-CCR8 antibody or antigen-binding fragment of the present invention for use in treating cancer. In an embodiment, the cancer is a solid tumor. In an embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer, pancreatic cancer, or metastatic castrate-resistant prostate cancer. In a more particular embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, or triple-negative breast cancer. In some embodiments, the use further comprises administering to the patient a PD-1 antagonist antibody or a PD-L1 antagonist antibody. In some such embodiments, the PD-1 antagonist antibody or PD-L1 antagonist antibody is administered prior to, concurrently with, and/or after administration of the anti-CCR8 antibody or antigen-binding fragment. In particular embodiments, the PD-1 antagonist antibody is pembrolizumab, nivolumab, cemiplimab, or zeluvalimab. In other particular embodiments, the PD-L1 antagonist antibody is atezolizumab, avelumab, or durvalumab. In some embodiments, the use further comprises administering to the patient a chemotherapeutic agent. In some such embodiments, the chemotherapeutic agent may be administered prior to, concurrently with, or after administration of the anti-CCR8 antibody or antigen-binding fragment. In some embodiments, the use comprises administering to the patient an anti-CCR8 antibody or antigen-binding fragment of the present invention and a chemotherapeutic agent. In some embodiments, the use comprises administering to the patient an anti-CCR8 antibody or antigen-binding fragment of the present invention, a PD-1 or PD-L1 antagonist antibody, and a chemotherapeutic agent. In an embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides an anti-CCR8 antibody or antigen-binding fragment of the present invention for the manufacture of a medicament for the treatment of cancer. In an embodiment, the cancer is a solid tumor. In an embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer, pancreatic cancer, or metastatic castrate-resistant prostate cancer. In a more particular embodiment, the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, or triple-negative breast cancer. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention also provides a pharmaceutical composition comprising an anti-CCR8 antibody of the present invention, or an antigen-binding fragment thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In an embodiment, the anti-CCR8 antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 594 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 595. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 354, and the LC comprises an amino acid sequence of SEQ ID NO: 355. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 573, and the LC comprises an amino acid sequence of SEQ ID NO: 355.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 596 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 597. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 364, and the LC comprises an amino acid sequence of SEQ ID NO: 365. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 574, and the LC comprises an amino acid sequence of SEQ ID NO: 365.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 598 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 599. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 374, and the LC comprises an amino acid sequence of SEQ ID NO: 375. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 575, and the LC comprises an amino acid sequence of SEQ ID NO: 375.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 600 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 601. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 384, and the LC comprises an amino acid sequence of SEQ ID NO: 385. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 576, and the LC comprises an amino acid sequence of SEQ ID NO: 385.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 602 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 603. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 394, and the LC comprises an amino acid sequence of SEQ ID NO: 395. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 577, and the LC comprises an amino acid sequence of SEQ ID NO: 395.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 604 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 605. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 404, and the LC comprises an amino acid sequence of SEQ ID NO: 405. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 578, and the LC comprises an amino acid sequence of SEQ ID NO: 405.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 606 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 607. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 414, and the LC comprises an amino acid sequence of SEQ ID NO: 415. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 579, and the LC comprises an amino acid sequence of SEQ ID NO: 415.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 608 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 609. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 424, and the LC comprises an amino acid sequence of SEQ ID NO: 425. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 580, and the LC comprises an amino acid sequence of SEQ ID NO: 425.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 610 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 611. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 434, and the LC comprises an amino acid sequence of SEQ ID NO: 435. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 581, and the LC comprises an amino acid sequence of SEQ ID NO: 435.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 612 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 613. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 444, and the LC comprises an amino acid sequence of SEQ ID NO: 445. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 582, and the LC comprises an amino acid sequence of SEQ ID NO: 445.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 614 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 615. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 454, and the LC comprises an amino acid sequence of SEQ ID NO: 455. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 583, and the LC comprises an amino acid sequence of SEQ ID NO: 455.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 616 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 617. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 464, and the LC comprises an amino acid sequence of SEQ ID NO: 465. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 584, and the LC comprises an amino acid sequence of SEQ ID NO: 465.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 618 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 619. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 474, and the LC comprises an amino acid sequence of SEQ ID NO: 475. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 585, and the LC comprises an amino acid sequence of SEQ ID NO: 475.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 620 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 621. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 484, and the LC comprises an amino acid sequence of SEQ ID NO: 485. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 586, and the LC comprises an amino acid sequence of SEQ ID NO: 485.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 622 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 623. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 494, and the LC comprises an amino acid sequence of SEQ ID NO: 495. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 587, and the LC comprises an amino acid sequence of SEQ ID NO: 495.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 624 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 625. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 504, and the LC comprises an amino acid sequence of SEQ ID NO: 505. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 588, and the LC comprises an amino acid sequence of SEQ ID NO: 505.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 626 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 627. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 514, and the LC comprises an amino acid sequence of SEQ ID NO: 515. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 589, and the LC comprises an amino acid sequence of SEQ ID NO: 515.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 628 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 629. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 524, and the LC comprises an amino acid sequence of SEQ ID NO: 525. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 590, and the LC comprises an amino acid sequence of SEQ ID NO: 525.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 630 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 631. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 534, and the LC comprises an amino acid sequence of SEQ ID NO: 535. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 591, and the LC comprises an amino acid sequence of SEQ ID NO: 535.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 632 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 633. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 544, and the LC comprises an amino acid sequence of SEQ ID NO: 545. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 592, and the LC comprises an amino acid sequence of SEQ ID NO: 545.

In an embodiment, the antibody of the present invention comprises a HC encoded by a polynucleotide sequence comprising SEQ ID NO: 634 and a LC encoded by a polynucleotide sequence comprising SEQ ID NO: 635. In a particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 554, and the LC comprises an amino acid sequence of SEQ ID NO: 555. In another particular embodiment, the HC comprises an amino acid sequence of SEQ ID NO: 593, and the LC comprises an amino acid sequence of SEQ ID NO: 555.

Also provided herein are one or more nucleic acid sequences encoding the anti-CCR8 antibody or antigen-binding fragment of the present invention. In some embodiments, the present invention provides a DNA molecule comprising a polynucleotide that encodes a HC of an antibody of the present invention. The present invention also provides a DNA molecule comprising a polynucleotide that encodes a LC of an antibody of the present invention. The present invention also provides a DNA molecule comprising a polynucleotide that encodes both a LC of an antibody of the present invention and a HC of an antibody of the present invention. In some embodiments, the invention provides a nucleic acid sequence encoding a heavy chain amino acid sequence of SEQ ID NOs: 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, or 1160. In other embodiments, the invention provides a nucleic acid sequence encoding a light chain amino acid sequence of SEQ ID NOs: 1128, 1130, 1132, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, or 1159.

The present invention also provides a DNA molecule comprising a polynucleotide that encodes an antibody LC wherein the LC has an amino acid sequence of SEQ ID NO: 16. In an embodiment, the polynucleotide comprises a polynucleotide sequence of SEQ ID NO: 28. The present invention also provides DNA molecules where one DNA molecule comprises a polynucleotide that encodes an antibody HC wherein the HC has an amino acid sequence of SEQ ID NO: 15, and another DNA molecule comprises a polynucleotide that encodes a LC wherein the LC has an amino acid sequence of SEQ ID NO: 16. In an embodiment, the polynucleotide that encodes the antibody HC comprises a polynucleotide sequence of SEQ ID NO: 27, and the polynucleotide that encodes the LC comprises a polynucleotide sequence of SEQ ID NO: 28.

The present invention further provides a mammalian cell transformed with a DNA molecule of the present invention, wherein the transformed mammalian cell is capable of expressing an antibody of the present invention, wherein the antibody comprises two HCs and two LCs.

The present invention further provides a mammalian cell transformed with a DNA molecule of the present invention, wherein the transformed mammalian cell is capable of expressing an antibody comprising two HCs and two LCs, wherein each HC comprises an amino acid sequence of SEQ ID NO: 15, and each LC comprises an amino acid sequence of SEQ ID NO: 16.

The present invention also provides a process for producing an antibody of the present invention, wherein the antibody comprises two HCs and two LCs, and wherein the process comprises cultivating a mammalian cell under conditions such that the antibody is expressed and recovering the expressed antibody. In an embodiment, the mammalian cell is transformed with a DNA molecule of the present invention, wherein the transformed mammalian cell is capable of expressing an antibody of the present invention comprising two HCs and two LCs. The present invention also provides an antibody obtainable by the process.

The present invention also provides a process for producing an antibody, wherein the antibody comprises two HCs and two LCs, each HC comprises an amino acid sequence of SEQ ID NO: 15 and each LC comprises an amino acid sequence of SEQ ID NO: 16. In an embodiment, the process comprises cultivating a mammalian cell under conditions such that the antibody is expressed and recovering the expressed antibody, and wherein the mammalian cell is transformed with a DNA molecule of the present invention, wherein the transformed mammalian cell is capable of expressing an antibody comprising two HCs and two LCs, wherein each HC comprises an amino acid sequence of SEQ ID NO: 15, and each LC comprises an amino acid sequence of SEQ ID NO: 16. The present invention also provides an antibody obtainable by the process.

The present invention provides a DNA molecule comprising a polynucleotide that encodes an antibody HC, wherein the HC has an amino acid sequence of SEQ ID NO: 19. In an embodiment, the polynucleotide sequence comprises SEQ ID NO: 29.

The present invention provides a DNA molecule comprising a polynucleotide that encodes an antibody LC wherein the LC has an amino acid sequence of SEQ ID NO: 20. In an embodiment, the polynucleotide sequence comprises SEQ ID NO: 30.

The present invention provides a DNA molecule comprising a polynucleotide that encodes an antibody HC wherein the HC has an amino acid sequence of SEQ ID NO: 19. In an embodiment, the polynucleotide that encodes the antibody HC comprises a polynucleotide sequence of SEQ ID NO: 29. The present invention also provides a DNA molecule comprising a polynucleotide that encodes an antibody LC wherein the LC has an amino acid sequence of SEQ ID NO: 20. In an embodiment, the polynucleotide that encodes the LC comprises a polynucleotide sequence of SEQ ID NO: 30. The present invention also provides a mammalian cell transformed with a DNA molecule of the present invention, wherein the transformed mammalian cell is capable of expressing an antibody comprising two HCs and two LCs, wherein each HC comprises an amino acid sequence of SEQ ID NO: 19, and each LC comprises an amino acid sequence of SEQ ID NO: 20.

In some embodiments, a nucleic acid sequence encoding an HC described herein may comprise any one of SEQ ID NOs: 1195, 1197, 1199, 1201, 1204, 1206, 1208, 1210, 1212, 1214, 1216, 1218, 1220, 1222, 1224, 1226, 1228, or 1230.

In some embodiments, a nucleic acid sequence encoding an LC described herein may comprise any one of SEQ ID NOs: 1196, 1198, 1200, 1202, 1203, 1205, 1207, 1209, 1211, 1213, 1215, 1217, 1219, 1221, 1223, 1225, 1227, or 1229.

In some embodiments, a nucleic acid sequence encoding an scFv described herein may comprise any one of SEQ ID NOs: 1163-1194.

The present invention also provides a process for producing an antibody, wherein the antibody comprises two HCs and two LCs, each HC comprises an amino acid sequence of SEQ ID NO: 19 and each LC comprises an amino acid sequence of SEQ ID NO: 20. In an embodiment, the process comprises cultivating a mammalian cell under conditions such that the antibody is expressed and recovering the expressed antibody, and wherein the mammalian cell is transformed with a DNA molecule of the present invention. In an embodiment, the transformed mammalian cell is capable of expressing an antibody comprising two HCs and two LCs, wherein each HC comprises an amino acid sequence of SEQ ID NO: 19, and each LC comprises an amino acid sequence of SEQ ID NO: 20. The present invention also provides an antibody obtainable by the process.

The present invention also provides a process for producing an antibody comprising two HCs and two LCs, wherein the process comprises cultivating the above-described mammalian cell under conditions such that the antibody is expressed and recovering the expressed antibody, wherein: (a) both HCs comprise an amino acid sequence of SEQ ID NOs: 15, 1125, 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, or 1160, or an amino acid sequence that is at least 90% identical to any one of the foregoing HC amino acid sequences; and (b) both LCs comprise an amino acid sequence of SEQ ID NOs: 16, 365, 1126, 1128, 1130, 1132, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, or 1159, or an amino acid sequence that is at least 90% identical to any one of the foregoing LC amino acid sequences.

In another embodiment, the present invention provides an antibody or antigen-binding fragment thereof that binds human CCR8 at an epitope wherein the epitope comprises at least one residue at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least two residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least three residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least four residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least five residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises six or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises seven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises eight or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises nine or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises ten or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises eleven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises all twelve amino acid residues at positions 1-12 of SEQ ID NO: 31. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 31. The amino acid sequence of amino acid residues 1-12 of SEQ ID NO: 31 is SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody does not block the binding of CCL1 to CCR8. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In another embodiment, the present invention provides an antibody or antigen-binding fragment thereof that binds human CCR8 at an epitope wherein the epitope consists of at least one residue at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least two residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least three residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least four residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least five residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of six or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of seven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of eight or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of nine or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of ten or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of eleven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of all twelve amino acid residues at positions 1-12 of SEQ ID NO: 31. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 31. The amino acid sequence of amino acid residues 1-12 of SEQ ID NO: 31 is SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody does not block the binding of CCL1 to CCR8. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody or antigen-binding fragment thereof binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody or antigen-binding fragment thereof binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody or antigen-binding fragment thereof binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556. In an embodiment, the anti-CCR8 antibody or fragment thereof is an antibody.

In another embodiment, the present invention provides an antibody or antigen-binding fragment thereof that binds human CCR8 at an epitope wherein the epitope comprises at least one residue of SEQ ID NO: 82. In an embodiment, the epitope comprises at least two residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least three residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least four residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least five residues of SEQ ID NO: 82. In an embodiment, the epitope comprises six or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises seven or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises eight or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises nine or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises ten or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises eleven or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises all twelve amino acid residues of SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody does not block the binding of CCL1 to CCR8. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody or antigen-binding fragment thereof binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody or antigen-binding fragment thereof binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody or antigen-binding fragment thereof binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556. In an embodiment, the anti-CCR8 antibody or fragment thereof is an antibody.

In another embodiment, the present invention provides an antibody or antigen-binding fragment thereof that binds human CCR8 at an epitope wherein the epitope consists of at least one residue of SEQ ID NO: 82. In an embodiment, the epitope consists of at least two residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least three residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least four residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least five residues of SEQ ID NO: 82. In an embodiment, the epitope consists of six or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of seven or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of eight or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of nine or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of ten or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of eleven or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of all twelve amino acid residues of SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody does not block the binding of CCL1 to CCR8. In an embodiment, the epitope is determined by epitope binning. In an embodiment, the epitope is determined by antibody binding to CCR8 peptide-nanobody complexes. In an embodiment, the epitope is determined by screening antibody binding to CCR8 by phage display. In an embodiment, the epitope is determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. In some embodiments, the epitope is determined by anti-CCR8 antibody or antigen-binding fragment thereof binding to the T4R mutation in cynomolgus monkey CCR8. In an embodiment, binding to the T4R mutation is determined in a cell based affinity assay, wherein antibody binding to cells expressing cynomolgus monkey CCR8 containing a T4R mutation is compared to antibody binding to cells expressing wild-type cynomolgus monkey CCR8 (comprising a threonine at position four). In some embodiments, an anti-CCR8 antibody or antigen-binding fragment thereof binds threonine at position four if it shows reduced binding to CCR8 comprising a T4R mutation. In particular embodiments, an anti-CCR8 antibody or antigen-binding fragment thereof binds threonine at position four if it shows no detectable binding to CCR8 comprising a T4R mutation. In some embodiments, wild-type cynomolgus monkey CCR8 comprises an amino acid sequence given by SEQ ID NO: 22. In some embodiments, cynomolgus monkey CCR8 comprising a T4R mutation comprises an amino acid sequence given by SEQ ID NO: 556. In an embodiment, the anti-CCR8 antibody or fragment thereof is an antibody.

In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids of SEQ ID NO: 83. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids of SEQ ID NO: 86. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids of SEQ ID NO: 84. In some embodiments, the epitope is determined by antibody binding to a peptide of amino acids of SEQ ID NO: 85, SEQ ID NO: 83, SEQ ID NO: 86, and/or SEQ ID NO: 84. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids at positions 13 through 35 of SEQ ID NO: 31. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids at positions 13, 14, or 15 of SEQ ID NO: 31.

In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids of SEQ ID NO: 83. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids of SEQ ID NO: 86. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids of SEQ ID NO: 84. In some embodiments, the epitope is determined by antibody binding to a peptide of amino acids of SEQ ID NO: 85, SEQ ID NO: 83, SEQ ID NO: 86, and/or SEQ ID NO: 84. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids at positions 13 through 35 of SEQ ID NO: 31. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids at positions 13, 14, or 15 of SEQ ID NO: 31

In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids residues at position 13-24 of SEQ ID NO: 31. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids residues at position 19-30 of SEQ ID NO: 31. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope comprising amino acids residues at position 25-35 of SEQ ID NO: 31. In some embodiments, the epitope is determined by antibody binding to a peptide of amino acids of SEQ ID NO: 85, SEQ ID NO: 83, SEQ ID NO: 86, and/or SEQ ID NO: 84.

In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids residues at position 13-24 of SEQ ID NO: 31. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids residues at position 19-30 of SEQ ID NO: 31. In some embodiments, an anti-CCR8 antibody or fragment thereof of the present invention does not bind an epitope consisting of amino acids residues at position 25-35 of SEQ ID NO: 31. In some embodiments, the epitope is determined by antibody binding to a peptide of amino acids of SEQ ID NO: 85, SEQ ID NO: 83, SEQ ID NO: 86, and/or SEQ ID NO: 84.

The term “epitope” as used herein refers to sites of an antigen that are in contact with the variable region of an antibody. The epitope may be continuous or non-continuous, and may be determined by a method known to a person of ordinary skill, including flow cytometry of bound antibody to peptides, hydrogen-deuterium exchange, alanine scanning, and/or x-ray crystallography.

The epitope may be an epitope comprising or consisting of amino acid residues that are determined by antibody binding to a peptide as described herein. In some such embodiments, the peptide comprises an amino acid sequence of SEQ ID NO: 82. In some such embodiments, the peptide comprises an amino acid sequence of residues at positions 1-12 of SEQ ID NO: 31.

The epitope may be an epitope comprising or consisting of amino acid residues that are determined by epitope binning. In some such embodiments, the epitope binning is performed with biotinylated N-terminus CCR8 peptides.

The epitope may be an epitope comprising or consisting of amino acid residues that are determined by antibody binding to CCR8 peptide-nanobody complexes.

The epitope may be an epitope comprising or consisting of amino acid residues that are determined by screening antibody binding to CCR8 by phage display.

The epitope may be an epitope comprising or consisting of threonine at position four of the N-terminal region of CCR8 as determined by reduced binding to CCR8 comprising a T4R mutation compared to binding to wild-type CCR8. Binding to the T4R mutation may be tested, for example, by determining binding to wild-type cynomolgus monkey CCR8 (comprising an amino acid sequence given by SEQ ID NO: 22) compared to binding cynomolgus monkey CCR8 comprising a T4R mutation (comprising an amino acid sequence given by SEQ ID NO: 556).

The epitope may be an epitope comprising or consisting of amino acid residues that are determined by determining binding to a CCR8 peptide expressed in human cells, wherein the peptide comprises an amino acid sequence given by SEQ ID NO: 82. The CCR8 peptide may be fused to a nanobody, or other protein or Fc, for expression in human cells.

The present invention further provides an antibody or antigen-binding fragment that binds to an epitope on human CCR8, wherein said epitope comprises or consists of SEQ ID NO: 82. In some embodiments, the present invention also provides an antibody or antigen-binding fragment, wherein said antibody or antigen-binding fragment: (a) binds to an epitope on human CCR8, wherein said epitope comprises or consists of SEQ ID NO: 82; and (b) does not block the binding of CCL1 to CCR8. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the present invention provides a molecule that competes for binding to CCR8 with an anti-CCR8 antibody or antigen-binding fragment of the present invention. Such molecule that competes for binding may be, for example, an antibody, antibody fragment, or polypeptide. In some embodiments, the present invention provides a molecule that binds the same epitope as an anti-CCR8 antibody or antigen-binding fragment of the present invention. In an embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering to the patient an effective amount of an antibody or antigen-binding fragment that binds human CCR8 at an epitope wherein the epitope comprises at least one residue at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least two residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least three residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least four residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises at least five residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises six or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises seven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises eight or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises nine or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises ten or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises eleven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope comprises all twelve amino acid residues at positions 1-12 of SEQ ID NO: 31. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 31. The amino acid sequence of amino acid residues 1-12 of SEQ ID NO: 31 is SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody or antigen-binding fragment does not block the binding of CCL1 to CCR8. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering to the patient an effective amount of an antibody or antigen-binding fragment that binds human CCR8 at an epitope wherein the epitope consists of at least one residue at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least two residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least three residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least four residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of at least five residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of six or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of seven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of eight or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of nine or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of ten or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of eleven or more residues at positions 1-12 of SEQ ID NO: 31. In an embodiment, the epitope consists of all twelve amino acid residues at positions 1-12 of SEQ ID NO: 31. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 31. The amino acid sequence of amino acid residues 1-12 of SEQ ID NO: 31 is SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody or antigen-binding fragment does not block the binding of CCL1 to CCR8. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering to the patient an effective amount of an antibody or antigen-binding fragment that binds human CCR8 at an epitope wherein the epitope comprises at least one residue of SEQ ID NO: 82. In an embodiment, the epitope comprises at least two residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least three residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least four residues of SEQ ID NO: 82. In an embodiment, the epitope comprises at least five residues of SEQ ID NO: 82. In an embodiment, the epitope comprises six or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises seven or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises eight or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises nine or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises ten or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises eleven or more residues of SEQ ID NO: 82. In an embodiment, the epitope comprises all twelve amino acid residues of SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 82. In a particular embodiment, the epitope comprises a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody or antigen-binding fragment does not block the binding of CCL1 to CCR8. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

The present invention provides a method of treating cancer in a patient comprising administering to the patient an effective amount of an antibody or antigen-binding fragment that binds human CCR8 at an epitope wherein the epitope consists of at least one residue of SEQ ID NO: 82. In an embodiment, the epitope consists of at least two residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least three residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least four residues of SEQ ID NO: 82. In an embodiment, the epitope consists of at least five residues of SEQ ID NO: 82. In an embodiment, the epitope consists of six or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of seven or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of eight or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of nine or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of ten or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of eleven or more residues of SEQ ID NO: 82. In an embodiment, the epitope consists of all twelve amino acid residues of SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 82. In a particular embodiment, the epitope consists of a threonine at position 4 of SEQ ID NO: 22. In some such embodiments, the anti-CCR8 antibody or antigen-binding fragment does not block the binding of CCL1 to CCR8. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, the present invention provides a method of treating cancer in a patient comprising administering to the patient an effective amount of a molecule that competes for binding to CCR8 with an anti-CCR8 antibody or antigen-binding fragment of the present invention. Such molecule that competes for binding may be, for example, an antibody, antibody fragment, or polypeptide. In some embodiments, the present invention provides a molecule that binds the same epitope as an anti-CCR8 antibody of the present invention. In an embodiment, the anti-CCR8 antibody or antigen-binding fragment thereof, is an antibody.

In some embodiments, an anti-CCR8 antibody or antigen-binding fragment of the present invention binds CCR8 from a non-human species. In some embodiments, an anti-CCR8 antibody or antigen-binding fragment of the present invention binds cynomolgus monkey CCR8. In some embodiments, an anti-CCR8 antibody or antigen-binding fragment of the present invention binds murine CCR8. In some embodiments, the anti-CCR8 antibody or antigen-binding fragment of the present invention binds both cynomolgus monkey CCR8 and human CCR8. In a particular embodiment, an anti-CCR8 antibody or antigen-binding fragment of the present invention bind cynomolgus monkey CCR8 and human CCR8 with affinities that are within 10-fold of one another. In an embodiment, the antibody or antigen-binding fragment thereof, is an antibody.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Anti-tumor activity of single agent muCLDN18.2 bispecific T-cell engager molecule (BiTE®) molecule (□), muCLDN18.2 BiTE molecule/anti-CTLA4 dual combination (Δ), muCLDN18.2 BiTE molecule/anti-PD-1/anti-4-1BB triple combination (⋄), control BiTE molecule/anti-PD-1/anti-4-1BB/anti-CTLA4 quadruple combination (▪), or muCLDN18.2 BiTE molecule/anti-PD-1/anti-4-1BB/anti-CTLA4 quadruple combination (∇) therapy in the KPC-M5 model.

FIGS. 2A-2C. Anti-tumor activity of CCR8 afucosylated mIgG2a antibody in an MC38 syngeneic mouse model. Individual tumor growth for isotype control mIgG2a antibody (dashed lines) or CCR8 afucosylated mIgG2a antibody (solid lines) are shown in FIGS. 2C and 2B, respectively. FIG. 2A demonstrates the mean tumor volume for each group through day 24. **** indicates p<0.0001.

FIG. 3. Percent survival of mice inoculated with MC38 tumor cells and treated with either isotype control mIgG2a antibody (dashed lines) or CCR8 afucosylated mIgG2a antibody (solid lines). **** indicates p<0.0001.

FIGS. 4A-4D. CD8+/Treg ratio in MC38 tumor-bearing mice treated with either isotype control mIgG2a antibody (⋅) or CCR8 afucosylated mIgG2a antibody (⋅). FIGS. 4A, 4B, 4C, and 4D represent % Foxp3+ Treg, % CD25+Foxp3+ Treg, CD8/Treg (Foxp3+), and CD8/Treg (CD25+Foxp3+), respectively.

FIGS. 5A-5D. Anti-tumor activity of CCR8 afucosylated mIgG2a as monotherapy and in combination with TAA-BiTE molecule in the B16F10 syngeneic tumor model expressing tumor-associated antigen (TAA). Individual tumor growth for the treatment groups is depicted as spider plots (FIGS. 5A to 5D). Animals with no measurable tumors defined as Complete Responders (CRs) have been assessed until day 48.

DETAILED DESCRIPTION

The present disclosure provides anti-CCR8 antibodies and methods of making and using said antibodies. The anti-CCR8 antibodies disclosed herein 1) are able to bind human and cynomolgus monkey CCR8 on tumor-resident Treg cells; 2) lead to specific depletion of tumor-resident Treg cells; 3) demonstrate an acceptable pharmacokinetic profile, and/or 4) display sufficient potency for the treatment of cancer. Anti-CCR8 antibodies of the present invention have an improved safety profile compared to other Treg-depleting therapeutic molecules targeting other markers that do not specifically deplete tumor-resident Tregs. In addition, anti-CCR8 depleting antibody treatment resulted in significantly increased CD8+/Treg ratios in tumors, thereby driving enhanced anti-tumor immunity.

The present invention includes anti-CCR8 antibodies that bind a unique epitope on CCR8 and do not block ligand binding to CCR8, and are therefore not neutralizing antibodies. Binding to this unique epitope, compared to antibodies that bind a different epitope, is thought to contribute to high affinity and bioactivity of the anti-CCR8 antibody, and also an acceptable pharmacokinetic profile.

In the presence of ligand (CCL1), the anti-CCR8 antibodies of the present invention, that bind a unique epitope on CCR8 and do not block ligand binding, demonstrate ADCC activity even at the highest concentrations of ligand tested in vitro. In contrast, anti-CCR8 antibodies that bind a different epitope (and block ligand binding) demonstrate reduced ADCC activity in the presence of increased levels of CCL1. Therefore, binding to this unique epitope is thought to contribute to greater potency (via ADCC) of the anti-CCR8 antibodies of the present invention, even in the presence of increased concentration of ligand. As CCL1 is highly expressed in tumors such as breast cancer (see e.g., Kuehnemuth et al., BMC Cancer 18, Article number: 1278 (2018)), anti-CCR8 antibodies that demonstrate ADCC activity in the presence of increased concentrations of ligand are preferred.

Anti-CCR8 antibodies of the present invention are preferably afucosylated and demonstrate enhanced ADCC activity.

Additional modes of action for depletion of Tregs contemplated by the anti-CCR8 antibodies or fragments thereof of the present invention include antibody-dependent cellular phagocytosis (ADCP) and/or complement-dependent cytotoxicity (CDC).

As used herein, an “antibody” is an immunoglobulin molecule comprising 2 heavy chains (HCs) and 2 light chains (LCs) interconnected by disulfide bonds. The amino terminal portion of each LC and HC includes a variable region of about 100-120 amino acids primarily responsible for antigen recognition via the CDRs contained therein. The CDRs are interspersed with regions that are more conserved, termed framework regions (“FR”). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) is composed of 3 CDRs and 4 FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The 3 CDRs of the LC are referred to as “LCDR1, LCDR2, and LCDR3,” and the 3 CDRs of the HC are referred to as “HCDR1, HCDR2, and HCDR3.” The CDRs contain most of the residues which form specific interactions with the antigen. The functional ability of an antibody to bind a particular antigen is, thus, largely influenced by the amino acid residues within the six CDRs. Assignment of amino acids to CDR domains within the LCVR and HCVR regions of the antibodies of the present invention is based on the well-known Kabat numbering convention (Kabat, et al., Ann. NY Acad. Sci. 190:382-93 (1971); Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991)). It is understood that other numbering conventions may also be used, such as, for example, Chothia (Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”, Journal of Molecular Biology, 196, 901-917 (1987); Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins”, Journal of Molecular Biology, 273, 927-948 (1997)), and/or North (North et al., “A New Clustering of Antibody CDR Loop Conformations”, Journal of Molecular Biology, 406, 228-256 (2011)). An “anti-CCR8 antibody” is an antibody that binds CCR8.

Antibodies of the present invention may be an IgG1, IgG2, or IgG4. Preferably, antibodies of the present invention are IgG1. IgG1 antibodies are known to trigger ADCC. The antibodies of the present invention may be human or humanized antibodies. In the context of monoclonal antibodies, the terms “human” and “humanized” are well-known to those of ordinary skill in the art (Weiner L J, J. Immunother. 2006; 29: 1-9; Mallbris L, et al., J. Clin. Aesthet. Dermatol. 2016; 9: 13-15).

In addition, antibodies of the present invention are preferably afucosylated. Removal of the core fucose from the biantennary complex-type oligosaccharides attached to the Fc greatly increased ADCC effector function without altering antigen binding or CDC effector function. Several ways are known for reducing or abolishing fucosylation of Fc-containing molecules, e.g., antibodies. These include recombinant expression in certain mammalian cell lines including a FUT8 knockout cell line, variant CHO line Lec13, rat hybridoma cell line YB2/0, a cell line comprising a small interfering RNA specifically against the FUT8 gene, and a cell line co-expressing α-1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Alternatively, the Fc-containing molecule may be expressed in a non-mammalian cell such as a plant cell, yeast, or prokaryotic cell, e.g., E. coli. Zinc-finger nucleases are another known method of generating afucosylated antibodies. See e.g., Haryadi et al., Bioengineered 4:2, 90-94; March/April 2013; Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Pereira et al. mAbs 2018 Jul.; 10(5): 693-711.

The anti-CCR8 antibodies or fragments thereof are also contemplated to be in formats including scFv, scFab, Fab, bispecific T-cell engager molecules, and bispecific antibodies (which binds two different epitopes on the same antigen or binds two different antigens).

An scFv or Fab can be converted into an antibody by known methods (see e.g. Reader et al., Molec. Bio. 61, 801-815 (2019)). Constant region sequences are known in the art. Constant region sequences are also exemplified herein, for example LC and HC constant region amino acid sequences are given by SEQ ID NO: 1079 and SEQ ID NO: 1080, respectively.

In particular embodiments, the anti-CCR8 antibodies or antigen-binding fragments thereof, of the invention are heterodimeric antibodies (used interchangeably herein with “hetero immunoglobulins” or “hetero Igs”), which refer to antibodies comprising two different light chains and two different heavy chains. In some embodiments, a hetero Ig comprises two Fabs and an Fc region. In some embodiments, the two Fabs are each N-terminal to the Fc region. In some embodiments, the two Fabs are each C-terminal to the Fc region. In some embodiments at least one Fab is an anti-CCR8 antibody fragment of the present invention.

The heterodimeric antibodies can comprise any immunoglobulin constant region. The term “constant region” as used herein refers to all domains of an antibody other than the variable region. The constant region is not involved directly in binding of an antigen, but exhibits various effector functions. As described above, antibodies are divided into particular isotypes (IgA, IgD, IgE, IgG, and IgM) and subtypes (IgG1, IgG2, IgG3, IgG4, IgA1 IgA2) depending on the amino acid sequence of the constant region of their heavy chains. The light chain constant region can be, for example, a kappa- or lambda-type light chain constant region, e.g., a human kappa- or lambda-type light chain constant region, which are found in all five antibody isotypes.

The heavy chain constant region of the heterodimeric antibodies can be, for example, an alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant region, e.g., a human alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant region. In some embodiments, the heterodimeric antibodies comprise a heavy chain constant region from an IgG1, IgG2, IgG3, or IgG4 immunoglobulin.

An example of a heterodimeric antibody is a Duobody™. Duobodies can be made by the DuoBody™ technology platform (Genmab A/S) as described, e.g., in International Publication Nos. WO 2008/119353, WO 2011/131746, WO 2011/147986, and WO 2013/060867, Labrijn A F et al., PNAS, 110(13): 5145-5150 (2013), Gramer et al., mAbs, 5(6): 962-973 (2013), and Labrijn et al., Nature Protocols, 9(10): 2450-2463 (2014). This technology can be used to combine one half of a first monospecific antibody containing two heavy and two light chains with one half of a second monospecific antibody containing two heavy and two light chains. The resultant heterodimer contains one heavy chain and one light chain from the first antibody paired with one heavy chain and one light chain from the second antibody. When both of the monospecific antibodies recognize different epitopes on different antigens, the resultant heterodimer is a multispecific antibody.

Another exemplary method of generating multispecific antibodies is by the knobs-into-holes technology (Ridgway et al., Protein Eng., 9:617-621 (1996); WO 2006/028936). The mispairing problem of Ig heavy chains that is a chief drawback for making multispecific antibodies is reduced in this technology by mutating selected amino acids forming the interface of the heavy chains in IgG. At positions within the heavy chain at which the two heavy chains interact directly, an amino acid with a small side chain (hole) is introduced into the sequence of one heavy chain and an amino acid with a large side chain (knob) into the counterpart interacting residue location on the other heavy chain. In some instances, antibodies of the disclosure have immunoglobulin chains in which the heavy chains have been modified by mutating selected amino acids that interact at the interface between two polypeptides so as to preferentially form a multispecific antibody. The multispecific antibodies can be composed of immunoglobulin chains of the same subclass or different subclasses.

Yet another method of generating multispecific antibodies is the CrossMab technology. CrossMab are chimeric antibodies constituted by the halves of two full-length antibodies. For correct chain pairing, it combines two technologies: (i) the knob-into-hole which favors a correct pairing between the two heavy chains; and (ii) an exchange between the heavy and light chains of one of the two Fabs to introduce an asymmetry which avoids light-chain mispairing. See, Ridgway et al., Protein Eng., 9:617-621 (1996); Schaefer et al., PNAS, 108:11187-11192 (2011). CrossMabs can combine two or more antigen-binding domains for targeting two or more targets or for introducing bivalency towards one target such as the 2:1 format.

Hetero-Ig molecules may also comprise a non-canonical disulfide bond and the generation of an asymmetric cysteine interface, as described in International Publication No. WO 2022/040466 which also discloses specific pairs of mutations that may be used in antibodies of the present invention. To facilitate the association of a particular heavy chain with its cognate light chain, both the heavy and light chains may contain complimentary amino acid substitutions. As used herein, “complimentary amino acid substitutions” refer to a substitution to a positively-charged amino acid in one chain paired with a negatively-charged amino acid substitution in the other chain. For example, the heavy chain comprises at least one amino acid substitution to introduce a charged amino acid and the corresponding light chain comprises at least one amino acid substitution to introduce a charged amino acid, wherein the charged amino acid introduced into the heavy chain has the opposite charge of the amino acid introduced into the light chain. One or more positively-charged residues (e.g., lysine, histidine or arginine) can be introduced into a first light chain (LC1) and one or more negatively-charged residues (e.g., aspartic acid or glutamic acid) can be introduced into the companion heavy chain (HCl) at the binding interface of LC1/HCl, whereas one or more negatively-charged residues (e.g., aspartic acid or glutamic acid) can be introduced into a second light chain (LC2) and one or more positively-charged residues (e.g., lysine, histidine or arginine) can be introduced into the companion heavy chain (HC2) at the binding interface of LC2/HC2. The electrostatic interactions will direct the LC1 to pair with HCl and LC2 to pair with HC2, as the opposite charged residues (polarity) at the interface attract. The heavy/light chain pairs having the same charged residues (polarity) at an interface (e.g. LC1/HC2 and LC2/HCl) will repel, resulting in suppression of the unwanted HC/LC pairings.

In some embodiments, a hetero Ig comprises at least one anti-CCR8 antibody fragment of the present invention. In particular embodiments, the anti-CCR8 antibody fragment is a Fab. In particular embodiments, the anti-CCR8 antibody fragment is a scFab. In particular embodiments, the anti-CCR8 antibody fragment is an scFv. Exemplary anti-CCR8 scFv amino acid sequences include, but are not limited to, any one of SEQ ID NOs: 1093-1124.

In some embodiments, a hetero Ig comprises an anti-CCR8 antibody fragment of the present invention attached to the hetero Ig. Said anti-CCR8 antibody fragment may be in any format as described herein, including scFv, Fab, or scFab. Such attachment may be via linker C-terminal or N-terminal to the Fc region, or N-terminal or C-terminal to another binding domain (e.g. Fab) in the hetero Ig. In some embodiments, a hetero Ig comprises at least one binding arm that is a single chain comprising an anti-CCR8 antibody fragment of the present invention and a further scFab or scFv.

The present invention also contemplates T cell engager (“TCE”) molecules comprising an anti-CCR8 antibody fragment of the present invention. Such TCE molecules are preferably single chain TCE molecules. A single-chain TCE molecule having the following orientation: scFv that binds CCR8 (VH, linker, VL), linker, scFv that binds CD3 (VH, linker, VL) is contemplated. In an embodiment, the TCE molecule further comprises a scFc, and has the following orientation: scFv that binds CCR8 (VH, linker, VL), linker, scFv that binds CD3 (VH, linker, VL)-Linker-Fc1 (hinge, CH2, CH3), linker, Fc2 (hinge, CH2, CH3). In some embodiments, the scFv that binds CCR8 is an anti-CCR8 antibody fragment of the present invention.

The present invention also contemplates a TCE molecule having the following orientation from N-terminus to C-terminus: scFv that binds CCR8 (VH, linker, VL)-Linker-scFv that binds CD3 (VH, linker, VL)-Linker-Fc1 (CH2-CH3)-Linker-Fc2 (CH2-CH3). In an embodiment, the TCE molecule binds CCR8 and CD3. The present invention also provides a TCE molecule having the following orientation from N-terminus to C-terminus: scFv that binds CCR8 (VL-Linker-VH)-Linker-scFv that binds CD3 (VH-Linker-VL)-Linker-Fc1 (CH2-CH3)-Linker-Fc2 (CH2-CH3). In an embodiment, the TCE molecule binds CCR8 and CD3. In some embodiments, the scFv that binds CCR8 is an anti-CCR8 antibody fragment of the present invention.

The present invention contemplates a TCE molecule comprising an orientation, from N-terminus to C-terminus, of a scFab that binds CCR8 (VH, CH1, linker, VL, either Cκ or Cλ, linker, an scFv that binds CD3 (VH, linker, VL). In some embodiments, the scFab that binds CCR8 is an anti-CCR8 antibody fragment of the present invention.

An scFc is a fusion protein in which a CH2 and CH3 (Fc1) are joined via a linker to another CH2 and CH3 (Fc2) to form a continuous protein chain wherein the linker is long enough to allow the protein chain to fold back on itself.

A “single-chain antigen-binding fragment” (“scFab”) is a fusion protein in which a VH and CH1 are joined via a linker to a VL and Cκ to form a continuous protein chain wherein the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen binding site. The linker may be, for example, a (G4S)6, (G4S)7, or (G4S)8 linker.

The scFab, scFv, and/or scFc may also have a cysteine clamp. A “cysteine clamp” involves the introduction of a cysteine into a polypeptide domain at a specific location, typically through replacing an existing amino acid at the specific location, so that when in proximity with another polypeptide domain, also having a cysteine introduced at a specific location, a disulfide bond (a “cysteine clamp”) may be formed between the two domains. In certain embodiments, an scFc comprises at least one cysteine clamp that results in a disulfide bond across both CH2 domains. In a further specific embodiment, an scFc comprises at least two cysteine clamps that results in a disulfide bond across both CH2 domains. In other embodiments, a binding construct's VH and VL domains may comprise the cysteine clamp(s) to result in disulfide bond formation between the VH and VL domains. These cysteine clamps will stabilize the VH and VL domains in an antigen-binding configuration.

A cysteine clamp may be naturally occurring or it may be a result of a molecule engineered to contain cysteines. For example, a scFab may have a natural cysteine clamp between the heavy and light chain constant domains. An scFab may also have a natural cysteine clamp between the heavy and light chain constant domains and an engineered cysteine clamp between cysteines at residue 44 of the heavy chain variable region and residue 100 of the light chain variable region. In addition, an anti-target scFv may also contain a cysteine clamp between cysteines at residue 44 of the heavy chain variable region and residue 100 of the light chain variable region, whereas an anti-CD3 scFv does not contain an engineered cysteine clamp. An scFc may contain hinge cysteine clamps, natural CH2/CH3 cysteine clamps, and/or an engineered CH2 cysteine clamp (intrachain).

Antigen binding fragments derived from an antibody can be obtained, for example, by proteolytic hydrolysis of the antibody, for example, pepsin or papain digestion of whole antibodies according to conventional methods. By way of example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment termed F(ab′)2. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab′ monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using papain produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. No. 4,331,647, Nisonoff et al., Arch. Biochem. Biophys. 89:230, 1960; Porter, Biochem. J. 73:119, 1959; Edelman et al., in Methods in Enzymology 1:422 (Academic Press 1967); and by Andrews, S. M. and Titus, J. A. in Current Protocols in Immunology (Coligan J. E., et al., eds), John Wiley & Sons, New York (2003). pages 2.8.1-2.8.10 and 2.10A.1-2.10A.5. Other methods for cleaving antibodies, such as separating heavy chains to form monovalent light-heavy chain fragments (Fd), further cleaving of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

An antibody fragment may also be any synthetic or genetically engineered protein. For example, antibody fragments include isolated fragments comprising the light chain variable region, “Fv” fragments comprising the variable regions of the heavy and light chains, and recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (scFv proteins).

Another form of an antibody fragment is a peptide comprising one or more complementarity determining regions (CDRs) of an antibody. CDRs (also termed “minimal recognition units”, or “hypervariable region”) can be obtained by constructing polynucleotides that encode the CDR of interest. Such polynucleotides are prepared, for example, by using the polymerase chain reaction to synthesize the variable region using mRNA of antibody-producing cells as a template (see, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2:106, 1991; Courtenay-Luck, “Genetic Manipulation of Monoclonal Antibodies,” in Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), page 166 (Cambridge University Press 1995); and Ward et al., “Genetic Manipulation and Expression of Antibodies,” in Monoclonal Antibodies: Principles and Applications, Birch et al., (eds.), page 137 (Wiley-Liss, Inc. 1995)).

Antibodies and antigen-binding fragments of the present invention bind human CCR8. Preferably, antigen-binding fragments of the present invention bind human CCR8 at an epitope comprising or consisting of amino acid residues of SEQ ID NO: 82. Particularly, antigen-binding fragments of the present invention bind human CCR8 and do not block ligand binding to CCR8.

In the most general sense, a T cell engager (“TCE”) molecule as described herein comprises a single chain polypeptide that can bind to two different antigens. A “TCE molecule” may be used interchangeably with a “BiTE molecule”. A BiTE molecule can comprise an scFv or scFab, as long as it is bispecific, meaning that it binds two targets (target antigen (here, CCR8) and CD3) at the same time. A TCE molecule is an antigen-binding molecule. A TCE molecule of the present invention may comprise an scFab that binds a target (e.g. tumor or target antigen; CCR8) and an scFv that binds CD3. Such molecule may have the orientation, from N-terminus to C-terminus: scFab (VH, CH1, linker, VL, either Cκ or CX), linker, scFv (VH, linker, VL). Such molecules may alternatively have the orientation, from N-terminus to C-terminus: scFab (VL, either Cκ or Cλ, linker, VH, CH1), linker, scFv (VH, linker, VL). In some embodiments, the scFab binds CCR8. In particular embodiments, the TCE molecule comprises a Cκ. Such TCE molecule may have the following orientation, from N-terminus to C-terminus: scFv that binds CCR8 (VH, linker, VL), linker, scFv that binds CD3 (VH, linker, VL). In some such embodiments, the scFv or scFab that binds CCR8 is an anti-CCR8 antibody fragment of the present invention.

A TCE molecule of the present invention may also have a half-life extending (HLE) moiety. An HLE moiety may extend the in vivo half-life of the TCE molecules of the present invention. Nonlimiting examples of half-life extending moieties include an Fc polypeptide, a single-chain Fc polypeptide (scFc), albumin, an albumin fragment, a moiety that binds to albumin or to the neonatal Fc receptor (FcRn), a derivative of fibronectin that has been engineered to bind albumin or a fragment thereof, a peptide, a single domain protein fragment, or other polypeptide that can increase serum half-life. In other embodiments, a half-life-extending moiety can be a non-polypeptide molecule such as, for example, polyethylene glycol (PEG). In some embodiments, the HLE is a single-chain Fc (“scFc”).

“Nucleic acid sequence” is intended to encompass a polymer of DNA or RNA, i.e., a polynucleotide, which can be single-stranded or double-stranded and which can contain non-natural or altered nucleotides. The terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid sequence,” and “polynucleotide” may be used interchangeably herein to refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). These terms refer to the primary structure of the molecule, and thus include double- and single-stranded DNA, and double- and single-stranded RNA. The terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, though not limited, to methylated and/or capped polynucleotides.

A DNA molecule of the present invention is a DNA molecule that comprises a non-naturally occurring polynucleotide sequence encoding a polypeptide having the amino acid sequence of at least one of the polypeptides in an anti-CCR8 antibody of the present invention (e.g., heavy chain, light chain, variable heavy chain, and variable light chain).

An isolated DNA encoding a HCVR region can be converted to a full-length heavy chain gene by operably linking the HCVR-encoding DNA to another DNA molecule encoding heavy chain constant regions. The sequences of human, as well as other mammalian, heavy chain constant region genes are known in the art. DNA fragments encompassing these regions can be obtained, e.g., by standard PCR amplification.

An isolated DNA encoding a LCVR region may be converted to a full-length light chain gene by operably linking the LCVR-encoding DNA to another DNA molecule encoding a light chain constant region. The sequences of human, as well as other mammalian, light chain constant region genes are known in the art. DNA fragments encompassing these regions can be obtained by standard PCR amplification. The light chain constant region can be a kappa or lambda constant region. In some embodiments, the light chain constant region is a kappa constant region.

The term “encoding” or “encodes” refers to a polynucleotide sequence encoding one or more amino acids. The term does not require a start or stop codon. The present invention encompasses nucleic acid molecules encoding anti-CCR8 antibody polypeptide sequences.

The polynucleotides of the present invention can be expressed in a host cell after the sequences have been operably linked to an expression control sequence. The expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline, neomycin, and dihydrofolate reductase, to permit detection of those cells transformed with the desired DNA sequences.

Transformed cells can be cultured under conditions that promote expression of the polypeptide, and the polypeptide recovered by conventional protein purification procedures. Polypeptides contemplated for use herein include substantially homogeneous recombinant mammalian polypeptides substantially free of contaminating endogenous materials. Cells containing the nucleic acid encoding an anti-CCR8 antibody of the present invention also include hybridomas.

A polynucleotide encoding an amino acid sequence of an anti-CCR8 antibody of the present invention can be any length as appropriate for the desired use or function, and can comprise one or more additional sequences, for example, regulatory sequences, and/or can be part of a larger nucleic acid, for example, a vector. The skilled artisan will appreciate that, due to the degeneracy of the genetic code, each of the polypeptide sequences disclosed herein is encoded by a large number of other nucleic acid sequences. Mutations can also be introduced into a nucleic acid without significantly altering the biological activity of a polypeptide that it encodes. For example, one can make nucleotide substitutions leading to amino acid substitutions at non-essential amino acid residues.

It will be appreciated that an anti-CCR8 antibody of the present invention may have at least one amino acid substitution, providing that the anti-CCR8 antibody retains the same or better desired binding specificity (e.g., binding to CCR8). Therefore, modifications to the anti-CCR8 antibody are encompassed within the scope of the invention. Such modifications may include amino acid substitutions, which may be conservative or non-conservative that do not destroy the desired binding capability of a binding construct. Conservative amino acid substitutions may encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties. A conservative amino acid substitution may also involve a substitution of a native amino acid residue with a normative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position.

Human CCR8 includes the wild-type human CCR8 sequence and variants and isoforms thereof. The amino acid sequence of human CCR8 comprises the amino acid sequence of SEQ ID NO: 21. The term “variant,” as used herein with respect to a nucleic acid sequence means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or the complement thereof; or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, complement thereof, or a sequences substantially identical thereto. With respect to a peptide or polypeptide, the term “variant,” as used herein, refers to a peptide or polypeptide that differs from a reference peptide or polypeptide in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retains at least one biological activity of the reference peptide or polypeptide. Variant can also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. The term “isoform” may be used herein to refer to a polypeptide or protein variant. Typically, a protein isoform is a member of a set of highly similar proteins that originate from a single gene or gene family and are the result of genetic differences. While some protein isoforms exhibit the same or similar biological functions, some isoforms have unique functions. Isoforms may be generated from alternative splicing, variable promoter usage, or other post-transcriptional modifications of a single gene.

A variant may be a nucleic acid sequence that is substantially identical over the full length of a full gene sequence or a fragment thereof. The nucleic acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof. In other embodiments, a variant may be an amino acid sequence that is substantially identical over the full length of the amino acid sequence or fragment thereof. The amino acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the amino acid sequence or a fragment thereof.

The amino acid sequence of cynomolgus monkey CCR8 comprises the amino acid sequence of SEQ ID NO: 22.

The antibodies of the present invention can readily be produced in mammalian cells, non-limiting examples of which includes CHO, NSO, HEK293 or COS cells. The host cells are cultured using techniques well known in the art.

Vectors containing the polynucleotide sequences of interest (e.g., the polynucleotides encoding the polypeptides of the antibody and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. Examples of vectors include, but are not limited to, plasmids, viral vectors, non-episomal mammalian vectors and expression vectors, for example, recombinant expression vectors.

The recombinant expression vectors of the invention can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. The recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells (e.g., SV40 early gene enhancer, Rous sarcoma virus promoter and cytomegalovirus promoter), those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences, see Voss et al., 1986, Trends Biochem. Sci. 11:287, Maniatis et al., 1987, Science 236:1237, incorporated by reference herein in their entireties), and those that direct inducible expression of a nucleotide sequence in response to particular treatment or condition (e.g., the metallothionin promoter in mammalian cells and the tet-responsive and/or streptomycin responsive promoter in both prokaryotic and eukaryotic systems (see id.). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

Typically, expression vectors used in any of the host cells will contain sequences for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as “flanking sequences” in certain embodiments will typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor splice site, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. The leader sequence may comprise an amino acid sequence of SEQ ID NO: 557 (MDMRVPAQLLGLLLLWLRGARC) which is encoded by SEQ ID NO: 558 (atggacatgagagtgcctgcacagctgctgggcctgctgctgctgtggctgagaggcgccagatgc). The leader sequence may comprise an amino acid sequence of SEQ ID NO: 559. (MAWALLLLTLLTQGTGSWA) which is encoded by SEQ ID NO: 560 (atggcctggg ctctgctgct cctcaccctc ctcactcagg gcacagggtc ctgggcc). The present invention contemplates antibody protein sequences without leader sequences.

The present invention also contemplates anti-CCR8 antibodies of the present invention that have clipping of the C-terminal lysine residue of the antibody HC. Anti-CCR8 antibodies comprising an antibody HC amino acid sequence lacking the C-terminal lysine residue are contemplated.

Various methods of protein purification may be employed to purify proteins, including, but not limited to, antibodies, and such methods are known in the art.

The anti-CCR8 antibodies of the invention can be biosynthesized, purified, and formulated for administration by well-known methods. For example, an appropriate host cell, such as HEK 293 or CHO, is either transiently or stably transfected with an expression system for secreting antibodies using a predetermined HC:LC vector ratio if two vectors are used, or a single vector system encoding both heavy chain and light chain. Vectors suitable for expression and secretion of antibodies from these commonly-used host cells are well-known. Following expression and secretion of the antibody, the medium is clarified to remove cells and the clarified medium is purified using any of many commonly-used techniques. For example, the medium may be applied to a Protein A or G column that has been equilibrated with a buffer, such as phosphate buffered saline (pH 7.4). The column is washed to remove nonspecific binding components. The bound antibody is eluted, for example, by a pH gradient (such as 0.1 M sodium phosphate buffer pH 6.8 to 0.1 M sodium citrate buffer pH 2.5). Antibody fractions are detected, such as by SDS-PAGE, and then are pooled. Further purification is optional, depending on the intended use. The antibody may be concentrated and/or sterile filtered using common techniques. Other materials than the antibody, such as host cell and growth medium components, and soluble aggregates and multimers of the antibody, may be effectively reduced or removed by common techniques, including size exclusion, hydrophobic interaction, cation exchange, anion exchange, affinity, or hydroxyapatite chromatography. The purity of the antibody after these chromatography steps is typically greater than 95%. The product may be frozen at −70° C. or may be lyophilized.

In exemplary aspects, an antibody of the present invention comprises a HC comprising a C-terminal lysine, as in SEQ ID NOs: 354, 364, 374, 384, 394, 404, 414, 424, 434, 444, 454, 464, 474, 484, 494, 504, 514, 524, 534, 544, 554, 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, or 1160. In alternative aspects, the antibody comprises a HC without the C-terminal lysine, as in SEQ ID NOs: 573-592 or SEQ ID NOs: 1238-1254. In addition, the HC N-terminal glutamine and/or the N-terminal glutamic acid of may be converted to pyroglutamic acid. Either form is envisioned for the antibodies of the present invention.

Similarly, in exemplary aspects, the anti-PD-1 antibody comprises a heavy chain comprising a C-terminal lysine, as in SEQ ID NOs: 41, for example. In alternative aspects, the anti-PD-1 antibody comprises the heavy chain of SEQ ID NOs: 636 without the C-terminal lysine. In other exemplary aspects, the anti-PD-1 antibody comprises a heavy chain comprising a C-terminal lysine. In alternative aspects, the anti-PD-1 antibody comprises a heavy chain without the C-terminal lysine.

An anti-CCR8 antibody of the present invention, or a pharmaceutical composition comprising the same, may be administered by parenteral routes, non-limiting examples of which are subcutaneous administration and intravenous administration. Intramuscular, intraarterial, intralesional, and peritoneal bolus injection are other possible routes of administration. An anti-CCR8 antibody can also be administered via infusion, for example intravenous or subcutaneous infusion. An anti-CCR8 antibody of the present invention may be administered to a patient with pharmaceutically acceptable carriers, diluents, or excipients in single or multiple doses. Optionally, the composition additionally comprises one or more physiologically active agents. Pharmaceutical compositions of the present invention can be prepared by methods well known in the art (e.g., Remington: The Science and Practice of Pharmacy, 22nd ed. (2012), A. Loyd et al., Pharmaceutical Press) and comprise an antibody, as disclosed herein, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

As used interchangeably herein, “treatment” and/or “treating” and/or “treat” are intended to refer to all processes wherein there may be a slowing, interrupting, arresting, controlling, stopping, or reversing of the progression of the disorders described herein, but does not necessarily indicate a total elimination of all disorder symptoms. Treatment includes administration of an anti-CCR8 antibody of the present invention for treatment of a disease or condition in a human that would benefit from activity of an anti-CCR8 antibody of the present invention, and includes: (a) inhibiting further progression of the disease; and (b) relieving the disease, i.e., causing regression of the disease or disorder or alleviating symptoms or complications thereof.

Therapeutically effective amounts (or dose) of an anti-CCR8 antibody of the present invention can be administered. As used herein, an “effective amount” means the amount of an anti-CCR8 antibody of the present invention or pharmaceutical composition comprising such an antibody that will elicit the biological or medical response of or desired therapeutic effect on a tissue, system, animal, mammal, or human that is being sought by the researcher, medical doctor, or other clinician. An effective amount of the antibody may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired response in the individual. An effective amount is also one in which any toxic or detrimental effect of the antibody is outweighed by the therapeutically beneficial effects. Such benefit includes improving signs or symptoms of cancer. An effective amount of an anti-CCR8 antibody of the present invention may be administered in a single dose or in multiple doses. In determining the effective amount for a patient, a number of factors are considered by the attending medical practitioner, including, but not limited to: the patient's size (e.g., weight or mass), body surface area, age, and general health; the specific disease or disorder involved; the degree of, or involvement, or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances known to medical practitioners.

Dosages, frequency of administration, formulation, and effective amount of an antagonist of the PD-1/PD-L1 pathway, a bispecific T-cell engager molecule, and/or an agonist of an immune cell co-stimulatory receptor can also be determined as described herein.

Suitable PD-L1 antagonist antibodies for use in methods of the present invention include, but are not limited to, atezolizumab, avelumab, or durvalumab. Examples of PD-1 antagonist antibodies suitable for use in methods of the invention include, but are not limited to pembrolizumab, nivolumab, cemiplimab, pidilizumab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, dostarlimab, Antibody 20C1.006, zeluvalimab, Antibody 20A2.003, Antibody 22D4.006, or Antibody 22D4.017, and any of the PD-1 antagonist antibodies described in WO 2019/140196. Such methods include a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody of the present invention and a PD-L1 antagonist antibody or PD-1 antagonist antibody. Such methods also include a method of treating cancer in a patient comprising administering to the patient an effective amount of a Treg depleting antibody and one or more of a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway.

Bispecific T-cell engager molecules are recombinant protein constructs made from two flexibly linked antibody derived binding domains. A “bispecific T-cell engager molecule” may be used interchangeably with a “BiTE® molecule”. One binding domain of bispecific T-cell engager is specific for a selected tumor-associated surface antigen on target cells; the second binding domain is specific for CD3, a subunit of the T cell receptor complex on T cells. By their particular design, bispecific T-cell engager molecules are uniquely suited to transiently connect T cells with target cells and, at the same time, potently activate the inherent cytolytic potential of T cells against target cells (Yang, Fa; Wen, Weihong; Qin, Weijun (2016). “Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies”. International Journal of Molecular Sciences. 18 (1): 48 (2016)). A bispecific T-cell engager molecule is bispecific, meaning that it binds two targets (target antigen and CD3) at the same time. Sequences of examples of scFvs that bind CD3 include I2E and I2C and are described in Table 15. Suitable bispecific T-cell engager molecules for use in methods of the present invention include, but are not limited to, the bispecific T-cell engager molecules given in Table 15.

The CD3 binding domain I2C comprises LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3, VH, VL, and VH-VL amino acids sequences of SEQ ID NO: 87-95, respectively. The CD3 binding domain I2E comprises LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3, VH, and VL amino acids sequences of SEQ ID NO: 96-103, respectively. An example of a CD33 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 104-118. An example of an EGFRVIII T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 119-129. An example of a MSLN T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 130-141. An example of a CDH19 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 142-159. An example of a FLT3 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 160-170. An example of a DLL3 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 171-181. An example of a CD19 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 182-191. An example of a BCMA T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 192-202. An example of a PSMA T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 203-240. An example of a CD70 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 241-250. An example of a CLDN18.2 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 251-266. An example of a MUC17 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 267-302. An example of a CDH3 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 303-313. An example of a CD19 T cell engager molecule is one that comprises CDR, VH/VL region, and bispecific single chain molecule amino acids sequences of SEQ ID NO: 314-332.

Methods of the present invention include a method of treating cancer in a patient comprising administering an effective amount of an anti-CCR8 antibody of the present invention and a bispecific T-cell engager molecule. Such methods also include a method of treating cancer in a patient comprising administering to the patient an effective amount of a Treg depleting antibody and one or more of a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway.

An agonist of an immune cell co-stimulatory receptor is a molecule that binds a co-stimulatory receptor on an immune cell (such as an activated T cell) and promotes activity of the receptor. Examples of co-stimulatory receptors include CD2, TNFRSF4 (OX40), TNFRSF5 (CD40), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB), TNFRSF14 (HVEM), TNFRSF18 (GITR), and ICOS.

EXAMPLES

Example 1: CCR8 Specificity

Transfected cells were used to assess an antibody's binding specificity using flow cytometry on host Human Embryonic Kidney (HEK) 293T cells. Proteins were expressed on HEK 293T cells by transfection using human CCR8 (SEQ ID NO: 21), human CCR8 with an A27G point mutation (SEQ ID NO: 23), murine CCR8 (SEQ ID NO: 24), rat CCR8 (SEQ ID NO: 25), human CCR4 (SEQ ID NO: 26), or control expression vectors, Gibco™ Opti-MEM® media (Gibco), and 293Fectin™ reagent (Invitrogen) according to the manufacturer's instructions. Human T-cell lymphoma (HuT78) cell lines were also used to determine specificity to endogenously expressed CCR8.

Transfected HEK293T cells (24 hours after transfection) or HuT78 cells were resuspended in FACS buffer (PBS+2% Fetal Bovine Serum) and added to a 96-well plate. Hybridoma supernatant samples containing control antibodies 433H (BD Biosciences) or L263G8 (BioLegend), Antibody 1 IgG2, or Antibody 2 IgG2 were added at a final concentration of 5.0 μg/mL, cells were resuspended and incubated for 1 hour at 4° C. Plates were washed twice with FACS buffer, centrifuged to pellet the cells, and supernatant was removed and resuspended in FACS buffer to remove unbound antibodies.

Alexa Fluor 647 goat anti-human or rat IgG (Fcγ fragment specific) secondary antibodies (Jackson ImmunoResearch) made up in FACS buffer at 5.0 μg/mL were added to each well, and cells were resuspended and incubated for 15 minutes at 4° C. Plates were washed twice with FACS buffer, centrifuged to pellet the cells, and supernatant was removed and resuspended in FACS buffer to remove unbound secondary antibodies. Samples were resuspended in FACS buffer and read on either IntelliCyt® iQue or BD Accuri™ Flow Cytometer with an Intellicyt HyperCyt autosampler. Data derived from three cohorts of immunized animals are represented in Table 2.

TABLE 2
Binding of hybridoma supernatants (final Ab concentration at 5 μg/ml) to native
conformation of CCR8 expressed on surface of cells as determined by FACS analysis.
	Human CCR8		Rat CCR8	Mouse CCR8
Antibody	[A27G] transiently		transiently	transiently
Hybridoma	expressed on	HUT78 (endogenous	expressed on	expressed on
Supernatant	HEK293T	human CCR8)	HEK293T	HEK293T
Antibody 1 IgG2	36924	7756.9	105325	24729
Antibody 2 IgG2	24205	1466.0	11023	3597
L263G8	41425	4500	N.D.	N.D.
SA214G2	N.D.	N.D.	1594	56829

These data demonstrate that hybridoma supernatant containing Antibody 1 IgG2 or Antibody 2 IgG2 bound human CCR8, including human CCR8 with the A27G mutation, rat, and mouse CCR8. None of the tested antibodies in supernatant bound to human CCR4 or 293T cells transfected with a control expression vector.

Example 2: Antibody Binding to Human and Cynomolgus Monkey Regulatory T Cells

Binding of anti-CCR8 antibodies to endogenous CCR8 expressed by primary human and cynomolgus monkey regulatory T cells (human or cyno T-regs) was assessed by flow cytometry. Freshly isolated human (N=3) and cynomolgus monkey (N=2) peripheral blood mononuclear cells (PBMCs) were incubated with anti-CCR8 hybridoma culture supernatants at 20% final concentration in the presence of human Fc Block for one hour at 4° C. The primary antibodies were washed out from the cells, and the secondary anti-human or anti-rat IgG Fc antibodies and the cocktail of human/cyno cross-reactive anti-CD4/anti-CD25/anti-CD127 antibodies were added and incubated for thirty minutes at 4° C. 200,000 events were collected using FACS Canto flow cytometer, and binding was detected on the CD4+/CD25+/CD127− gated viable cells. The percent positive cells represents the percentage of human or cyno Tregs that were stained by the hybridoma culture supernatant containing the antibody under investigation. Control antibody 433H was purified and used at a concentration of 20 μg/ml. Results are shown in Table 3.

TABLE 3
Binding of hybridoma supernatants to primary
human and cynomolgus monkey regulatory T cells.
	CCR8 + CD127 − CD25 + CD4, % positive
		Cynomolgus Monkey
Antibody	Human (3 samples)	(2 samples)
Antibody 2 IgG2	24.4	9.4	11.9	8.5	17.9
Antibody 1 IgG2	23.3	Not tested	32.7	9.4	17.1
Antibody 3 IgG2	55.6	Not tested	15.1	15.5	21.9
Antibody 4 IgG2	72.6	26.5	34.8	7.7	17.6
Hu IgG2b	1.5	0.0	1.9	11.9	11.3
433H	83.4	29.4	67.5	66.2	63.7
Cyno IgG2a	0.0	0.1	0.0	0.3	0.8

These data demonstrate that hybridoma supernatants containing antibodies of the present invention bind to endogenously expressed human and cynomolgus CCR8 expressed on primary T-cells.

Example 3: Epitope Binning

To enable epitope mapping of the anti-CCR8 antibodies, human CCR8-binding hybridoma supernatants were tested for binding to five biotinylated N-terminus CCR8 peptides generated from the 1-35 amino acid N-terminal portion of CCR8 (SEQ ID NO: 31). Each of the five peptides was twelve amino acids long with six amino acids overlapping. The amino acid sequences of Peptide 1, Peptide 2, Peptide 3, Peptide 4, and Peptide 5 comprise amino acids 1-12 (SEQ ID NO: 82), 7-18 (SEQ ID NO: 85), 13-24 (SEQ ID NO: 83), 19-30 (SEQ ID NO: 86), and 25-35 (SEQ ID NO: 84) of SEQ ID NO. 31, respectively.

The biotinylated human CCR8 peptides were captured on streptavidin polystyrene beads (Spherotech) in FACS buffer (PBS+2% Fetal Bovine Serum) at a final protein concentration of 50-100 ng/mL and incubated for 30 minutes at room temperature. Beads were washed twice with FACS buffer to remove unbound protein, centrifuged to pellet the beads, and resuspended and pooled together in StabilGuard (SurModics). The pooled biotinylated human CCR8 coated beads were added to hybridoma supernatant samples in a 96-well plate, such that the final antibody concentration was 5.0 μg/mL, and then incubated for one hour at room temperature.

Plates were washed twice with FACS buffer, centrifuged to pellet the beads, and supernatant was removed and resuspended in FACS buffer to remove unbound antibodies. Alexa Fluor 488 goat anti-human or rat IgG (Fcγ fragment specific) secondary antibodies (Jackson ImmunoResearch) made up in FACS buffer at 5.0 μg/mL were added to each well, resuspended with beads and incubated for 15 minutes at room temperature. Plates were washed twice with FACS buffer, centrifuged to pellet the beads, and supernatant was removed and resuspended in FACS buffer to remove unbound secondary antibodies. Samples were then resuspended in FACS buffer and read on either IntelliCyt® iQue Flow Cytometer.

Results are shown in Table 4. Data are represented as a ratio of geometric mean binding to beads coated with specific peptide divided by geometric mean of binding to a bead coated with a negative control peptide (peptide with unrelated sequence). A value above two represents presence of binding.

TABLE 4
Binding of hybridoma supernatants to biotinylated peptides
coated on streptavidin beads as determined by FACS.
	Peptide Antigen Coating: 100 ng/mL
	Peptide	Peptide	Peptide	Peptide	Peptide
Antibody	1	2	3	4	5
Antibody 2 IgG2	0	0	157	1	0
Antibody 1 IgG2	3	0	0	0	1
Antibody 3 IgG2	1	1	83	1	1
Antibody 4 IgG2	1	2	8	2	1
Antibody 5 IgG2	0	0	120	0	0
Antibody 6 IgG2	0	0	154	0	0
433H	1	1	1	1	1
L263G8	1	0	0	1	0

Interestingly, hybridoma supernatants containing Antibody 1 IgG2 bound to the most N-terminal region (1-12), suggesting Antibody 1 IgG2 binds a unique epitope on CCR8, which is thought to contribute to the high affinity and bioactivity of Antibody 1 IgG2.

Example 4: Epitope Clustering

The extracellular domain of human CCR8 comprises three loops and a N-terminal peptide of 35 amino acids. For epitope mapping, the N-terminal peptide of human CCR8 (designated P_1-35 (SEQ ID NO: 31)) was divided into three consecutive segments (designated P_1-12 (SEQ ID NO: 82), P_13-24 (SEQ ID NO: 83), and P_25-35 (SEQ ID NO: 84)). To cover the adjacent N- or C-terminal regions of the consecutive segments, two additional overlapping fragments (designated P_7-18 (SEQ ID NO: 85 and P_19-30 (SEQ ID NO: 86)) were made. At the C-terminal end of the full-length N-terminal peptide and all truncated N-terminal peptides of human CCR8 described above, a V5 tag was fused via a G4S-linker. Following the V5 tag, chicken albumin was fused via a further G4S-linker followed by a FLAG tag, BAP (biotin acceptor protein) for in vivo biotinylation, and H3G, each fused via a SG-linker. All constructs described above were cloned into a pEFDHFR vector and transiently transfected into HEK 293 cells.

HEK 293 cells (1×10⁸) were resuspended in 100 ml FreeStyle expression medium (Gibco 12338-018) and transfected with 4 ml OptiMEM (Gibco 31985-047), 100 μl 293fectin (Invitrogen 12347-019), and 50 μg DNA encoding either the full-length or truncated N-terminal CCR8 constructs according to the manufacturers protocol. Cells were grown in FreeStyle expression medium for 72 hours at 130 rpm in a humidified incubator with 8% CO₂. Cells were centrifuged at 1,500 rpm for 10 minutes and the supernatant was harvested. 10 ml of the supernatant of each of the transfected cells or 9 ml of HEK 293 cells as negative control were 20× concentrated with Amicon Ultra-15 tubes (UFC901008) to 500 μL. For each of the full-length and truncated N-terminal CCR8 constructs, as well as HEK 293 negative control, 18×10⁶ washed streptavidin-beads (Streptavidin Microspheres, 6 μm; Polysciences 24172-1) were resuspended in 500 μL of the concentrated supernatant and incubated slowly shaking for one hour. Beads coupled with the respective antigen or negative control were washed and stored at 4° C. overnight.

To verify expression and binding of the full-length and truncated N-terminal CCR8 constructs to streptavidin-beads, 2×10⁵ beads per staining were incubated with 5 μg/mL of an anti-FLAG antibody (clone M2, Sigma F3165/F1804), 5 μg/mL of an anti-V5 antibody (clone SV5-Pk1; AbD Serotec, MCA 1360), and a 1:100 dilution of PE-labeled anti mouse Fcy secondary antibody (Jackson 115-116-071). Antigen-bound beads were incubated with three different anti-human CCR8 antibodies. Binding of two of the anti-human CCR8 antibodies (clone L263G8; BioLegend, 360602 and clone 433H; BD 747578; 5 μg/ml each) was detected with a 1:100 dilution of a PE-labeled anti mouse Fcy secondary antibody (Jackson 115-116-071). Binding of anti-human CCR8 antibody (polyclonal; Abcam, ab140796) was detected with a 1:50 dilution of PE-labeled anti goat Fcy secondary antibody (Jackson 109-116-098).

Binding of CCR8-binding TCE molecules and scFab-containing CCR8-binding TCE molecules to the full-length and truncated N-terminal CCR8 constructs bound to streptavidin-beads was determined. In the most general sense, a T cell engager (“TCE”) molecule comprises a single chain polypeptide that can bind to two different antigens. The term “TCE molecule” may be used interchangeably with the terms “BiTE® molecule” or “bispecific T-cell engager” molecule. Tested TCE molecules included molecules comprising an scFab that binds CCR8 and an scFv binds CD3 (scFab-containing TCE molecules), and molecules comprising an scFv that binds CCR8 and an scFv that binds CD3. The tested TCE molecules also included an scFc at the C-terminus as a half-life extending (HLE) moiety. The CDRs of Antibody 1 antibodies are the same as the CDRs of TCE1 (TCE1 CDR amino acid sequences comprise SEQ ID NOs 561 to 566). The CDRs of Antibody 2 IgG2 are the same as the CDRs of TCE2 (TCE2 CDR amino acid sequences comprise SEQ ID NOs 567 to 572).

Beads were incubated with 5 μg/mL of the respective TCE molecule. Binding of these CCR8-binding TCE molecules and scFab-containing CCR8-binding TCE molecules was detected using 2 μg/ml of an anti-Histidine-antibody (clone AD1.1.10; AbD Serotec MCA 1396) and a 1:100 dilution of a PE-labeled anti mouse Fcy secondary antibody (Jackson 115-116-071). All antibodies, CCR8-binding TCE molecules, and scFab-containing CCR8-binding TCE molecules were diluted in PBS with 2% FBS and all incubations were performed at 4° C. for 45 minutes (primary antibodies) or for 30 minutes (secondary antibodies). Washes were performed using PBS with 2% FBS, and the final suspension buffer prior to FACS analysis was also PBS with 2% FBS. Antibody and TCE binding was detected using an Intellicyte IQue. Changes in mean fluorescence were analyzed with an Intellicyte IQue and FlowJo. Binding to the various full-length and truncated N-terminal CCR8 constructs was reflected as a positive signal detected by flow cytometry.

Expression and binding of the full-length and the various truncated N-terminal CCR8 constructs to streptavidin-beads were verified by flow cytometry, as shown in Tables 5 and 6.

TABLE 5
Flow Cytometry Binding Analysis of CCR8 Antibodies to
Full-length or Truncated N-terminal Peptides of Human CCR8.
	Peptide or controls
	Beads	HEK
	(control)	(control)	1-35	1-12	7-18	13-24	19-30	25-35
	Median Fluorescence of Sample/Median
Sample	Fluorescence of Negative Control
PBS	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.9
Flag	0.9	0.9	522.0	596.0	588.7	628.1	589.5	582.0
V5 Tag	0.9	0.9	952.6	1091.5	1085.9	1303.2	1016.2	1094.2
anti-CCR8	1.2	0.9	751.2	0.9	0.9	284.8	0.9	0.9
(clone L263G8)
anti-CCR8	1.8	0.9	290.2	0.9	0.9	300.3	0.9	0.9
(clone BV510)
anti-CCR8	0.9	1.0	259.7	0.9	222.6	385.6	0.9	0.9
(polyclonal)

The data in Table 5 demonstrate that anti-human CCR8 antibodies bound the full-length N-terminal peptide of human CCR8 P_1-35, indicating they recognized the N-terminal peptide of human CCR8. None of the antibodies showed binding to either streptavidin-beads alone or to the HEK 293 control. The anti-human CCR8 antibodies (clone L263G8 and clone 433H) showed the same binding pattern, while the polyclonal anti-human CCR8 antibody showed additional binding to the overlapping fragment P_7-18.

TABLE 6
Flow Cvtometry Binding Analysis of CCR8 Antibodies
and scFab-containing CCR8-binding TCE molecules to
Full-length or Truncated N-terminal Peptides of Human CCR8.
	Peptide or controls
	Beads	HEK
	(control)	(control)	1-35	1-12	7-18	13-24	19-30	25-35
	Median Fluorescence of Sample/Median
Construct	Fluorescence of Negative Control
PBS	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
CCR8 TCE1	1.2	1.1	470.8	413.5	1.0	1.1	1.1	1.1
scFab × I2E ×
scFc
CCR8 TCE1	1.1	1.0	381.8	306.2	1.0	1.1	1.1	1.0
scFv × I2E ×
scFc
CCR8 TCE2	1.0	1.0	814.0	1.0	1.0	432.5	1.1	1.0
scFab × I2E ×
scFc
Negative	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1
control

The data in Table 5 demonstrate that CCR8-binding TCE molecules and scFab-containing CCR8-binding TCE molecules bound to the full-length N-terminal CCR8 peptide P_1-35. TCE2 bound to the truncated N-terminal CCR8 peptide P_13-24. Interestingly, TCE1 bound to the truncated N-terminal CCR8 peptide P_1-12, demonstrating that TCE1 binds a unique epitope on CCR8.

Example 5: Antibody Functional Activity

Hybridoma supernatants were tested for blocking of CLL-1 dependent chemotaxis in HUT78 cells (human T lymphocyte cell line that endogenously expresses CCR8). Testing was done in a 96-well transwell plate with 5 μm pore size in complete HUT-78 growth medium. The cells were pre-incubated with purified antibodies for thirty minutes and transferred to the top transwell chambers (total 50 μl volume and 50,000 cells per well).

Recombinant Hu CCL1 (R&D) was prepared at suboptimal concentration of 100 μM and added to the bottom transwell chambers at 100 μl per well. The transwell plates were incubated at 37° C. with 5% CO₂ overnight. The suboptimal concentration of CCL1 was established based on the cells' chemotactic dose response curve and allowed for selection of antibodies with IC₅₀≤100 μM. At the end of incubation, the top chambers were removed and 50 μl/well of CellTiterGlo reagent (Promega) was added to the bottom chambers with migrated cells. After ten minutes of incubation at room temperature, 100 μl of the mixture from the bottom chamber was transferred to the black well clear bottom plates for Luminescence readout (Envision plate reader). Percent inhibition of chemotaxis was calculated using Basal and Max chemotaxis control wells present on each plate. Percent inhibition and IC₅₀ values were calculated using Screener analysis software. The average of three experiments is shown in Table 7.

TABLE 7
Inhibition of CCR8-expressing
HUT78 chemotaxis following
treatment with antibody.
                  Percent
                  Inhibition
Antibody          (IC50 nM)
Antibody 1 IgG1   >690
Antibody 2.2 IgG1 0.076
Antibody 3.0 IgG1 3.7
Antibody 4.0 IgG1 8.4
Antibody 5.0 IgG1 13.6
Antibody 6.0 IgG1 20.1

These data demonstrate that Antibody 1, which binds a unique epitope, does not block chemotactic activity, despite binding CCR8, and is not a neutralizing antibody. These data demonstrate that Antibody 1 does not block ligand binding to CCR8. Similar data were also observed in an experiment testing antibodies in hybridoma supernatant.

Example 6: Antibody-Mediated Cytotoxicity Assay

To determine if anti-CCR8 antibodies can mediate antibody-mediated cytotoxicity (ADCC), a killing assay was developed using HUT78.luc target cells, which were stably transfected with a luciferase reporter gene and express endogenous human CCR8. Primary NK cells with VF phenotype from six different donors were used as effector cells (for data from Table 8a and Table 8b); Primary NK cells with VF phenotype from two different donors were used as effector cells (for data from Table 8c), or Primary NK cells with FF phenotype from three different donors were used with three separate bleeds for one of them as effector cells (for data from Table 8d). NK cells negative selection was done from leukopak using StemCell EasySep Hu NK isolation kit.

Purified antibodies were tested in a range of concentrations, starting at 5 μg/ml (35 nM with 1:10 dilutions). The antibodies were incubated with target and effector cells in a 384-well plate at 5% CO₂ 37° C. in a humidified incubator overnight. The effector to target ratio was 5:1 with 20,000 target cells per well in total 50 μl per well. At the end of the incubation, 30 μl per well of BioGlo (Tables 8a and 8b) or SteadyGlo (Table 8c) reagent was added, mixed, and luminescence was read on an Envision plate reader. Luminescence signal was proportional to the amount of viable target cells. The percent ADCC was calculated as (1−(luminescence signal in the presence of Ab/luminescence signal for T+E cells alone))×100. The EC₅₀ was calculated using GraphPad Prism 7. Results are shown in Tables 8a, 8b, 8c, and 8d (N.D. means not determined).

TABLE 8a
Anti-CCR8 Antibody mediated ADCC
of CCR8-expressing HUT78 cells (EC50 pM).
Percent Non-Viable cells (EC50 pM)
Antibody	Donor 1	Donor 2	Donor 3
Antibody 1 IgG1	<0.256	5.582	1.3
Antibody 1.1 IgG1	<0.256	8.129	2.2
Antibody 2.1 IgG1	<0.256	13.3	1
Antibody 2.2 IgG1	<0.256	6.035	1.8
Antibody 3.0 IgG1	<0.256	15.47	N.D.
Antibody 4.0 IgG1	<0.256	217.9	N.D.
Antibody 5.0 IgG1	<0.256	167	N.D.
Antibody 6.0 IgG1	2	37.39	N.D.

TABLE 8b
Anti-CCR8 Antibody mediated ADCC
of CCR8-expressing HUT78 cells (EC50 pM).
Percent Non-Viable cells (EC50 pM)
	Antibody	Donor 4	Donor 5	Donor 6
	Antibody 5.1 IgG1	3.684	0.8653	4.891
	Antibody 5.2 IgG1	6.198	1.008	6.112
	Antibody 5.3 IgG1	3.342	0.6424	3.479
	Antibody 5.4 IgG1	3.429	0.8886	4.615
	Antibody 5.5 IgG1	4.891	0.837	3.771
	Antibody 6.1 IgG1	4.518	1.047	3.617
	Antibody 6.2 IgG1	4.119	2.04	5.136

TABLE 8c
Anti-CCR8 Antibody mediated ADCC of
CCR8-expressing HUT78 cells (EC50 pM).
Percent Non-Viable cells (EC50 pM)
Antibody            Donor 7
HC SEQ ID NO: 1239; 0.52
LC SEQ ID NO: 1130
HC SEQ ID NO: 1240; 0.28
LC SEQ ID NO: 1132
HC SEQ ID NO: 1238; 0.48
LC SEQ ID NO: 1128
HC SEQ ID NO: 573;  1.14
LC SEQ ID NO: 16

TABLE 8d
Anti-CCR8 Antibody mediated ADCC of
CCR8-expressing HUT78 cells (EC50 pM).
Percent Non-Viable cells (EC50 pM)
Antibody	Donor 8	Donor 9
huCCR8(32360LC:K38R)_huIgG1z(mAb)	3.0	2.7
(HC SEQ ID NO: 1237; LC SEQ ID NO: 1126

These data demonstrate that antibodies of the present invention exhibit ADCC based killing via CCR8 receptor expressed on the surface of HUT78 cells.

Example 7: Affinity of Anti-CCR8 Antibodies

Hybridoma supernatants containing Antibody 1 IgG2, Antibody 2 IgG2, or Antibody 4 IgG2 were evaluated by a Kinetic Exclusion Assay (KinExA) for their affinity to native cynomolgus CCR8 transiently expressed on 293T cells or to native human CCR8 expressed on HUT78 cells.

Cynomolgus CCR8: 293T Cells

KinExA was performed in which the K_d was determined from the concentration of free antibody that remains in solution after equilibrium has been established between the antibody and the cell-surface-expressed antigen. KinExA provides a more sensitive determination of binding affinity for the native form of CCR8 compared to soluble CCR8. The Kinetic Exclusion Assay method was performed as essentially described in Rathanaswami et al. Anal. Biochem: 373(1): 52-60 (2008).

Briefly, equilibrium sets were set up for each antibody using either human CCR8-expressing HUT78 cells or cynomolgus monkey CCR8-expressing 293T cells. The cells were counted using a hemocytometer. The HUT78 cells were titrated and incubated with two different constant antibody concentrations, one at 48 pM and the other at 2 nM, in HUT media (RPMI 1640, 10% FBS, 10 mM HEPES, 2 mM L-Glut, 1 mM Sod. Pyr, 0.1 mM NEAA, 50 uM 2-ME) with 0.05% Sodium Azide. For the high [Ab] equilibrium set, HUT78 cells were titrated from 62.5 million per milliliter concentration 1:2 for 10 points in eppendorf tubes and equilibrated with 2 nM antibody in a total volume of 400 μl. For the low [Ab] equilibrium set, HUT78 cells were titrated from 3.89 million per milliliter concentration, 1:2 for 10 points in 50 ml Fulcon tubes and equilibrated with 48 pM antibody in a total volume of 15.5 mL.

The cyno CCR8-expressing 293T cells were titrated and incubated with two different constant antibody concentrations, one at 118 pM and the other at 5 nM, in 293T media (Freestyle expression 293T media with 2% FBS and 50 μg/ml G418) with 0.05% Sodium Azide. For the high [Ab] equilibrium set, 293T cells were titrated from 25 million per milliliter concentration 1:3 for 10 points in eppendorf tubes and equilibrated with 5 nM antibody in a total volume of 200 μl. For the low [Ab] equilibrium set, 293T cells were titrated from 0.98 million per milliliter concentration 1:3 for 10 points in 15 ml Fulcon tubes and equilibrated with 118 pM antibody in a total volume of 10.2 mL.

For each equilibrium set, reference point controls included a sample with cell media only and a sample without cells. The equilibrium sets were incubated for 24 hours at room temperature, with shaking. After 24 hours of incubation, the supernatants were separated from the cell pellets via centrifugation at 500×g for five minutes. The supernatants of both high [Ab] and low [Ab] equilibrium sets were then run through a KinExA 3200 machine.

Each equilibrium sample set was read in duplicate on the KinExA machine. For low [Ab] equilibrium samples, 6.8 mL and 4.6 mL of each sample were run in duplicate, respectively, for human and cyno CCR8 equilibrium experiments. For high [Ab] equilibrium samples 16 μL and 75 μL of each sample were run in duplicate, respectively for human and cyno CCR8 equilibrium experiments.

PMMA (Polymethyl Methacrylate Particles) beads were coated with goat anti-human Fc Ab or Goat anti-hIgG (H+L) Ab and subsequently blocked with a blocking solution (1×PBS pH7.4+10 mg/mL BSA+0.05% Sodium Azide). For each equilibrium sample the free [Ab] was detected by running the equilibrium samples through the coated beads followed by a quick wash with the running buffer (1×PBS pH7.4+1% BSA+0.05% Sodium Azide). The secondary detection antibody (goat anti-huIgG (H+L) Alexa 647) was run through the flow cell at 680 ng/mL and 500 μL per run. The KinExA voltage output signal was used in KinExA software to calculate the K_d. From the plots at two different initial total [Ab] concentrations the K_d was obtained from curve fitting using n-curve analysis in KinExA Pro software version 4.3.11 (Sapidyne Instruments Inc.). The 95% confidence interval was given as K_d low and K_d high. Results are shown in Table 9.

TABLE 9
Determination of Kd of hybridoma supernatants
containing CCR8 antibodies for
cell-membrane-expressed cynomolgus CCR8.
		95% confidence interval
Antibody	Kd	Kd Low	Kd High
Antibody 1 IgG2	229	pM	73.2	pM	552.9	pM
Antibody 2 IgG2	>50	nM	<1.85	nM	>500	nM
Antibody 4 IgG2	>50	nM	<2	pM	>179	nM

Native Human CCR8 Expressed on HUT78 Cells

Cells in media were serially diluted and incubated with 48 pM or 2 nM active binding site concentration of antibody in media in the presence of 0.05% NaN3, and allowed to equilibrate. The free mAb left in the supernatant was measured as described above. The percent free antibody was plotted against the cell concentration. N-curve analysis was performed using the equilibrium; a whole cell method was performed to determine optimal values for K_d and the antigen expression level. The 95% confidence intervals were determined by the software by changing iteratively the optimized value for Kd or antigen expression level while keeping other parameters at their optimal values.

The affinities of tested antibodies to endogenous human CCR8 expressed on HUT78 cells is shown in Table 10.

TABLE 10
Affinity of hybridoma supernatant containing antibodies
to endogenous human CCR8 expressed on HUT78 cells.
		95% confidence interval
Antibody	Kd	Kd Low	Kd High
Antibody 1 IgG2	216	pM	112.5	pM	420.1	pM
Antibody 2 IgG2	>5	nM	816	pM	>50	nM
Antibody 4 IgG2	378	pM	275.5	pM	540.6	pM

IgG2 antibodies were further engineered to increase affinity to human and/or cynomolgus monkey CCR8.

Example 8: Cynomolgus CCR8 T4R Variant: CHO Cells

CHO cells expressing cynomolgus monkey CCR8 (comprising threonine at position four; SEQ ID NO: 22) or cynomolgus monkey CCR8 (T4R; comprising arginine at position four; SEQ ID NO: 556) were incubated with decreasing concentrations of anti-CCR8 antibodies (0.005-100 nM, step 1:3, 10 steps) for 30 minutes at 4° C. Bound anti-CCR8 antibody molecules were detected with Alexa Fluor 647 conjugated Goat anti-Human IgG (H+L). Cells were subsequently stained with Zombie Violet viability dye, fixed with 4% PFA on ice, and detected by fluorescence cytometry. Equilibrium dissociation constant (K_d) values were calculated by non-linear regression with the one site specific binding evaluation tool of the GraphPad Prism software. The affinities of the anti-CCR8 antibodies are shown in Table 11. “N.D.” means not detectable.

TABLE 11
Affinity of anti-CCR8 antibodies to cell-membrane-
expressed cynomolgus CCR8 variant T4R.
	Cell based affinity	Cell based
	cyno CCR8	affinity cy CCR8
Antibody	Kd [nM]	(T4R) Kd [nM]
HuIgG1 Negative	N.D.	N.D.
Control
Antibody 1 IgG1	0.635	N.D.
Antibody 1.1 IgG1	0.172	N.D.
Antibody 2.2 IgG1	0.399	0.989

These data demonstrate that binding of Antibody 1 antibodies to cynomolgus CCR8 was reduced with the T4R mutation while Antibody 2 was unaffected, consistent with their respective epitope binning and clustering determined above. These data demonstrate that antibodies that bind a unique epitope as described herein bind CCR8 at threonine at position four.

Example 9: IgG1 Afucosylated Antibodies

Afucosylated anti-CCR8 IgG1 antibodies were generated. Examples of antibody amino acid sequences of afucosylated antibodies are SEQ ID NOs.: 346 to 555, SEQ ID NOs: 1125-1160, and SEQ ID NOs: 1238-1254. SEQ ID NOs 573 to 592 and SEQ ID NOs: 1237-1254 correspond to an antibody HCs without the C-terminal lysine. Antibodies were designated according to the parental molecule. For example, Antibody 5.1, Antibody 5.2, Antibody 5.3, Antibody 5.4, Antibody 5.5, Antibody 5.6, Antibody 5.7, Antibody 5.8, and Antibody 5.9 all refer to antibodies engineered from Antibody 5. “Antibody 1 IgG2” and “Antibody 2 IgG2” refer to an IgG2 antibody, whereas “Antibody 1 IgG1” and “Antibody 2 IgG1” refer to an IgG1 afucosylated antibody. In addition, and for example, Antibody 2 IgG1 molecules were further engineered from Antibody 2 IgG2 antibodies, as described in the sequences table (Table 16), to obtain Antibody 2.1 and Antibody 2.2 IgG1 afucosylated antibodies. Antibody 2.2 IgG1, for example, comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, HCVR, LCVR, HC, and LC amino acid sequences as set out in SEQ ID NOs. 376-385, respectively.

Engineered molecules may demonstrate desirable properties, such as, but not limited to, increased affinity to human and/or cynomolgus monkey. Sites of engineering are described in the sequence table (Table 19).

The Examples described herein demonstrate the activity of afucosylated anti-CCR8 antibodies, for example ADCC activity (Example 16), in vivo studies demonstrating anti-tumor activity (Example 11) and increased survival (Example 12).

Example 10: Treg Depleting Combination Therapy

Efficacy of administration of a bispecific T-cell engager molecule, PD-1 antagonist antibody, 4-1BB agonist antibody, and a Treg depleting antibody was determined. Mice genetically engineered to express a humanized CD3ε molecule at the surface of their T cells were implanted subcutaneously with the KPC-M5 syngeneic tumor cell line with an inoculum consisting of 10⁵ KPC-M5 cancer cells in 50 μl of PBS mixed with 50 μl of Matrigel. When tumors reached a volume of 50-100 mm³, mice were injected with one or more of a bispecific T-cell engager molecule (a bispecific molecule that binds CD3 and a target antigen), PD-1 antagonist antibody, 4-1BB agonist antibody, and a Treg depleting antibody, and tumor volume was measured over time. Depending on the bispecific T-cell engager molecule administered, the bispecific T-cell engager molecule was administered at doses ranging from 15 to 5,000 μg/kg.

Tumor-bearing mice were injected once weekly with an anti-mouse CLDN18.2 BiTE® molecule via intravenous administration at a dose of 150 μg/kg. Mice were co-injected via intravenous administration every three days with an anti-mouse PD-1 mIgG1 antagonist antibody at a dose of 100 μg per mouse, an agonist antibody to the 4-1BB co-stimulatory receptor (anti-mouse 41BB rIgG1 (Clone LOB12.3, BioXcell)) at a dose of 150 μg per mouse, and/or with a Treg-depleting antibody (mIgG1) at a dose of 300 μg per mouse. Tumor volume was measured on days 7, 10, 14, 17, and 20 post-implantation.

The data in FIG. 1 demonstrate that while minimal activity was observed with combination of anti-CTLA4 with 4-1BB agonist+anti-PD-1 or CLDN18.2 BiTE® molecule alone, the quadruple combination of CLDN18.2 BiTE® molecule+4-1BB agonist+anti-PD-1+anti-CTLA4 demonstrated robust efficacy, similar to that observed with CD4⁺ T cell depletion. Notably, this anti-tumor effect was associated with a pronounced increase in the intra-tumoral CD8⁺ T cell:Treg ratio. Taken together, these data demonstrate the selective activity and dependence of bispecific T-cell engager molecules on CD8⁺ T cells and suggest context dependent inhibitory roles for CD4⁺ T cells on bispecific T-cell engager molecule-mediated anti-tumor efficacy. The results also suggest a potential dominant role for Tregs in suppressing the activity bispecific T-cell engager+anti-4-1BB+anti-PD-1 combination immunotherapy.

Example 11: CCR8 Depleting Antibody is Efficacious in the MC38 In Vivo Tumor Model

Anti-tumor activity of afucosylated anti-CCR8 mIgG2a in the MC38 syngeneic tumor model was determined. MC38 tumor cells were implanted subcutaneously in the right flank of female hCD3eKI animals on study day 0. On day 10, tumors were assigned to different treatment groups (n=10/group) with an average tumor volume of 99.93 mm³. Animals were dosed intra-peritoneally with 10 mg/kg of either control isotype mIgG2a or anti-CCR8 afucosylated mIgG2a on study days 11, 14, 17 and 20 (Q3D×4). The anti-CCR8 afucosylated mIgG2a antibody comprises LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3, LCVR, HCVR, LC, and HC amino acid sequences of SEQ ID NOs 637 through 646, respectively.

Tumor volume was measured twice per week. Statistical analysis to evaluate effect of treatment on tumor size over time of anti-CCR8 antibody relative to isotype control was performed using Linear Mixed Effects (LME) model with Dunnett's post-hoc analysis. **** indicates p<0.0001.

Individual tumor growth for the treatment groups is depicted as spider plots in FIGS. 2C and 2B. FIG. 2A demonstrates the mean tumor volume+/−SEM for each group until the last timepoint (day 24). Mice treated with the anti-CCR8 afucosylated mIgG2a antibody showed a statistically reduced tumor volume by day 24 compared to isotype control treated animals. There was one complete responder, as shown in FIG. 2B. This complete responder animal was assessed until day 48, at which time there was no measurable tumor. Animals with no measurable tumors defined as Complete Responders (CRs) were assessed until day 48. These data demonstrate that MC38 tumor-bearing animals showed a significant reduction in tumor volume when treated with an anti-CCR8 afucosylated mIgG2a antibody (66.44% TGI, ****p<0.0001) compared to isotype control.

Example 12: CCR8 Depleting Antibody Treatment Extends Survival In Vivo

MC38 tumor cells were implanted subcutaneously in the right flank of female hCD3eKI animals on study day 0. On day 10, tumors were assigned to different treatment groups (n=10/group) with an average tumor volume of 99.93 mm³. Animals were dosed intra-peritoneally with 10 mg/kg of either isotype control mIgG2a or anti-CCR8 afucosylated mIgG2a antibody on study days 11, 14, 17 and 20 (Q3D×4). All animals were assessed until their tumors reached 800 mm³ or according to IACUC standards of animal welfare. Statistical analysis was performed using the Log-rank (Mantel-Cox) test comparing anti-CCR8 afucosylated mIgG2a antibody (treatment Grp2) to isotype control mIgG2a (control Grp1). **** indicates p<0.0001.

Survival data is shown in FIG. 3. The median survival for isotype control mIgG2a treated animals was 24 days, whereas the median survival for anti-CCR8 afucosylated mIgG2a antibody treated animals was 27 days (****p<0.0001). These data demonstrate that MC38 tumor-bearing animals have increased survival when treated with an anti-CCR8 afucosylated mIgG2a antibody as compared to animals treated with an isotype control antibody.

Example 13: Treg Depletion with CCR8 mIgG2a Antibody Leads to Enhanced CD8+/Treg Ratio in Tumors

MC38 tumor bearing animals were treated with a single 10 mg/kg dose of either control isotype mIgG2a or anti-CCR8 afucosylated mIgG2a intra-peritoneally on study day eleven. PD evaluation was performed at 48 hours post treatment (day 13). Tumor weights were collected during harvest for the different groups and used for normalization to determine absolute cell counts in tumors. Single cell suspensions of tumor, draining lymph node (DLN), and spleen were prepared for flow cytometry analysis of T cell proportions and phenotypes.

Total T cells were gated using TCRβ+Thy1.2+ staining within the Live/CD45+ fraction. Percentage and absolute numbers of Treg cells depicted in FIG. 4A were assessed within the CD4+ T cell compartment using both Foxp3+ and CD25+Foxp3+ gating. CD8+ T cells were gated on total T cells and CD8/Treg ratios in tumor were calculated as depicted in FIG. 4B. Each dot represents data obtained from an individual mouse. Statistical analysis was performed using Unpaired T-test (two-tailed) comparing treatment to control group (* p<0.05, ** p<0.01).

These data demonstrate a reduction in percent Tregs following a single dose of anti-CCR8 afucosylated antibody, as assessed using both Foxp3+ and CD25+Foxp3+ gating schemes (FIGS. 4A and 4B). Importantly, anti-CCR8 depleting antibody treatment resulted in significantly increased CD8+/Treg ratios in tumors (FIGS. 4C and 4D), thereby driving enhanced anti-tumor immunity.

Example 14: CCR8-Binding scFvs Screened by Phage Display

A preferred type of an amino acid substitutional variation of the CCR8-binding molecules described herein involves substituting one or more CDR residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. One way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several CDR sides (e.g., 6-7 sides) were mutated to generate all possible amino acid substitutions at each side. The antibody variants thus generated were displayed in a monovalent fashion from filamentous phage particles as fusions to, e.g., the gene III product of M13 packaged within each particle. The phage-displayed variants were then screened for their biological activity (e.g., binding affinity) as disclosed herein. In order to identify candidate CDR sides for modification, alanine scanning mutagenesis was performed to identify CDR residues contributing significantly to antigen binding.

Once such variants were generated, the panel of variants was subjected to screening as described herein and antibodies with superior properties in one or more relevant assays were selected for further development. Phage display is described, for example, in Ladner et al., U.S. Pat. No. 5,223,409; Smith (1985) Science 228:1315-1317, Clackson et al., Nature, 352: 624-628 (1991) and Marks et al., J. Mol. Biol., 222: 581-597 (1991).

Anti-CCR8 scFvs that bind in the 1-12 amino acid epitope (amino acid sequence given by SEQ ID NO: 82) were generated and screened for epitope binding by phage display essentially as described above. Heavy and light chain amino acid sequences of scFvs that bind CCR8 in the 1-12 amino acid epitope cluster are shown in Table 12.

TABLE 12
HCVR and LCVR amino acid
SEQ ID NOs of anti-CCR8 scFvs.
	HCVR Amino	LCVR
	Acid SEQ	Amino Acid
scFv Molecule	ID NO	SEQ ID NO
MPK20298-A4_SCFV huCCR8	953	954
MPK20299-D2_SCFV huCCR8	955	956
MPK20299-F11_SCFV huCCR8	957	958
MPK20298-H6_SCFV huCCR8	959	960
MPK20297-A4_SCFV huCCR8	961	962
MPK20299-H8_SCFV huCCR8	963	964
MPK20300-C11_SCFV huCCR8	965	966
MPK20298-B1_SCFV huCCR8	967	968
MPK20297-E5_SCFV huCCR8	969	970
MPK20299-A3_SCFV huCCR8	971	972
MPK20297-B4_SCFV huCCR8	973	974
MPK20298-F6_SCFV huCCR8	975	976
MPK20299-H3_SCFV huCCR8	977	978
MPK20298-B9_SCFV huCCR8	979	980
MPK20299-E2_SCFV huCCR8	981	982
MPK20299-D6_SCFV huCCR8	983	984
MPK20299-A4_SCFV huCCR8	985	986
MPK20300-G5_SCFV huCCR8	987	988
MPK20299-C3_SCFV huCCR8	989	990
MPK20299-B7_SCFV huCCR8	991	992
MPK20299-A5_SCFV huCCR8	993	994
MPK20299-D1_SCFV huCCR8	995	996
MPK20299-C5_SCFV huCCR8	997	998
MPK20299-B5_SCFV huCCR8	999	1000
MPK20299-G9_SCFV huCCR8	1001	1002
MPK20299-G5_SCFV huCCR8	1003	1004
MPK20298-C10_SCFV huCCR8	1005	1006
MPK20298-B5_SCFV huCCR8	1007	1008
MPK20299-F2_SCFV huCCR8	1009	1010
MPK20298-D4_SCFV huCCR8	1011	1012
MPK20297-F5_SCFV huCCR8	1013	1014
MPK20299-D9_SCFV huCCR8	1015	1016

The anti-CCR8 scFv MPK20299-A4 was further engineered and converted into afucosylated anti-CCR8 antibodies to generate additional anti-CCR8 antibodies that bind 1-12.

Example 15: Affinity of CCR8-Binding Antibodies to CCR8 Peptide-Nanobody Complexes

Binding affinities (K_D equilibrium dissociation constant) and rate constants (k_a association rate constant, k_d dissociation rate constant) of an Antibody 1 Fab and CCR8-binding monoclonal antibodies (mAbs) of the present invention to a CCR8 1-12 epitope (SEQ ID NO: 82)-nanobody (Nb) fusion protein were measured using an OCTET® Biolayer Interferometry system (Sartorius A G, Göttingen, Germany). The CCR8-nanobody fusion proteins were expressed in human cells. For Fab binding, biotinylated CCR8 peptide-Nb fusions were captured on streptavidin SAX biosensors to loading levels between 2 and 4 nm and then incubated with a dilution series of the soluble Fab (top 100 nM, 6-point, 1:3 serial dilution) for 300 seconds followed by 500 seconds in buffer for dissociation. For mAb binding, mAbs were captured on an anti-huIgG Fc capture biosensor to 1 to 2 nm loading level and then incubated with a dilution series of non-biotinylated CCR8 peptide-Nb fusions (top 100 nM, 6-point, 1:3 serial dilution) for 300 seconds followed by 500 seconds in buffer for dissociation.

The OCTET® system acquires data over time (seconds) using a mechanism called Biolayer Interferometry; as proteins bind to biosensor tips, a sensitive binding signal in nm is measured by the instrument. All fiber optic tips were used once and then discarded, i.e., no regeneration. OCTET® buffer baselines, dissociation steps, and protein dilutions were made with OCTET® buffer (10 mM TRIS pH 7.5, 150 mM NaCl, 1 mM CaCl₂), 0.13% (v/v) Triton X-100 and 0.10 mg/mL BSA).

Raw data was processed with GeneData Screener v18 SPR package which uses the same data processing as the OCTET® instrument Data Analysis software (subtract average of two reference wells per column; Align Y-axis to baseline; Interstep correction align to dissociation; and Savitzky-Golay filtering). Each Fab or mAb interaction was grouped into its own sensorgram and globally fit with a 1:1 binding model to determine the association rate constant (k_a; units M⁻sec⁻¹) and the dissociation rate constant (k_d; units sec⁻¹). The equilibrium dissociation constant (K_D; units nanomolar (nM)=1×10⁻⁹ mol/L) was then calculated as a ratio of k_d/k_a.

Results are shown in Table 13a and 13b. Errors in the 1:1 model fit to the processed data were reported as standard errors (i.e., k_a error was the standard error of the association rate constant measurement while the k_d error was the standard error of the dissociation rate constant measurement). The standard error of the equilibrium dissociation constant (ΔK_D) is calculated from the statistical propagation of error as defined for the ratio of two measured variables and their standard errors (k_a, Δk_a, k_d, Δk_d).

TABLE 13a
Binding Affinities and Rate Constants of CCR8-Binding
Antibodies to CCR8 Epitope-Nanobody Complexes (1-12).
	huCCR8 (1-12)-Nb
	ka	ka	kd	kd	KD	KD	isotype
CCR8 Fab & mAbs	(M−1s−1)	error	(s−1)	error	(nM)	Error	Nb
Fab	5.84E+05	6.19E+03	1.32E−02	9.20E−05	22.6	0.2	no
(HCVR SEQ ID NO: 13;							binding
LCVR SEQ ID NO: 14)
huCCR8_44379	1.42E+05	1.05E+03	1.34E−03	1.15E−05	9.5	0.1	no
(VH: D61A_D72A,							binding
VL: N67Q_M99E_
W109F_S111A)_
huIgG1z (mAb)
(HC SEQ ID NO: 1239;
LC SEQ ID NO: 1130)
huCCR8_44379	1.32E+05	1.40E+03	1.07E−03	1.60E−05	8.1	0.2	no
(VH: D61S, VL:							binding
N67Q_M99G_
W109F_S111A)_
huIgG1z (mAb)
(HC SEQ ID NO: 1240;
LC SEQ ID NO: 1132)
huCCR8_44379	1.22E+05	1.11E+03	1.10E−03	1.33E−05	9.0	0.1	no
(VH: D72S, VL:							binding
N67A_S68A_M99G_
W109F_S111A)_
huIgG1z (mAb)
(HC SEQ ID NO: 1238;
LC SEQ ID NO: 1128)
huCCR8	3.97E+05	1.42E+04	2.40E−02	5.59E−04	60.6	2.1	no
(32360LC: K38R)_							binding
huIg1z (mAb)
(HC SEQ ID NO: 1237;
LC SEQ ID NO: 1126

TABLE 13b
Binding Affinities and Rate Constants of CCR8-Binding
Antibodies to CCR8 Epitope-Nanobody Complexes (1-25).
	huCCR8 (1-25)[C25S]-Nb
	ka	ka	kd	kd	KD	KD	isotype
CCR8 Fab & mAbs	(M−1s−1)	error	(s−1)	error	(nM)	Error	Nb
Fab	6.06E+05	5.75E+03	1.06E−02	6.36E−05	17.4	0.2	no
(HCVR SEQ ID NO: 13;							binding
LCVR SEQ ID NO: 14)
huCCR8_44379	1.46E+05	1.32E+03	1.14E−03	1.39E−05	7.8	0.1	no
(VH: D61A_D72A,							binding
VL: N67Q_M99E_
W109F_S111A)_
huIgG1z (mAb)
(HC SEQ ID NO: 1239;
LC SEQ ID NO: 1130)
huCCR8_44379	1.10E+05	1.18E+03	7.98E−04	1.53E−05	7.2	0.2	no
(VH: D61S,							binding
VL: N67Q_M99G_
W109F_S111A)_
huIgG1z (mAb)
(HC SEQ ID NO: 1240;
LC SEQ ID NO: 1132)
huCCR8_44379	9.93E+04	9.76E+02	9.75E−04	1.37E−05	9.8	0.2	no
(VH: D72S, VL:							binding
N67A_S68A_M99G_
W109F_S111A)_
huIgGlz (mAb)
(HC SEQ ID NO: 1238;
LC SEQ ID NO: 1128)
huCCR8	Biphasic Binding	no
(32360LC: K38R)_		binding
huIgGlz (mAb)
(HC SEQ ID NO: 1237;
LC SEQ ID NO: 1126

These data demonstrate that CCR8-binding antibodies of the present invention bind to N-terminal peptides of human CCR8 containing amino acids 1-12 (SEQ ID NO: 82) and amino acids 1-25 (residues 1-25 of SEQ ID NO: 31), expressed in human cells, with high affinity.

Example 16: ADCC in the Presence or Absence of Ligand

To determine ADCC with anti-CCR8 antibodies that either block ligand binding or do not block ligand binding, flow cytometry was utilized to measure live and dead cells in the presence of varying concentrations of ligand and anti-CCR8 antibody. In an experiment (“Study A”), 100 pM of an afucosylated anti-CCR8 antibody of the present invention which binds a unique epitope and does not block ligand binding (antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 amino acid sequences of SEQ ID NOs 1-6, respectively; “Non-blocking mAb”) or three anti-CCR8 antibodies that block ligand binding (“Blocking mAb”) were incubated with HUT78 cells that express CCR8, NK cell line NK92MI expressing CD16 (effector cells), and increasing concentrations of CCL1 (ligand) from 0.128 pM to 50 nM. In another experiment (“Study B”), similar procedures were followed as described above except increasing concentrations of CCL1 was first added to the HUT78 cells for thirty minutes, followed by addition of 100 pM antibody and effector cells. IC₅₀ values and bottom % killing values are reported in Table 14.

Following procedures essentially as described, the following data were obtained.

TABLE 14
ADCC activity of blocking and non-blocking
anti-CCR8 antibodies in the presence of CCL1.
	Study A	Study A	Study B	Study B
	IC50 (CCL1)	Bottom %	IC50 (CCL1)	Bottom %
Antibody	nM	Killing	nM	Killing
Non-blocking mAb	0.34	19.6	1.0	12.9
Blocking mAb 1	3.0	−2.6	2.3	−8.7
Blocking mAb 2	1.0	4.3	1.1	7.0
Blocking mAb 3	2.4	3.6	2.8	2.8
huIgG1 control	N/A	−1.5	N/A	1.3

These data demonstrate in both Study A and Study B, in the presence of ligand, the anti-CCR8 antibody of the present invention that binds a unique epitope and does not block ligand binding had high potency and also demonstrated the highest Bottom % Killing, which measures the ADCC ability at high concentrations of CCL1.

Example 17: Anti-CCR8 and BiTE® Molecule Combination In Vivo

CCR8 depleting mouse surrogate antibody was evaluated in combination with surrogate TAA-BiTE molecule for its ability to enhance anti-tumor activity in the B16F10 tumor model. The B16F10 tumor model was chosen for this combination efficacy study since this model is refractory to checkpoint inhibitors (anti-PD1 and anti-CTLA4), and therefore can be used to assess meaningful differences with the combination therapy of BiTE molecule and anti-CCR8 mAb in this Example.

B16F10 tumor cells were engineered to express the BiTE molecule tumor-associated antigen (TAA) and implanted on the immunocompetent humanized CD3e KI strain that enables evaluation of TAA-BiTE molecules with an I2C anti-CD3 scFv recognizing human CD3e. B16F10-TAA tumor-bearing animals were treated with either single agents of CCR8 depleting mIgG2a antibody, TAA-BiTE molecule, or a combination of CCR8 depleting mIgG2a antibody and TAA-BiTE molecule.

B16F10-TAA expressing tumor cells were implanted subcutaneously in an immunocompetent mouse model expressing a humanized CD3e chain (huCD3e KI) on day 0. Tumors were assigned on day 12 into different treatment groups (n=10/group) with an average tumor volume of 108.37 mm3. Animals were dosed retro-orbitally with 50 μg/kg of either control BiTE molecule or TAA-BiTE on study days 13 and 20 (QWk×2). Animals also received 10 mg/kg of either control isotype mIgG2a or a CCR8 afucosylated mIgG2a antibody dosed intra-peritoneally on study days 13, 16, and 19 (Q3D×3).

Tumor volume was measured twice per week. Individual tumor growth for the treatment groups is depicted as spider plots in FIGS. 5A-5D. Animals with no measurable tumors defined as Complete Responders (CRs) have been assessed until day 48.

As shown in FIGS. 5A-5D, monotherapy of CCR8 mIgG2a (Grp3; FIG. 5C) was not efficacious in this cold tumor model refractory to anti-CTLA4. Monotherapy with TAA-BiTE (Grp2; FIG. 5B) led to tumor growth delay and 1 tumor-free/complete responder (CR) at end of the study. Interestingly, the combination of CCR8 mIgG2a and TAA-BiTE (Grp4; FIG. 5D) led to 7 CRs, demonstrating the significant benefit of combining CCR8 depleting mAbs with BiTE molecules to boost anti-tumor immunity.

SEQUENCES
Antibody 1 IgG2 HCDR1 (SEQ ID NO: 1)
NARMG
Antibody 1 IgG2 HCDR2 (SEQ ID NO: 2)
RIKSKTEGGTRDYAAPVKG
Antibody 1 IgG2 HCDR3 (SEQ ID NO: 3)
YSGV
Antibody 1 IgG2 LCDR1 (SEQ ID NO: 4)
KSSQSVLYSSNNKNYLA
Antibody 1 IgG2 LCDR2 (SEQ ID NO: 5)
WASTRES
Antibody 1 IgG2 LCDR3 (SEQ ID NO: 6)
QQYYSIPIT
Antibody 2 IgG2 HCDR1 (SEQ ID NO: 7)
NYGMH
Antibody 2 IgG2 HCDR2 (SEQ ID NO: 8)
VISYDGSNKFYADSVKG
Antibody 2 IgG2 HCDR3 (SEQ ID NO: 9)
AGGIGRFDY
Antibody 2 IgG2 LCDR1 (SEQ ID NO: 10)
KYSQSLLHSDGKTYLF
Antibody 2 IgG2 LCDR2 (SEQ ID NO: 11)
EVSNRFS
Antibody 2 IgG2 LCDR3 (SEQ ID NO: 12)
MQTLKLPLT
Antibody 1 IgG2 HCVR (SEQ ID NO: 13)
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARMGWVRQAPGKGLEWVGRIKSKTE
GGTRDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYSGVWGQGTMV
TVSS
Antibody 1 IgG2 LCVR (SEQ ID NO: 14)
DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYHQKPGQSPKLLISWA
STRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPITFGGGTKVEIKR
Antibody 1 IgG2 HC (SEQ ID NO: 15)
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARMGWVRQAPGKGLEWVGRIKSKTE
GGTRDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYSGVWGQGTMV
TVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
AVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPA
PPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGS
FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Antibody 1 IgG2 LC (SEQ ID NO: 16)
DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYHQKPGQSPKLLISWA
STRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPITFGGGTKVEIKRTV
AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Antibody 2 IgG2 HCVR (SEQ ID NO: 17)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISYDG
SNKFYADSVKGRFTISRDNSKKTLYLQMSSLRVEDTAVYYCARAGGIGRFDYWGQG
TLVTVSS
Antibody 2 IgG2 LCVR (SEQ ID NO: 18)
DFVMTQTPLSLSVTPGQPASISCKYSQSLLHSDGKTYLFWYLQKPGQPPHLLIYEVSN
RFSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQTLKLPLTFGGGTKVEIN
Antibody 2 IgG2 HC (SEQ ID NO: 19)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISYDG
SNKFYADSVKGRFTISRDNSKKTLYLQMSSLRVEDTAVYYCARAGGIGRFDYWGQG
TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPP
CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN
AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQP
REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Antibody 2 IgG2 LC (SEQ ID NO: 20)
DFVMTQTPLSLSVTPGQPASISCKYSQSLLHSDGKTYLFWYLQKPGQPPHLLIYEVSN
RFSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQTLKLPLTFGGGTKVEINRTVA
APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
hCCR8 (SEQ ID NO: 21)
MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGKLLLAVFYCLLFVFSLLGNSLVIL
VLVVCKKLRSITDVYLLNLALSDLLFVFSFPFQTYYLLDQWVFGTVMCKVVSGFYYI
GFYSSMFFITLMSVDRYLAVVHAVYALKVRTIRMGTTLCLAVWLTAIMATIPLLVFY
QVASEDGVLQCYSFYNQQTLKWKIFTNFKMNILGLLIPFTIFMFCYIKILHQLKRCQN
HNKTKAIRLVLIVVIASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLTYATHVTEIISF
THCCVNPVIYAFVGEKFKKHLSEIFQKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSS
SVDYIL
Cyno CCR8 (SEQ ID NO: 22)
MDYTLDPSMTTMTDYYYPDSLSSPCDGELIQRNDKLLLAVFYCLLFVFSLLGNSLVIL
VLVVCKKLRNITDIYLLNLALSDLLFVFSFPFQTYYQLDQWVFGTVMCKVVSGFYYI
GFYSSMFFITLMSVDRYLAVVHAVYAIKVRTIRMGTTLSLVVWLTAIMATIPLLVFY
QVASEDGVLQCYSFYNQQTLKWKIFTNFEMNILGLLIPFTIFMFCYIKILHQLKRCQN
HNKTKAIRLVLIVVIASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLNYATHVTEIISF
THCCVNPVIYAFVGEKFKKHLSEIFQKSCSHIFIYLGRQMPRESCEKSSSCQQHSFRSS
SIDYIL
humanCCR8[A27G] (SEQ ID NO: 23)
MDYTLDLSVTTVTDYYYPDIFSSPCDGELIQTNGKLLLAVFYCLLFVFSLLGNSLVIL
VLVVCKKLRSITDVYLLNLALSDLLFVFSFPFQTYYLLDQWVFGTVMCKVVSGFYYI
GFYSSMFFITLMSVDRYLAVVHAVYALKVRTIRMGTTLCLAVWLTAIMATIPLLVFY
QVASEDGVLQCYSFYNQQTLKWKIFTNFKMNILGLLIPFTIFMFCYIKILHQLKRCQN
HNKTKAIRLVLIVVIASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLTYATHVTEIISF
THCCVNPVIYAFVGEKFKKHLSEIFQKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSS
SVDYIL
mCCR8 (SEQ ID NO: 24)
MDYTMEPNVTMTDYYPDFFTAPCDAEFLLRGSMLYLAILYCVLFVLGLLGNSLVILV
LVGCKKLRSITDIYLLNLAASDLLFVLSIPFQTHNLLDQWVFGTAMCKVVSGLYYIGF
FSSMFFITLMSVDRYLAIVHAVYAIKVRTASVGTALSLTVWLAAVTATIPLMVFYQV
ASEDGMLQCFQFYEEQSLRWKLFTHFEINALGLLLPFAILLFCYVRILQQLRGCLNHN
RTRAIKLVLTVVIVSLLFWVPFNVALFLTSLHDLHILDGCATRQRLALAIHVTEVISFT
HCCVNPVIYAFIGEKFKKHLMDVFQKSCSHIFLYLGRQMPVGALERQLSSNQRSSHSS
TLDDIL
Rat CCR8 (SEQ ID NO: 25)
MDYTLEPNVTMTDYYPDFFTTPCDTELLLRGGTLYLAVLYCILFVLGLLGNSLVILVL
VACKKLRSITDVYLLNLAASDLLFVLSIPFQTHNLLDQWVFGTVMCKVVSGLYYIGF
FSSMLFITLMSVDRYLAVVHPVHAIKVRTARVGTALSLAVWLAAIAATVPLMVFYQ
VSSEDGMLQCFQLYDEQSLRWKLFTHFEVNALGLLLPFAILLFCYVRILQQLRGCLN
HNRTRAIKLVLTIVVVSLLFWVPFNVVLFLTSLHDMHILEGCATRQRLALATHVTEVI
SFMHCCVNPVIYAFIGEKFKKHLVDVFQKSCSHIFLYVGRQMPVGALERQLSSNQRS
SHSSTLDYIL
hCCR4 (SEQ ID NO: 26)
MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFGELFLPPLYSLVFVFGLLGNSV
VVLVLFKYKRLRSMTDVYLLNLAISDLLFVFSLPFWGYYAADQWVFGLGLCKMISW
MYLVGFYSGIFFVMLMSIDRYLAIVHAVFSLRARTLTYGVITSLATWSVAVFASLPGF
LFSTCYTERNHTYCKTKYSLNSTTWKVLSSLEINILGLVIPLGIMLFCYSMIIRTLQHC
KNEKKNKAVKMIFAVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFERYLDYAIQAT
ETLAFVHCCLNPIIYFFLGEKFRKYILQLFKTCRGLFVLCQYCGLLQIYSADTPSSSYT
QSTMDHDLHDAL
Antibody 1 IgG2 HC DNA (SEQ ID NO: 27)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTG
AGACTCTCCTGTGCAGCCTCTGGATTTACTTTCAGTAACGCCCGGATGGGCTGGG
TCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAA
CTGAAGGTGGGACAAGAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCT
CAAGAGATGATTCAAAAAACACGCTGTATCTGCAAATGAACAGCCTGAAAACCG
AGGACACAGCCGTGTATTATTGTACCTCGTATAGTGGGGTCTGGGGCCAAGGGA
CAATGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGC
GCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGC
GGCGTGCACACCTTCCCAGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCA
GCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGT
AGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTG
TGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTC
TTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGT
GCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACG
TGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCA
ACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTTGTGCACCAGGACTGGCTGAA
CGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGA
GAAAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCT
GCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT
CAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC
GGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCTTC
CTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTC
TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCT
CCCTGTCTCCGGGTAAATAG
Antibody 1 IgG2 LC DNA (SEQ ID NO: 28)
GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAG
GGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGTTCCAACAATA
AGAACTACTTAGCTTGGTACCATCAGAAACCAGGACAGTCTCCTAAGCTGCTC
ATTTCCTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAG
CGGGTCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGGCTGAAGATG
TGGCAGTTTATTACTGTCAACAATATTATAGTATTCCGATCACTTTCGGCGGAG
GGACCAAGGTGGAGATCAAACGA
Antibody 2 IgG2 HC DNA (SEQ ID NO: 29)
CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG
AGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGGCATGCACTGGG
TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTCATATCATATGATG
GAAGTAATAAATTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAG
ACAATTCCAAGAAGACTCTGTATCTTCAAATGAGCAGCCTGAGAGTTGAGGACA
CGGCTGTATATTATTGTGCGAGAGCCGGGGGTATAGGGCGTTTTGACTACTGGGG
CCAGGGAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTC
CCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTC
TGACCAGCGGCGTGCACACCTTCCCAGCTGTCCTACAGTCCTCAGGACTCTACTC
CCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACC
TGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGC
AAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAG
TCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
GGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGA
GCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTTGTGCACCAGGAC
TGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCC
CCCATCGAGAAAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTG
TACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC
TGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGC
TCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG
AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGA
AGAGCCTCTCCCTGTCTCCGGGTAAATAG
Antibody 2 IgG2 LC DNA (SEQ ID NO: 30)
GATTTTGTAATGACCCAGACTCCACTCTCTCTGTCCGTCACCCCTGGACAGCCGG
CCTCCATCTCCTGCAAGTATAGTCAGAGCCTCCTGCACAGTGATGGAAAGACCTA
TTTGTTTTGGTACCTGCAGAAGCCAGGCCAGCCTCCACACCTCCTGATCTATGAA
GTTTCCAACCGGTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
CAGATTTCACACTGAAGATCAGCCGGGTGGAGGCTGAGGATGTTGGGCTTTATTA
CTGCATGCAAACTTTAAAGCTTCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAG
ATCAACCGA
Human CCR8 1-35 (SEQ ID NO: 31)
MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGK
zeluvalimab LCDR1 (SEQ ID NO: 32)
RASQGISNWLA
zeluvalimab LCDR2 (SEQ ID NO: 33)
AASSLQS
zeluvalimab LCDR3 (SEQ ID NO: 34)
QQAESFPHT
zeluvalimab HCDR1 (SEQ ID NO: 35)
SYDMS
zeluvalimab HCDR2 (SEQ ID NO: 36)
LISGGGSQTYYAESVKG
zeluvalimab HCDR3 (SEQ ID NO: 37)
PSGHYFYAMDV
zeluvalimab VL (SEQ ID NO: 38)
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSG
VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIK
zeluvalimab VH (SEQ ID NO: 39)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGS
QTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWG
QGTTVTVSS
zeluvalimab LC (SEQ ID NO: 40)
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSG
VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
zeluvalimab HC (SEQ ID NO: 41)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGS
QTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWG
QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Antibody 20A2.003 LCDR1 (SEQ ID NO: 42)
SGDKLGDKYAS
Antibody 20A2.003 LCDR2 (SEQ ID NO: 43)
QDRKRPS
Antibody 20A2.003 LCDR3 (SEQ ID NO: 44)
QAFESSTEV
Antibody 20A2.003 HCDR1 (SEQ ID NO: 45)
NYGMH
Antibody 20A2.003 HCDR2 (SEQ ID NO: 46)
LIWYDASKKYYAESVKG
Antibody 20A2.003 HCDR3 (SEQ ID NO: 47)
DPSSLTGSTGYYGMDV
Antibody 20A2.003 VL (SEQ ID NO: 48)
SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGIP
ERFSGSNSGNTATLTISGTQAMDEADYYCQAFESSTEVFGGGTKLTVL
Antibody 20A2.003 VH (SEQ ID NO: 49)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVALIWYDA
SKKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAAYYCARDPSSLTGSTGYYG
MDVWGQGTTVTVSS
Antibody 20A2.003 LC (SEQ ID NO: 50)
SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGIP
ERFSGSNSGNTATLTISGTQAMDEADYYCQAFESSTEVFGGGTKLTVLGQPKAAPSV
TLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKY
AASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
Antibody 20A2.003 HC (SEQ ID NO: 51)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVALIWYDA
SKKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAAYYCARDPSSLTGSTGYYG
MDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
SPGK
Antibody 22D4.006 LCDR1 (SEQ ID NO: 52)
SGDALPKKYAY
Antibody 22D4.006 LCDR2 (SEQ ID NO: 53)
EDAKRPS
Antibody 22D4.006 LCDR3 (SEQ ID NO: 54)
YSTDASGNHRV
Antibody 22D4.006 HCDR1 (SEQ ID NO: 55)
DYSMS
Antibody 22D4.006 HCDR2 (SEQ ID NO: 56)
GINWNGGRTRYADAVKG
Antibody 22D4.006 HCDR3 (SEQ ID NO: 57)
EFNNFESNWFDP
Antibody 22D4.006 VL (SEQ ID NO: 58)
SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIP
ERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVL
Antibody 22D4.006 VH (SEQ ID NO: 59)
EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNG
GRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPW
GQGTLVTVSS
Antibody 22D4.006 LC (SEQ ID NO: 60)
SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIP
ERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVLGQPKAAP
SVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNN
KYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
Antibody 22D4.006 HC (SEQ ID NO: 61)
EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNG
GRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Antibody 22D4.017 LCDR1 (SEQ ID NO: 62)
SGDALPKKYAY
Antibody 22D4.017 LCDR2 (SEQ ID NO: 63)
EDAKRPS
Antibody 22D4.017 LCDR3 (SEQ ID NO: 64)
YSTDASGNHRV
Antibody 22D4.017 HCDR1 (SEQ ID NO: 65)
DYSMS
Antibody 22D4.017 HCDR2 (SEQ ID NO: 66)
GINWNAGRTRYADAVKG
Antibody 22D4.017 HCDR3 (SEQ ID NO: 67)
EFNNFESNWFDP
Antibody 22D4.017 VL (SEQ ID NO: 68)
SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIP
ERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVL
Antibody 22D4.017 VH (SEQ ID NO: 69)
EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNA
GRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPW
GQGTLVTVSS
Antibody 22D4.017 LC (SEQ ID NO: 70)
SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIP
ERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVLGQPKAAP
SVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNN
KYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
Antibody 22D4.017 HC (SEQ ID NO: 71)
EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNA
GRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Antibody 20C1.006 LCDR1 (SEQ ID NO: 72)
RASQGISNWLA
Antibody 20C1.006 LCDR2 (SEQ ID NO: 73)
AASSLQS
Antibody 20C1.006 LCDR3 (SEQ ID NO: 74)
QQAESFPHT
Antibody 20C1.006 HCDR1 (SEQ ID NO: 75)
SYDMS
Antibody 20C1.006 HCDR2 (SEQ ID NO: 76)
LISGGGSNTYYAESVKG
Antibody 20C1.006 HCDR3 (SEQ ID NO: 77)
PSGHYFYAMDV
Antibody 20C1.006 VL (SEQ ID NO: 78)
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSG
VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIK
Antibody 20C1.006 VH (SEQ ID NO: 79)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGS
NTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWG
QGTTVTVSS
Antibody 20C1.006 LC (SEQ ID NO: 80)
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSG
VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Antibody 20C1.006 HC (SEQ ID NO: 81)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGS
NTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWG
QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
CCR8 P_1-12 peptide (SEQ ID NO: 82)
MDYTLDLSVTTV
CCR8 P_13-24 peptide (SEQ ID NO: 83)
TDYYYPDIFSSP
CCR8 P_25-35 peptide (SEQ ID NO: 84)
CDAELIQTNGK
CCR8 P_7-18 peptide (SEQ ID NO: 85)
LSVTTVTDYYYP
CCR8 P_19-30 peptide (SEQ ID NO: 86)
DIFSSPCDAELI

TABLE 15
BiTE Molecule Sequences.
	DESCRIPTION	SEQUENCE
CD3 BINDING DOMAIN (I2C)
87	Anti-CD3 CDR-L1	GSSTGAVTSGNYPN
	(I2C)
88	Anti-CD3 CDR-L2	GTKFLAP
	(I2C)
89	Anti-CD3 CDR-L3	VLWYSNRWV
	(I2C)
90	Anti-CD3 CDR-H1	KYAMN
	(I2C)
91	Anti-CD3 CDR-H2	RIRSKYNNYATYYADSVKD
	(I2C)
92	Anti-CD3 CDR-H3	HGNFGNSYISYWAY
	(I2C)
93	Anti-CD3 VH (I2C)	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWV
		RQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRD
		DSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYW
		AYWGQGTLVTVSS
94	Anti-CD3 VL (I2C)	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWV
		QQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL
		SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
95	Anti-CD3 VH-VL	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWV
	(I2C)	RQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRD
		DSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYW
		AYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPS
		LTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPR
		GLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA
		EYYCVLWYSNRWVFGGGTKLTVL
CD3 BINDING DOMAIN (I2E)
96	Anti-CD3 CDR-L1	GSSTGAVTSGNYPN
	(I2E)
97	Anti-CD3 CDR-L2	GTKFLAP
	(I2E)
98	Anti-CD3 CDR-L3	VLWYSNRWV
	(I2E)
99	Anti-CD3 CDR-H1	KYAIN
	(I2E)
100	Anti-CD3 CDR-H2	RIRSKYNNYATYYADAVKD
	(I2E)
101	Anti-CD3 CDR-H3	AGNFGSSYISYWAY
	(I2E)
102	Anti-CD3 VH (I2E)	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVR
		QAPGKGLEWVARIRSKYNNYATYYADAVKDRFTISRD
		DSKNTVYLQMNNLKTEDTAVYYCARAGNFGSSYISYW
		AYWGQGTLVTVSS
103	Anti-CD3 VL (I2E)	QTVVTQEPSLTVSPGGTVTITCGSSTGAVTSGNYPNWV
		QKKPGQAPRGLIGGTKFLAPGTPARFSGSLSGGKAALTL
		SGVQPEDEAEYYCVLWYSNRWVFGSGTKLTVL
CD33
104	Anti-CD33 CDR-L1	KSSQSVLDSSTNKNSLA
	(E11)
105	Anti-CD33 CDR-L2	WASTRES
	(E11)
106	Anti-CD33 CDR-L3	QQSAHFPIT
	(E11)
107	Anti-CD33 CDR-H1	NYGMN
	(E11)
108	Anti-CD33 CDR-H2	WINTYTGEPTYADKFQG
	(E11)
109	Anti-CD33 CDR-H3	WSWSDGYYVYFDY
	(E11)
110	Anti-CD33 VH with	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNW
	cys-clamp (E11)	VKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTT
		DTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYF
		DYWGQGTSVTVSS
ill	Anti-CD33 VH without	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNW
	cys-clamp (E11)	VKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTT
		DTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYF
		DYWGQGTSVTVSS
112	Anti-CD33 VL with	DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSL
	cys-clamp (E11)	AWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFT
		LTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK
113	Anti-CD33 VL without	DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSL
	cys-clamp (E11)	AWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFT
		LTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK
114	CD33 scFv with cys-	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNW
	clamp E11	VKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTT
		DTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYF
		DYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPD
		SLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPG
		QPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPE
		DSATYYCQQSAHFPITFGCGTRLEIK
115	CD33 scFv without	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNW
	cys-clamp El l	VKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTT
		DTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYF
		DYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPD
		SLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPG
		QPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPE
		DSATYYCQQSAHFPITFGQGTRLEIK
116	Anti-CD33 with cys-	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNW
	clamp (E11) x anti-	VKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTT
	CD3 (I2C)	DTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYF
	Bispecific molecule	DYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPD
		SLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPG
		QPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPE
		DSATYYCQQSAHFPITFGCGTRLEIKSGGGGSEVQLVES
		GGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK
		GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA
		YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQ
		GTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPG
		GTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT
		KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCV
		LWYSNRWVFGGGTKLTVL
117	Anti-CD33 with cys-	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNW
	clamp (E11) x anti-	VKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTT
	CD3 (I2C)	DTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYF
	scFc Bispecific HLE	DYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPD
	molecule	SLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPG
		QPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPE
		DSATYYCQQSAHFPITFGCGTRLEIKSGGGGSEVQLVES
		GGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK
		GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA
		YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQ
		GTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPG
		GTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT
		KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCV
		LWYSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ
		DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
		NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
		VMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSG
		GGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGK
118	Anti-CD33 bispecific	QVQLVQSGAE VKKPGESVKV SCKASGYTFT
	molecule with His-tag	NYGMNWVKQA PGQGLEWMGW INTYTGEPTY
	(no cys clamp)	ADKFQGRVTM TTDTSTSTAY MEIRNLGGDD
		TAVYYCARWS WSDGYYVYFD YWGQGTSVTV
		SSGGGGSGGG GSGGGGSDIV MTQSPDSLTV
		SLGERTTINC KSSQSVLDSS TNKNSLAWYQ
		QKPGQPPKLL LSWASTRESG IPDRFSGSGS
		GTDFTLTIDS PQPEDSATYY CQQSAHFPIT
		FGQGTRLEIK SGGGGSEVQL VESGGGLVQP
		GGSLKLSCAA SGFTFNKYAM NWVRQAPGKG
		LEWVARIRSK YNNYATYYAD SVKDRFTISR
		DDSKNTAYLQ MNNLKTEDTA VYYCVRHGNF
		GNSYISYWAY WGQGTLVTVS SGGGGSGGGG
		SGGGGSQTVV TQEPSLTVSP GGTVTLTCGS
		STGAVTSGNY PNWVQQKPGQ APRGLIGGTK
		FLAPGTPARF SGSLLGGKAA LTLSGVQPED
		EAEYYCVLWY SNRWVFGGGT KLTVLHHHHH H
EGFRVIII
119	Anti-EGFRvIII CDR-	RSSQSLVHSDGNTYLS
	L1
120	Anti-EGFRvIII CDR-	RISRRFS
	L2
121	Anti-EGFRvIII CDR-	MQSTHVPRT
	L3
122	Anti-EGFRvIII CDR-	NYGMH
	H1
123	Anti-EGFRvIII CDR-	VIWYDGSDKYYADSVRG
	H2
124	Anti-EGFRvIII CDR-	DGYDILTGNPRDFDY
	H3
125	Anti-EGFRvIII VH	QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWV
		RQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDN
		SKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDF
		DYWGQGTLVTVSS
126	Anti-EGFRvIII VL	DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLS
		WLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTL
		EISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK
127	EGFRvIII scFv	QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWV
		RQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDN
		SKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDF
		DYWGQGTLVTVSSGGGGSGGGGSGGGGSDTVMTQTPL
		SSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQP
		PRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDV
		GVYYCMQSTHVPRTFGCGTKVEIK
128	EGFRvIII_CCxCD3	QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWV
	Bispecific molecule	RQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDN
		SKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDF
		DYWGQGTLVTVSSGGGGSGGGGSGGGGSDTVMTQTPL
		SSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQP
		PRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDV
		GVYYCMQSTHVPRTFGCGTKVEIKSGGGGSEVQLVESG
		GGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL
		EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVL
129	EGFRvIII_CCxCD3-	QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWV
	scFc Bispecific HLE	RQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDN
	molecule	SKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDF
		DYWGQGTLVTVSSGGGGSGGGGSGGGGSDTVMTQTPL
		SSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQP
		PRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDV
		GVYYCMQSTHVPRTFGCGTKVEIKSGGGGSEVQLVESG
		GGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL
		EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGP
		SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
		SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGG
		SGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
		NAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCK
		VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
		QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
		SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
ANTI-MSLN
130	Anti-MSLN CDR-H1	DYYMT
131	Anti-MSLN CDR-H2	YISSSGSTIYYADSVKG
132	Anti-MSLN CDR-H3	DRNSHFDY
133	Anti-MSLN CDR-L1	RASQGINTWLA
134	Anti-MSLN CDR-L2	GASGLQS
135	Anti-MSLN CDR-L3	QQAKSFPRT
136	Anti-MSLN VH	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIR
		QAPGKGLEWLSYISSSGSTIYYADSVKGRFTISRDNAKN
		SLFLQMNSLRAEDTAVYYCARDRNSHFDYWGQGTLVT
		VSS
137	Anti-MSLN VL	DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQ
		KPGKAPKLLIYGASGLQSGVPSRFSGSGSGTDFTLTISSL
		QPEDFATYYCQQAKSFPRTFGQGTKVEIK
138	Anti-MSLN scFv	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIR
		QAPGKGLEWLSYISSSGSTIYYADSVKGRFTISRDNAKN
		SLFLQMNSLRAEDTAVYYCARDRNSHFDYWGQGTLVT
		VSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRVT
		ITCRASQGINTWLAWYQQKPGKAPKLLIYGASGLQSGV
		PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPRTF
		GQGTKVEIK
139	Anti-MSLN_5 x CD3	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIR
	(I2C)	QAPGKGLEWLSYISSSGSTIYYADSVKGRFTISRDNAKN
	bispecific molecule	SLFLQMNSLRAEDTAVYYCARDRNSHFDYWGQGTLVT
		VSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRVT
		ITCRASQGINTWLAWYQQKPGKAPKLLIYGASGLQSGV
		PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPRTF
		GQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCA
		ASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYA
		TYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVY
		YCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGG
		GSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS
		GNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLL
		GGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK
		LTVL
140	MSLN_5xCD3-scFc	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIR
	Bispecific HLE	QAPGKGLEWLSYISSSGSTIYYADSVKGRFTISRDNAKN
	molecule	SLFLQMNSLRAEDTAVYYCARDRNSHFDYWGQGTLVT
		VSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRVT
		ITCRASQGINTWLAWYQQKPGKAPKLLIYGASGLQSGV
		PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPRTF
		GQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCA
		ASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYA
		TYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVY
		YCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGG
		GSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS
		GNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLL
		GGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK
		LTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL
		MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
		TKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSN
		KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
		LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
		SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGG
		SDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQ
		YGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
		EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
		LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
		K
141	MSLN_5_CCxCD3-	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIR
	scFc Bispecific HLE	QAPGKCLEWLSYISSSGSTIYYADSVKGRFTISRDNAKN
	molecule (with cys-	SLFLQMNSLRAEDTAVYYCARDRNSHFDYWGQGTLVT
	clamp)	VSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRVT
		ITCRASQGINTWLAWYQQKPGKAPKLLIYGASGLQSGV
		PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPRTF
		GCGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCA
		ASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYA
		TYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVY
		YCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGG
		GSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS
		GNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLL
		GGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK
		LTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL
		MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
		TKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSN
		KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
		LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
		SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGG
		SDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQ
		YGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
		EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
		LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
		K
CDH19
142	Anti-CDH19 CDR-H1	SYGMH
143	Anti-CDH19 CDR-H2	FIWYEGSNKYYAESVKD
144	Anti-CDH19 CDR-H3	RAGIIGTIGYYYGMDV
145	Anti-CDH19 CDR-L1	SGDRLGEKYTS
146	Anti-CDH19 CDR-L2	QDTKRPS
147	Anti-CDH19 CDR-L3	QAWESSTVV
148	Anti-CDH19 VH	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
		RQAPGKGLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSS
149	CDH19 65254.007 VH	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	with Cys clamp	RQAPGKCLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSS
150	Anti-CDH19 VL	SYELTQPPSVSVSPGQTASITCSGDRLGEKYTSWYQQRP
		GQSPLLVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQA
		MDEADYYCQAWESSTVVFGGGTKLTVLS
151	CDH19 65254.007 VL	SYELTQPPSVSVSPGQTASITCSGDRLGEKYTSWYQQRP
	with Cys clamp	GQSPLLVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQA
		MDEADYYCQAWESSTVVFGCGTKLTVL
152	Anti-CDH19 VH-VL	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
		RQAPGKGLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGGGTKLTVLS
153	CDH19 65254.007	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	scFv with cys clamp	RQAPGKCLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGCGTKLTVL
154	Anti-CDH19	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	Bispecific molecule	RQAPGKGLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGGGTKLTVLSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVLHHHHHH
155	CDH19 65254.007	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	Bispecific molecule	RQAPGKCLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
	with cys clamp	KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGCGTKLTVLSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVL
156	CDH19 65254.007 x	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	I2C -scFc Bispecific	RQAPGKGLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
	HLE molecule	KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGGGTKLTVLSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
		DGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
		EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG
		GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
		LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
		KTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVS
		NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV
		SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
		KSLSLSPGK
157	CDH19 65254.007 x	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	I2C -scFc_ Bispecific	RQAPGKGLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
	HLE molecule	KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
		DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGGGTKLTVLSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
		DGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
		EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
158	CDH19 65254.007 x	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	I2C -scFc Bispecific	RQAPGKCLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
	HLE molecule with cys	KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
	clamp	DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
		VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGCGTKLTVLSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
		DGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
		EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG
		GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
		LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
		KTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVS
		NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV
		SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
		KSLSLSPGK
159	CDH19 65254.007 x	QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYGMHWV
	I2C -scFc_delGK	RQAPGKCLEWVAFIWYEGSNKYYAESVKDRFTISRDNS
	Bispecific HLE	KNTLYLQMNSLRAEDTAVYYCARRAGIIGTIGYYYGM
	molecule with cys	DVWGQGTTVTVSSGGGGSGGGGSGGGGSSYELTQPPS
	clamp	VSVSPGQTASITCSGDRLGEKYTSWYQQRPGQSPLLVIY
		QDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYC
		QAWESSTVVFGCGTKLTVLSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
		DGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
		EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
FLT3
160	Anti-FLT3 CDR-H1	NARMGVS
161	Anti-FLT3 CDR-H2	HIFSNDEKSYSTSLKN
162	Anti-FLT3 CDR-H3	IVGYGSGWYGFFDY
163	Anti-FLT3 CDR-L1	RASQGIRNDLG
164	Anti-FLT3 CDR-L2	AASTLQS
165	Anti-FLT3 CDR-L3	LQHNSYPLT
166	Anti-FLT3 VH	QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWI
		RQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKT
		QVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYW
		GQGTLVTVSS
167	Anti-FLT3 VL	DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQ
		KPGKAPKRLIYAASTLQSGVPSRFSGSGSGTEFTLTISSL
		QPEDFATYYCLQHNSYPLTFGCGTKVEIK
168	Anti-FLT3 VH-VL	QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWI
		RQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKT
		QVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYW
		GQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSA
		SVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAA
		STLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQH
		NSYPLTFGCGTKVEIK
169	FLT3_7 A8xCD3	QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWI
	Bispecific molecule	RQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKT
		QVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYW
		GQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSA
		SVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAA
		STLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQH
		NSYPLTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGG
		SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS
		KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKT
		EDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGG
		GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSS
		TGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR
		FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF
		GGGTKLTVL
170	FLT3_7 A8xCD3-scFc	QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWI
	Bispecific HLE	RQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKT
	molecule	QVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYW
		GQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSA
		SVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAA
		STLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQH
		NSYPLTFGCGTKVEIKSGGGGSEVQLVESGGGLVQPGG
		SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS
		KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKT
		EDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGG
		GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSS
		TGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR
		FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF
		GGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPK
		PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE
		VHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK
		CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
		KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
		LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		HYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGG
		SGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
ANTI-DLL3
171	Anti-DLL3 HCDR1	SYYWS
172	Anti-DLL3 HCDR2	YVYYSGTTNYNPSLKS
173	Anti-DLL3 HCDR3	IAVTGFYFDY
174	Anti-DLL3 LCDR1	RASQRVNNNYLA
175	Anti-DLL3 LCDR2	GASSRAT
176	Anti-DLL3 LCDR3	QQYDRSPLT
177	Anti-DLL3 VH with	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQ
	cys-clamp	PPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQF
		SLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTV
		SS
178	Anti-DLL3 VL with	EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQ
	cys-clamp	QRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR
		LEPEDFAVYYCQQYDRSPLTFGCGTKLEIK
179	Anti-DLL3 VH-VL	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQ
	with cys-clamp	PPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQF
		SLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTV
		SSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLS
		CRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIP
		DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTF
		GCGTKLEIK
180	DLL3_1_CCxCD3	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQ
	Bispecific molecule	PPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQF
		SLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTV
		SSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLS
		CRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIP
		DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTF
		GCGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCA
		ASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYA
		TYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVY
		YCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGG
		GSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS
		GNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLL
		GGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK
		LTVL
181	DLL3_1_CCxCD3-	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQ
	scFc_ Bispecific HLE	PPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQF
	molecule	SLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTV
		SSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLS
		CRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIP
		DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTF
		GCGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCA
		ASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYA
		TYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVY
		YCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGG
		GSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS
		GNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLL
		GGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK
		LTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL
		MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
		TKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSN
		KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
		LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
		SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSD
		KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYG
		STYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT
		ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
		KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
ANTI-CD19
182	Anti-CD19 CDR-H1	SYGMH
	(97-G1RE-C2)
183	Anti-CD19 CDR-H2	VISYEGSNKYYAESVKG
184	Anti-CD19 CDR-H3	DRGTIFGNYGLEV
185	Anti-CD19 CDR-L1	RSSQSLLHKNAFNYLD
186	Anti-CD19 CDR-L2	LGSNRAS
187	Anti-CD19 CDR-L3	MQALQTPFT
188	Anti-CD19 VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWV
		RQAPGKCLEWVAVISYEGSNKYYAESVKGRFTISRDNS
		KNTLYLQMNSLRDEDTAVYYCARDRGTIFGNYGLEVW
		GQGTTVTVSS
189	Anti-CD19 VL	DIVMTQSPLSLPVISGEPASISCRSSQSLLHKNAFNYLDW
		YLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLK
		ISRVEAEDVGVYYCMQALQTPFTFGCGTKVDIK
190	Anti-CD19 VL-VH	DIVMTQSPLSLPVISGEPASISCRSSQSLLHKNAFNYLDW
		YLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLK
		ISRVEAEDVGVYYCMQALQTPFTFGCGTKVDIKGGGGS
		GGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGF
		TFSSYGMHWVRQAPGKCLEWVAVISYEGSNKYYAESV
		KGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARDRGT
		IFGNYGLEVWGQGTTVTVSSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVL
191	CD19 97-G1RE-C2 CC	DIVMTQSPLSLPVISGEPASISCRSSQSLLHKNAFNYLDW
	x I2C-scFc	YLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLK
		ISRVEAEDVGVYYCMQALQTPFTFGCGTKVDIKGGGGS
		GGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGF
		TFSSYGMHWVRQAPGKCLEWVAVISYEGSNKYYAESV
		KGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARDRGT
		IFGNYGLEVWGQGTTVTVSSGGGGSEVQLVESGGGLV
		QPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV
		ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN
		NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVT
		VSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTL
		TCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP
		GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSN
		RWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVF
		LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
		DGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
		EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
		LHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG
		GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
		LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
		KTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVS
		NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV
		SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
		GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
		KSLSLSPGK
BCMA
192	Anti-BCMA CDR-H1	NHIIH
	(27-C4-G7)
193	Anti-BCMA CDR-H2	YINPYPGYHAYNEKFQG
194	Anti-BCMA CDR-H3	DGYYRDTDVLDY
195	Anti-BCMA CDR-L1	QASQDISNYLN
196	Anti-BCMA CDR-L2	YTSRLHT
197	Anti-BCMA CDR-L3	QQGNTLPWT
198	Anti-BCMA VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVR
		QAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTS
		TSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWG
		QGTLVTVSS
199	Anti-BCMA VL	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQ
		KPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSL
		EPEDIATYYCQQGNTLPWTFGCGTKLEIK
200	Anti-BCMA VH-VL	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVR
		QAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTS
		TSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWG
		QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTS
		RLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGN
		TLPWTFGCGTKLEIK
201	Anti-BCMA Ic320	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVR
	bispecific molecule	QAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTS
	HLE	TSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWG
	With cys-clamp	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTS
		RLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGN
		TLPWTFGCGTKLEIKSGGGGSEVQLVESGGGLVQPGGS
		LKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSK
		YNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTE
		DTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGG
		GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSS
		TGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR
		FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF
		GGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPK
		PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE
		VHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK
		CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
		KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
		LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
		HYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGG
		SGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
202	Anti-BCMA IC20	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVR
	bispecific molecule	QAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTS
	With cys-clamp	TSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWG
		QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTS
		RLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGN
		TLPWTFGCGTKLEIKSGGGGSEVQLVESGGGLVQPGGS
		LKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSK
		YNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTE
		DTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGG
		GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSS
		TGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR
		FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF
		GGGTKLTVLHHHHHH
PSMA
203	Anti-PSMA CDR-H1	DYYMY
	PM76-B10.17
204	Anti-PSMA CDR-H2	IISDAGYYTYYSDIIKG
205	Anti-PSMA CDR-H3	GFPLLRHGAMDY
206	Anti-PSMA CDR-L1	KASQNVDANVA
207	Anti-PSMA CDR-L2	SASYVYW
208	Anti-PSMA CDR-L3	QQYDQQLIT
209	Anti-PSMA VH with	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	cys-clamp	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	PM76-B10.17	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSS
210	Anti-PSMA VL with	DIQMTQSPSSLSASVGDRVTITCKASQNVDANVAWYQQ
	cys-clamp	KPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISS
	PM76-B10.17	VQSEDFATYYCQQYDQQLITFGCGTKLEIK
211	Anti-PSMA VH-VL	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	with cys-clamp	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	PM76-B10.17	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIK
212	Anti-PSMA x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	bispecific molecule	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	with cys-clamp	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	PM76-B10.17	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVL
213	Anti-PSMA x CD3 -	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	scFc bispecific	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	PM76-B10.17	VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
214	Anti-PSMA x CD3 -	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	scFc -bispecific	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	PM76-B10.17	VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS
		GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
215	PM76-B10.17 (cys	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	clamp) x CD3 (Cys	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	clamp 103/43)	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	bispecific molecule	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVL
216	PM76-B10.17 (cys	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	clamp) x CD3 (cys	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	clamp 103/43)-scFc	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	bispecific	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	HLE molecule	VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
217	PM76-B10.17 (cys	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	clamp) x CD3 (cys	RQAPGKCLEWVAIISDAGYYTYYSDIIKGRFTISRDNAK
	clamp 103/43)-scFc	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	bispecific	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	HLE molecule	VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSA
		SYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS
		GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
PSMA
218	Anti-PSMA CDR-H1	DYYMY
	(PM76-B10.11)
219	Anti-PSMA CDR-H2	IISDGGYYTYYSDIIKG
220	Anti-PSMA CDR-H3	GFPLLRHGAMDY
221	Anti-PSMA CDR-L1	KASQNVDTNVA
222	Anti-PSMA CDR-L2	SASYVYW
223	Anti-PSMA CDR-L3	QQYDQQLIT
224	Anti-PSMA VH	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	without cys-clamp	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	PM76-B10.11	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSS
225	Anti-PSMA VH with	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	cys-clamp	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	PM76-B10.11	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSS
226	Anti-PSMA VL	DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQ
	without cys-clamp	KPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISS
	PM76-B10.11	VQSEDFATYYCQQYDQQLITFGGGTKLEIK
227	Anti-PSMA VL with	DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQ
	cys-clamp	KPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISS
	PM76-B10.11	VQSEDFATYYCQQYDQQLITFGCGTKLEIK
228	Anti-PSMA VH-VL	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	without cys-clamp	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	PM76-B10.11	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIK
229	Anti-PSMA VH-VL	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	with cys-clamp	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	PM76-B10.11	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIK
230	Anti-PSMA x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	without cys-clamp	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	Bispecific molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	PM76-B10.11	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVL
231	Anti-PSMA x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	with cys-clamp	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	Bispecific molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	PM76-B10.11	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVL
232	Anti-PSMA x CD3 -	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	scFc without cys-clamp	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	Bispecific molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	PM76-B10.11	VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
233	PM76-B10.11 x CD3 -	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	scFc_ bispecific	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	HLE molecule (without	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	cys clamp)	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS
		GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
234	PM76-B10.11 x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	(cys clamp 103/43)	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	bispecific molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
		QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVL
235	PM76-B10.11 x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	(cys clamp 103/43)-	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	scFc bispecific	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE molecule	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
236	PM76-B10.11 x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	(cys clamp 103/43)-	RQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	scFc_ bispecific	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE molecule	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGGGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS
		GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
237	Anti-PSMA x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	with cys-clamp, scFc	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	Bispecific molecule	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	PM76-B10.11	VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
238	PM76-B10.11 CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	with cys-clamp, scFc_	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	bispecific	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	HLE molecule	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
		VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS
		GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
239	PM76-B10.11 x CD3	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	scFc bispecific	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	HLE molecule (with	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	cys-clamp; second cys	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	clamp at CD3 103/43)	VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG
		GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
		ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
		KPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNK
		ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL
		TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
240	PM76-B10.11 x CD3 -	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWV
	scFc_ bispecific	RQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAK
	HLE molecule (with	NSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWG
	cys-clamp; second cys	QGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS
	clamp at CD3 103/43-)	VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSAS
		YVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQ
		YDQQLITFGCGTKLEIKSGGGGSEVQLVESGGGLVQPG
		GSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIR
		SKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLK
		TEDTAVYYCVRHGNFGNSYISYWAYCGQGTLVTVSSG
		GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGS
		STGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTPA
		RFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWV
		FGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPP
		KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
		EVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEY
		KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
		TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
		VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
		NHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS
		GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
		RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
		CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKAL
		PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
		LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGK
CD70
241	Anti-CD70 CDR-H1	TYAMS
242	Anti-CD70 CDR-H2	AISGSGGRTFYAESVEG
243	Anti-CD70 CDR-H3	HDYSNYPYFDY
244	Anti-CD70 CDR-L1	RASQSVRSTYLA
245	Anti-CD70 CDR-L2	GASSRAT
246	Anti-CD70 CDR-L3	QQYGDLPFT
247	Anti-CD70 VH	EVQLLESGGGMVQPGGSLRLSCAASGFTFSTYAMSWV
		RQAPGKCLEWVSAISGSGGRTFYAESVEGRFTISRDNSK
		NTLYLQMNSLRAEDTAVYYCAKHDYSNYPYFDYWGQ
		GTLVTVSS
248	Anti-CD70 VL	EIVLTQSPGTLSLSPGERATLSCRASQSVRSTYLAWYQQ
		K
		PGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
		PEDFAVYSCQQYGDLPFTFGCGTKLEIK
249	Anti-CD70 scFv (cys	EVQLLESGGGMVQPGGSLRLSCAASGFTFSTYAMSWV
	clamp)	RQAPGKCLEWVSAISGSGGRTFYAESVEGRFTISRDNSK
		NTLYLQMNSLRAEDTAVYYCAKHDYSNYPYFDYWGQ
		GTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPG
		ERATLSCRASQSVRSTYLAWYQQKPGQAPRLLIYGASS
		RATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYSCQQYGD
		LPFTFGCGTKLEIK
250	Anti-CD70 VH-VL	EVQLLESGGGMVQPGGSLRLSCAASGFTFSTYAMSWV
	scFc	RQAPGKCLEWVSAISGSGGRTFYAESVEGRFTISRDNSK
		NTLYLQMNSLRAEDTAVYYCAKHDYSNYPYFDYWGQ
		GTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPG
		ERATLSCRASQSVRSTYLAWYQQKPGQAPRLLIYGASS
		RATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYSCQQYGD
		LPFTFGCGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK
		LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYN
		NYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT
		AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGS
		GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGA
		VTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSG
		SLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG
		TKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKD
		TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
		AKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKV
		SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
		VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
		DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGG
		GGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEE
		QYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAP
		IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
		LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
		K
CLDN18.2
251	VH CDR-H1	GYYMH
	CL-1 and CL-2
252	VH CDR-H2	WINPNSGGTKYAQKFQG
253	VH CDR-H3	DRITVAGTYYYYGMDV
254	VL CDR-L1	RASQGVNNWLA
255	VL CDR-L2	TASSLQS
256	VL CDR-L3	QQANSFPIT
257	VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHW
	CL-1	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
		DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSS
258	VL	DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQ
	CL-1	QKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRS
		LQPEDFATYYCQQANSFPITFGCGTRLEIK
259	scFv	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHW
	CL-1	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
		DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ
		SPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKA
		PKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFA
		TYYCQQANSFPITFGCGTRLEIK
260	bispecific	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHW
	molecule	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
	CL-1 xI2C	DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ
		SPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKA
		PKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFA
		TYYCQQANSFPITFGCGTRLEIKSGGGGSEVQLVESGGG
		LVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLE
		WVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVL
261	Bispecific scFc	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHW
	molecule	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
	CL-1 xI2C-scFc	DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ
		SPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKA
		PKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFA
		TYYCQQANSFPITFGCGTRLEIKSGGGGSEVQLVESGGG
		LVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLE
		WVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGP
		SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
		SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGG
		SGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
		NAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCK
		VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
		QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
		SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
262	VH	QVQMVQSGAEVKKHGASVKVSCKASGYTFTGYYMHW
	CL-2	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
		DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSS
263	VL	DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQ
	CL-2	QKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRS
		LQPEDFATYYCQQANSFPITFGCGTRLEIK
264	scFv	QVQMVQSGAEVKKHGASVKVSCKASGYTFTGYYMHW
	CL-2	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
		DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ
		SPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKA
		PKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFA
		TYYCQQANSFPITFGCGTRLEIK
265	bispecific	QVQMVQSGAEVKKHGASVKVSCKASGYTFTGYYMHW
	molecule	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
	CL-2xI2C	DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ
		SPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKA
		PKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFA
		TYYCQQANSFPITFGCGTRLEIKSGGGGSEVQLVESGGG
		LVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLE
		WVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVL
266	Bispecific scFc	QVQMVQSGAEVKKHGASVKVSCKASGYTFTGYYMHW
	molecule	VRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTR
	CL-2xI2C-scFc	DTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYY
		GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ
		SPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKA
		PKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFA
		TYYCQQANSFPITFGCGTRLEIKSGGGGSEVQLVESGGG
		LVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLE
		WVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGP
		SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
		SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGG
		SGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
		NAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCK
		VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
		QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
		SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
MUC17
267	VH CDR1 MU-2-C2	NHGMH
268	VH CDR2 MU-2-C2	GIWSEGSNKYYADAVKG
269	VH CDR3 MU-2-C2	ATYTTGWSYFDY
270	VL CDR1 MU-2-C2	SGDKLGDKYAS
271	VL CDR2 MU-2-C2	QDAKRPS
272	VL CDR3 MU-2-C2	QAFHQSTWV
273	VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNHGMHWV
	MU-2-C2	RQAPGKCLEWVAGIWSEGSNKYYADAVKGRFTISRDN
		SKNTLYLQMNSLRAEDTAVYYCARATYTTGWSYFDY
		WGQGTLVTVSS
274	VL	SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQK
	MU-2-C2	SGQSPVLVIYQDAKRPSGIPERFSGSNSGNTATLTISGTQ
		AMDEADYYCQAFHQSTWVFGCGTQLTVL
275	bispecific	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNHGMHWV
	molecule	RQAPGKCLEWVAGIWSEGSNKYYADAVKGRFTISRDN
	MU-2-C2 x CD3 -	SKNTLYLQMNSLRAEDTAVYYCARATYTTGWSYFDY
	scFc (MUC17 scFv	WGQGTLVTVSSGGGGSGGGGSGGGGSSYELTQPPSVSV
	underlined)	SPGQTASITCSGDKLGDKYASWYQQKSGQSPVLVIYQD
		AKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQA
		FHQSTWVFGCGTQLTVL
		SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKY
		AMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKD
		RFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFG
		NSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQT
		VVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQ
		KPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSG
		VQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
		GGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
		TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPC
		EEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALP
		APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
		SPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKT
		HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTY
		RCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
		AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI
		AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
		RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
276	VH CDR1	NHAMH
	MU-32-G6
277	VHCDR2	GIWSEGSNKYYAESVKG
	MU-32-G6
278	VH CDR3	ATYTTGWSYFDY
	MU-32-G6
279	VL CDR1	SGDKLGDKYAS
	MU-32-G6
280	VL CDR2	QDRKRPS
	MU-32-G6
281	VL CDR3	QAYDASTWV
	MU-32-G6
282	VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNHAMHWV
	MU-32-G6	RQAPGKCLEWVAGIWSEGSNKYYAESVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARATYTTGWSYFDYW
		GQGTLVTVSS
283	VL	SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQK
	MU-32-G6	SGQSPVLVIYQDRKRPSGIPERFSGSNSGNTATLTISGTQ
		AMDEADYYCQAYDASTWVFGCGTQLTVL
284	bispecific	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNHAMHWV
	molecule	RQAPGKCLEWVAGIWSEGSNKYYAESVKGRFTISRDNS
	MU-32-G6 x CD3 -	KNTLYLQMNSLRAEDTAVYYCARATYTTGWSYFDYW
	scFc (MUC17 scFv	GQGTLVTVSSGGGGSGGGGSGGGGSSYELTQPPSVSVS
	underlined)	PGQTASITCSGDKLGDKYASWYQQKSGQSPVLVIYQDR
		KRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAY
		DASTWVFGCGTQLTVL
		SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKY
		AMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKD
		RFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFG
		NSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQT
		VVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQ
		KPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSG
		VQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGDK
		THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGST
		YRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
		KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGG
		GSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCP
		APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVL
		TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
		EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
		NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
		VFSCSVMHEALHNHYTQKSLSLSPGK
285	VH CDR1	GYYWS
	MU 8-B7
286	VH CDR2	DIDASGSTKYNPSLKS
	MU 8-B7
287	VH CDR3	KKYSTVWSYFDN
	MU 8-B7
288	VL CDR1	SGDKLGDKYAS
	MU 8-B7
289	VL CDR2	QDRKRPS
	MU 8-B7
290	VL CDR3	QAWGSSTAV
	MU 8-B7
291	VH	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWI
	MU 8-B7	RQPPGKCLEWIGDIDASGSTKYNPSLKSRVTISLDTSKN
		QFSLKLNSVTAADTAVYFCARKKYSTVWSYFDNWGQG
		TLVTVSS
292	VL	SYELTQPSSVSVPPGQTASITCSGDKLGDKYASWYQQK
	MU 8-B7	PGQSPVLVIYQDRKRPSGVPERFSGSNSGNTATLTISGTQ
		AMDEADYYCQAWGSSTAVFGCGTKLTVL
293	bispecific	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWI
	molecule	RQPPGKCLEWIGDIDASGSTKYNPSLKSRVTISLDTSKN
	MU 8-B7 x CD3 - scFc	QFSLKLNSVTAADTAVYFCARKKYSTVWSYFDNWGQG
	(MUC17 scFv	TLVTVSSGGGGSGGGGSGGGGSSYELTQPSSVSVPPGQ
	underlined)	TASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRP
		SGVPERFSGSNSGNTATLTISGTQAMDEADYYCQAWGS
		STAVFGCGTKLTVL
		SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKY
		AMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKD
		RFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFG
		NSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQT
		VVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQ
		KPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSG
		VQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGDK
		THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGST
		YRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
		KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGG
		GSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCP
		APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVL
		TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
		EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
		NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
		VFSCSVMHEALHNHYTQKSLSLSPGK
294	VH CDR1	GYYWS
	MU 1-B6
295	VH CDR2	DIDYSGSTKYNPSLKS
	MU 1-B6
296	VH CDR3	KKYSTVWSYFDY
	MU 1-B6
297	VL CDR1	SGDKLGDKYAN
	MU 1-B6
298	VL CDR2	HDNKRPS
	MU 1-B6
299	VL CDR3	QAYGISSAV
	MU 1-B6
300	VH	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWI
	MU 1-B6	RQPPGKCLEWIGDIDYSGSTKYNPSLKSRVTISLDTSKN
		QFSLKLNSVTAADTAVYFCARKKYSTVWSYFDYWGQG
		TLVTVSS
301	VL	SYELTQPASASVSPGQTASITCSGDKLGDKYANWYQQK
	MU 1-B6	PGQSPILVIYHDNKRPSGIPERFSGSNSGNTATLTISGTQA
		MDEADYYCQAYGISSAVFGCGTKLTVL
302	bispecific	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWI
	molecule	RQPPGKCLEWIGDIDYSGSTKYNPSLKSRVTISLDTSKN
	MU 1-B6xCD3-scFc	QFSLKLNSVTAADTAVYFCARKKYSTVWSYFDYWGQG
	(MUC17 scFv	TLVTVSSGGGGSGGGGSGGGGSSYELTQPASASVSPGQ
	underlined)	TASITCSGDKLGDKYANWYQQKPGQSPILVIYHDNKRP
		SGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAYGIS
		SAVFGCGTKLTVL
		SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKY
		AMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKD
		RFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFG
		NSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQT
		VVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQ
		KPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSG
		VQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGDK
		THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
		VVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGST
		YRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
		DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
		KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGG
		GSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCP
		APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVL
		TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
		EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
		NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
		VFSCSVMHEALHNHYTQKSLSLSPGK
CDH3
303	VH CDR1 CDH3 G8A	SYPIN
	6-B12
304	VH CDR2 CDH3 G8A	VIWTGGGTNYASSVKG
	6-B12
305	VH CDR3 CDH3 G8A	SRGVYDFDGRGAMDY
	6-B12
306	VL CDR1 CDH3 G8A	KSSQSLLYSSNQKNYFA
	6-B12
307	VL CDR2 CDH3 G8A	WASTRES
	6-B12
308	VL CDR3 CDH3 G8A	QQYYSYPYT
	6-B12
309	VH CDH3 G8A 6-B12	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQ
		APGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNT
		VYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDY
		WGQGTLVTVSS
310	VL CDH3 G8A 6-B12	DIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNQKNYF
		AWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDF
		TLTISSLQAEDVAVYYCQQYYSYPYTFGQGTKLEIK
311	CDH3 G8A 6-B12	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQ
	scFv	APGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNT
		VYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDY
		WGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSL
		AVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQP
		PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDV
		AVYYCQQYYSYPYTFGQGTKLEIK
312	CDH3 G8A 6-B12x	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQ
	CD3 bispecific	APGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNT
	molecule	VYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDY
		WGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSL
		AVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQP
		PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDV
		AVYYCQQYYSYPYTFGQGTKLEIKSGGGGSEVQLVESG
		GGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL
		EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVL
313	CDH3 G8A 6-B12x	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYPINWVRQ
	I2C0 bispecific	APGKGLEWVGVIWTGGGTNYASSVKGRFTISRDNSKNT
	molecule HLE	VYLQMNSLRAEDTAVYYCAKSRGVYDFDGRGAMDY
		WGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSL
		AVSLGERATINCKSSQSLLYSSNQKNYFAWYQQKPGQP
		PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDV
		AVYYCQQYYSYPYTFGQGTKLEIKSGGGGSEVQLVESG
		GGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL
		EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL
		QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGT
		LVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT
		VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF
		LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLW
		YSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGP
		SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
		YVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL
		NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
		SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
		EALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGG
		SGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPK
		DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
		NAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCK
		VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
		QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
		SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
		TQKSLSLSPGK
CD19
314	CD19 VL CDR1	KASQSVDYDGDSYLN
315	CD19 VL CDR2	DASNLVS
316	CD19 VL CDR3	QQSTEDPWT
317	CD19 VH CDR1	SYWMN
318	CD19 VH CDR2	QIWPGDGDTNYNGKFKG
319	CD19 VH CDR3	RETTTVGRYYYAMDY
320	CD19 VL	DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
		WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLN
		IHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK
321	CD19 VH	QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWV
		KQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADE
		SSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMD
		YWGQGTTVTVSS
322	CD19 scFv	DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
		WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLN
		IHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGS
		GGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYA
		FSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKF
		KGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETT
		TVGRYYYAMDYWGQGTTVTVSS
323	CD3 VH CDR1	RYTMH
324	CD3 VH CDR2	YINPSRGYTNYNQKFKD
325	CD3 VH CDR3	YYDDHYCLDY
326	CD3 VL CDR1	RASSSVSYMN
327	CD3 VL CDR2	DTSKVAS
328	CD3 VL CDR3	QQWSSNPLT
329	CD3 VH	DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWV
		KQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKS
		SSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQG
		TTLTVSS
330	CD3 VL	VDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQ
		QKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISS
		MEAEDAATYYCQQWSSNPLTFGAGTKLELK
331	CD3 scFv	DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWV
		KQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKS
		SSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQG
		TTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSAS
		PGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTS
		KVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQ
		WSSNPLTFGAGTKLELK
332	CD19xCD3 scFv incl	DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
	linker and his-tag	WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLN
		IHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGS
		GGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYA
		FSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKF
		KGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETT
		TVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAE
		LARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLE
		WIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLS
		SLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVE
		GGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMT
		CRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPY
		RFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG
		AGTKLELKHHHHHH
333	Peptide linker	GGGG
334	Peptide linker	GGGGS
335	Peptide linker	GGGGQ
336	Peptide linker	PGGGGS
337	Peptide linker	PGGDGS
338	Peptide linker	SGGGGS
339	Peptide linker	GGGGSGGGS
340	Peptide linker	GGGGSGGGGS
341	Peptide linker	GGGGSGGGGSGGGGS
342	Peptide linker	(GGGGS)x, x = 1, 2, 3, or 4
343	Histidine tag	HHHHHH
344	scFc 1	DKTHTCPPCP APELLGGPSV FLFPPKPKDT
		LMISRTPEVT CVVVDVSHED PEVKFNWYVD
		GVEVHNAKTK PCEEQYGSTY RCVSVLTVLH
		QDWLNGKEYK CKVSNKALPA PIEKTISKAK
		GQPREPQVYT LPPSREEMTK NQVSLTCLVK
		GFYPSDIAVE WESNGQPENN YKTTPPVLDS
		DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
		ALHNHYTQKS LSLSPGKGGG GSGGGGSGGG
		GSGGGGSGGG GSGGGGSDKT HTCPPCPAPE
		LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV
		VDVSHEDPEV KFNWYVDGVE VHNAKTKPCE
		EQYGSTYRCV SVLTVLHQDW LNGKEYKCKV
		SNKALPAPIE KTISKAKGQP REPQVYTLPP
		SREEMTKNQV SLTCLVKGFY PSDIAVEWES
		NGQPENNYKT TPPVLDSDGS FFLYSKLTVD
		KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK
345	scFc 2	DKTHTCPPCP APELLGGPSV FLFPPKPKDT
		LMISRTPEVT CVVVDVSHED PEVKFNWYVD
		GVEVHNAKTK PCEEQYGSTY RCVSVLTVLH
		QDWLNGKEYK CKVSNKALPA PIEKTISKAK
		GQPREPQVYT LPPSREEMTK NQVSLTCLVK
		GFYPSDIAVE WESNGQPENN YKTTPPVLDS
		DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
		ALHNHYTQKS LSLSPGGGGS GGGGSGGGGS
		GGGGSGGGGS GGGGSDKTHT CPPCPAPELL
		GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
		VSHEDPEVKF NWYVDGVEVH NAKTKPCEEQ
		YGSTYRCVSV LTVLHQDWLN GKEYKCKVSN
		KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
		EEMTKNQVSL TCLVKGFYPS DIAVEWESNG
		QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
		RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK

TABLE 16
Exemplary sequences of anti-CCR8 antibodies of the present invention.
SEQ ID NO.	Description	Sequence
346	Antibody 1 IgG1 HCDR1	NARMG
347	Antibody 1 IgG1 HCDR2	RIKSKTEGGTRDYAAPVKG
348	Antibody 1 IgG1 HCDR3	YSGV
349	Antibody 1 IgG1 LCDR1	KSSQSVLYSSNNKNYLA
350	Antibody 1 IgG1 LCDR2	WASTRES
351	Antibody 1 IgG1 LCDR3	QQYYSIPIT
352	Antibody 1 IgG1 HCVR	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARM
		GWVRQAPGKGLEWVGRIKSKTEGGTRDYAAPVKG
		RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYS
		GVWGQGTMVTVSS
353	Antibody 1 IgG1 LCVR	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSN
		NKNYLAWYHQKPGQSPKLLISWASTRESGVPDRF
		SGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPI
		TFGGGTKVEIKR
354	Antibody 1 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARM
		GWVRQAPGKGLEWVGRIKSKTEGGTRDYAAPVKG
		RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYS
		GVWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
		VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
		TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
		PGK
355	Antibody 1 IgG1 LC	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSN
		NKNYLAWYHQKPGQSPKLLISWASTRESGVPDRF
		SGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPI
		TFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
		SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT
		EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
356	Antibody 1.1 IgG1 (LC: H45Q_S51P)	NARMG
	HCDR1
357	Antibody 1.1 IgG1 (LC: H45Q_S51P)	RIKSKTEGGTRDYAAPVKG
	HCDR2
358	Antibody 1.1 IgG1 (LC: H45Q_S51P)	YSGV
	HCDR3
359	Antibody 1.1 IgG1 (LC: H45Q_S51P)	KSSQSVLYSSNNKNYLA
	LCDR1
360	Antibody 1.1 IgG1 (LC: H45Q_S51P)	WASTRES
	LCDR2
361	Antibody 1.1 IgG1 (LC: H45Q_S51P)	QQYYSIPIT
	LCDR3
362	Antibody 1.1 IgG1 (LC: H45Q_S51P)	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARM
	HCVR	GWVRQAPGKGLEWVGRIKSKTEGGTRDYAAPVKG
		RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYS
		GVWGQGTMVTVSS
363	Antibody 1.1 IgG1 (LC: H45Q_S51P)	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSN
	LCVR	NKNYLAWYQQKPGQPPKLLISWASTRESGVPDRF
		SGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPI
		TFGGGTKVEIKR
364	Antibody 1.1 IgG1 (LC: H45Q_S51P)	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARM
	HC	GWVRQAPGKGLEWVGRIKSKTEGGTRDYAAPVKG
		RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYS
		GVWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
		VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
		SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
		FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
		FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
		LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD
		IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
		TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
		PGK
365	Antibody 1.1 IgG1 (LC: H45Q_S51P)	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSN
	LC	NKNYLAWYQQKPGQPPKLLISWASTRESGVPDRF
		SGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPI
		TFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
		SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT
		EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
		QGLSSPVTKSFNRGEC
366	Antibody 2.1 IgG1 HCDR1	NYGMH
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A_
	S26A, HC: A71I_D72R)
367	Antibody 2.1 IgG1 HCDR2	VISYDGSNKFYIRSVKG
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A_
	S26A, HC: A71I_D72R)
368	Antibody 2.1 IgG1 HCDR3	AGGIGRFDY
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A_
	S26A, HC: A71I_D72R)
369	Antibody 2.1 IgG1 LCDR1	KAAQSLLHSDGKTYLF
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A_
	S26A, HC: A71I_D72R)
370	Antibody 2.1 IgG1 LCDR2	EVSNRFS
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A_
	S26A, HC: A71I_D72R)
371	Antibody 2.1 IgG1 LCDR3	MQTLKLPLT
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A
	S26A, HC: A71I D72R)
372	Antibody 2.1 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGM
	(LC: F2I_P51S_H53Q_L103V_N148	HWVRQAPGKGLEWVAVISYDGSNKFYIRSVKGRF
	K, HC: K87N_S94N_V98A)(LC: Y25A_	TISRDNSKNTLYLQMNSLRAEDTAVYYCARAGGI
	_S26A, HC: A71I_D72R)	GRFDYWGQGTLVTVSS
373	Antibody 2.1 IgG1 LCVR	DIVMTQTPLSLSVTPGQPASISCKAAQSLLHSDG
	(LC: F2I_P51S_H53Q_L103V_N148K,	KTYLFWYLQKPGQSPQLLIYEVSNRFSGVPDRFS
	HC: K87N_S94N_V98A)(LC: Y25A_	GSGSGTDFTLKISRVEAEDVGVYYCMQTLKLPLT
	S26A, HC: A71I_D72R)	FGGGTKVEIKR
374	Antibody 2.1 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGM
	(LC: F2I_P51S_H53Q_L103V_N148K,	HWVRQAPGKGLEWVAVISYDGSNKFYIRSVKGRF
	HC: K87N_S94N_V98A)(LC: Y25A_	TISRDNSKNTLYLQMNSLRAEDTAVYYCARAGGI
	S26A, HC: A71I_D72R)	GRFDYWGQGTLVTVSSASTKGPSVFPLAPSSKST
		SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
		FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
		HKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
		PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
		EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
		KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
		PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
		SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
		SLSPGK
375	Antibody 2.1 IgG1 LC	DIVMTQTPLSLSVTPGQPASISCKAAQSLLHSDG
	(LC: F2I_P51S_H53Q_L103V_N148K,	KTYLFWYLQKPGQSPQLLIYEVSNRFSGVPDRFS
	HC: K87N_S94N_V98A)(LC: Y25A_	GSGSGTDFTLKISRVEAEDVGVYYCMQTLKLPLT
	S26A, HC: A71I_D72R)	FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
376	Antibody 2.2 IgG1 HCDR1	NYGMH
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A,
	HC: A71L_D72K)
377	Antibody 2.2 IgG1 HCDR2	VISYDGSNKFYLKSVKG
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A,
	HC: A71L_D72K)
378	Antibody 2.2 IgG1 HCDR3	AGGIGRFDY
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A,
	HC: A71L_D72K)
379	Antibody 2.2 IgG1 LCDR1	KASQSLLHSDGKTYLF
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A,
	HC: A71L_D72K)
380	Antibody 2.2 IgG1 LCDR2	EVSNRFS
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A,
	HC: A71L_D72K)
381	Antibody 2.2 IgG1 LCDR3	MQTLKLPLT
	(LC: F2I_P51S_H53Q_L103V_N148K,
	HC: K87N_S94N_V98A)(LC: Y25A,
	HC: A71L_D72K)
382	Antibody 2.2 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGM
	(LC: F2I_P51S_H53Q_L103V_N148K,	HWVRQAPGKGLEWVAVISYDGSNKFYLKSVKGRF
	HC: K87N_S94N_V98A)(LC: Y25A,	TISRDNSKNTLYLQMNSLRAEDTAVYYCARAGGI
	HC: A71L_D72K)	GRFDYWGQGTLVTVSS
383	Antibody 2.2 IgG1 LCVR	DIVMTQTPLSLSVTPGQPASISCKASQSLLHSDG
	(LC: F2I_P51S_H53Q_L103V_N148K,	KTYLFWYLQKPGQSPQLLIYEVSNRFSGVPDRFS
	HC: K87N_S94N_V98A)(LC: Y25A,	GSGSGTDFTLKISRVEAEDVGVYYCMQTLKLPLT
	HC: A71L_D72K)	FGGGTKVEIKR
384	Antibody 2.2 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGM
	(LC: F2I_P51S_H53Q_L103V_N148K,	HWVRQAPGKGLEWVAVISYDGSNKFYLKSVKGRF
	HC: K87N_S94N_V98A)(LC: Y25A,	TISRDNSKNTLYLQMNSLRAEDTAVYYCARAGGI
	HC: A71L_D72K)	GRFDYWGQGTLVTVSSASTKGPSVFPLAPSSKST
		SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
		FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
		SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
		VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL
		TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
		GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP
		SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
		LSPGK
385	Antibody 2.2 IgG1 LC	DIVMTQTPLSLSVTPGQPASISCKASQSLLHSDG
	(LC: F2I_P51S_H53Q_L103V_N148K,	KTYLFWYLQKPGQSPQLLIYEVSNRFSGVPDRFS
	HC: K87N_S94N_V98A)(LC: Y25A,	GSGSGTDFTLKISRVEAEDVGVYYCMQTLKLPLT
	HC: A71L_D72K)	FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
386	Antibody 3.0 IgG1 HCDR1	NAWMS
387	Antibody 3.0 IgG1 HCDR2	RIKRRTDGGTTDYAAPVKD
388	Antibody 3.0 IgG1 HCDR3	VTMVRGVIADY
389	Antibody 3.0 IgG1 LCDR1	RASQSVSSGSLA
390	Antibody 3.0 IgG1 LCDR2	GASSRAT
391	Antibody 3.0 IgG1 LCDR3	QQYGSSRT
392	Antibody 3.0 IgG1 HCVR	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWM
		SWVRQAPGKGLEWVARIKRRTDGGTTDYAAPVKD
		RFTISRDDSKNTLFLQMNSLKTEDTAVYYCTTVT
		MVRGVIADYWGQGTLVTVSS
393	Antibody 3.0 IgG1 LCVR	EIVLTQSPGTLSLSPGERATLSCRASQSVSSGSL
		AWYQQKLGQAPRLLIYGASSRATGIPDRFSGSGS
		GTDFTLTISSLEPEDFAVYYCQQYGSSRTFGQGT
		KVELKR
394	Antibody 3.0 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWM
		SWVRQAPGKGLEWVARIKRRTDGGTTDYAAPVKD
		RFTISRDDSKNTLFLQMNSLKTEDTAVYYCTTVT
		MVRGVIADYWGQGTLVTVSSASTKGPSVFPLAPS
		SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
		GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
		LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
		VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT
		ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPGK
395	Antibody 3.0 IgG1 LC	EIVLTQSPGTLSLSPGERATLSCRASQSVSSGSL
		AWYQQKLGQAPRLLIYGASSRATGIPDRFSGSGS
		GTDFTLTISSLEPEDFAVYYCQQYGSSRTFGQGT
		KVELKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
		VTKSFNRGEC
396	Antibody 4.0 IgG1 HCDR1	NAWMS
397	Antibody 4.0 IgG1 HCDR2	RIKRKTDGGTTDYAAPVKG
398	Antibody 4.0 IgG1 HCDR3	VTLVRGIIFDY
399	Antibody 4.0 IgG1 LCDR1	RVSQSVSSSQLA
400	Antibody 4.0 IgG1 LCDR2	GASSRAT
401	Antibody 4.0 IgG1 LCDR3	QQYGNSRT
402	Antibody 4.0 IgG1 HCVR	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWM
		SWVRQAPGKGLEWVGRIKRKTDGGTTDYAAPVKG
		RFTISRDDSKNTLYLLMNSLKIEDTAVYYCTVVT
		LVRGIIFDYWGQGTLVTVSS
403	Antibody 4.0 IgG1 LCVR	EIVLTQSPGTLSLSPGESATLSCRVSQSVSSSQL
		AWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQQYGNSRTFGQGT
		KVEIKR
404	Antibody 4.0 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWM
		SWVRQAPGKGLEWVGRIKRKTDGGTTDYAAPVKG
		RFTISRDDSKNTLYLLMNSLKIEDTAVYYCTVVT
		LVRGIIFDYWGQGTLVTVSSASTKGPSVFPLAPS
		SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
		GVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYIC
		NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
		LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
		VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
		SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
		GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
		FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
		KSLSLSPGK
405	Antibody 4.0 IgG1 LC	EIVLTQSPGTLSLSPGESATLSCRVSQSVSSSQL
		AWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS
		GTDFTLTISRLEPEDFAVYYCQQYGNSRTFGQGT
		KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
		VTKSFNRGEC
406	Antibody 4.1 IgG1 HCDR1	NAWLQ
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65Q_G66L)
407	Antibody 4.1 IgG1 HCDR2	RIKRKTDQLTTDYAAPVKG
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65Q G66L)
408	Antibody 4.1 IgG1 HCDR3	VTRSRGIIFDY
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65Q G66L)
409	Antibody 4.1 IgG1 LCDR1	RVSQSVSSSQLA
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65Q G66L)
410	Antibody 4.1 IgG1 LCDR2	GASSRAT
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65Q G66L)
411	Antibody 4.1 IgG1 LCDR3	QQYGNPRT
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65Q G66L)
412	Antibody 4.1 IgG1 HCVR	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWL
	(VH: M41L_S42Q_L111R_V112S, VL:	QWVRQAPGKGLEWVGRIKRKTDQLTTDYAAPVKG
	S18R_S136P)_huIgG1z	RFTISRDDSKNTLYLLMNSLKIEDTAVYYCTVVT
	mAb(LC: R18S, HC: G65Q_G66L)	RSRGIIFDYWGQGTLVTVSS
413	Antibody 4.1 IgG1 LCVR	EIVLTQSPGTLSLSPGESATLSCRVSQSVSSSQL
	(VH: M41L_S42Q_L111R_V112S, VL:	AWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS
	S18R_S136P)_huIgG1z	GTDFTLTISRLEPEDFAVYYCQQYGNPRTFGQGT
	mAb(LC: R18S, HC: G65Q_G66L)	KVEIKR
414	Antibody 4.1 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWL
	(VH: M41L_S42Q_L111R_V112S, VL:	QWVRQAPGKGLEWVGRIKRKTDQLTTDYAAPVKG
	S18R_S136P)_huIgG1z	RFTISRDDSKNTLYLLMNSLKIEDTAVYYCTVVT
	mAb(LC: R18S, HC: G65Q_G66L)	RSRGIIFDYWGQGTLVTVSSASTKGPSVFPLAPS
		SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
		GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
		LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
		VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT
		ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPGK
415	Antibody 4.1 IgG1 LC	EIVLTQSPGTLSLSPGESATLSCRVSQSVSSSQL
	(VH: M41L_S42Q_L111R_V112S, VL:	AWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS
	S18R_S136P)_huIgG1z	GTDFTLTISRLEPEDFAVYYCQQYGNPRTFGQGT
	mAb(LC: R18S, HC: G65Q_G66L)	KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
		VTKSFNRGEC
416	Antibody 4.2 IgG1 HCDR1	NAWLQ
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65A_G66S)
417	Antibody 4.2 IgG1 HCDR2	RIKRKTDASTTDYAAPVKG
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65A_G66S)
418	Antibody 4.2 IgG1 HCDR3	VTRSRGIIFDY
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65A_G66S)
419	Antibody 4.2 IgG1 LCDR1	RVSQSVSSSQLA
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65A_G66S)
420	Antibody 4.2 IgG1 LCDR2	GASSRAT
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65A_G66S)
421	Antibody 4.2 IgG1 LCDR3	QQYGNPRT
	(VH: M41L_S42Q_L111R_V112S, VL:
	S18R_S136P)_huIgG1z
	mAb(LC: R18S, HC: G65A_G66S)
422	Antibody 4.2 IgG1 HCVR	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWL
	(VH: M41L_S42Q_L111R_V112S, VL:	QWVRQAPGKGLEWVGRIKRKTDASTTDYAAPVKG
	S18R_S136P)_huIgG1z	RFTISRDDSKNTLYLLMNSLKIEDTAVYYCTVVT
	mAb(LC: R18S, HC: G65A_G66S)	RSRGIIFDYWGQGTLVTVSS
423	Antibody 4.2 IgG1 LCVR	EIVLTQSPGTLSLSPGESATLSCRVSQSVSSSQL
	(VH: M41L_S42Q_L111R_V112S, VL:	AWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS
	S18R_S136P)_huIgG1z	GTDFTLTISRLEPEDFAVYYCQQYGNPRTFGQGT
	mAb(LC: R18S, HC: G65A_G66S)	KVEIKR
424	Antibody 4.2 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWL
	(VH: M41L_S42Q_L111R_V112S, VL:	QWVRQAPGKGLEWVGRIKRKTDASTTDYAAPVKG
	S18R_S136P)_huIgG1z	RFTISRDDSKNTLYLLMNSLKIEDTAVYYCTVVT
	mAb(LC: R18S, HC: G65A_G66S)	RSRGIIFDYWGQGTLVTVSSASTKGPSVFPLAPS
		SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
		GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
		LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
		HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
		VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT
		ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPGK
425	Antibody 4.2 IgG1 LC	EIVLTQSPGTLSLSPGESATLSCRVSQSVSSSQL
	(VH: M41L_S42Q_L111R_V112S, VL:	AWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGS
	S18R_S136P)_huIgG1z	GTDFTLTISRLEPEDFAVYYCQQYGNPRTFGQGT
	mAb(LC: R18S, HC: G65A_G66S)	KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
		NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
		STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
		VTKSFNRGEC
426	Antibody 5.0 IgG1 HCDR1	SYGMH
427	Antibody 5.0 IgG1 HCDR2	VISYDGSNKYYADSVKG
428	Antibody 5.0 IgG1 HCDR3	GRYFDWFLFDY
429	Antibody 5.0 IgG1 LCDR1	KSSQSLLHSDGKTYLF
430	Antibody 5.0 IgG1 LCDR2	EVSNRFS
431	Antibody 5.0 IgG1 LCDR3	MQSLRLPLT
432	Antibody 5.0 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
		HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
		TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSS
433	Antibody 5.0 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
		KTYLFWYLQKPGQPPQLLISEVSNRFSGVPDRFS
		GSGSGTDFTLKISRVEAEDVGFYYCMQSLRLPLT
		FGGGTKVEIKR
434	Antibody 5.0 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
		HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
		TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
435	Antibody 5.0 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
		KTYLFWYLQKPGQPPQLLISEVSNRFSGVPDRFS
		GSGSGTDFTLKISRVEAEDVGFYYCMQSLRLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
436	Antibody 5.1 IgG1 HCDR1	SYGMH
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z mAb
437	Antibody 5.1 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z mAb
438	Antibody 5.1 IgG1 HCDR3	GRYFDWTLFDY
	(VH: F134T, VL: S34R_S57Y_F103V)__
	huIgG1z mAb
439	Antibody 5.1 IgG1 LCDR1	KSSQSLLHRDGKTYLF
	(VH: F134T, VL: S34R_S57Y_F103V)
	huIgG1z mAb
440	Antibody 5.1 IgG1 LCDR2	EVSNRFS
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z mAb
441	Antibody 5.1 IgG1 LCDR3	MQSLRLPLT
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z mAb
442	Antibody 5.1 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: F134T, VL: S34R_S57Y_F103V)_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWTLFDYWGQGTLVTVSS
443	Antibody 5.1 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHRDG
	(VH: F134T, VL: S34R_S57Y_F103V)_	KTYLFWYLQKPGQPPQLLIYEVSNRFSGVPDRFS
	huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKR
444	Antibody 5.1 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: F134T, VL: S34R_S57Y_F103V)_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWTLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
445	Antibody 5.1 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHRDG
	(VH: F134T, VL: S34R_S57Y_F103V)_	KTYLFWYLQKPGQPPQLLIYEVSNRFSGVPDRFS
	huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
446	Antibody 5.2 IgG1 HCDR1	SYPMH
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z mAb
447	Antibody 5.2 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z mAb
448	Antibody 5.2 IgG1 HCDR3	GRYFDWTLFDY
	(VH: G40PF134T, VL: S57_YE58L_
	V67R_F103V)_huIgG1z mAb
449	Antibody 5.2 IgG1 LCDR1	KSSQSLLHSDGKTYLF
	(VH: G40PF134T, VL: S57_YE58L_
	V67R_F103V)_huIgG1z mAb
450	Antibody 5.2 IgG1 LCDR2	LRSNRFS
	(VH: G40PF134T, VL: S57_YE58L_
	V67R_F103V)_huIgG1z mAb
451	Antibody 5.2 IgG1 LCDR3	MQSLRLPLT
	(VH: G40PF134T, VL: S57_YE58L_
	V67R F103V) huIgG1z mAb
452	Antibody 5.2 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPM
	(VH: G40PF134T, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	V67R_F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWTLFDYWGQGTLVTVSS
453	Antibody 5.2 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: G40PF134T, VL: S57Y_E58L_	KTYLFWYLQKPGQPPQLLIYLRSNRFSGVPDRFS
	V67R_F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKR
454	Antibody 5.2 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPM
	(VH: G40PF134T, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	V67R_F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWTLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
455	Antibody 5.2 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: G40PF134T, VL: S57_YE58L_	KTYLFWYLQKPGQPPQLLIYLRSNRFSGVPDRFS
	V67R_F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
456	Antibody 5.3 IgG1 HCDR1	SYGMH
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z mAb
457	Antibody 5.3 IgG1 HCDR2	VISYDGSNKYYSRSVKG
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z mAb
458	Antibody 5.3 IgG1 HCDR3	GRYFDWFLFDY
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z mAb
459	Antibody 5.3 IgG1 LCDR1	KSSQSLLHSDGKTYLF
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z mAb
460	Antibody 5.3 IgG1 LCDR2	LSSNRFS
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z mAb
461	Antibody 5.3 IgG1 LCDR3	MQSLRLPLT
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z mAb
462	Antibody 5.3 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: A71S_D72R, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYSRSVKGRF
	V67S_F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSS
463	Antibody 5.3 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: A71S_D72R, VL: S57Y_E58L_	KTYLFWYLQKPGQPPQLLIYLSSNRFSGVPDRFS
	V67S_F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKR
464	Antibody 5.3 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: A71S_D72R, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYSRSVKGRF
	V67S_F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
465	Antibody 5.3 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: A71S_D72R, VL: S57Y_E58L_	KTYLFWYLQKPGQPPQLLIYLSSNRFSGVPDRFS
	V67S_F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
466	Antibody 5.4 IgG1 HCDR1	SYAMH
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z mAb
467	Antibody 5.4 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z mAb
468	Antibody 5.4 IgG1 HCDR3	GRYFDWFLFDY
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z mAb
469	Antibody 5.4 IgG1 LCDR1	KSSQSLLHSDGKTYLF
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z mAb
470	Antibody 5.4 IgG1 LCDR2	LTSNRFS
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z mAb
471	Antibody 5.4 IgG1 LCDR3	MQSLRLPLT
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z mAb
472	Antibody 5.4 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAM
	(VH: G40A, VL: S57Y_E58L_V67T_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSS
473	Antibody 5.4 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: G40A, VL: S57Y_E58L_V67T_	KTYLFWYLQKPGQPPQLLIYLTSNRFSGVPDRFS
	F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKR
474	Antibody 5.4 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAM
	(VH: G40A, VL: S57Y_E58L_V67T_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
475	Antibody 5.4 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: G40A, VL: S57Y_E58L_V67T_	KTYLFWYLQKPGQPPQLLIYLTSNRFSGVPDRFS
	F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
476	Antibody 5.5 IgG1 HCDR1	SYPVH
	(VH: G40P_M41V, VL: S57Y_E58L_
	V67T_F103V)_huIgG1z mAb
477	Antibody 5.5 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: G40P_M41V, VL: S57Y_E58L_
	V67T_F103V)_huIgG1z mAb
478	Antibody 5.5 IgG1 HCDR3	GRYFDWFLFDY
	(VH: G40P_M41V, VL: S57Y_E58L_
	V67T_F103V)_huIgG1z mAb
479	Antibody 5.5 IgG1 LCDR1	KSSQSLLHSDGKTYLF
	(VH: G40P_M41V, VL: S57Y_E58L_
	V67T_F103V)_huIgG1z mAb
480	Antibody 5.5 IgG1 LCDR2	LTSNRFS
	(VH: G40P_M41V, VL: S57Y_E58L_
	V67T F103V) huIgG1zmAb
481	Antibody 5.5 IgG1 LCDR3	MQSLRLPLT
	(VH: G40P_M41V, VL: S57Y_E58L_
	V67T_F103V)_huIgG1z mAb
482	Antibody 5.5 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPV
	(VH: G40P_M41V, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	V67T_F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSS
483	Antibody 5.5 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: G40P_M41V, VL: S57Y_E58L_	KTYLFWYLQKPGQPPQLLIYLTSNRFSGVPDRFS
	V67T_F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKR
484	Antibody 5.5 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPV
	(VH: G40P_M41V, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	V67T_F103V)_huIgG1z mAb	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
		DWFLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
485	Antibody 5.5 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDG
	(VH: G40P_M41V, VL: S57Y_E58L_	KTYLFWYLQKPGQPPQLLIYLTSNRFSGVPDRFS
	V67T_F103V)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGVYYCMQSLRLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
486	Antibody 5.6 IgG1 HCDR1	SYGMH
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z
	mAb(LC: G37A K38R M107L)
487	Antibody 5.6 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z
	mAb(LC: G37A_K38R_M107L)
488	Antibody 5.6 IgG1 HCDR3	GRYFDWTLFDY
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z
	mAb(LC: G37A_K38R_M107L)
489	Antibody 5.6 IgG1 LCDR1	KSSQSLLHRDARTYLF
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z
	mAb(LC: G37A_K38R_M107L)
490	Antibody 5.6 IgG1 LCDR2	EVSNRFS
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z
	mAb(LC: G37A_K38R_M107L)
491	Antibody 5.6 IgG1 LCDR3	LQSLRLPLT
	(VH: F134T, VL: S34R_S57Y_F103V)_
	huIgG1z
	mAb(LC: G37A_K38R_M107L)
492	Antibody 5.6 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: F134T, VL: S34R_S57Y_F103V)_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWTLFDYWGQGTLVTVSS
493	Antibody 5.6 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHRDA
	(VH: F134T, VL: S34R_S57Y_F103V)_	RTYLFWYLQKPGQPPQLLIYEVSNRFSGVPDRFS
	huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKR
494	Antibody 5.6 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: F134T, VL: S34R_S57Y_F103V)_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWTLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
495	Antibody 5.6 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHRDA
	(VH: F134T, VL: S34R_S57Y_F103V)_	RTYLFWYLQKPGQPPQLLIYEVSNRFSGVPDRFS
	huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
496	Antibody 5.7 IgG1 HCDR1	SYGMH
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
497	Antibody 5.7 IgG1 HCDR2	VISYDGSNKYYSRSVKG
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
498	Antibody 5.7 IgG1 HCDR3	GRYFDWFLFDY
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
499	Antibody 5.7 IgG1 LCDR1	KSSQSLLHSDARTYLF
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
500	Antibody 5.7 IgG1 LCDR2	LSSNRFS
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
501	Antibody 5.7 IgG1 LCDR3	LQSLRLPLT
	(VH: A71S_D72R, VL: S57Y_E58L_
	V67S_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
502	Antibody 5.7 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: A71S_D72R, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYSRSVKGRF
	V67S_F103V)_huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWFLFDYWGQGTLVTVSS
503	Antibody 5.7 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDA
	(VH: A71S_D72R, VL: S57Y_E58L_	RTYLFWYLQKPGQPPQLLIYLSSNRFSGVPDRFS
	V67S_F103V)_huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKR
504	Antibody 5.7 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
	(VH: A71S_D72R, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYSRSVKGRF
	V67S_F103V)_huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWFLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
505	Antibody 5.7 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDA
	(VH: A71S_D72R, VL: S57Y_E58L_	RTYLFWYLQKPGQPPQLLIYLSSNRFSGVPDRFS
	V67S_F103V)_huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
506	Antibody 5.8 IgG1 HCDR1	SYPMH
	(VH: G40PF134T, VL: S57Y_E58L_
	67R_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
507	Antibody 5.8 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
508	Antibody 5.8 IgG1 HCDR3	GRYFDWTLFDY
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
509	Antibody 5.8 IgG1 LCDR1	KSSQSLLHSDARTYLF
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
510	Antibody 5.8 IgG1 LCDR2	LRSNRFS
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
511	Antibody 5.8 IgG1 LCDR3	LQSLRLPLT
	(VH: G40PF134T, VL: S57Y_E58L_
	V67R_F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
512	Antibody 5.8 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPM
	(VH: G40PF134T, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	V67R_F103V)_huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWTLFDYWGQGTLVTVSS
513	Antibody 5.8 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDA
	(VH: G40PF134T, VL: S57Y_E58L_	RTYLFWYLQKPGQPPQLLIYLRSNRFSGVPDRFS
	V67R_F103V)_huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKR
514	Antibody 5.8 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPM
	(VH: G40PF134T, VL: S57Y_E58L_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	V67R_F103V)_huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWTLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
515	Antibody 5.8 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDA
	(VH: G40PF134T, VL: S57Y_E58L_	RTYLFWYLQKPGQPPQLLIYLRSNRFSGVPDRFS
	V67R_F103V)_huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
516	Antibody 5.9 IgG1 HCDR1	SYAMH
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
517	Antibody 5.9 IgG1 HCDR2	VISYDGSNKYYADSVKG
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
518	Antibody 5.9 IgG1 HCDR3	GRYFDWFLFDY
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
519	Antibody 5.9 IgG1 LCDR1	KSSQSLLHSDARTYLF
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
520	Antibody 5.9 IgG1 LCDR2	LTSNRFS
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
521	Antibody 5.9 IgG1 LCDR3	LQSLRLPLT
	(VH: G40A, VL: S57Y_E58L_V67T_
	F103V)_huIgG1z
	mAb(LC: G37A_K38R_M107L)
522	Antibody 5.9 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAM
	(VH: G40A, VL: S57Y E58L V67T_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	F103V)_huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWFLFDYWGQGTLVTVSS
523	Antibody 5.9 IgG1 LCVR	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDA
	(VH: G40A, VL: S57Y_E58L_V67T_	RTYLFWYLQKPGQPPQLLIYLTSNRFSGVPDRFS
	F103V)_huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKR
524	Antibody 5.9 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAM
	(VH: G40A, VL: S57Y_E58L_V67T_	HWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRF
	F103V)_huIgG1z	TISRDNSKNTLYLQMNSLRAEDTAVYYCARGRYF
	mAb(LC: G37A_K38R_M107L)	DWFLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
525	Antibody 5.9 IgG1 LC	DTVMTQTPLSLSVTPGQPASISCKSSQSLLHSDA
	(VH: G40A, VL: S57Y_E58L_V67T_	RTYLFWYLQKPGQPPQLLIYLTSNRFSGVPDRFS
	F103V)_huIgG1z	GSGSGTDFTLKISRVEAEDVGVYYCLQSLRLPLT
	mAb(LC: G37A_K38R_M107L)	FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
526	Antibody 6.0 IgG1 HCDR1	SYVMH
527	Antibody 6.0 IgG1 HCDR2	VISYDGSSQYYTDSVKG
528	Antibody 6.0 IgG1 HCDR2	GRLATAILFDY
529	Antibody 6.0 IgG1 LCDR1	KSSQSLLYSDGKTYLF
530	Antibody 6.0 IgG1 LCDR2	EVSNRFS
531	Antibody 6.0 IgG1 LCDR3	MQSIKLPLT
532	Antibody 6.0 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVM
		HWVRQAPGKGLEWVSVISYDGSSQYYTDSVKGRF
		TISRDNSKNTLNLQMNSLRAEDTAVYYCVRGRLA
		TAILFDYWGQGTLVTVSS
533	Antibody 6.0 IgG1 LCVR	DILMTQTPLSLSVTPGQPASISCKSSQSLLYSDG
		KTYLFWYLQRPGQPPQLLIYEVSNRFSGVPDRFS
		GSGSGTDFTLKISRVEAEDVGIYYCMQSIKLPLT
		FGGGTKVEIKR
534	Antibody 6.0 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVM
		HWVRQAPGKGLEWVSVISYDGSSQYYTDSVKGRF
		TISRDNSKNTLNLQMNSLRAEDTAVYYCVRGRLA
		TAILFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
535	Antibody 6.0 IgG1 LC	DILMTQTPLSLSVTPGQPASISCKSSQSLLYSDG
		KTYLFWYLQRPGQPPQLLIYEVSNRFSGVPDRFS
		GSGSGTDFTLKISRVEAEDVGIYYCMQSIKLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
536	Antibody 6.1 IgG1 HCDR1	SYVMH
	(VH: S67R_A114S_I134P, VL: F71L)_
	huIgG1z mAb
537	Antibody 6.1 IgG1 HCDR2	VISYDGSRQYYTDSVKG
	(VH: S67R_A114S_I134P, VL: F71L)_
	huIgG1z mAb
538	Antibody 6.1 IgG1 HCDR3	GRLATSPLFDY
	(VH: S67R_A114S_I134P, VL: F71L)_
	huIgG1z mAb
539	Antibody 6.1 IgG1 LCDR1	KSSQSLLYSDGKTYLF
	(VH: S67R_A114S_I134P, VL: F71L)_
	huIgG1z mAb
540	Antibody 6.1 IgG1 LCDR2	EVSNRLS
	(VH: S67R_A114S_I134P, VL: F71L)_
	huIgG1z mAb
541	Antibody 6.1 IgG1 LCDR3	MQSIKLPLT
	(VH: S67R_A114S_I134P, VL: F71L)_
	huIgG1z mAb
542	Antibody 6.1 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVM
	(VH: S67R_A114S_I134P, VL: F71L)_	HWVRQAPGKGLEWVSVISYDGSRQYYTDSVKGRF
	huIgG1z mAb	TISRDNSKNTLNLQMNSLRAEDTAVYYCVRGRLA
		TSPLFDYWGQGTLVTVSS
543	Antibody 6.1 IgG1 LCVR	DILMTQTPLSLSVTPGQPASISCKSSQSLLYSDG
	(VH: S67R_A114S_I134P, VL: F71L)_	KTYLFWYLQRPGQPPQLLIYEVSNRLSGVPDRFS
	huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGIYYCMQSIKLPLT
		FGGGTKVEIKR
544	Antibody 6.1 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVM
	(VH: S67R_A114S_I134P, VL: F71L)_	HWVRQAPGKGLEWVSVISYDGSRQYYTDSVKGRF
	huIgG1z mAb	TISRDNSKNTLNLQMNSLRAEDTAVYYCVRGRLA
		TSPLFDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
		VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
		GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
		KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG
		FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
		LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPGK
545	Antibody 6.1 IgG1 LC	DILMTQTPLSLSVTPGQPASISCKSSQSLLYSDG
	(VH: S67R_A114S_I134P, VL: F71L)_	KTYLFWYLQRPGQPPQLLIYEVSNRLSGVPDRFS
	huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGIYYCMQSIKLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC
546	Antibody 6.2 IgG1 HCDR1	SYVMH
	(VH: S67R_Q68A_L135K_F136L, VL:
	S109T_I110L) huIgG1z mAb
547	Antibody 6.2 IgG1 HCDR2	VISYDGSRAYYTDSVKG
	(VH: S67R_Q68A_L135K_F136L, VL:
	S109T_I110L) huIgG1z mAb
548	Antibody 6.2 IgG1 HCDR3	GRLATAIKLDY
	(VH: S67R_Q68A_L135K_F136L, VL:
	S109T_I110L) huIgG1z mAb
549	Antibody 6.2 IgG1 LCDR1	KSSQSLLYSDGKTYLF
	(VH: S67R_Q68A_L135K_F136L, VL:
	S109T_I110L) huIgG1z mAb
550	Antibody 6.2 IgG1 LCDR2	EVSNRFS
	(VH: S67R_Q68A_L135K_F136L, VL:
	S109T_I110L) huIgG1z mAb
551	Antibody 6.2 IgG1 LCDR3	MQTLKLPLT
	(VH: S67R_Q68A_L135K_F136L, VL:
	S109T_I110L) huIgG1z mAb
552	Antibody 6.2 IgG1 HCVR	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVM
	(VH: S67R_Q68A_L135K_F136L, VL:	HWVRQAPGKGLEWVSVISYDGSRAYYTDSVKGRF
	S109T_1110L)_huIgG1z mAb	TISRDNSKNTLNLQMNSLRAEDTAVYYCVRGRLA
		TAIKLDYWGQGTLVTVSS
553	Antibody 6.2 IgG1 LCVR	DILMTQTPLSLSVTPGQPASISCKSSQSLLYSDG
	(VH: S67R_Q68A_L135K_F136L, VL:	KTYLFWYLQRPGQPPQLLIYEVSNRFSGVPDRFS
	S109T_1110L)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGIYYCMQTLKLPLT
		FGGGTKVEIKR
554	Antibody 6.2 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVM
	(VH: S67R_Q68A_L135K_F136L, VL:	HWVRQAPGKGLEWVSVISYDGSRAYYTDSVKGRF
	S109T_1110L)_huIgG1z mAb	TISRDNSKNTLNLQMNSLRAEDTAVYYCVRGRLA
		TAIKLDYWGQGTLVTVSSASTKGPSVFPLAPSSK
		STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
		HTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNV
		NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
		GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
		PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
		VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
		AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
		YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS
		LSLSPGK
555	Antibody 6.2 IgG1 LC	DILMTQTPLSLSVTPGQPASISCKSSQSLLYSDG
	(VH: S67R_Q68A_L135K_F136L, VL:	KTYLFWYLQRPGQPPQLLIYEVSNRFSGVPDRFS
	S109T_1110L)_huIgG1z mAb	GSGSGTDFTLKISRVEAEDVGIYYCMQTLKLPLT
		FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
		VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
		QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
		GLSSPVTKSFNRGEC

Cynomolgus monkey Mauritian origin T4R CCR8
(SEQ ID NO: 556)
MDYRLDPSMTTMTDYYYPDSLSSPCDGELIQRNDKLLLAVFYCLLFVFS
LLGNSLVILVLVVCKKLRNITDIYLLNLALSDLLFVFSFPFQTYYQLDQ
WVFGTVMCKVVSGFYYIGFYSSMFFITLMSVDRYLAVVHAVYAIKVRTI
RMGTTLSLVVWLTAIMATIPLLVFYQVASEDGVLQCYSFYNQQTLKWKI
FTNFEMNILGLLIPFTIFMFCYIKILHQLKRCQNHNKTKAIRLVLIVVI
ASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLNYATHVTEIISFTHCC
VNPVIYAFVGEKFKKHLSEIFQKSCSHIFIYLGRQMPRESCEKSSSCQQ
HSFRSSSIDYIL
Leader sequence
(SEQ ID NO: 557)
MDMRVPAQLLGLLLLWLRGARC
DNA encoding leader sequence of SEQ ID NO: 557
(SEQ ID NO: 558)
atggacatgagagtgcctgcacagctgctgggcctgctgctgctgtggc
tgagaggcgccagatgc
Leader sequence
(SEQ ID NO: 559)
MAWALLLLTLLTQGTGSWA
DNA encoding leader sequence of SEQ ID NO: 559
(SEQ ID NO: 560)
atggcctgggctctgctgctcctcaccctcctcactcagggcacagggt
cctgggcc
TCE1 CCR8 HCDR1
(SEQ ID NO: 561)
NARMG
TCE1 CCR8 HCDR2
(SEQ ID NO: 562)
RIKSKTEGGTRDYAAPVKG
TCE1 CCR8 HCDR3
(SEQ ID NO: 563)
YSGV
TCE1 CCR8 LCDR1
(SEQ ID NO: 564)
KSSQSVLYSSNNKNYLA
TCE1 CCR8 LCDR2
(SEQ ID NO: 565)
WASTRES
TCE1 CCR8 LCDR3
(SEQ ID NO: 566)
QQYYSIPIT
TCE2 CCR8 HCDR1
(SEQ ID NO: 567)
NYGMH
TCE2 CCR8 HCDR2
(SEQ ID NO: 568)
VISYDGSNKFYADSVKG
TCE2 CCR8 HCDR3
(SEQ ID NO: 569)
AGGIGRFDY
TCE2 CCR8 LCDR1
(SEQ ID NO: 570)
KYSQSLLHSDGKTYLF
TCE2 CCR8 LCDR2
(SEQ ID NO: 571)
EVSNRFS
TCE2 CCR8 LCDR3
(SEQ ID NO: 572)
MQTLKLPLT

TABLE 17
Exemplary sequences of HCs without the C-terminal lysine
of antibodies of the present invention.
SEQ ID NO:	Designation	Sequence
573	Antibody 1 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARMGWVRQAPGKG
		LEWVGRIKSKTEGGTRDYAAPVKGRFTISRDDSKNTLYLQMNSL
		KTEDTAVYYCTSYSGVWGQGTMVTVSSASTKGPSVFPLAPSSKS
		TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
		LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK
		THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
		SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
		REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
		LSPG
574	Antibody 1.1 IgG1	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNARMGWVRQAPGKG
	(LC: H45Q_S51P) HC	LEWVGRIKSKTEGGTRDYAAPVKGRFTISRDDSKNTLYLQMNSL
		KTEDTAVYYCTSYSGVWGQGTMVTVSSASTKGPSVFPLAPSSKS
		TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
		LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK
		THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
		SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
		QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
		REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
		LSPG
575	Antibody 2.1 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKG
	(LC: F2I_P51S_H53Q_	LEWVAVISYDGSNKFYIRSVKGRFTISRDNSKNTLYLQMNSLRA
	L103V_N148K, HC: K87N_	EDTAVYYCARAGGIGRFDYWGQGTLVTVSSASTKGPSVFPLAPS
	S94N_V98A)(LC:	SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
	Y25A_S26A, HC: A71I_	SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
	D72R)	CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
		VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPG
576	Antibody 2.2 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKG
	(LC: F2I_P51S_H53Q_	LEWVAVISYDGSNKFYLKSVKGRFTISRDNSKNTLYLQMNSLRA
	L103V_N148K, HC: K87N_	EDTAVYYCARAGGIGRFDYWGQGTLVTVSSASTKGPSVFPLAPS
	S94N_V98A)(LC:	SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
	Y25A, HC: A71L_D72K)	SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
		CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
		VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
		VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
		PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK
		SLSLSPG
577	Antibody 3.0 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWMSWVRQAPGKG
		LEWVARIKRRTDGGTTDYAAPVKDRFTISRDDSKNTLFLQMNSL
		KTEDTAVYYCTTVTMVRGVIADYWGQGTLVTVSSASTKGPSVFP
		LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
		AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPG
578	Antibody 4.0 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWMSWVRQAPGKG
		LEWVGRIKRKTDGGTTDYAAPVKGRFTISRDDSKNTLYLLMNSL
		KIEDTAVYYCTVVTLVRGIIFDYWGQGTLVTVSSASTKGPSVFP
		LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
		AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPG
579	Antibody 4.1 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWLQWVRQAPGKG
	(VH: M41L_S42Q_L111R_	LEWVGRIKRKTDQLTTDYAAPVKGRFTISRDDSKNTLYLLMNSL
	V112S, VL: S18R_S136P)_	KIEDTAVYYCTVVTRSRGIIFDYWGQGTLVTVSSASTKGPSVFP
	huIgG1z	LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
	mAb(LC: R18S, HC: G65Q_	AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
	G66L)	EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPG
580	Antibody 4.2 IgG1 HC	EVQLVESGGGLVKPGGSLRLSCAASGFIFSNAWLQWVRQAPGKG
	(VH: M41L_S42Q_L111R_	LEWVGRIKRKTDASTTDYAAPVKGRFTISRDDSKNTLYLLMNSL
	V112S, VL: S18R_S136P)_	KIEDTAVYYCTVVTRSRGIIFDYWGQGTLVTVSSASTKGPSVFP
	huIgG1z	LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
	mAb(LC: R18S, HC: G6	AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
	5A_G66S)	EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
		TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
		SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
		KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
		YTQKSLSLSPG
581	Antibody 5.0 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKG
		LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
		EDTAVYYCARGRYFDWFLFDYWGQGTLVTVSSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
582	Antibody 5.1 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKG
	(VH: F134T, VL: S34R_	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_F103V)_huIgG1z	EDTAVYYCARGRYFDWTLFDYWGQGTLVTVSSASTKGPSVFPLA
	mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
583	Antibody 5.2 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPMHWVRQAPGKG
	(VH: G40P_F134T, VL:	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_E58L_V67R_F103V)_	EDTAVYYCARGRYFDWTLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgG1z mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
584	Antibody 5.3 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKG
	(VH: A71S_D72R, VL:	LEWVAVISYDGSNKYYSRSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_E58L_V67S_F103V)_	EDTAVYYCARGRYFDWFLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgG1z mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
585	Antibody 5.4 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKG
	(VH: G40A, VL: S57Y_	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	E58L_V67T_F103V)_	EDTAVYYCARGRYFDWFLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgGIz mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
586	Antibody 5.5 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPVHWVRQAPGKG
	(VH: G40P_M41V, VL:	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_E58L_V67T_F103V)_	EDTAVYYCARGRYFDWFLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgG1z mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
587	Antibody 5.6 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKG
	(VH: F134T, VL: S34R_	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_F103V)_huIgG1z	EDTAVYYCARGRYFDWTLFDYWGQGTLVTVSSASTKGPSVFPLA
	mAb(LC: G37A_K38R_	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
	M107L)	LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
588	Antibody 5.7 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKG
	(VH: A71S_D72R, VL:	LEWVAVISYDGSNKYYSRSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_E58L_V67S_F103V)_	EDTAVYYCARGRYFDWFLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgGIz mAb(LC:	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
	G37A_K38R_M107L)	LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
589	Antibody 5.8 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPMHWVRQAPGKG
	(VH: G40P_F134T, VL:	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	S57Y_E58L_V67R_F103V)_	EDTAVYYCARGRYFDWTLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgG1z mAb(LC:	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
	G37A_K38R_M107L)	LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
590	Antibody 5.9 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKG
	(VH: G40A, VL: S57Y_	LEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
	E58L_V67T_F103V)_	EDTAVYYCARGRYFDWFLFDYWGQGTLVTVSSASTKGPSVFPLA
	huIgGIz mAb(LC:	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
	G37A_K38R_M107L)	LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
591	Antibody 6.0 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVMHWVRQAPGKG
		LEWVSVISYDGSSQYYTDSVKGRFTISRDNSKNTLNLQMNSLRA
		EDTAVYYCVRGRLATAILFDYWGQGTLVTVSSASTKGPSVFPLA
		PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
592	Antibody 6.1 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVMHWVRQAPGKG
	(VH: S67R_A114S_I13	LEWVSVISYDGSRQYYTDSVKGRFTISRDNSKNTLNLQMNSLRA
	4P, VL: F71L)_huIgG1z	EDTAVYYCVRGRLATSPLFDYWGQGTLVTVSSASTKGPSVFPLA
	mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG
593	Antibody 6.2 IgG1 HC	QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYVMHWVRQAPGKG
	(VH: S67R_Q68A_L135K_	LEWVSVISYDGSRAYYTDSVKGRFTISRDNSKNTLNLQMNSLRA
	F136L, VL: S109T_	EDTAVYYCVRGRLATAIKLDYWGQGTLVTVSSASTKGPSVFPLA
	I110L)_huIgG1z mAb	PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
		LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
		KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
		VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
		LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
		TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
		QKSLSLSPG

TABLE 18
Exemplary nucleic acid sequences that encode antibodies of the present invention.
SEQ ID NO:	Designation	Sequence
594	Antibody 1 IgG1 HC DNA	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGG
		GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTTACTTTCA
		GTAACGCCCGGATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGG
		CTGGAGTGGGTTGGCCGTATTAAAAGCAAAACTGAAGGTGGGAC
		AAGAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAA
		GAGATGATTCAAAAAACACGCTGTATCTGCAAATGAACAGCCTG
		AAAACCGAGGACACAGCCGTGTATTATTGTACCTCGTATAGTGG
		GGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCCTCCA
		CCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
		ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTA
		CTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
		CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGA
		CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTT
		GGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCA
		ACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAA
		ACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGG
		ACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA
		TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGG
		CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT
		ACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
		CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCA
		AAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCC
		CGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT
		CAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
		ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG
		GACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGA
		CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
		TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC
		CTGTCTCCGGGCAAATAG
595	Antibody 1 IgG1 LC DNA	GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCT
		GGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTT
		TATACAGTTCCAACAATAAGAACTACTTAGCTTGGTACCATCAG
		AAACCAGGACAGTCTCCTAAGCTGCTCATTTCCTGGGCATCTAC
		CCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTG
		GGACAGATTTCACTCTCACCATCAACAGCCTGCAGGCTGAAGAT
		GTGGCAGTTTATTACTGTCAACAATATTATAGTATTCCGATCAC
		TTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTG
		CACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAA
		TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCC
		CAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAAT
		CGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC
		AGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGA
		CTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG
		GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
		TAG
596	Antibody 1.1 IgG1 (LC: H45Q_S51P)	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGG
	HC DNA	GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTTACTTTCA
		GTAACGCCCGGATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGG
		CTGGAGTGGGTTGGCCGTATTAAAAGCAAAACTGAAGGTGGGAC
		AAGAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAA
		GAGATGATTCAAAAAACACGCTGTATCTGCAAATGAACAGCCTG
		AAAACCGAGGACACAGCCGTGTATTATTGTACCTCGTATAGTGG
		GGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCCTCCA
		CCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
		ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTA
		CTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
		CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGA
		CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTT
		GGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCA
		ACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAA
		ACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGG
		ACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA
		TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
		AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGG
		CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT
		ACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
		CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCA
		AAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCC
		CGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT
		CAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
		ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG
		GACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGA
		CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
		TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC
		CTGTCTCCGGGCAAATAG
597	Antibody 1.1 IgG1 (LC: H45Q_S51P)	GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCT
	LC DNA	GGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTT
		TATACAGTTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAG
		AAACCAGGACAGCCCCCTAAGCTGCTCATTTCCTGGGCATCTAC
		CCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTG
		GGACAGATTTCACTCTCACCATCAACAGCCTGCAGGCTGAAGAT
		GTGGCAGTTTATTACTGTCAACAATATTATAGTATTCCGATCAC
		TTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTG
		CACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAA
		TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCC
		CAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAAT
		CGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC
		AGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGA
		CTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGG
		GCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
		TAG
598	Antibody 2.1 IgG1 HC	CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(LC: F2I_P51S_H53Q_L103V_N148K,	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	HC: K87N_S94N_V98A)(LC: Y25A_	GTAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
	S26A, HC: A71I_D72R) DNA	CTGGAGTGGGTGGCAGTCATATCATATGATGGAAGTAATAAATT
		CTATATCAGATCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACTCTGTATCTTCAAATGAACAGCCTGAGAGCC
		GAGGACACGGCTGTATATTATTGTGCGAGAGCCGGGGGTATAGG
		GCGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT
		CAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCC
		TCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
		CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAG
		GCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG
		TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTC
		CAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACA
		AGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCT
		TGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACT
		CCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG
		ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTG
		GTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA
		CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
		GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
		GGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCT
		CCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTG
		CCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGAC
		CTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT
		GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
		CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCT
		CACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT
		GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAG
		AGCCTCTCCCTGTCTCCGGGCAAATAG
599	Antibody 2.1 IgG1 LC	GATATCGTAATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(LC: F2I_P51S_H53Q_L103V_N148K,	TGGACAGCCGGCCTCCATCTCCTGCAAGGCCGCCCAGAGCCTCC
	HC: K87N_S94N_V98A)(LC: Y25A_	TGCACAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
	S26A, HC: A71I_D72R) DNA	CCAGGCCAGAGCCCACAGCTCCTGATCTATGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAGATCAGCCGGGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAACTTTAAAGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAGCGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
600	Antibody 2.2 IgG1 HC	CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(LC: F2I_P51S_H53Q_L103V_N148K,	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	HC: K87N_S94N_V98A)(LC: Y25A,	GTAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
	HC: A71L_D72K) DNA	CTGGAGTGGGTGGCAGTCATATCATATGATGGAAGTAATAAATT
		CTATCTGAAGTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACTCTGTATCTTCAAATGAACAGCCTGAGAGCC
		GAGGACACGGCTGTATATTATTGTGCGAGAGCCGGGGGTATAGG
		GCGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT
		CAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCC
		TCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
		CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAG
		GCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG
		TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTC
		CAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACA
		AGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCT
		TGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACT
		CCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGG
		ACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTG
		GTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTA
		CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
		GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
		GGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCT
		CCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTG
		CCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGAC
		CTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT
		GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
		CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCT
		CACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT
		GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAG
		AGCCTCTCCCTGTCTCCGGGCAAATAG
601	Antibody 2.2 IgG1 LC	GATATCGTAATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(LC: F2I_P51S_H53Q_L103V_N148K,	TGGACAGCCGGCCTCCATCTCCTGCAAGGCCAGTCAGAGCCTCC
	HC: K87N_S94N_V98A)(LC: Y25A,	TGCACAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
	HC: A71L_D72K) DNA	CCAGGCCAGAGCCCACAGCTCCTGATCTATGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAGATCAGCCGGGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAACTTTAAAGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAGCGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
602	Antibody 3.0 IgG1 HC DNA	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGG
		GGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCATTTTTA
		GTAATGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGG
		CTGGAGTGGGTTGCCCGTATTAAAAGGAGAACTGATGGTGGGAC
		AACTGACTACGCTGCACCCGTGAAAGACAGATTCACCATCTCAA
		GAGATGATTCAAAAAACACGCTGTTTCTGCAAATGAACAGCCTG
		AAAACCGAGGACACAGCCGTGTATTACTGTACCACAGTTACTAT
		GGTTCGGGGAGTTATTGCTGATTACTGGGGCCAGGGAACCCTGG
		TCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCC
		CTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT
		GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
		GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT
		GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCC
		AGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC
		ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGA
		CAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA
		GTACAAGTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAG
		GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCA
		GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACA
		TCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
		CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA
		ACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC
		TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
603	Antibody 3.0 IgG1 LC DNA	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCC
		AGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTA
		GCAGCGGCTCCTTAGCCTGGTACCAGCAGAAACTTGGCCAGGCT
		CCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCAT
		CCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTC
		TCACCATCAGCAGCCTGGAGCCTGAAGATTTTGCAGTGTATTAC
		TGTCAACAGTATGGTAGCTCACGGACGTTCGGCCAAGGGACCAA
		GGTGGAGCTCAAACGAACGGTGGCTGCACCATCTGTCTTCATCT
		TCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTT
		GTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
		GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGA
		GTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC
		AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT
		CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGTTAG
604	Antibody 4.0 IgG1 HC DNA	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGG
		GGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCATTTTCA
		GTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGG
		CTGGAGTGGGTTGGCCGTATAAAAAGGAAAACTGATGGTGGTAC
		AACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAA
		GAGATGATTCAAAAAACACGTTGTATCTGCTAATGAACAGCCTG
		AAAATCGAGGACACAGCCGTGTATTATTGTACCGTCGTAACTTT
		GGTTCGGGGAATTATCTTTGACTACTGGGGCCAGGGAACCCTGG
		TCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCC
		CTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT
		GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
		GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT
		GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCC
		AGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC
		ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGA
		CAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA
		GTACAAGTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAG
		GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCA
		GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACA
		TCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
		CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA
		ACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC
		TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
605	Antibody 4.0 IgG1 LC DNA	GAAATTGTGTTGACGCAGTCTCCGGGCACCCTGTCTTTGTCTCC
		AGGGGAAAGCGCCACCCTCTCCTGTAGGGTCAGTCAGAGTGTCA
		GCAGCAGCCAGTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCT
		CCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCAT
		CCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTC
		TCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTAC
		TGTCAGCAGTATGGTAACTCACGGACGTTCGGCCAAGGGACCAA
		GGTGGAAATCAAACGAACGGTGGCTGCACCATCTGTCTTCATCT
		TCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTT
		GTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
		GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGA
		GTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC
		AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT
		CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGTTAG
606	Antibody 4.1 IgG1 HC	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGG
	(VH: M41L_S42Q_L111R_V112S, VL:	GGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCATTTTCA
	S18R_S136P)_huIgG1z	GTAACGCCTGGCTGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGG
	mAb(LC: R18S, HC: G65Q_G66L)	CTGGAGTGGGTTGGCCGTATCAAAAGGAAAACTGATCAGCTGAC
	DNA	AACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAA
		GAGATGATTCAAAAAACACGTTGTATCTGCTAATGAACAGCCTG
		AAAATCGAGGACACAGCCGTGTATTATTGTACCGTCGTAACTAG
		AAGCCGGGGAATTATCTTTGACTACTGGGGCCAGGGAACCCTGG
		TCACCGTGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCC
		CTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT
		GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
		GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT
		GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCC
		AGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC
		ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGA
		CAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA
		GTACAAGTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAG
		GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCA
		GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACA
		TCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
		CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA
		ACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC
		TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
607	Antibody 4.1 IgG1 LC	GAAATTGTGTTGACGCAGTCTCCGGGCACCCTGTCTTTGTCTCC
	(VH: M41L_S42Q_L111R_V112S, VL:	AGGGGAAAGCGCCACCCTCTCCTGTAGGGTCAGTCAGAGTGTCA
	S18R_S136P)_huIgG1z	GCAGCAGCCAGTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCT
	mAb(LC: R18S, HC: G65Q_G66L)	CCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCAT
	DNA	CCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTC
		TCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTAC
		TGTCAGCAGTATGGTAACCCCCGGACGTTCGGCCAAGGGACCAA
		GGTGGAAATCAAACGAACGGTGGCTGCACCATCTGTCTTCATCT
		TCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTT
		GTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
		GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGA
		GTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC
		AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT
		CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGTTAG
608	Antibody 4.2 IgG1 HC	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGG
	(VH: M41L_S42Q_L111R_V112S, VL:	GGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCATTTTCA
	S18R_S136P)_huIgG1z	GTAACGCCTGGCTGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGG
	mAb(LC: R18S, HC: G65A_G66S)	CTGGAGTGGGTTGGCCGTATCAAAAGGAAAACTGATGCCAGCAC
	DNA	AACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAA
		GAGATGATTCAAAAAACACGTTGTATCTGCTAATGAACAGCCTG
		AAAATCGAGGACACAGCCGTGTATTATTGTACCGTCGTAACTAG
		AAGCCGGGGAATTATCTTTGACTACTGGGGCCAGGGAACCCTGG
		TCACCGTGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCC
		CTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT
		GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGT
		CGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
		GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGT
		GACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT
		GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCC
		AGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC
		ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGA
		CAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
		AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA
		GTACAAGTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCG
		AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAG
		GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCA
		GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACA
		TCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
		AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
		CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA
		ACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC
		TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
609	Antibody 4.2 IgG1 LC	GAAATTGTGTTGACGCAGTCTCCGGGCACCCTGTCTTTGTCTCC
	(VH: M41L_S42Q_L111R_V112S, VL:	AGGGGAAAGCGCCACCCTCTCCTGTAGGGTCAGTCAGAGTGTCA
	S18R_S136P)_huIgG1z	GCAGCAGCCAGTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCT
	mAb(LC: R18S, HC: G65A_G66S)	CCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCAT
	DNA	CCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTC
		TCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTAC
		TGTCAGCAGTATGGTAACCCCCGGACGTTCGGCCAAGGGACCAA
		GGTGGAAATCAAACGAACGGTGGCTGCACCATCTGTCTTCATCT
		TCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTT
		GTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
		GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGA
		GTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC
		AGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT
		CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCA
		CAAAGAGCTTCAACAGGGGAGAGTGTTAG
610	Antibody 5.0 IgG1 HC DNA	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
		GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
		GTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGTTCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
611	Antibody 5.0 IgG1 LC DNA	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
		TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
		TACATAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
		CCAGGCCAGCCTCCACAGCTCCTGATCAGTGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGTTTTATTACTGCATGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
612	Antibody 5.1 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: F134T, VL: S34R_S57Y_F103V)	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	huIgG1z mAb DNA	GTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGACCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
613	Antibody 5.1 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: F134T, VL: S34R_S57Y_F103V)	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	huIgG1z mAb DNA	TACATAGAGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
		CCAGGCCAGCCTCCACAGCTCCTGATCTACGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
614	Antibody 5.2 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: G40PF134T, VL: S57Y_E58L_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	V67R_F103V)_huIgG1z mAb DNA	GTAGCTATCCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGACCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
615	Antibody 5.2 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: G40PF134T, VL: S57Y_E58L_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	V67R_F103V)_huIgG1z mAb DNA	TACATAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
		CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGAGATCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
616	Antibody 5.3 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: A71S_D72R, VL: S57Y_E58L_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	V67S_F103V)_huIgG1z mAb DNA	GTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATAGCAGATCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGTTCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
617	Antibody 5.3 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: A71S_D72R, VL: S57Y_E58L_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	V67S_F103V)_huIgG1z mAb DNA	TACATAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
		CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGAGCTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
618	Antibody 5.4 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: G40A, VL: S57Y_E58L_V67T_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	F103V)_huIgG1z mAb DNA	GTAGCTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGTTCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
619	Antibody 5.4 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: G40A, VL: S57Y_E58L_V67T_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	F103V)_huIgG1z mAb DNA	TACATAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
		CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGACCTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
620	Antibody 5.5 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: G40P_M41V, VL: S57Y_E58L_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	V67T_F103V)_huIgG1z mAb DNA	GTAGCTATCCCGTGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGTTCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
621	Antibody 5.5 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: G40P_M41V, VL: S57Y_E58L_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	V67T_F103V)_huIgG1z mAb DNA	TACATAGTGATGGAAAGACCTATTTGTTTTGGTACCTGCAGAAG
		CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGACCTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCATGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
622	Antibody 5.6 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: F134T, VL: S34R_S57Y_F103V)_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	huIgG1z	GTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
	mAb(LC: G37A_K38R_M107L) DNA	CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGACCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
623	Antibody 5.6 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: F134T, VL: S34R_S57Y_F103V)_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	huIgG1z	TACATAGAGATGCCAGAACCTATTTGTTTTGGTACCTGCAGAAG
	mAb(LC: G37A_K38R_M107L) DNA	CCAGGCCAGCCTCCACAGCTCCTGATCTACGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCCTGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
624	Antibody 5.7 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: A71S_D72R, VL: S57Y_E58L_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	V67S_F103V)_huIgG1z	GTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
	mAb(LC: G37A_K38R_M107L) DNA	CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATAGCAGATCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGTTCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
625	Antibody 5.7 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: A71 S_D72R, VL: S57Y_E58L_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	V67S_F103V)_huIgG1z	TACATAGTGATGCCAGAACCTATTTGTTTTGGTACCTGCAGAAG
	mAb(LC: G37A_K38R_M107L) DNA	CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGAGCTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCCTGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
626	Antibody 5.8 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: G40PF134T, VL: S5 7YE5 8L_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	V67R_F103V)_huIgG1z	GTAGCTATCCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
	mAb(LC: G37A_K38R_M107L) DNA	CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGACCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
627	Antibody 5.8 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: G40P_F134T, VL: S57Y_E58L_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	V67R_F103V)_huIgG1z	TACATAGTGATGCCAGAACCTATTTGTTTTGGTACCTGCAGAAG
	mAb(LC: G37A_K38R_M107L) DNA	CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGAGATCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCCTGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
628	Antibody 5.9 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: G40A, VL: S57Y_E58L_V67T_	GAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCA
	F103V)_huIgG1z	GTAGCTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
	mAb(LC: G37A_K38R_M107L) DNA	CTGGAGTGGGTGGCAGTTATCTCATATGATGGAAGTAATAAATA
		CTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGCGAGGGGGCGATATTTTGA
		CTGGTTCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
629	Antibody 5.9 IgG1 LC	GATACTGTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: G40A, VL: S57Y_E58L_V67T_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCC
	F103V)_huIgG1z	TACATAGTGATGCCAGAACCTATTTGTTTTGGTACCTGCAGAAG
	mAb(LC: G37A_K38R_M107L) DNA	CCAGGCCAGCCTCCACAGCTCCTGATCTACCTGACCTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGTGTGGAGGCTGAGGATGTT
		GGGGTGTATTACTGCCTGCAAAGTTTACGGCTTCCGCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
630	Antibody 6.0 IgG1 HC DNA	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
		GAGGTCCCTGAGACTCTCCTGTGAAGCCTCTGGATTCACCTTCA
		GTAGCTATGTCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGTCAGTTATATCATATGATGGAAGTAGTCAATA
		CTATACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAATACGCTGAATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGTGAGAGGCCGTTTGGCCAC
		TGCTATCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
631	Antibody 6.0 IgG1 LC DNA	GATATTTTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
		TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGCCAGAGCCTCC
		TATATAGTGATGGAAAGACCTATTTATTTTGGTACCTGCAGAGG
		CCAGGCCAACCTCCACAGCTCCTGATCTATGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGGGTGGAGGCTGAGGATGTT
		GGGATTTATTACTGCATGCAAAGTATAAAACTTCCTCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
632	Antibody 6.1 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: S67R_A114S_I134P, VL: F71L)_	GAGGTCCCTGAGACTCTCCTGTGAAGCCTCTGGATTCACCTTCA
	huIgG1z mAb DNA	GTAGCTATGTCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGTCAGTTATCTCATATGATGGAAGTAGACAATA
		CTATACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAATACGCTGAATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGTGAGAGGCCGTTTGGCCAC
		TAGCCCCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
633	Antibody 6.1 IgG1 LC	GATATTTTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: S67R_A114S_I134P, VL: F71L)_	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGCCAGAGCCTCC
	huIgG1z mAb DNA	TATATAGTGATGGAAAGACCTATTTATTTTGGTACCTGCAGAGG
		CCAGGCCAACCTCCACAGCTCCTGATCTATGAAGTTTCCAACCG
		GCTGTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGGGTGGAGGCTGAGGATGTT
		GGGATTTATTACTGCATGCAAAGTATCAAACTTCCTCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
634	Antibody 6.2 IgG1 HC	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGG
	(VH: S67R_Q68A_L135K_F136L, VL:	GAGGTCCCTGAGACTCTCCTGTGAAGCCTCTGGATTCACCTTCA
	S109T_I110L)_huIgG1z mAb DNA	GTAGCTATGTCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG
		CTGGAGTGGGTGTCAGTTATCTCATATGATGGAAGTAGAGCCTA
		CTATACAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAATACGCTGAATCTGCAAATGAACAGCCTGAGAGCT
		GAGGACACGGCTGTGTATTACTGTGTGAGAGGCCGTTTGGCCAC
		TGCTATCAAGCTGGACTACTGGGGCCAGGGAACCCTGGTCACCG
		TGTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCA
		CCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
		CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGA
		ACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
		CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
		GCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGA
		ATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
		AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
		TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
		CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
		GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
		CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
		CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
		CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAA
		GTGCAAGGTGTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAA
		CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAG
		CCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCG
		TGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACC
		ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAG
		CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
		TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
		CAGAAGAGCCTCTCCCTGTCTCCGGGCAAATAG
635	Antibody 6.2 IgG1 LC	GATATTTTGATGACCCAGACTCCACTCTCTCTGTCCGTCACCCC
	(VH: S67R_Q68A_L135K_F136L, VL:	TGGACAGCCGGCCTCCATCTCCTGCAAGTCTAGCCAGAGCCTCC
	S109T_I110L)_huIgG1z mAb DNA	TATATAGTGATGGAAAGACCTATTTATTTTGGTACCTGCAGAGG
		CCAGGCCAACCTCCACAGCTCCTGATCTATGAAGTTTCCAACCG
		GTTCTCTGGAGTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGA
		CAGATTTCACACTGAAAATCAGCCGGGTGGAGGCTGAGGATGTT
		GGGATTTATTACTGCATGCAAACCCTGAAACTTCCTCTCACTTT
		CGGCGGAGGGACCAAGGTGGAGATCAAACGAACGGTGGCTGCAC
		CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCT
		GGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAG
		AGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGG
		GTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC
		ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTA
		CGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCC
		TGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG

zeluvalimab HC without C-terminal lysine
(SEQ ID NO: 636)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVS
LISGGGSQTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAS
PSGHYFYAMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP
CEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
KSLSLSPG

TABLE 19
Amino acid sequences of afucosy ated CCR8 mIgG2a antibody.
SEQ ID NO:	Designation	Sequence
637	CCR8 mIgG2a LCDR1	KYSQSLLHSDGKTYLF
638	CCR8 mIgG2a LCDR2	EVSNRFS
639	CCR8 mIgG2a LCDR3	MQTLKLPLT
640	CCR8 mIgG2a HCDR1	NYGMH
641	CCR8 mIgG2a HCDR2	VISYDGSRNFYADSVKG
642	CCR8 mIgG2a HCDR3	AGGNGRFDY
643	CCR8 mIgG2a LCVR 1	DIVMTQTPLSLSVTPGQPASISCKYSQSLLHS
		DGKTYLFWYLQKPGQSPQLLIYEVSNRFSGV
		PDRFSGSGSGTDFTLKISRVEAEDVGVYYCM
		QTLKLPLTFGGGTKVEIKR
644	CCR8 mIgG2a HCVR	QVQLVESGGGVVQPGRSLRLSCAASGFTFSN
		YGMHWVRQAPGKGLEWVAVISYDGSRNFY
		ADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
		AVYYCARAGGNGRFDYWGQGTLVTVSS
645	CCR8 mIgG2a LC	DIVMTQTPLSLSVTPGQPASISCKYSQSLLHS
		DGKTYLFWYLQKPGQSPQLLIYEVSNRFSGV
		PDRFSGSGSGTDFTLKISRVEAEDVGVYYCM
		QTLKLPLTFGGGTKVEIKRADAAPTVSIFPPS
		SEQLTSGGASVVCFLNNFYPKDINVKWKIDG
		SERQNGVLNSWTDQDSKDSTYSMSSTLTLTK
		DEYERHNSYTCEATHKTSTSPIVKSFNRNEC
646	CCR8 mIgG2aHC	QVQLVESGGGVVQPGRSLRLSCAASGFTFSN
		YGMHWVRQAPGKGLEWVAVISYDGSRNFY
		ADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
		AVYYCARAGGNGRFDYWGQGTLVTVSSAK
		TTAPSVYPLAPVCGDTTGSSVTLGCLVKGYF
		PEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLS
		SSVTVTSSTWPSQSITCNVAHPASSTKVDKKI
		EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIK
		DVLMISLSPIVTCVVVDVSEDDPDVQISWFV
		NNVEVHTAQTQTHREDYNSTLRVVSALPIQH
		QDWMSGKEFKCKVNNKDLPAPIERTISKPKG
		SVRAPQVYVLPPPEEEMTKKQVTLTCMVTD
		FMPEDIYVEWTNNGKTELNYKNTEPVLDSD
		GSYFMYSKLRVEKKNWVERNSYSCSVVHEG
		LHNHHTTKSFSRTPGK

TABLE 20
Amino acid sequences.
SEQ
ID NO:	Designation	Sequence
647	MPK20298-A4_SCFV huCCR8 HV hv_cdr1	NNGMH
648	MPK20298-A4_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
649	MPK20298-A4_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRNYYGMDV
650	MPK20298-A4_SCFV huCCR8 LV lv_cdr1	GGNNIGSQNVH
651	MPK20298-A4_SCFV huCCR8 LV lv_cdr2	RDSNRPS
652	MPK20298-A4_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
653	MPK20299-D2_SCFV huCCR8 HV hv_cdr1	NYGMH
654	MPK20299-D2_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
655	MPK20299-D2_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
656	MPK20299-D2_SCFV huCCR8 LV lv_cdr1	GGHNIGSKGVH
657	MPK20299-D2_SCFV huCCR8 LV lv_cdr2	RNSNRPS
658	MPK20299-D2_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
659	MPK20299-F11_SCFV huCCR8 HV hv_cdr1	NYGMH
660	MPK20299-F11_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
661	MPK20299-F11_SCFV huCCR8 HV hv_cdr3	VYYGSGSYYKKRYYYGMDV
662	MPK20299-F11_SCFV huCCR8 LV lv_cdr1	GGNNIGSQNVH
663	MPK20299-F11_SCFV huCCR8 LV lv_cdr2	RDSNRPS
664	MPK20299-F11_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
665	MPK20298-H6_SCFV huCCR8 HV hv_cdr1	SSGMH
666	MPK20298-H6_SCFV huCCR8 HV hv_cdr2	VISYDGTNKYYADSVKG
667	MPK20298-H6_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
668	MPK20298-H6_SCFV huCCR8 LV lv_cdr1	GGHNIGSKGVH
669	MPK20298-H6_SCFV huCCR8 LV lv_cdr2	RNSNRPS
670	MPK20298-H6_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
671	MPK20297-A4_SCFV huCCR8 HV hv_cdr1	NYGMH
672	MPK20297-A4_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
673	MPK20297-A4_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
674	MPK20297-A4_SCFV huCCR8 LV lv_cdr1	GGHNIGSQNVH
675	MPK20297-A4_SCFV huCCR8 LV lv_cdr2	RDSNRPS
676	MPK20297-A4_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
677	MPK20299-H8_SCFV huCCR8 HV hv_cdr1	NYGMH
678	MPK20299-H8_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
679	MPK20299-H8_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
680	MPK20299-H8_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
681	MPK20299-H8_SCFV huCCR8 LV lv_cdr2	RNSNRPS
682	MPK20299-H8_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
683	MPK20300-C11_SCFV huCCR8 HV	SYGMH
	hv_cdr1
684	MPK20300-C11_SCFV huCCR8 HV	VISYDGSNKYYADSVKG
	hv_cdr2
685	MPK20300-C11_SCFV huCCR8 HV	VYYGSGSYYKNRYYYGMDV
	hv_cdr3
686	MPK20300-C11_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
687	MPK20300-C11_SCFV huCCR8 LV lv_cdr2	RDINRPS
688	MPK20300-C11_SCFV huCCR8 LV lv_cdr3	QVWDSSVV
689	MPK20298-B1_SCFV huCCR8 HV hv_cdr1	NYGMH
690	MPK20298-B1_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
691	MPK20298-B1_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
692	MPK20298-B1_SCFV huCCR8 LV lv_cdr1	EGNNIGSKNVH
693	MPK20298-B1_SCFV huCCR8 LV lv_cdr2	RNSNRPS
694	MPK20298-B1_SCFV huCCR8 LV lv_cdr3	QAWDSSTVV
695	MPK20297-E5_SCFV huCCR8 HV hv_cdr1	NNGMH
696	MPK20297-E5_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYTDSVKG
697	MPK20297-E5_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
698	MPK20297-E5_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
699	MPK20297-E5_SCFV huCCR8 LV lv_cdr2	RDSNRPS
700	MPK20297-E5_SCFV huCCR8 LV lv_cdr3	QVWDSSSDHVV
701	MPK20299-A3_SCFV huCCR8 HV hv_cdr1	NYGMH
702	MPK20299-A3_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
703	MPK20299-A3_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
704	MPK20299-A3_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
705	MPK20299-A3_SCFV huCCR8 LV lv_cdr2	RNSNRPS
706	MPK20299-A3_SCFV huCCR8 LV lv_cdr3	QAWDSSNVV
707	MPK20297-B4_SCFV huCCR8 HV hv_cdr1	RNGMH
708	MPK20297-B4_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
709	MPK20297-B4_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNNYYYGMDV
710	MPK20297-B4_SCFV huCCR8 LV lv_cdr1	GGNNIGSQNVH
711	MPK20297-B4_SCFV huCCR8 LV lv_cdr2	RDSNRPS
712	MPK20297-B4_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
713	MPK20298-F6_SCFV huCCR8 HV hv_cdr1	RNGMH
714	MPK20298-F6_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
715	MPK20298-F6_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
716	MPK20298-F6_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
717	MPK20298-F6_SCFV huCCR8 LV lv_cdr2	RDSNRPS
718	MPK20298-F6_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
719	MPK20299-H3_SCFV huCCR8 HV hv_cdr1	NYGMH
720	MPK20299-H3_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
721	MPK20299-H3_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
722	MPK20299-H3_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
723	MPK20299-H3_SCFV huCCR8 LV lv_cdr2	RNSNRPS
724	MPK20299-H3_SCFV huCCR8 LV lv_cdr3	QIWDSSTVV
725	MPK20298-B9_SCFV huCCR8 HV hv_cdr1	RNGMH
726	MPK20298-B9_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
727	MPK20298-B9_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKNYYYGMDV
728	MPK20298-B9_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
729	MPK20298-B9_SCFV huCCR8 LV lv_cdr2	RDSNRPS
730	MPK20298-B9_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
731	MPK20299-E2_SCFV huCCR8 HV hv_cdr1	NNGMH
732	MPK20299-E2_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYTDSVKG
733	MPK20299-E2_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
734	MPK20299-E2_SCFV huCCR8 LV lv_cdr1	EGNNIGSQNVH
735	MPK20299-E2_SCFV huCCR8 LV lv_cdr2	RDSNRPS
736	MPK20299-E2_SCFV huCCR8 LV lv_cdr3	QVWDGSAVV
737	MPK20299-D6_SCFV huCCR8 HV hv_cdr1	SYGMH
738	MPK20299-D6_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
739	MPK20299-D6_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
740	MPK20299-D6_SCFV huCCR8 LV lv_cdr1	EGNNIGSQNVH
741	MPK20299-D6_SCFV huCCR8 LV lv_cdr2	RDSNRPS
742	MPK20299-D6_SCFV huCCR8 LV lv_cdr3	QVWDGSAVV
743	MPK20299-A4_SCFV huCCR8 HV hv_cdr1	NYGFH
744	MPK20299-A4_SCFV huCCR8 HV hv_cdr2	VISYDGSNRYYADSVKG
745	MPK20299-A4_SCFV huCCR8 HV hv_cdr3	VYYGSGTYYKNRYYYGMDV
746	MPK20299-A4_SCFV huCCR8 LV lv_cdr1	GGHNIGSKGVH
747	MPK20299-A4_SCFV huCCR8 LV lv_cdr2	RNSNRPS
748	MPK20299-A4_SCFV huCCR8 LV lv_cdr3	QAWDSGTVV
749	MPK20300-G5_SCFV huCCR8 HV hv_cdr1	NYGFH
750	MPK20300-G5_SCFV huCCR8 HV hv_cdr2	VISYDGSNRYYADSVKG
751	MPK20300-G5_SCFV huCCR8 HV hv_cdr3	VYYGSGTYYKNRYYYGMDV
752	MPK20300-G5_SCFV huCCR8 LV lv_cdr1	GANNIGSKNVH
753	MPK20300-G5_SCFV huCCR8 LV lv_cdr2	RDFNRPS
754	MPK20300-G5_SCFV huCCR8 LV lv_cdr3	QVWDSSTGNVV
755	MPK20299-C3_SCFV huCCR8 HV hv_cdr1	NYGFH
756	MPK20299-C3_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
757	MPK20299-C3_SCFV huCCR8 HV hv_cdr3	VYYGSGSYYKNRYYYGMDV
758	MPK20299-C3_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
759	MPK20299-C3_SCFV huCCR8 LV lv_cdr2	RDSNRPS
760	MPK20299-C3_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
761	MPK20299-B7_SCFV huCCR8 HV hv_cdr1	NYGMH
762	MPK20299-B7_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
763	MPK20299-B7_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
764	MPK20299-B7_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
765	MPK20299-B7_SCFV huCCR8 LV lv_cdr2	RDSNRPS
766	MPK20299-B7_SCFV huCCR8 LV lv_cdr3	QVWDSSSAHVI
767	MPK20299-A5_SCFV huCCR8 HV hv_cdr1	GYGMH
768	MPK20299-A5_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
769	MPK20299-A5_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
770	MPK20299-A5_SCFV huCCR8 LV lv_cdr1	GGNNLGSKNVH
771	MPK20299-A5_SCFV huCCR8 LV lv_cdr2	RNSNRPS
772	MPK20299-A5_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
773	MPK20299-D1_SCFV huCCR8 HV hv_cdr1	NNGMH
774	MPK20299-D1_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
775	MPK20299-D1_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
776	MPK20299-D1_SCFV huCCR8 LV lv_cdr1	GGNRIGSKNVH
777	MPK20299-D1_SCFV huCCR8 LV lv_cdr2	RDSNRPS
778	MPK20299-D1_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
779	MPK20299-C5_SCFV huCCR8 HV hv_cdr1	NYGFH
780	MPK20299-C5_SCFV huCCR8 HV hv_cdr2	VISYDGSNRYYADSVKG
781	MPK20299-C5_SCFV huCCR8 HV hv_cdr3	VYYGSGTYYKNRYYYGMDV
782	MPK20299-C5_SCFV huCCR8 LV lv_cdr1	GGHNIGSKGVH
783	MPK20299-C5_SCFV huCCR8 LV lv_cdr2	RNSNRPS
784	MPK20299-C5_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
785	MPK20299-B5_SCFV huCCR8 HV hv_cdr1	NYGMH
786	MPK20299-B5_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
787	MPK20299-B5_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
788	MPK20299-B5_SCFV huCCR8 LV lv_cdr1	GGHNIGSKGVH
789	MPK20299-B5_SCFV huCCR8 LV lv_cdr2	RNSNRPS
790	MPK20299-B5_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
791	MPK20299-G9_SCFV huCCR8 HV hv_cdr1	NNGMH
792	MPK20299-G9_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVRG
793	MPK20299-G9_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
794	MPK20299-G9_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
795	MPK20299-G9_SCFV huCCR8 LV lv_cdr2	RNSNRPS
796	MPK20299-G9_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
797	MPK20299-G5_SCFV huCCR8 HV hv_cdr1	NNGMH
798	MPK20299-G5_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVRG
799	MPK20299-G5_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
800	MPK20299-G5_SCFV huCCR8 LV lv_cdr1	EGNNIGSKNVH
801	MPK20299-G5_SCFV huCCR8 LV lv_cdr2	RDSNRPS
802	MPK20299-G5_SCFV huCCR8 LV lv_cdr3	QVWDSSAVV
803	MPK20298-C10_SCFV huCCR8 HV	SSGMH
	hv_cdr1
804	MPK20298-C10_SCFV huCCR8 HV	VISNDGSNKYYADSVRG
	hv_cdr2
805	MPK20298-C10_SCFV huCCR8 HV	VYYGSGIYYKNNYYYGMDV
	hv_cdr3
806	MPK20298-C10_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
807	MPK20298-C10_SCFV huCCR8 LV lv_cdr2	RNSNRPS
808	MPK20298-C10_SCFV huCCR8 LV lv_cdr3	QAWDSSTVV
809	MPK20298-B5_SCFV huCCR8 HV hv_cdr1	NYGMH
810	MPK20298-B5_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
811	MPK20298-B5_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
812	MPK20298-B5_SCFV huCCR8 LV lv_cdr1	GGNNIGSQNVH
813	MPK20298-B5_SCFV huCCR8 LV lv_cdr2	RDSNRPS
814	MPK20298-B5_SCFV huCCR8 LV lv_cdr3	QVWDSSAVV
815	MPK20299-F2_SCFV huCCR8 HV hv_cdr1	SSGMH
816	MPK20299-F2_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVRG
817	MPK20299-F2_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNRYYYGMDV
818	MPK20299-F2_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
819	MPK20299-F2_SCFV huCCR8 LV lv_cdr2	RDSNRPS
820	MPK20299-F2_SCFV huCCR8 LV lv_cdr3	QAWDSGTVV
821	MPK20298-D4_SCFV huCCR8 HV hv_cdr1	NYGMH
822	MPK20298-D4_SCFV huCCR8 HV hv_cdr2	VISYDGSNKYYADSVKG
823	MPK20298-D4_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKKRYYYGMDV
824	MPK20298-D4_SCFV huCCR8 LV lv_cdr1	GGNNIGGKNVH
825	MPK20298-D4_SCFV huCCR8 LV lv_cdr2	RDSNRPS
826	MPK20298-D4_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
827	MPK20297-F5_SCFV huCCR8 HV hv_cdr1	RNGMH
828	MPK20297-F5_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
829	MPK20297-F5_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNNYYYGMDV
830	MPK20297-F5_SCFV huCCR8 LV lv_cdr1	GGNNIGSKNVH
831	MPK20297-F5_SCFV huCCR8 LV lv_cdr2	RNSNRPS
832	MPK20297-F5_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
833	MPK20299-D9_SCFV huCCR8 HV hv_cdr1	RNGMH
834	MPK20299-D9_SCFV huCCR8 HV hv_cdr2	VISNDGSNKYYADSVKG
835	MPK20299-D9_SCFV huCCR8 HV hv_cdr3	VYYGSGIYYKNNYYYGMDV
836	MPK20299-D9_SCFV huCCR8 LV lv_cdr1	GGNNIESKNVH
837	MPK20299-D9_SCFV huCCR8 LV lv_cdr2	RDSNRPS
838	MPK20299-D9_SCFV huCCR8 LV lv_cdr3	QVWDSSTVV
839	huCCR8_32360_huIgG1z	NARMG
	mAb(LC:K38R)_HC huCCR8 HV hv_cdr1
840	huCCR8_32360_huIgG1z	RIKSKTEGGTRDYAAPVKG
	mAb(LC:K38R)_HC huCCR8 HV hv_cdr2
841	huCCR8_32360_huIgG1z	YSGV
	mAb(LC:K38R)_HC huCCR8 HV hv_cdr3
842	huCCR8_32360_huIgG1z	KSSQSVLYSSNNRNYLA
	mAb(LC:K38R)_LC huCCR8 LV lv_cdr1
843	huCCR8_32360_huIgG1z	WASTRES
	mAb(LC:K38R)_LC huCCR8 LV lv_cdr2
844	huCCR8_32360_huIgG1z	QQYYSIPIT
	mAb(LC:K38R)_LC huCCR8 LV lv_cdr3
845	anti-	NYGFH
	huCCR8_44379(VH:D72S, VL:N67A_S68A_
	M99G_W109F_S111A)_huIgG1z (mAb)_HC
	huCCR8 HV hv_cdr1
846	anti-	VISYDGSNRYYASSVKG
	huCCR8_44379(VH:D72S, VL:N67A_S68A_
	M99G_W109F_S111A)_huIgG1z (mAb)_HC
	huCCR8 HV hv_cdr2
847	anti-	VYYGSGTYYKNRYYYGMDV
	huCCR8_44379(VH:D72S, VL:N67A_S68A_
	M99G_W109F_S111A)_huIgG1z (mAb)_HC
	huCCR8 HV hv_cdr3
848	anti-	GGHNIGSKGVH
	huCCR8_44379(VH:D72S, VL:N67A_S68A_
	M99G_W109F_S111A)_huIgG1z (mAb)_LC
	huCCR8 LV lv_cdr1
849	anti-	RAANRPS
	huCCR8_44379(VH:D72S, VL:N67A_S68A_
	M99G_W109F_S111A)_huIgG1z (mAb)_LC
	huCCR8 LV lv_cdr2
850	anti-	QAFDAGTVV
	huCCR8_44379(VH:D72S, VL:N67A_S68A_
	M99G_W109F_S111A)_huIgG1z (mAb)_LC
	huCCR8 LV lv_cdr3
851	anti-	NYGFH
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_
	M99E_W109F_S111A)_huIgG1z
	(mAb)_HC huCCR8 HV hv_cdr1
852	anti-	VISYAGSNRYYAASVKG
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_
	M99E_W109F_S111A)_huIgG1z
	(mAb)_HC huCCR8 HV hv_cdr2
853	anti-	VYYGSGTYYKNRYYYGMDV
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_
	M99E_W109F_S111A)_huIgG1z
	(mAb)_HC huCCR8 HV hv_cdr3
854	anti-	GGHNIGSKGVH
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_
	M99E_W109F_S111A)_huIgG1z
	(mAb)_LC huCCR8 LV lv_cdr1
855	anti-	RQSNRPS
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_
	M99E_W109F_S111A)_huIgG1z
	(mAb)_LC huCCR8 LV lv_cdr2
856	anti-	QAFDAGTVV
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_
	M99E_W109F_S111A)_huIgG1z
	(mAb)_LC huCCR8 LV lv_cdr3
857	anti-	NYGFH
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_
	W109F_S111A)_huIgG1z (mAb)_HC
	huCCR8 HV hv_cdr1
858	anti-	VISYSGSNRYYADSVKG
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_
	W109F_S111A)_huIgG1z (mAb)_HC
	huCCR8 HV hv_cdr2
859	anti-	VYYGSGTYYKNRYYYGMDV
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_
	W109F_S111A)_huIgG1z (mAb)_HC
	huCCR8 HV hv_cdr3
860	anti-	GGHNIGSKGVH
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_
	W109F_S111A)_huIgG1z (mAb)_LC
	huCCR8 LV lv_cdr1
861	anti-	RQSNRPS
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_
	W109F_S111A)_huIgG1z (mAb)_LC
	huCCR8 LV lv_cdr2
862	anti-	QAFDAGTVV
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_
	W109F_S111A)_huIgG1z (mAb)_LC
	huCCR8 LV lv_cdr3
863	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	GGHNIGSKGVH
	mAb_LC huCCR8 LV lv_cdr1
864	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	RNSNRPS
	mAb_LC huCCR8 LV lv_cdr2
865	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	QVWDISTVV
	mAb_LC huCCR8 LV lv_cdr3
866	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	NCGMH
	mAb_HC huCCR8 HV hv_cdr1
867	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	VISYDGGNKYHADSVKG
	mAb_HC huCCR8 HV hv_cdr2
868	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	VYYGSGIYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
869	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	GGHNIGSKGVH
	mAb_LC huCCR8 LV lv_cdr1
870	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	RNSNRPS
	mAb_LC huCCR8 LV lv_cdr2
871	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
872	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	NCGMH
	mAb_HC huCCR8 HV hv_cdr1
873	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	VISYDGGNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
874	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	VYYGSGIYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
875	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
876	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	RDSNRPS
	mAb_LC huCCR8 LV lv_cdr2
877	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	QVWDSNTVV
	mAb_LC huCCR8 LV lv_cdr3
878	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	NNGMH
	mAb_HC huCCR8 HV hv_cdr1
879	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	VISNDGSNKYYADSVRG
	mAb_HC huCCR8 HV hv_cdr2
880	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	VYYGSGIYYKNNYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
881	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
882	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	RNSNRPS
	mAb_LC huCCR8 LV lv_cdr2
883	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
884	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	TYGMH
	mAb_HC huCCR8 HV hv_cdr1
885	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	VISYDGSNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
886	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	VYYGSGSYYKKNYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
887	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	GGNNIGGKNVH
	mAb_LC huCCR8 LV lv_cdr1
888	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	RDSNRPS
	mAb_LC huCCR8 LV lv_cdr2
889	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
890	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	SYGFH
	mAb_HC huCCR8 HV hv_cdr1
891	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	VISYDGSNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
892	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	VYYGSGTYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
893	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	GGNNIGSKNVH
	mAh_LC huCCR8 LV lv_cdr1
894	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	RDSNRPS
	mAb_LC huCCR8 LV lv_cdr2
895	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
896	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	NNGMH
	mAb_HC huCCR8 HV hv_cdr1
897	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	VISNDGSNKYYPDSVKG
	mAb_HC huCCR8 HV hv_cdr2
898	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	VYYGSGNYYKNNYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
899	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	EGNNIGSQNVH
	mAb_LC huCCR8 LV lv_cdr1
900	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	RDSNRPS
	mAb_LC huCCR8 LV lv_cdr2
901	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	QVWDGSAVV
	mAb_LC huCCR8 LV lv_cdr3
902	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	SSGMH
	mAb_HC huCCR8 HV hv_cdr1
903	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	VISHDGSNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
904	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	VYYGSGIYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
905	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	GGHNIGSKGVH
	mAb_LC huCCR8 LV lv_cdr1
906	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	RNSNRPS
	mAb_LC huCCR8 LV lv_cdr2
907	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
908	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	DCGMH
	mAb_HC huCCR8 HV hv_cdr1
909	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	VISYDGGNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
910	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	VYYGSGIYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
911	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
912	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	RSSNRPS
	mAb_LC huCCR8 LV lv_cdr2
913	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	QIWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
914	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	SYGMH
	mAb_HC huCCR8 HV hv_cdr1
915	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	VISFDGNNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
916	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	VYYGSGSYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
917	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
918	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	RDSNRPS
	mAb_LC huCCR8 LV lv_cdr2
919	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
920	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	SNGMH
	mAb_HC huCCR8 HV hv_cdr1
921	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	VISNDGSNKYYGDSVKG
	mAb_HC huCCR8 HV hv_cdr2
922	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	VYYGSGIYYRNNYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
923	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
924	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	RNTNRPS
	mAb_LC huCCR8 LV lv_cdr2
925	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
926	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	GYGMH
	mAb_HC huCCR8 HV hv_cdr1
927	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	VISYDGSNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
928	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	VYYGSGIYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
929	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
930	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	RNTNRPS
	mAb_LC huCCR8 LV lv_cdr2
931	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
932	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	GYGMH
	mAb_HC huCCR8 HV hv_cdr1
933	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	VISYDGSNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
934	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	VYYGSGIYYKNRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
935	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	GGNNIGDKNVH
	mAb_LC huCCR8 LV lv_cdr1
936	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	RNNVRPS
	mAb_LC huCCR8 LV lv_cdr2
937	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
938	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	NFGMH
	mAb_HC huCCR8 HV hv_cdr1
939	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	VISYDGGNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
940	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	VYYGSGSYYKKRYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
941	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	GGNNIGSKNVH
	mAb_LC huCCR8 LV lv_cdr1
942	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	RDSNRPS
	mAb_LC huCCR8 LV lv_cdr2
943	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	QVWDSSTVV
	mAb_LC huCCR8 LV lv_cdr3
944	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	SCGMH
	mAb_HC huCCR8 HV hv_cdr1
945	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	VISYDGTNKYYADSVKG
	mAb_HC huCCR8 HV hv_cdr2
946	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	VYYGSGIYYKKNYYYGMDV
	mAb_HC huCCR8 HV hv_cdr3
947	huCCR8_32360_huIgG1z mAb_HC huCCR8	NARMG
	HV hv_cdr1
948	huCCR8_32360_huIgG1z mAb_HC huCCR8	RIKSKTEGGTRDYAAPVKG
	HV hv_cdr2
949	huCCR8_32360_huIgG1z mAb_HC huCCR8	YSGV
	HV hv_cdr3
950	huCCR8_32360_huIgG1z mAb_LC huCCR8	KSSQSVLYSSNNKNYLA
	LV lv_cdr1
951	huCCR8_32360_huIgG1z mAb_LC huCCR8	WASTRES
	LV lv_cdr2
952	huCCR8_32360_huIgG1z mAb_LC huCCR8	QQYYSIPIT
	LV lv_cdr3
953	MPK20298-A4_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRTEDTAVYYCAKV
		YYGSGIYYKNRNYYGMDVWGQGTT
		VTVSS
954	MPK20298-A4_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGNN
		IGSQNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPDRFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVL
955	MPK20299-D2_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
956	MPK20299-D2_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGHN
		IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTITRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVL
957	MPK20299-F11_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAPS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLFLQMNSLRAEDTAVYFCARVY
		YGSGSYYKKRYYYGMDVWGQGTT
		VTVSS
958	MPK20299-F11_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGNN
		IGSQNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTQ
		LTVL
959	MPK20298-H6_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSSGMHWVRQAPGKGLEWVA
		VISYDGTNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
960	MPK20298-H6_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGHN
		IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTQ
		LTVL
961	MPK20297-A4_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAVS
		GFNFSNYGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKKRYYYGMDVWGQGTT
		VTVSS
962	MPK20297-A4_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGHN
		IGSQNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTQ
		LTVL
963	MPK20299-H8_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
964	MPK20299-H8_SCFV LV huCCR8	SYELTQPPSVSVAPGQTARITCGGNNI
		GSKNVHWYQQKAGQAPVQVIYRNS
		NRPSGIPARFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVL
965	MPK20300-C11_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGSYYKNRYYYGMDVWGQGT
		TVTVSS
966	MPK20300-C11_SCFV LV huCCR8	SYELTQPPSVSVAPGQTARIPCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRDIN
		RPSGIPERFSGSNSGNTATLTISRAQA
		GDEADYYCQVWDSSVVFGGGTKLT
		VL
967	MPK20298-B1_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
968	MPK20298-B1_SCFV LV huCCR8	SYELTQPPSVSVALGQTARLTCEGNN
		IGSKNVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRVQ
		AGDEADYYCQAWDSSTVVFGGGTQ
		LTVL
969	MPK20297-E5_SCFV HV huCCR8	QVQLVESGGGLVKPGGSLRLSCAVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISYDGSNKYYTDSVKGRFTISRDNS
		KNTLYLQMNSLRTEDTAVYYCAKV
		YYGSGIYYKKRYYYGMDVWGQGTT
		VTVSS
970	MPK20297-E5_SCFV LV huCCR8	SYELTQPLSVSEALGQTARITCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSNSGNAATLTISRVEA
		GDEADYYCQVWDSSSDHVVFGGGT
		QLTVL
971	MPK20299-A3_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
972	MPK20299-A3_SCFV LV huCCR8	SYELTQPPSVSVAPGQTARITCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRNSN
		RPSGIPERFSGSNSGNTATLTISGTQA
		MDEADYYCQAWDSSNVVFGGGTQL
		TVL
973	MPK20297-B4_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSS
974	MPK20297-B4_SCFV LV huCCR8	SYELTQPLSVSVALGQTARITCGGNN
		IGSQNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPDRFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTQ
		LTVL
975	MPK20298-F6_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
976	MPK20298-F6_SCFV LV huCCR8	SYELTQPPSVSVAPGQTARITCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGTTATLTISRAQA
		GDEAEYYCQVWDSSTVVFGGGTELT
		VL
977	MPK20299-H3_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
978	MPK20299-H3_SCFV LV huCCR8	SYELTQPLSVSVALGQTARITCGGNN
		IGSKNVHWYQQKPGQAPVLAIYRNS
		NRPSGIPERFTGSNSGNTATLTISRAQ
		AGDESDYYCQIWDSSTVVFGGGTKL
		TVL
979	MPK20298-B9_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKKNYYYGMDVWGQGTT
		VTVSS
980	MPK20298-B9_SCFV LV huCCR8	SYELTQPPSVSVALGQTARISCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGTTATLTISRAQA
		GDEAEYYCQVWDSSTVVFGGGTQLT
		VL
981	MPK20299-E2_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISYDGSNKYYTDSVKGRFTISRDNS
		KNTLYLQMNSLRTEDTAVYYCAKV
		YYGSGIYYKKRYYYGMDVWGQGTT
		VTVSS
982	MPK20299-E2_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCEGNNI
		GSQNVHWYQQKPGQAPVLVMYRDS
		NRPSGIPERFSGSKSGNTATLAISRAQ
		AGDESDYYCQVWDGSAVVFGGGTK
		LTVL
983	MPK20299-D6_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
984	MPK20299-D6_SCFV LV huCCR8	SYELTQPLSVSVALGQTARITCEGNNI
		GSQNVHWYQQKPGQAPVLVMYRDS
		NRPSGIPERFSGSKSGNTATLAISRAQ
		AGDESDYYCQVWDGSAVVFGGGTQ
		LTVL
985	MPK20299-A4_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSNYGFHWVRQTPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSS
986	MPK20299-A4_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGHN
		IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISGTQ
		AMDEADYYCQAWDSGTVVFGGGTQ
		LTVL
987	MPK20300-G5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSNYGFHWVRQTPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSS
988	MPK20300-G5_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGANN
		IGSKNVHWYQQKPGQPPVLVIYRDF
		NRPSGIPERFSASNSGNTATLTISRGQ
		AGDEADYYCQVWDSSTGNVVFGGG
		TKLTVL
989	MPK20299-C3_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFIFSNYGFHWVRQTPGKGLEWVAV
		ISYDGSNKYYADSVKGRFTISRDNSK
		NTLYLQMNSLRGEDTAVYYCARVY
		YGSGSYYKNRYYYGMDVWGQGTT
		VTVSS
990	MPK20299-C3_SCFV LV huCCR8	SYELTQPPSVSVAPGQTARITCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGTTATLTISRAQA
		GDEADYYCQVWDSSTVVFGGGTELT
		VL
991	MPK20299-B7_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
992	MPK20299-B7_SCFV LV huCCR8	SYELTQSSSVSVAPGQTARITCGGNNI
		GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGTTATLTISRVEA
		GDEADYYCQVWDSSSAHVIFGGGTK
		LTVL
993	MPK20299-A5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCGAS
		GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
994	MPK20299-A5_SCFV LV huCCR8	SYELTQPPSGSVALGQTARITCGGNN
		LGSKNVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVL
995	MPK20299-D1_SCFV HV huCCR8	QVQLVESGGGLVKPGGSLRLSCAAS
		GFTFSNNGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
996	MPK20299-D1_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGNRI
		GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGTTATLTISRAQA
		GDEAEYYCQVWDSSTVVFGGGTKLT
		VL
997	MPK20299-C5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSNYGFHWVRQTPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSS
998	MPK20299-C5_SCFV LV huCCR8	SYELTQLPSVSVALGQTARITCGGHN
		IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVL
999	MPK20299-B5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKNRYYYGMDVWGQGTTV
		TVSS
1000	MPK20299-B5_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGHN
		IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTQ
		LTVL
1001	MPK20299-G9_SCFV HV huCCR8	QVQLVESGGDLVQPGRSLRLSCAAS
		GFTFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
1002	MPK20299-G9_SCFV LV huCCR8	SYELTQPLSVSVALGQTARITCGGNN
		IGSKNVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTLSRVQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVL
1003	MPK20299-G5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
1004	MPK20299-G5_SCFV LV huCCR8	SYELTQPPSVSVALGQTARLTCEGNN
		IGSKNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLAISRAQ
		AGDESDYYCQVWDSSAVVFGGGTK
		LTVL
1005	MPK20298-C10_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSSGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSS
1006	MPK20298-C10_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGNN
		IGSKNVHWYQQKPGQAPVLAIYRNS
		NRPSGIPERFTGSNSGNTATLTISGTQ
		AMDEADYYCQAWDSSTVVFGGGTK
		LTVL
1007	MPK20298-B5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
1008	MPK20298-B5_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGNN
		IGSQNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLAISRAQ
		AGDESDYYCQVWDSSAVVFGGGTQ
		LTVL
1009	MPK20299-F2_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTLSSSGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
1010	MPK20299-F2_SCFV LV huCCR8	SYELTQPPSVSVALGQTARISCGGNNI
		GSKNVHWYQQKPGQAPVLVMYRDS
		NRPSGIPERFSGSNSGNTATLTISGTQ
		AMDEADYYCQAWDSGTVVFGGGTK
		LTVL
1011	MPK20298-D4_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSS
1012	MPK20298-D4_SCFV LV huCCR8	SYELTQPPSVSVALGQTARITCGGNN
		IGGKNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDESDYYCQVWDSSTVVFGGGTQ
		LTVL
1013	MPK20297-F5_SCFV HV huCCR8	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSS
1014	MPK20297-F5_SCFV LV huCCR8	SYELTQPLSVSVALGQTARITCGGNN
		IGSKNVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVL
1015	MPK20299-D9_SCFV HV huCCR8	QVQLVESGGGLVKPGGSLRLSCAAS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSS
1016	MPK20299-D9_SCFV LV huCCR8	SYELTQPPSVSVALGQTARISCGGNNI
		ESKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGTTATLTISRAQA
		GDEAEYYCQVWDSSTVVFGGGTQLT
		VL
1017	huCCR8_32360_huIgG1z	EVQLVESGGGLVKPGGSLRLSCAAS
	mAb(LC:K38R)_HC HV huCCR8	GFTFSNARMGWVRQAPGKGLEWVG
		RIKSKTEGGTRDYAAPVKGRFTISRD
		DSKNTLYLQMNSLKTEDTAVYYCTS
		YSGVWGQGTMVTVSS
1018	huCCR8_32360_huIgG1z	DIVMTQSPDSLAVSLGERATINCKSS
	mAb(LC:K38R)_LC LV huCCR8	QSVLYSSNNRNYLAWYHQKPGQSPK
		LLISWASTRESGVPDRFSGSGSGTDFT
		LTINSLQAEDVAVYYCQQYYSIPITFG
		GGTKVEIKR
1019	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	GFTFSNYGFHWVRQTPGKGLEWVA
	M99G_W109F_S111A)_huIgG1z (mAb)_HC	VISYDGSNRYYASSVKGRFTISRDNS
	HV huCCR8	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSS
1020	anti-	SYELTQPPSVSVALGQTARITCGGHN
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	IGSKGVHWYQQKPGQAPVLVIYRAA
	M99G_W109F_S111A)_huIgG1z (mAb)_LC	NRPSGIPERFSGSNSGNTATLTISGTQ
	LV huCCR8	AGDEADYYCQAFDAGTVVFGGGTQ
		LTVLG
1021	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	GFTFSNYGFHWVRQTPGKGLEWVA
	M99E_W109F_S111A)_huIgG1z	VISYAGSNRYYAASVKGRFTISRDNS
	(mAb)_HC HV huCCR8	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSS
1022	anti-	SYELTQPPSVSVALGQTARITCGGHN
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	IGSKGVHWYQQKPGQAPVLVIYRQS
	M99E_W109F_S111A)_huIgG1z	NRPSGIPERFSGSNSGNTATLTISGTQ
	(mAb)_LC LV huCCR8	AEDEADYYCQAFDAGTVVFGGGTQ
		LTVLG
1023	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	GFTFSNYGFHWVRQTPGKGLEWVA
	W109F_S111A)_huIgG1z (mAb)_HC HV	VISYSGSNRYYADSVKGRFTISRDNS
	huCCR8	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSS
1024	anti-	SYELTQPPSVSVALGQTARITCGGHN
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	IGSKGVHWYQQKPGQAPVLVIYRQS
	W109F_S111A)_huIgG1z (mAb)_LC LV	NRPSGIPERFSGSNSGNTATLTISGTQ
	huCCR8	AGDEADYYCQAFDAGTVVFGGGTQ
		LTVLG
1025	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGHN
	mAb_LC LV huCCR8	IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDISTVVFGGGTEL
		TVLG
1026	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFNFSNCGMHWVRQAPGKGLEWVA
		VISYDGGNKYHADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
1027	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGHN
	mAb_LC LV huCCR8	IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGKTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVLG
1028	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFNFSNCGMHWVRQAPGKGLEWVA
		VISYDGGNKYYADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSS
1029	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQKRPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSNTVVFGGGTN
		LTVLG
1030	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCVVS
	mAb_HC HV huCCR8	GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYSCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSS
1031	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQQKAGQAPVQVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVLG
1032	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFNFNTYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KSTLYLQMNSLRAEDTAVYYCARVY
		YGSGSYYKKNYYYGMDVWGQGTT
		VTVSS
1033	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGGKNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDESDYYCQVWDSSTVVFGGGTTL
		TVLG
1034	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFTLSSYGFHWVRQTPGKGLEWVAV
		ISYDGSNKYYADSVKGRFTISRDNSK
		NTLYLQMNSLRGEDTAVYYCARVY
		YGSGTYYKNRYYYGMDVWGQGTT
		VTVSS
1035	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	SYELTQPLSVSEALGQTARITCGGNNI
	mAb_LC LV huCCR8	GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGNTATLTISRAQA
		GDEADYYCQVWDSSTVVFGGGTKV
		TVLG
1036	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCVVS
	mAb_HC HV huCCR8	GFNFINNGMHWVRQAPGKGLDWVA
		VISNDGSNKYYPDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDSAVYYCAKV
		YYGSGNYYKNNYYYGMDVWGQGT
		TVTVSS
1037	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	SYELTQPLSVSVALGQTARITCEGNNI
	mAb_LC LV huCCR8	GSQNVHWYQQKPGQAPVLVMYRDS
		NRPSGIPERFSGSKSGNTATLAISRAQ
		AGDESDYYCQVWDGSAVVFGGGTT
		LTVLG
1038	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	QMQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFTFSSSGMHWVRQAPGKGLEWVA
		VISHDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLGGEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VIVSS
1039	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGHN
	mAb_LC LV huCCR8	IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVLG
1040	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFNFSDCGMHWVRQAPGKGLEWVA
		VISYDGGNKYYADSVKGRFTISRDDS
		KNTLYLQTDSLRTEDTAVYYCAKVY
		YGSGIYYKNRYYYGMDVWGQGTTV
		TVSS
1041	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	SYELTQPLSVSVALGQTGRITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQQKPGQAPVLVIYRSS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDESDYYCQIWDSSTVVFGGGTKL
		TVLG
1042	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFTFSSYGMHWVRQAPGKGLEWVA
		VISFDGNNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGSYYKNRYYYGMDVWGQGT
		TVTVST
1043	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQQRPGQAPVLVIYRDS
		NRPSGIPERLSGSKAGNTATLTISRAH
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVQG
1044	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAVS
	mAb_HC HV huCCR8	GFTFSSNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYGDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYRNNYYYGMDVWGQGTT
		VTVSS
1045	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQQKPGQAPILVIYRNTN
		RPSGIPERFSGSNSGNTATLTISRAQV
		GDESDYFCQVWDSSTVVFGGGTKLT
		VLG
1046	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCGAS
	mAb_HC HV huCCR8	GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFPISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VAVSS
1047	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQQKPGQAPILVIYRNTN
		RPSGIPERFSGSNSGNTATLTISRAQV
		GDESDYFCQVWDSSTVVFGGGTKLT
		VLG
1048	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCGAS
	mAb_HC HV huCCR8	GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VAVSS
1049	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	SYDLTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGDKNVHWYQQKPGQAPVLVIYRNN
		VRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVLG
1050	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GLNFSNFGMHWVRQAPGKGLDWVA
		VISYDGGNKYYADSVKGRFTVSRDN
		SKNTLFLQMNSLRAEDTALYYCAKV
		YYGSGSYYKKRYYYGMDVWGQGT
		TVTVSS
1051	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC LV huCCR8	IGSKNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGAK
		LTVLG
1052	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC HV huCCR8	GFNFSSCGMHWVRQAPGKGLEWVA
		VISYDGTNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKKNYYYGMDVWGQGTT
		VTVSS
1053	huCCR8_32360_huIgG1z mAb_HC HV	EVQLVESGGGLVKPGGSLRLSCAAS
	huCCR8	GFTFSNARMGWVRQAPGKGLEWVG
		RIKSKTEGGTRDYAAPVKGRFTISRD
		DSKNTLYLQMNSLKTEDTAVYYCTS
		YSGVWGQGTMVTVSS
1054	huCCR8_32360_huIgG1z mAb_LC LV	DIVMTQSPDSLAVSLGERATINCKSS
	huCCR8	QSVLYSSNNKNYLAWYHQKPGQSPK
		LLISWASTRESGVPDRFSGSGSGTDFT
		LTINSLQAEDVAVYYCQQYYSIPITFG
		GGTKVEIKR
1055	huCCR8_32360_huIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb(LC:K38R)_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1056	huCCR8_32360_huIgG1z	TVAAPSVFIFPPSDEQLKSGTASVVCL
	mAb(LC:K38R)_LC Constant	LNNFYPREAKVQWKVDNALQSGNS
		QESVTEQDSKDSTYSLSSTLTLSKAD
		YEKHKVYACEVTHQGLSSPVTKSFN
		RGEC
1057	anti-	ASTKGPSVFPLAPSSKSTSGGTAALG
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	CLVKDYFPEPVTVSWNSGALTSGVH
	M99G_W109F_S111A)_huIgG1z (mAb)_HC	TFPAVLQSSGLYSLSSVVTVPSSSLGT
	Constant	QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1058	anti-	QPKAAPSVTLFPPSSEELQANKATLV
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	CLISDFYPGAVTVAWKADSSPVKAG
	M99G_W109F_S111A)_huIgG1z (mAb)_LC	VETTTPSKQSNNKYAASSYLSLTPEQ
	Constant	WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1059	anti-	ASTKGPSVFPLAPSSKSTSGGTAALG
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	CLVKDYFPEPVTVSWNSGALTSGVH
	M99E_W109F_S111A)_huIgG1z	TFPAVLQSSGLYSLSSVVTVPSSSLGT
	(mAb)_HC Constant	QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1060	anti-	QPKAAPSVTLFPPSSEELQANKATLV
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	CLISDFYPGAVTVAWKADSSPVKAG
	M99E_W109F_S111A)_huIgG1z	VETTTPSKQSNNKYAASSYLSLTPEQ
	(mAb)_LC Constant	WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1061	anti-	ASTKGPSVFPLAPSSKSTSGGTAALG
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	CLVKDYFPEPVTVSWNSGALTSGVH
	W109F_S111A)_huIgG1z (mAb)_HC	TFPAVLQSSGLYSLSSVVTVPSSSLGT
	Constant	QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1062	anti-	QPKAAPSVTLFPPSSEELQANKATLV
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	CLISDFYPGAVTVAWKADSSPVKAG
	W109F_S111A)_huIgG1z (mAb)_LC	VETTTPSKQSNNKYAASSYLSLTPEQ
	Constant	WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1063	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1064	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1065	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1066	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1067	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1068	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1069	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1070	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1071	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1072	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1073	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1074	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1075	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1076	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1077	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1078	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1079	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1080	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1081	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1082	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1083	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1084	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1085	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1086	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1087	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1088	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1089	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	QPKAAPSVTLFPPSSEELQANKATLV
	mAb_LC Constant	CLISDFYPGAVTVAWKADSSPVKAG
		VETTTPSKQSNNKYAASSYLSLTPEQ
		WKSHRSYSCQVTHEGSTVEKTVAPT
		ECS
1090	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	ASTKGPSVFPLAPSSKSTSGGTAALG
	mAb_HC Constant	CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1091	huCCR8_32360_huIgG1z mAb_HC Constant	ASTKGPSVFPLAPSSKSTSGGTAALG
		CLVKDYFPEPVTVSWNSGALTSGVH
		TFPAVLQSSGLYSLSSVVTVPSSSLGT
		QTYICNVNHKPSNTKVDKKVEPKSC
		DKTHTCPPCPAPELLGGPSVFLFPPKP
		KDTLMISRTPEVTCVVVDVSHEDPEV
		KFNWYVDGVEVHNAKTKPREEQYN
		STYRVVSVLTVLHQDWLNGKEYKC
		KVSNKALPAPIEKTISKAKGQPREPQ
		VYTLPPSREEMTKNQVSLTCLVKGF
		YPSDIAVEWESNGQPENNYKTTPPVL
		DSDGSFFLYSKLTVDKSRWQQGNVF
		SCSVMHEALHNHYTQKSLSLSPGK
1092	huCCR8_32360_huIgG1z mAb_LC Constant	TVAAPSVFIFPPSDEQLKSGTASVVCL
		LNNFYPREAKVQWKVDNALQSGNS
		QESVTEQDSKDSTYSLSSTLTLSKAD
		YEKHKVYACEVTHQGLSSPVTKSFN
		RGEC
1093	MPK20298-A4_SCFV	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRTEDTAVYYCAKV
		YYGSGIYYKNRNYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCGGNNIGSQN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPDRFSGSKSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTKLTVL
1094	MPK20299-D2_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVALGQTARITCGGHNIGSKGV
		HWYQQKPGQAPVLVIYRNSNRPSGIP
		ERFSGSNSGNTATLTITRAQAGDEAD
		YYCQVWDSSTVVFGGGTKLTVL
1095	MPK20299-F11_SCFV	QVQLVESGGGVVQPGRSLRLSCAPS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLFLQMNSLRAEDTAVYFCARVY
		YGSGSYYKKRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCGGNNIGSQN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTQLTVL
1096	MPK20298-H6_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSSGMHWVRQAPGKGLEWVA
		VISYDGTNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCGGHNIGSKG
		VHWYQQKPGQAPVLVIYRNSNRPSG
		IPERFSGSNSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTQLTVL
1097	MPK20297-A4_SCFV	QVQLVESGGGVVQPGRSLRLSCAVS
		GFNFSNYGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKKRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCGGHNIGSQN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTQLTVL
1098	MPK20299-H8_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVAPGQTARITCGGNNIGSKNV
		HWYQQKAGQAPVQVIYRNSNRPSGI
		PARFSGSNSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTKLTVL
1099	MPK20300-C11_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGSYYKNRYYYGMDVWGQGT
		TVTVSSGGGGSGGGGSGGGGSSYEL
		TQPPSVSVAPGQTARIPCGGNNIGSK
		NVHWYQQKPGQAPVLVIYRDINRPS
		GIPERFSGSNSGNTATLTISRAQAGDE
		ADYYCQVWDSSVVFGGGTKLTVL
1100	MPK20298-B1_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVALGQTARLTCEGNNIGSKNV
		HWYQQKPGQAPVLVIYRNSNRPSGIP
		ERFSGSNSGNTATLTISRVQAGDEAD
		YYCQAWDSSTVVFGGGTQLTVL
1101	MPK20297-E5_SCFV	QVQLVESGGGLVKPGGSLRLSCAVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISYDGSNKYYTDSVKGRFTISRDNS
		KNTLYLQMNSLRTEDTAVYYCAKV
		YYGSGIYYKKRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPLSVSEALGQTARITCGGNNIGSKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSNSGNAATLTISRVEAGDEA
		DYYCQVWDSSSDHVVFGGGTQLTV
		L
1102	MPK20299-A3_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVAPGQTARITCGGNNIGSKNV
		HWYQQKPGQAPVLVIYRNSNRPSGIP
		ERFSGSNSGNTATLTISGTQAMDEAD
		YYCQAWDSSNVVFGGGTQLTVL
1103	MPK20297-B4_SCFV	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPLSVSVALGQTARITCGGNNIGSQN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPDRFSGSKSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTQLTVL
1104	MPK20298-F6_SCFV	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVAPGQTARITCGGNNIGSKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGTTATLTISRAQAGDEA
		EYYCQVWDSSTVVFGGGTELTVL
1105	MPK20299-H3_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PLSVSVALGQTARITCGGNNIGSKNV
		HWYQQKPGQAPVLAIYRNSNRPSGIP
		ERFTGSNSGNTATLTISRAQAGDESD
		YYCQIWDSSTVVFGGGTKLTVL
1106	MPK20298-B9_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKKNYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARISCGGNNIGSKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGTTATLTISRAQAGDEA
		EYYCQVWDSSTVVFGGGTQLTVL
1107	MPK20299-E2_SCFV	QVQLVESGGGVVQPGRSLRLSCAVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISYDGSNKYYTDSVKGRFTISRDNS
		KNTLYLQMNSLRTEDTAVYYCAKV
		YYGSGIYYKKRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCEGNNIGSQN
		VHWYQQKPGQAPVLVMYRDSNRPS
		GIPERFSGSKSGNTATLAISRAQAGDE
		SDYYCQVWDGSAVVFGGGTKLTVL
1108	MPK20299-D6_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PLSVSVALGQTARITCEGNNIGSQNV
		HWYQQKPGQAPVLVMYRDSNRPSGI
		PERFSGSKSGNTATLAISRAQAGDES
		DYYCQVWDGSAVVFGGGTQLTVL
1109	MPK20299-A4_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSNYGFHWVRQTPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSGGGGSGGGGSGGGGSSYEL
		TQPPSVSVALGQTARITCGGHNIGSK
		GVHWYQQKPGQAPVLVIYRNSNRPS
		GIPERFSGSNSGNTATLTISGTQAMDE
		ADYYCQAWDSGTVVFGGGTQLTVL
1110	MPK20300-G5_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSNYGFHWVRQTPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSGGGGSGGGGSGGGGSSYEL
		TQPPSVSVALGQTARITCGANNIGSK
		NVHWYQQKPGQPPVLVIYRDFNRPS
		GIPERFSASNSGNTATLTISRGQAGDE
		ADYYCQVWDSSTGNVVFGGGTKLT
		VL
1111	MPK20299-C3_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFIFSNYGFHWVRQTPGKGLEWVAV
		ISYDGSNKYYADSVKGRFTISRDNSK
		NTLYLQMNSLRGEDTAVYYCARVY
		YGSGSYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVAPGQTARITCGGNNIGSKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGTTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTELTVL
1112	MPK20299-B7_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		SSSVSVAPGQTARITCGGNNIGSKNV
		HWYQQKPGQAPVLVIYRDSNRPSGIP
		ERFSGSKSGTTATLTISRVEAGDEAD
		YYCQVWDSSSAHVIFGGGTKLTVL
1113	MPK20299-A5_SCFV	QVQLVESGGGVVQPGRSLRLSCGAS
		GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSGSVALGQTARITCGGNNLGSKN
		VHWYQQKPGQAPVLVIYRNSNRPSG
		IPERFSGSNSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTKLTVL
1114	MPK20299-D1_SCFV	QVQLVESGGGLVKPGGSLRLSCAAS
		GFTFSNNGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCGGNRIGSKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGTTATLTISRAQAGDEA
		EYYCQVWDSSTVVFGGGTKLTVL
1115	MPK20299-C5_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSNYGFHWVRQTPGKGLEWVA
		VISYDGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSGGGGSGGGGSGGGGSSYEL
		TQLPSVSVALGQTARITCGGHNIGSK
		GVHWYQQKPGQAPVLVIYRNSNRPS
		GIPERFSGSNSGNTATLTISRAQAGDE
		ADYYCQVWDSSTVVFGGGTELTVL
1116	MPK20299-B5_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKNRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVALGQTARITCGGHNIGSKGV
		HWYQQKPGQAPVLVIYRNSNRPSGIP
		ERFSGSNSGNTATLTISRAQAGDEAD
		YYCQVWDSSTVVFGGGTQLTVL
1117	MPK20299-G9_SCFV	QVQLVESGGDLVQPGRSLRLSCAAS
		GFTFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPLSVSVALGQTARITCGGNNIGSKN
		VHWYQQKPGQAPVLVIYRNSNRPSG
		IPERFSGSNSGNTATLTLSRVQAGDE
		ADYYCQVWDSSTVVFGGGTKLTVL
1118	MPK20299-G5_SCFV	QVQLVESGGGVVQPGRSLRLSCAVS
		GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARLTCEGNNIGSKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGNTATLAISRAQAGDES
		DYYCQVWDSSAVVFGGGTKLTVL
1119	MPK20298-C10_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTFSSSGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARITCGGNNIGSKN
		VHWYQQKPGQAPVLAIYRNSNRPSG
		IPERFTGSNSGNTATLTISGTQAMDE
		ADYYCQAWDSSTVVFGGGTKLTVL
1120	MPK20298-B5_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVALGQTARITCGGNNIGSQNV
		HWYQQKPGQAPVLVIYRDSNRPSGIP
		ERFSGSKSGNTATLAISRAQAGDESD
		YYCQVWDSSAVVFGGGTQLTVL
1121	MPK20299-F2_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFTLSSSGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARISCGGNNIGSKN
		VHWYQQKPGQAPVLVMYRDSNRPS
		GIPERFSGSNSGNTATLTISGTQAMDE
		ADYYCQAWDSGTVVFGGGTKLTVL
1122	MPK20298-D4_SCFV	QVQLVESGGGVVQPGRSLRLSCAAS
		GFNFSNYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYFCARVY
		YGSGIYYKKRYYYGMDVWGQGTTV
		TVSSGGGGSGGGGSGGGGSSYELTQ
		PPSVSVALGQTARITCGGNNIGGKNV
		HWYQQKPGQAPVLVIYRDSNRPSGIP
		ERFSGSKSGNTATLTISRAQAGDESD
		YYCQVWDSSTVVFGGGTQLTVL
1123	MPK20297-F5_SCFV	QVQLVESGGGVVQPGRSLRLSCVVS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPLSVSVALGQTARITCGGNNIGSKN
		VHWYQQKPGQAPVLVIYRNSNRPSG
		IPERFSGSNSGNTATLTISRAQAGDEA
		DYYCQVWDSSTVVFGGGTKLTVL
1124	MPK20299-D9_SCFV	QVQLVESGGGLVKPGGSLRLSCAAS
		GFNFSRNGMHWVRQVPGRGLDWVA
		VISNDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSSGGGGSGGGGSGGGGSSYELT
		QPPSVSVALGQTARISCGGNNIESKN
		VHWYQQKPGQAPVLVIYRDSNRPSG
		IPERFSGSKSGTTATLTISRAQAGDEA
		EYYCQVWDSSTVVFGGGTQLTVL
1125	huCCR8_32360_huIgG1z	EVQLVESGGGLVKPGGSLRLSCAAS
	mAb(LC:K38R)_HC	GFTFSNARMGWVRQAPGKGLEWVG
		RIKSKTEGGTRDYAAPVKGRFTISRD
		DSKNTLYLQMNSLKTEDTAVYYCTS
		YSGVWGQGTMVTVSSASTKGPSVFP
		LAPSSKSTSGGTAALGCLVKDYFPEP
		VTVSWNSGALTSGVHTFPAVLQSSG
		LYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCP
		APELLGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVL
		TVLHQDWLNGKEYKCKVSNKALPA
		PIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWE
		SNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
1126	huCCR8_32360_huIgG1z	DIVMTQSPDSLAVSLGERATINCKSS
	mAb(LC:K38R)_LC	QSVLYSSNNRNYLAWYHQKPGQSPK
		LLISWASTRESGVPDRFSGSGSGTDFT
		LTINSLQAEDVAVYYCQQYYSIPITFG
		GGTKVEIKRTVAAPSVFIFPPSDEQLK
		SGTASVVCLLNNFYPREAKVQWKVD
		NALQSGNSQESVTEQDSKDSTYSLSS
		TLTLSKADYEKHKVYACEVTHQGLS
		SPVTKSFNRGEC
1127	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	GFTFSNYGFHWVRQTPGKGLEWVA
	M99G_W109F_S111A)_huIgG1z (mAb)_HC	VISYDGSNRYYASSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1128	anti-	SYELTQPPSVSVALGQTARITCGGHN
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	IGSKGVHWYQQKPGQAPVLVIYRAA
	M99G_W109F_S111A)_huIgG1z (mAb)_LC	NRPSGIPERFSGSNSGNTATLTISGTQ
		AGDEADYYCQAFDAGTVVFGGGTQ
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1129	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	GFTFSNYGFHWVRQTPGKGLEWVA
	M99E_W109F_S111A)_huIgG1z	VISYAGSNRYYAASVKGRFTISRDNS
	(mAb)_HC	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1130	anti-	SYELTQPPSVSVALGQTARITCGGHN
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	IGSKGVHWYQQKPGQAPVLVIYRQS
	M99E_W109F_S111A)_huIgG1z	NRPSGIPERFSGSNSGNTATLTISGTQ
	(mAb)_LC	AEDEADYYCQAFDAGTVVFGGGTQ
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1131	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	GFTFSNYGFHWVRQTPGKGLEWVA
	W109F_S111A)_huIgG1z (mAb)_HC	VISYSGSNRYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1132	anti-	SYELTQPPSVSVALGQTARITCGGHN
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	IGSKGVHWYQQKPGQAPVLVIYRQS
	W109F_S111A)_huIgG1z (mAb)_LC	NRPSGIPERFSGSNSGNTATLTISGTQ
		AGDEADYYCQAFDAGTVVFGGGTQ
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1133	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGHN
	mAb_LC	IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDISTVVFGGGTEL
		TVLGQPKAAPSVTLFPPSSEELQANK
		ATLVCLISDFYPGAVTVAWKADSSP
		VKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1134	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC	GFNFSNCGMHWVRQAPGKGLEWVA
		VISYDGGNKYHADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1135	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGHN
	mAb_LC	IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGKTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1136	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC	GFNFSNCGMHWVRQAPGKGLEWVA
		VISYDGGNKYYADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1137	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGSKNVHWYQKRPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSNTVVFGGGTN
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1138	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCVVS
	mAb_HC	GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYSCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1139	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGSKNVHWYQQKAGQAPVQVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1140	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC	GFNFNTYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KSTLYLQMNSLRAEDTAVYYCARVY
		YGSGSYYKKNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1141	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGGKNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDESDYYCQVWDSSTVVFGGGTTL
		TVLGQPKAAPSVTLFPPSSEELQANK
		ATLVCLISDFYPGAVTVAWKADSSP
		VKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1142	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC	GFTLSSYGFHWVRQTPGKGLEWVAV
		ISYDGSNKYYADSVKGRFTISRDNSK
		NTLYLQMNSLRGEDTAVYYCARVY
		YGSGTYYKNRYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1143	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	SYELTQPLSVSEALGQTARITCGGNNI
	mAb_LC	GSKNVHWYQQKPGQAPVLVIYRDSN
		RPSGIPERFSGSKSGNTATLTISRAQA
		GDEADYYCQVWDSSTVVFGGGTKV
		TVLGQPKAAPSVTLFPPSSEELQANK
		ATLVCLISDFYPGAVTVAWKADSSP
		VKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1144	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCVVS
	mAb_HC	GFNFINNGMHWVRQAPGKGLDWVA
		VISNDGSNKYYPDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDSAVYYCAKV
		YYGSGNYYKNNYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1145	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	SYELTQPLSVSVALGQTARITCEGNNI
	mAb_LC	GSQNVHWYQQKPGQAPVLVMYRDS
		NRPSGIPERFSGSKSGNTATLAISRAQ
		AGDESDYYCQVWDGSAVVFGGGTT
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1146	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	QMQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC	GFTFSSSGMHWVRQAPGKGLEWVA
		VISHDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLGGEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VIVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1147	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGHN
	mAb_LC	IGSKGVHWYQQKPGQAPVLVIYRNS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1148	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC	GFNFSDCGMHWVRQAPGKGLEWVA
		VISYDGGNKYYADSVKGRFTISRDDS
		KNTLYLQTDSLRTEDTAVYYCAKVY
		YGSGIYYKNRYYYGMDVWGQGTTV
		TVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTS
		GVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVE
		PKSCDKTHTCPPCPAPELLGGPSVFLF
		PPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPRE
		EQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQP
		REPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLYSKLTVDKSRWQQG
		NVFSCSVMHEALHNHYTQKSLSLSP
		GK
1149	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	SYELTQPLSVSVALGQTGRITCGGNN
	mAb_LC	IGSKNVHWYQQKPGQAPVLVIYRSS
		NRPSGIPERFSGSNSGNTATLTISRAQ
		AGDESDYYCQIWDSSTVVFGGGTKL
		TVLGQPKAAPSVTLFPPSSEELQANK
		ATLVCLISDFYPGAVTVAWKADSSP
		VKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1150	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC	GFTFSSYGMHWVRQAPGKGLEWVA
		VISFDGNNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGSYYKNRYYYGMDVWGQGT
		TVTVSTASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1151	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGSKNVHWYQQRPGQAPVLVIYRDS
		NRPSGIPERLSGSKAGNTATLTISRAH
		AGDEADYYCQVWDSSTVVFGGGTE
		LTVQGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1152	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAVS
	mAb_HC	GFTFSSNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYGDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYRNNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1153	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGSKNVHWYQQKPGQAPILVIYRNTN
		RPSGIPERFSGSNSGNTATLTISRAQV
		GDESDYFCQVWDSSTVVFGGGTKLT
		VLGQPKAAPSVTLFPPSSEELQANKA
		TLVCLISDFYPGAVTVAWKADSSPV
		KAGVETTTPSKQSNNKYAASSYLSLT
		PEQWKSHRSYSCQVTHEGSTVEKTV
		APTECS
1154	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCGAS
	mAb_HC	GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFPISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VAVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1155	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGSKNVHWYQQKPGQAPILVIYRNTN
		RPSGIPERFSGSNSGNTATLTISRAQV
		GDESDYFCQVWDSSTVVFGGGTKLT
		VLGQPKAAPSVTLFPPSSEELQANKA
		TLVCLISDFYPGAVTVAWKADSSPV
		KAGVETTTPSKQSNNKYAASSYLSLT
		PEQWKSHRSYSCQVTHEGSTVEKTV
		APTECS
1156	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCGAS
	mAb_HC	GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VAVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1157	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	SYDLTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGDKNVHWYQQKPGQAPVLVIYRNN
		VRPSGIPERFSGSNSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGTK
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1158	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC	GLNFSNFGMHWVRQAPGKGLDWVA
		VISYDGGNKYYADSVKGRFTVSRDN
		SKNTLFLQMNSLRAEDTALYYCAKV
		YYGSGSYYKKRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1159	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	SYELTQPLSVSVALGQTARITCGGNN
	mAb_LC	IGSKNVHWYQQKPGQAPVLVIYRDS
		NRPSGIPERFSGSKSGNTATLTISRAQ
		AGDEADYYCQVWDSSTVVFGGGAK
		LTVLGQPKAAPSVTLFPPSSEELQAN
		KATLVCLISDFYPGAVTVAWKADSS
		PVKAGVETTTPSKQSNNKYAASSYLS
		LTPEQWKSHRSYSCQVTHEGSTVEK
		TVAPTECS
1160	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC	GFNFSSCGMHWVRQAPGKGLEWVA
		VISYDGTNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKKNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PGK
1161	huCCR8_32360_huIgG1z mAb_HC	EVQLVESGGGLVKPGGSLRLSCAAS
		GFTFSNARMGWVRQAPGKGLEWVG
		RIKSKTEGGTRDYAAPVKGRFTISRD
		DSKNTLYLQMNSLKTEDTAVYYCTS
		YSGVWGQGTMVTVSSASTKGPSVFP
		LAPSSKSTSGGTAALGCLVKDYFPEP
		VTVSWNSGALTSGVHTFPAVLQSSG
		LYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCP
		APELLGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVL
		TVLHQDWLNGKEYKCKVSNKALPA
		PIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWE
		SNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPGK
1162	huCCR8_32360_huIgG1z mAb_LC	DIVMTQSPDSLAVSLGERATINCKSS
		QSVLYSSNNKNYLAWYHQKPGQSPK
		LLISWASTRESGVPDRFSGSGSGTDFT
		LTINSLQAEDVAVYYCQQYYSIPITFG
		GGTKVEIKRTVAAPSVFIFPPSDEQLK
		SGTASVVCLLNNFYPREAKVQWKVD
		NALQSGNSQESVTEQDSKDSTYSLSS
		TLTLSKADYEKHKVYACEVTHQGLS
		SPVTKSFNRGEC
1163	MPK20298-A4_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGTAGTCT
		CTGGATTCAACTTCAGTAACAATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGACTGGAGTGGGTGGCA
		GTTATTTCAAATGATGGAAGTAATA
		AATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAACTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAACAGGAACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGACCGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGGACC
		AAGCTGACCGTCCTA
1164	MPK20299-D2_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGACACAACATTGGAAG
		TAAAGGTGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCACCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGGACC
		AAGCTGACCGTCCTA
1165	MPK20299-F11_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCACCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAAAACACGCTGTTTCTGCA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGAGTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1166	MPK20298-H6_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCGT
		CTGGATTCACCTTCAGTAGCTCTGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAACTAATA
		AATACTATGCGGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAACAGGTACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGACACAACATTGGAAG
		TAAAGGTGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1167	MPK20297-A4_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGTCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGTTCCA
		GGCAGGGGGCTAGATTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCAGACTCCGTGAAG
		GGCCGATTCACCATTTCCAGAGACA
		ATTCCAAGAACACACTGTATCTGCA
		AATGGACAGCCTGAGAACTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGACACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1168	MPK20299-H8_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGGA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCGGTGTCAGTGGC
		CCCAGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGGCAGGCCAGGCCCCTGTGCA
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGCGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAGGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGTGGGACCA
		AGCTGACCGTCCTA
1169	MPK20300-C11_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCACCTTCAGTAGCTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCGGTGTATTACTGTGCGAG
		AGTTTACTATGGTTCGGGGAGTTAT
		TATAAAAACCGCTACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCGGTGTCAGTGGC
		CCCAGGACAGACGGCCAGGATTCC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTACT
		GGTCATCTATAGGGATATCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		GTGGTATTCGGCGGAGGGACCAAG
		CTGACCGTCCTC
1170	MPK20298-B1_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGCTTAC
		CTGTGAGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACTATTAGCAGAGTCC
		AAGCCGGGGATGAGGCTGACTATT
		ACTGTCAGGCGTGGGACAGCAGCA
		CTGTGGTATTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1171	MPK20297-E5_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCCTGGTCAAGCCTGGGGGG
		TCCCTGAGACTCTCCTGTGCAGTCT
		CTGGATTCAACTTCAGTAACAATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTCATATCGTATGATGGAAGTAATA
		AATACTATACAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAACTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACTCTCAGTGTCAGAGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTACT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCAGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCTGGGAACGCGG
		CCACCCTGACCATCAGTAGGGTCG
		AAGCCGGGGATGAGGCCGACTATT
		ACTGTCAGGTGTGGGATAGTAGCA
		GTGATCATGTGGTATTCGGCGGAG
		GCACCCAGCTGACCGTCCTA
1172	MPK20299-A3_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCGGTGTCAGTGGC
		CCCAGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTACT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCTGGGAACACAG
		CCACTCTGACCATCAGCGGGACCC
		AGGCTATGGATGAGGCTGACTATT
		ACTGTCAGGCGTGGGACAGCAGCA
		ATGTGGTATTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1173	MPK20297-B4_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGTAGTCT
		CTGGATTCAACTTCAGTAGGAATGG
		CATGCACTGGGTCCGCCAGGTTCCA
		GGCAGGGGGCTAGATTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCAGACTCCGTGAAG
		GGCCGATTCACCATCTCCAGAGAC
		AATTCCAAGAACACGCTGTATCTGC
		AAATGAACAGCCTGAGAGCTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGGATTTAT
		TATAAAAATAACTACTATTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACTCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGACCGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1174	MPK20298-F6_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGTAGTCT
		CTGGATTCAACTTCAGTAGGAATGG
		CATGCACTGGGTCCGCCAGGTTCCA
		GGCAGGGGGCTAGATTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCAGACTCCGTGAAG
		GGCCGATTCACCATCTCCAGAGAC
		AATTCCAAGAACACGCTGTATCTGC
		AAATGAACAGCCTGAGAGCTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGGATTTAT
		TATAAAAACCGCTATTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCGGTGTCAGTGGC
		CCCAGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGACCACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGAGTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGGACC
		GAGCTGACCGTCCTA
1175	MPK20299-H3_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CACAGCCACTCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGCCATCTATAGGAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		ACTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGTCTGACTAT
		TACTGTCAAATATGGGACAGCAGC
		ACTGTGGTATTCGGCGGAGGCACC
		AAGCTGACCGTCCTA
1176	MPK20298-B9_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAGGAATGG
		CATGCACTGGGTCCGCCAGGTTCCA
		GGCAGGGGGCTAGATTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCGGACTCCGTGAAG
		GGCCGATTCACCATCTCCAGAGAC
		AATTCCAAGAACACGCTGTATCTGC
		AAATGAACAGCCTGAGAGCTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGTATTTAT
		TATAAAAAGAACTACTACTACGGT
		ATGGACGTCTGGGGCCAAGGGACC
		ACGGTCACCGTCTCCTCAGGTGGTG
		GTGGTTCTGGCGGCGGCGGCTCCG
		GTGGTGGTGGTTCTTCATATGAGCT
		GACTCAGCCACCCTCGGTGTCAGTG
		GCCCTGGGACAGACGGCCAGGATT
		TCCTGTGGGGGAAACAACATTGGA
		AGTAAAAATGTGCACTGGTACCAG
		CAGAAGCCAGGCCAGGCCCCTGTG
		CTGGTCATCTATAGGGATAGCAACC
		GGCCCTCTGGGATCCCTGAGCGATT
		CTCTGGCTCCAAGTCGGGGACCAC
		GGCCACCCTGACCATCAGCAGAGC
		CCAAGCCGGGGATGAGGCTGAGTA
		TTACTGTCAGGTGTGGGACAGCAG
		CACTGTGGTTTTCGGCGGAGGCACC
		CAGCTGACCGTCCTA
1177	MPK20299-E2_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGTCT
		CTGGATTCAACTTCAGTAACAATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTCATATCGTATGATGGAAGTAATA
		AATACTATACAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAACTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGAGGGAAACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATGTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAACGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGGCCATCAGCAGAGCC
		CAAGCCGGGGATGAGTCTGACTAT
		TACTGTCAGGTGTGGGACGGCAGT
		GCCGTGGTATTCGGCGGAGGGACC
		AAGCTGACCGTCCTA
1178	MPK20299-D6_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCGT
		CTGGATTCACCTTCAGTAGCTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACTCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGAGGGAAACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATGTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAACGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGGCCATCAGCAGAGCC
		CAAGCCGGGGATGAGTCTGACTAT
		TACTGTCAGGTGTGGGACGGCAGT
		GCCGTGGTATTCGGCGGAGGCACC
		CAGCTGACCGTCCTA
1179	MPK20299-A4_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCGT
		CTGGATTCACCTTCAGTAACTATGG
		CTTTCACTGGGTCCGCCAGACTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		GATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTCCA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCGCTATATTACTGTGCGAGA
		GTTTACTATGGTTCGGGGACTTATT
		ATAAAAACCGCTACTACTACGGTAT
		GGACGTCTGGGGCCAAGGGACCAC
		GGTCACCGTCTCCTCAGGTGGTGGT
		GGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGACACAACATTGGAAG
		TAAAGGTGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTACT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCTGGGAACACAG
		CCACTCTGACCATCAGCGGGACCC
		AGGCTATGGATGAGGCTGACTATT
		ACTGTCAGGCGTGGGACAGCGGCA
		CTGTGGTATTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1180	MPK20300-G5_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCACCTTCAGTAACTATGG
		CTTTCACTGGGTCCGCCAGACTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		GATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTCCA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCGCTATATTACTGTGCGAGA
		GTTTACTATGGTTCGGGGACTTATT
		ATAAAAACCGCTACTACTACGGTAT
		GGACGTCTGGGGCCAAGGGACCAC
		GGTCACCGTCTCCTCAGGTGGTGGT
		GGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGCAAACAACATTGGAAG
		TAAAAATGTTCACTGGTACCAGCA
		GAAGCCAGGCCAGCCCCCTGTGCT
		GGTCATCTATAGAGATTTCAACCGG
		CCCTCTGGGATCCCTGAGCGATTCT
		CTGCCTCCAACTCGGGGAACACGG
		CCACCCTGACCATCAGCAGAGGCC
		AAGCCGGGGATGAGGCTGACTATT
		ACTGTCAGGTGTGGGACAGCAGCA
		CTGGGAATGTGGTATTCGGCGGAG
		GGACCAAGCTGACCGTCCTA
1181	MPK20299-C3_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCATCTTCAGTAACTATGG
		CTTTCACTGGGTCCGCCAGACTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCGGTGTATTACTGTGCGAG
		AGTTTACTATGGTTCGGGGAGTTAT
		TATAAAAACCGCTACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCGGTGTCAGTGGC
		CCCAGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGACCACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGGACC
		GAGCTGACCGTCCTA
1182	MPK20299-B7_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGTCATCCTCGGTGTCAGTGGC
		CCCAGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGTT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGACCACG
		GCCACCCTGACCATCAGCAGGGTC
		GAAGCCGGGGATGAGGCCGACTAT
		TACTGTCAGGTGTGGGATAGTAGTA
		GTGCTCATGTGATATTCGGCGGAGG
		GACCAAGCTGACCGTCCTA
1183	MPK20299-A5_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGGAGCCT
		CTGGATTCACCTTCAGTGGCTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCAAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCGGTGTATTACTGTGCGAG
		AGTTTATTATGGTTCGGGGATTTAT
		TATAAAAACCGCTACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGGGTCAGTGGC
		CCTGGGACAGACGGCCAGGATCAC
		CTGTGGGGGAAACAACCTTGGAAG
		TAAAAATGTGCACTGGTACCAACA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAGGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTATTCGGCGGTGGGACC
		AAGCTGACCGTCCTA
1184	MPK20299-D1_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCCTGGTCAAGCCTGGGGGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCACCTTCAGTAACAATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTCATATCGTATGATGGAAGTAATA
		AATACTATGCGGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTATTATGGTTCGGGGATTTATT
		ATAAAAACAGGTATTACTACGGGA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAGAATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGTT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGACCACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGAGTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGGACC
		AAGCTGACCGTCCTA
1185	MPK20299-C5_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCACCTTCAGTAACTATGG
		CTTTCACTGGGTCCGCCAGACTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		GATACTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGGTGAGGA
		CACGGCGCTATATTACTGTGCGAGA
		GTTTACTATGGTTCGGGGACTTATT
		ATAAAAACCGCTACTACTACGGTAT
		GGACGTCTGGGGCCAAGGGACCAC
		GGTCACCGTCTCCTCAGGTGGTGGT
		GGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CACAGCTACCTTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGACACAACATTGGAAG
		TAAAGGTGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGGACC
		GAGCTGACCGTCCTA
1186	MPK20299-B5_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAACCGCTATTACTACGGTAT
		GGACGTCTGGGGCCAAGGGACCAC
		GGTCACCGTCTCCTCAGGTGGTGGT
		GGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGACACAACATTGGAAG
		TAAAGGTGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGTAGT
		ACTGTGGTTTTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1187	MPK20299-G9_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGACTTGGTACAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCGT
		CTGGATTCACCTTCAGTAACAATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGACTGGAGTGGGTGGCA
		GTTATTTCAAATGATGGCAGTAATA
		AATATTATGCAGATTCCGTGAGGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTGCA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTATTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAACAGGTACTACTACGGGA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACTCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACTCTTAGCAGAGTCC
		AAGCCGGGGATGAGGCTGACTATT
		ACTGTCAGGTGTGGGACAGCAGCA
		CTGTGGTTTTCGGCGGAGGGACCA
		AGCTGACCGTCCTA
1188	MPK20299-G5_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGTCT
		CTGGATTCAACTTCAGTAACAATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGACTGGAGTGGGTGGCA
		GTTATTTCAAATGATGGCAGTAATA
		AATATTATGCAGATTCCGTGAGGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACACTGTATCTGCA
		AATGGACAGCCTGAGAACTGAGGA
		CACGGCTGTGTATTACTGTGCGAAA
		GTTTACTATGGTTCGGGTATTTATT
		ATAAAAACAGGTACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGCTTAC
		CTGTGAGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGTT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGCTTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGGCCATCAGCAGAGCC
		CAAGCCGGGGATGAGTCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGT
		GCCGTGGTATTCGGCGGAGGCACC
		AAGCTGACCGTCCTA
1189	MPK20298-C10_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCACCTTCAGTAGCTCTGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCAGACTCCGTGAAG
		GGCCGATTCACCATCTCCAGAGAC
		AATTCCAAGAACACGCTGTATCTGC
		AAATGAACAGCCTGAGAGCTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGGATTTAT
		TATAAAAATAACTACTATTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGCCATCTATAGGAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		ACTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCGGGACC
		CAGGCTATGGATGAGGCTGACTATT
		ACTGTCAGGCGTGGGACAGCAGCA
		CTGTGGTATTCGGCGGAGGGACCA
		AGCTGACCGTCCTA
1190	MPK20298-B5_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TCAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGCTTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGGCCATCAGCAGAGCC
		CAAGCCGGGGATGAGTCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGT
		GCCGTGGTATTCGGCGGAGGCACC
		CAGCTGACCGTCCTA
1191	MPK20299-F2_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCACCCTCAGTAGCTCTGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAGTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCGGACTCCGTGAAG
		GGCCGGTTCACCATCTCCAGAGAC
		GATTCCAAGAACACACTGTATCTGC
		AAATGGACAGCCTGAGAACTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGTATTTAT
		TATAAAAACAGGTACTACTACGGG
		ATGGACGTCTGGGGCCAAGGGACC
		ACGGTCACCGTCTCCTCAGGTGGTG
		GTGGTTCTGGCGGCGGCGGCTCCG
		GTGGTGGTGGTTCTTCATATGAGCT
		GACTCAGCCACCCTCAGTGTCAGTG
		GCCCTGGGACAGACGGCCAGGATT
		TCCTGTGGGGGAAACAACATTGGA
		AGTAAAAATGTGCACTGGTACCAG
		CAGAAGCCAGGCCAGGCCCCTGTG
		CTGGTCATGTATAGGGATAGCAAC
		CGGCCCTCAGGGATCCCTGAGCGA
		TTCTCTGGCTCCAACTCTGGGAACA
		CAGCCACTCTGACCATCAGCGGGA
		CCCAGGCTATGGATGAGGCTGACT
		ATTACTGTCAGGCGTGGGACAGCG
		GCACTGTGGTATTCGGCGGAGGGA
		CCAAGCTGACCGTCCTA
1192	MPK20298-D4_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAACTATGG
		CATGCACTGGGTCCGCCAGGCTCCA
		GGCAAGGGGCTGGAATGGGTGGCA
		GTTATATCATATGATGGAAGTAATA
		AATATTATGCAGACTCCGTGAAGG
		GCCGATTCACCATCTCCAGAGACA
		ATTCCAAGAACACGCTGTATCTACA
		AATGAACAGCCTGAGAGCTGAGGA
		CACGGCTGTGTATTTCTGTGCGAGA
		GTTTACTATGGTTCGGGGATTTATT
		ATAAAAAGAGATACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGAATTAC
		CTGTGGGGGAAACAACATTGGAGG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGTCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTATTCGGCGGAGGCACC
		CAGCTGACCGTCCTA
1193	MPK20297-F5_SCFV	CAGGTGCAGCTGGTGGAGTCTGGG
		GGAGGCGTGGTCCAGCCTGGGAGG
		TCCCTGAGACTCTCCTGTGTAGTCT
		CTGGATTCAACTTCAGTAGGAATGG
		CATGCACTGGGTCCGCCAGGTTCCA
		GGCAGGGGGCTAGATTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCAGACTCCGTGAAG
		GGCCGATTCACCATCTCCAGAGAC
		AATTCCAAGAACACGCTGTATCTGC
		AAATGAACAGCCTGAGAGCTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGGATTTAT
		TATAAAAATAACTACTATTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACTCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTAC
		CTGTGGGGGAAACAACATTGGAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGCT
		GGTCATCTATAGAAATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAACTCGGGGAACACG
		GCCACCCTGACCATCAGCAGAGCC
		CAGGCCGGGGATGAGGCTGACTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGTGGGACCA
		AGCTGACCGTCCTA
1194	MPK20299-D9_SCFV	CAGGTGCAGCTGGTGGAGTCCGGG
		GGAGGCTTGGTCAAGCCTGGAGGG
		TCCCTGAGACTCTCCTGTGCAGCCT
		CTGGATTCAACTTCAGTAGGAATGG
		CATGCACTGGGTCCGCCAGGTTCCA
		GGCAGGGGGCTAGATTGGGTGGCA
		GTTATATCAAATGATGGAAGTAAT
		AAATACTATGCAGACTCCGTGAAG
		GGCCGATTCACCATCTCCAGAGAC
		AATTCCAAGAACACGCTGTATCTGC
		AAATGAACAGCCTGAGAGCTGAGG
		ACACGGCTGTGTATTACTGTGCGAA
		AGTTTACTATGGTTCGGGGATTTAT
		TATAAAAATAACTACTACTACGGTA
		TGGACGTCTGGGGCCAAGGGACCA
		CGGTCACCGTCTCCTCAGGTGGTGG
		TGGTTCTGGCGGCGGCGGCTCCGGT
		GGTGGTGGTTCTTCATATGAGCTGA
		CTCAGCCACCCTCAGTGTCAGTGGC
		CCTGGGACAGACGGCCAGGATTTC
		CTGTGGGGGAAACAACATTGAAAG
		TAAAAATGTGCACTGGTACCAGCA
		GAAGCCAGGCCAGGCCCCTGTGTT
		GGTCATCTATAGGGATAGCAACCG
		GCCCTCTGGGATCCCTGAGCGATTC
		TCTGGCTCCAAGTCGGGGACCACG
		GCCACCCTGACCATCAGCAGAGCC
		CAAGCCGGGGATGAGGCTGAGTAT
		TACTGTCAGGTGTGGGACAGCAGC
		ACTGTGGTTTTCGGCGGAGGCACCC
		AGCTGACCGTCCTA
1195	huCCR8_32360_huIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb(LC:K38R)_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTGAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCT
		TGGTAAAGCCTGGGGGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		TACTTTCAGTAACGCCCGGATGGGC
		TGGGTCCGCCAGGCTCCAGGGAAG
		GGGCTGGAGTGGGTTGGCCGTATT
		AAAAGCAAAACTGAAGGTGGGACA
		AGAGACTACGCTGCACCCGTGAAA
		GGCAGATTCACCATCTCAAGAGAT
		GATTCAAAAAACACGCTGTATCTGC
		AAATGAACAGCCTGAAAACCGAGG
		ACACAGCCGTGTATTATTGTACCTC
		GTATAGTGGGGTCTGGGGCCAAGG
		GACAATGGTCACCGTGTCTTCAGCC
		TCCACCAAGGGCCCATCGGTCTTCC
		CCCTGGCACCCTCCTCCAAGAGCAC
		CTCTGGGGGCACAGCGGCCCTGGG
		CTGCCTGGTCAAGGACTACTTCCCC
		GAACCGGTGACGGTGTCGTGGAAC
		TCAGGCGCCCTGACCAGCGGCGTG
		CACACCTTCCCGGCTGTCCTACAGT
		CCTCAGGACTCTACTCCCTCAGCAG
		CGTGGTGACCGTGCCCTCCAGCAGC
		TTGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACA
		CCAAGGTGGACAAGAAAGTTGAGC
		CCAAATCTTGTGACAAAACTCACAC
		ATGCCCACCGTGCCCAGCACCTGA
		ACTCCTGGGGGGACCGTCAGTCTTC
		CTCTTCCCCCCAAAACCCAAGGACA
		CCCTCATGATCTCCCGGACCCCTGA
		GGTCACATGCGTGGTGGTGGACGT
		GAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGT
		GGAGGTGCATAATGCCAAGACAAA
		GCCGCGGGAGGAGCAGTACAACAG
		CACGTACCGTGTGGTCAGCGTCCTC
		ACCGTCCTGCACCAGGACTGGCTG
		AATGGCAAGGAGTACAAGTGCAAG
		GTGTCCAACAAAGCCCTCCCAGCCC
		CCATCGAGAAAACCATCTCCAAAG
		CCAAAGGGCAGCCCCGAGAACCAC
		AGGTGTACACCCTGCCCCCATCCCG
		GGAGGAGATGACCAAGAACCAGGT
		CAGCCTGACCTGCCTGGTCAAAGG
		CTTCTATCCCAGCGACATCGCCGTG
		GAGTGGGAGAGCAATGGGCAGCCG
		GAGAACAACTACAAGACCACGCCT
		CCCGTGCTGGACTCCGACGGCTCCT
		TCTTCCTCTATAGCAAGCTCACCGT
		GGACAAGAGCAGGTGGCAGCAGGG
		GAACGTCTTCTCATGCTCCGTGATG
		CATGAGGCTCTGCACAACCACTAC
		ACGCAGAAGAGCCTCTCCCTGTCTC
		CGGGCAAATAG
1196	huCCR8_32360_huIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb(LC:K38R)_LC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTGACATCG
		TGATGACCCAGTCTCCAGACTCCCT
		GGCTGTGTCTCTGGGCGAGAGGGC
		CACCATCAACTGCAAGTCCAGCCA
		GAGTGTTTTATACAGTTCCAACAAT
		AGAAACTACTTAGCTTGGTACCATC
		AGAAACCAGGACAGTCTCCTAAGC
		TGCTCATTTCCTGGGCATCTACCCG
		GGAATCCGGGGTCCCTGACCGATTC
		AGTGGCAGCGGGTCTGGGACAGAT
		TTCACTCTCACCATCAACAGCCTGC
		AGGCTGAAGATGTGGCAGTTTATTA
		CTGTCAACAATATTATAGTATTCCG
		ATCACTTTCGGCGGAGGGACCAAG
		GTGGAGATCAAACGAACGGTGGCT
		GCACCATCTGTCTTCATCTTCCCGC
		CATCTGATGAGCAGTTGAAATCTGG
		AACTGCCTCTGTTGTGTGCCTGCTG
		AATAACTTCTATCCCAGAGAGGCC
		AAAGTACAGTGGAAGGTGGATAAC
		GCCCTCCAATCGGGTAACTCCCAGG
		AGAGTGTCACAGAGCAGGACAGCA
		AGGACAGCACCTACAGCCTCAGCA
		GCACCCTGACGCTGAGCAAAGCAG
		ACTACGAGAAACACAAAGTCTACG
		CCTGCGAAGTCACCCATCAGGGCCT
		GAGCTCGCCCGTCACAAAGAGCTT
		CAACAGGGGAGAGTGTTAG
1197	anti-	ATGGACATGAGGGTGCCCGCTCAG
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	CTCCTGGGGCTCCTGCTGCTGTGGC
	M99G_W109F_S111A)_huIgG1z (mAb)_HC	TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCCGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CACCTTCAGTAACTATGGCTTTCAC
		TGGGTCCGCCAGACTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATC
		TCATATGATGGAAGTAATAGATACT
		ATGCAAGCTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAACACGCTGTATCTCCAAATGAA
		CAGCCTGAGAGGTGAGGACACGGC
		GCTATATTACTGTGCGAGAGTTTAC
		TATGGTTCGGGGACTTATTATAAAA
		ACCGCTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCAC
		CGTGTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1198	anti-	ATGGCCTGGGCTCTGCTGCTCCTCA
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	CCCTCCTCACTCAGGGCACAGGGTC
	M99G_W109F_S111A)_huIgG1z (mAb)_LC	CTGGGCCTCATATGAGCTGACTCAG
		CCACCCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGACACAACATTGGAAGTAAAG
		GTGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTACTGGTCAT
		CTATAGAGCCGCCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCTGGGAACACAGCCACTCT
		GACCATCAGCGGGACCCAGGCTGG
		CGATGAGGCTGACTATTACTGTCAG
		GCGTTCGACGCCGGCACTGTGGTAT
		TCGGCGGAGGCACCCAGCTGACCG
		TCCTAGGTCAGCCCAAGGCTGCACC
		CTCGGTCACTCTGTTCCCGCCCTCC
		TCTGAGGAGCTTCAAGCCAACAAG
		GCCACACTGGTGTGTCTCATCAGTG
		ACTTCTACCCGGGAGCCGTGACAGT
		GGCCTGGAAGGCAGATAGCAGCCC
		CGTCAAGGCGGGAGTGGAAACCAC
		CACACCCTCCAAACAAAGCAACAA
		CAAGTACGCGGCCAGCAGCTATCT
		GAGCCTGACGCCTGAGCAGTGGAA
		GTCCCACAGAAGCTACAGCTGCCA
		GGTCACGCATGAAGGGAGCACCGT
		GGAGAAGACAGTGGCCCCTACAGA
		ATGTTCATAG
1199	anti-	ATGGACATGAGGGTGCCCGCTCAG
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	CTCCTGGGGCTCCTGCTGCTGTGGC
	M99E_W109F_S111A)_huIgG1z	TGAGAGGTGCGCGCTGTCAGGTGC
	(mAb)_HC	AGCTGGTGGAGTCCGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CACCTTCAGTAACTATGGCTTTCAC
		TGGGTCCGCCAGACTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATC
		TCATATGCCGGAAGTAATAGATACT
		ATGCAGCCTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAACACGCTGTATCTCCAAATGAA
		CAGCCTGAGAGGTGAGGACACGGC
		GCTATATTACTGTGCGAGAGTTTAC
		TATGGTTCGGGGACTTATTATAAAA
		ACCGCTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCAC
		CGTGTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1200	anti-	ATGGCCTGGGCTCTGCTGCTCCTCA
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	CCCTCCTCACTCAGGGCACAGGGTC
	M99E_W109F_S111A)_huIgG1z	CTGGGCCTCATATGAGCTGACTCAG
	(mAb)_LC	CCACCCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGACACAACATTGGAAGTAAAG
		GTGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTACTGGTCAT
		CTATAGACAGAGCAACCGGCCCTC
		TGGGATCCCTGAGCGATTCTCTGGC
		TCCAACTCTGGGAACACAGCCACTC
		TGACCATCAGCGGGACCCAGGCTG
		AAGATGAGGCTGACTATTACTGTCA
		GGCGTTCGACGCCGGCACTGTGGT
		ATTCGGCGGAGGCACCCAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1201	anti-	ATGGACATGAGGGTGCCCGCTCAG
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	CTCCTGGGGCTCCTGCTGCTGTGGC
	W109F_S111A)_huIgG1z (mAb)_HC	TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCCGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CACCTTCAGTAACTATGGCTTTCAC
		TGGGTCCGCCAGACTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATC
		TCATATAGCGGAAGTAATAGATAC
		TATGCAGACTCCGTGAAGGGCCGA
		TTCACCATCTCCAGAGACAATTCCA
		AGAACACGCTGTATCTCCAAATGA
		ACAGCCTGAGAGGTGAGGACACGG
		CGCTATATTACTGTGCGAGAGTTTA
		CTATGGTTCGGGGACTTATTATAAA
		AACCGCTACTACTACGGTATGGAC
		GTCTGGGGCCAAGGGACCACGGTC
		ACCGTGTCCTCAGCCTCCACCAAGG
		GCCCATCGGTCTTCCCCCTGGCACC
		CTCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1202	anti-	ATGGCCTGGGCTCTGCTGCTCCTCA
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	CCCTCCTCACTCAGGGCACAGGGTC
	W109F_S111A)_huIgG1z (mAb)_LC	CTGGGCCTCATATGAGCTGACTCAG
		CCACCCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGACACAACATTGGAAGTAAAG
		GTGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTACTGGTCAT
		CTATAGACAGAGCAACCGGCCCTC
		TGGGATCCCTGAGCGATTCTCTGGC
		TCCAACTCTGGGAACACAGCCACTC
		TGACCATCAGCGGGACCCAGGCTG
		GCGATGAGGCTGACTATTACTGTCA
		GGCGTTCGACGCCGGCACTGTGGT
		ATTCGGCGGAGGCACCCAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1203	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAACTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGACACAACATTGGAAGTAAAG
		GTGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGAAATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACATCAGCACTGTGGTT
		TTCGGCGGAGGGACCGAGCTGACC
		GTCCTAGGTCAGCCCAAGGCTGCA
		CCCTCGGTCACTCTGTTCCCGCCCT
		CCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1204	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCG
		TGGCCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CAACTTCAGTAACTGTGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATATGATGGAGGTAATAAATATC
		ATGCGGACTCCGTGAAGGGCCGGT
		TCACCATCTCCAGAGACGATTCCAA
		GAACACACTGTATCTGCAAATGGA
		CAGCCTGAGAACTGAGGACACGGC
		TGTGTATTACTGTGCGAAAGTTTAC
		TATGGTTCGGGTATTTATTATAAAA
		ACAGGTACTACTACGGGATGGACG
		TCtGGGGCCAAGGGACCACGGTCAC
		CGTCTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1205	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGACACAACATTGGAAGTAAAG
		GTGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGAAATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAAAACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		TTTCGGCGGAGGGACCGAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1206	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCG
		TGGCCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CAACTTCAGTAACTGTGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATATGATGGAGGTAATAAATATT
		ATGCGGACTCCGTGAAGGGCCGGT
		TCACCATCTCCAGAGACGATTCCAA
		GAACACACTGTATCTGCAAATGGA
		CAGCCTGAGAACTGAGGACACGGC
		TGTGTATTACTGTGCGAAAGTTTAC
		TATGGTTCGGGTATTTATTATAAAA
		ACAGGTATTACTACGGGATGGACG
		TCTGGGGCCAAGGGACCACGGTCA
		CCGTCTCCTCAGCCTCCACCAAGGG
		CCCATCGGTCTTCCCCCTGGCACCC
		TCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1207	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTGCACTGGTACCAGAAGAGGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGGGATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAAGTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAACACTGTGGT
		TTTCGGCGGAGGGACCAACCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1208	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGTAGTCTCTGGATT
		CAACTTCAGTAACAATGGCATGCA
		CTGGGTCCGCCAGGCTCCAGGCAA
		GGGACTGGAGTGGGTGGCAGTTAT
		TTCAAATGATGGCAGTAATAAATAT
		TATGCAGATTCCGTGAGGGGCCGA
		TTCACCATCTCCAGAGACAATTCCA
		AGAACACGCTGTATCTGCAAATGA
		ACAGCCTGAGAGCTGAGGACACGG
		CTGTGTATTCCTGTGCGAAAGTTTA
		CTATGGTTCGGGAATTTATTACAAA
		AATAACTACTACTACGGTATGGAC
		GTCTGGGGCCAAGGGACCACGGTC
		ACCGTCTCCTCAGCCTCCACCAAGG
		GCCCATCGGTCTTCCCCCTGGCACC
		CTCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1209	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTcctATGAGCTGACTCAGC
		CACTCTCAGTGTCAGTGGCCCTGGG
		ACAGACGGCCAGGATTACCTGTGG
		GGGAAACAACATTGGAAGTAAAAA
		TGTGCACTGGTACCAGCAGAAGGC
		AGGCCAGGCCCCTGTGCAGGTCAT
		CTATAGAAATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAGGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		TTTCGGCGGTGGGACCAAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1210	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CAACTTCAATACCTATGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATATGATGGAAGTAATAAATATT
		ATGCAGACTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAGCACGCTGTATCTGCAAATGAA
		CAGCCTGAGAGCTGAGGACACGGC
		TGTGTATTACTGTGCGAGAGTTTAC
		TATGGTTCGGGGAGTTATTATAAAA
		AGAATTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCAC
		CGTCTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1211	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAGGTAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGGGATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAAGTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGTCTGACTATTACTGTCA
		GGTTTGGGACAGCAGCACTGTGGT
		ATTCGGCGGAGGGACCACGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1212	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGGTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CACCCTCAGTAGTTATGGCTTTCAC
		TGGGTCCGCCAGACTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATATGATGGAAGTAATAAATAct
		ATGCAGACTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAACACGCTGTATCTCCAAATGAA
		CAGCCTGAGAGGTGAGGACACGGC
		GGTGTATTACTGTGCGAGAGTTTAC
		TATGGTTCGGGGACTTATTATAAAA
		ACCGCTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCAC
		CGTCTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1213	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGAGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTACTGGTCAT
		CTATAGGGATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAAGTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		TTTCGGCGGAGGGACCAAGGTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1214	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGTAGTCTCTGGATT
		CAACTTCATTAACAATGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGACTGGGTGGCAGTTATA
		TCAAATGATGGAAGTAATAAATAC
		TATCCAGACTCCGTGAAGGGCCGA
		TTCACCATCTCCAGAGACAATTCCA
		AGAACACGCTGTATCTGCAAATGA
		ACAGCCTGAGAGCTGAGGACTCGG
		CTGTGTATTACTGTGCGAAAGTTTA
		CTATGGTTCGGGAAATTATTATAAA
		AACAACTACTACTACGGTATGGAC
		GTCTGGGGCCAAGGGACCACGGTC
		ACCGTCTCCTCAGCCTCCACCAAGG
		GCCCATCGGTCTTCCCCCTGGCACC
		CTCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1215	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		AGGGAAACAACATTGGAAGTCAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		GTATAGGGATAGCAACCGGCCCTC
		TGGGATCCCTGAACGATTCTCTGGC
		TCCAAGTCGGGGAACACGGCCACC
		CTGGCCATCAGCAGAGCCCAAGCC
		GGGGATGAGTCTGACTATTACTGTC
		AGGTGTGGGACGGCAGTGCCGTGG
		TATTCGGCGGAGGGACCACGCTGA
		CCGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1216	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGATGC
		AGGTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CACCTTCAGTAGCTCTGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGCCTGGAGTGGGTGGCAGTTATA
		TCACATGATGGAAGTAATAAATAC
		TATGCAGACTCCGTGAAGGGCCGA
		TTCACCATCTCCAGAGACAATTCCA
		AGAACACGCTGTATCTGCAAATGA
		ATAGCCTGGGAGGTGAGGACACGG
		CGGTGTATTACTGTGCGAAAGTTTA
		CTATGGTTCGGGGATTTATTATAAA
		AACCGCTATTACTACGGTATGGACG
		TCTGGGGCCAAGGGACCACGGTCA
		TCGTCTCGTCAGCCTCCACCAAGGG
		CCCATCGGTCTTCCCCCTGGCACCC
		TCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1217	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGACACAACATTGGAAGTAAAG
		GTGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGAAATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		TTTCGGCGGAGGGACCGAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1218	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGctGGTGGAGtctGGGGGAGGCGTG
		GCCCAGCCTGGGAGGTCCCTGAGA
		CTCTCCTGTGCAGCCTCTGGATTCA
		ACTTCAGTGattGTGGCATGCACTGG
		GTCCGCCaggCTCCAGGCAAGGGGC
		TGGAGTGGGTGGCAGTTATATCATA
		TGATGGAGGTAATAAATATTATGC
		GGACTCCGTGAAGGGCCGGTTCAC
		CATCTCCAGAGacgATTCCAAGAAC
		ACACTGTAtcTGCAAacggacAGCCTG
		AGAACTGAGGACACGGCTGTGTAT
		TACTGTGCGAAAGTTTACTATGGTT
		CGGGTATTTATTATAAAAACAGGTA
		CTACTACGGGATGGACGTctggggCC
		AAGGGACCACGGTcaccgTCTCCTCA
		GCCTCCACCAAGGGCCCATCGGTCT
		TCCCCCTGGCACCCTCCTCCAAGAG
		CACCTCTGGGGGCACAGCGGCCCT
		GGGCTGCCTGGTCAAGGACTACTTC
		CCCGAACCGGTGACGGTGTCGTGG
		AACTCAGGCGCCCTGACCAGCGGC
		GTGCACACCTTCCCGGCTGTCCTAC
		AGTCCTCAGGACTCTACTCCCTCAG
		CAGCGTGGTGACCGTGCCCTCCAGC
		AGCTTGGGCACCCAGACCTACATCT
		GCAACGTGAATCACAAGCCCAGCA
		ACACCAAGGTGGACAAGAAAGTTG
		AGCCCAAATCTTGTGACAAAACTC
		ACACATGCCCACCGTGCCCAGCAC
		CTGAACTCCTGGGGGGACCGTCAG
		TCTTCCTCTTCCCCCCAAAACCCAA
		GGACACCCTCATGATCTCCCGGACC
		CCTGAGGTCACATGCGTGGTGGTG
		GACGTGAGCCACGAAGACCCTGAG
		GTCAAGTTCAACTGGTACGTGGAC
		GGCGTGGAGGTGCATAATGCCAAG
		ACAAAGCCGCGGGAGGAGCAGTAC
		AACAGCACGTACCGTGTGGTCAGC
		GTCCTCACCGTCCTGCACCAGGACT
		GGCTGAATGGCAAGGAGTACAAGT
		GCAAGGTGTCCAACAAAGCCCTCC
		CAGCCCCCATCGAGAAAACCATCT
		CCAAAGCCAAAGGGCAGCCCCGAG
		AACCACAGGTGTACACCCTGCCCCC
		ATCCCGGGAGGAGATGACCAAGAA
		CCAGGTCAGCCTGACCTGCCTGGTC
		AAAGGCTTCTATCCCAGCGACATCG
		CCGTGGAGTGGGAGAGCAATGGGC
		AGCCGGAGAACAACTACAAGACCA
		CGCCTCCCGTGCTGGACTCCGACGG
		CTCCTTCTTCCTCTATAGCAAGCTC
		ACCGTGGACAAGAGCAGGTGGCAG
		CAGGGGAACGTCTTCTCATGCTCCG
		TGATGCATGAGGCTCTGCACAACC
		ACTACACGCAGAAGAGCCTCTCCCT
		GTCTCCGGGCAAATAG
1219	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGGCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGGAGTAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGTCTGACTATTACTGTCA
		AATATGGGACAGCAGCACTGTGGT
		ATTCGGCGGAGGGACCAAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1220	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGGTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CACCTTCAGTAGCTATGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATTTGATGGAAATAATAAATACT
		ATGCAGACTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAACACGCTATATCTGCAAATGAA
		CAGCCTGAGAGGTGAGGACACGGC
		GGTGTATTACTGTGCGAGAGTTTAT
		TATGGTTCGGGGAGTTATTATAAAA
		ACCGCTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCAC
		CGTCTCCACAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1221	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAACTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTACACTGGTACCAGCAGAGGC
		CAGGCCAGGCCCCTGTGTTGGTCAT
		CTACAGGGATAGCAACCGGCCCTC
		TGGGATCCCTGAGCGATTATCTGGC
		TCCAAAGCGGGGAACACGGCCACC
		CTGACCATCAGCAGAGCCCACGCC
		GGGGATGAGGCTGACTATTACTGTC
		AGGTGTGGGACAGCAGCACTGTGG
		TTTTCGGCGGAGGGACCGAGCTGA
		CCGTCCAAGGTCAGCCCAAGGCTG
		CACCCTCGGTCACTCTGTTCCCGCC
		CTCCTCTGAGGAGCTTCAAGCCAAC
		AAGGCCACACTGGTGTGTCTCATCA
		GTGACTTCTACCCGGGAGCCGTGAC
		AGTGGCCTGGAAGGCAGATAGCAG
		CCCCGTCAAGGCGGGAGTGGAAAC
		CACCACACCCTCCAAACAAAGCAA
		CAACAAGTACGCGGCCAGCAGCTA
		TCTGAGCCTGACGCCTGAGCAGTG
		GAAGTCCCACAGAAGCTACAGCTG
		CCAGGTCACGCATGAAGGGAGCAC
		CGTGGAGAAGACAGTGGCCCCTAC
		AGAATGTTCATAG
1222	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AATTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCTCTGAG
		ACTCTCCTGTGCAGTCTCTGGATTC
		ACGTTCAGTAGCAATGGCATGCACT
		GGGTCCGCCAGGCTCCAGGCAAGG
		GGCTGGAGTGGGTGGCAGTTATAT
		CAAATGATGGAAGTAATAAATATT
		ATGGAGACTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAACACGCTGTATCTGCAAATGAA
		CAGCCTGAGAGCTGAGGACACGGC
		TGTGTATTACTGTGCGAAAGTTTAC
		TATGGTTCGGGAATTTATTACAGAA
		ACAACTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCAC
		CGTCTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1223	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTATACTGGTCAT
		CTATAGGAATACCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGTCG
		GGGATGAGTCTGACTATTTCTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		ATTCGGCGGAGGGACCAAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1224	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGGTGGTGGAGtctGGGGGAGGCGT
		GGTCCAGccTGGGAGGTCcCTGAGA
		CTCTCCTGTGGAGCCTCTGGATTCA
		CcttCAGtggcTATGGCATgcACTGGGT
		CcgcCAggcTCCAGGCAAGGGGCTGG
		AGTGGGTGGCAGTTATATCATATGA
		TGGAAGTAATAAATACTATGCAGA
		CTCCGTgAAGGGCCGATTCCCCATC
		TCAAGAgaCAATTCCAAGAACACGC
		TGTATCTGCAAATGAACAGcCTGAG
		AGGTGAGGACACGGCGGTGTATTA
		CTGTgcGAGAGTTTATTATGGTTCGG
		GGATTTATTATAAAAACCGCTacTaC
		TACGGTAtgGACGtctGGGGCCAAGG
		GACCACGGTcgcCGTCTCCTCAGCCT
		CCACCAAGGGCCCATCGGTCTTCCC
		CCTGGCACCCTCCTCCAAGAGCACC
		TCTGGGGGCACAGCGGCCCTGGGC
		TGCCTGGTCAAGGACTACTTCCCCG
		AACCGGTGACGGTGTCGTGGAACT
		CAGGCGCCCTGACCAGCGGCGTGC
		ACACCTTCCCGGCTGTCCTACAGTC
		CTCAGGACTCTACTCCCTCAGCAGC
		GTGGTGACCGTGCCCTCCAGCAGCT
		TGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACA
		CCAAGGTGGACAAGAAAGTTGAGC
		CCAAATCTTGTGACAAAACTCACAC
		ATGCCCACCGTGCCCAGCACCTGA
		ACTCCTGGGGGGACCGTCAGTCTTC
		CTCTTCCCCCCAAAACCCAAGGACA
		CCCTCATGATCTCCCGGACCCCTGA
		GGTCACATGCGTGGTGGTGGACGT
		GAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGT
		GGAGGTGCATAATGCCAAGACAAA
		GCCGCGGGAGGAGCAGTACAACAG
		CACGTACCGTGTGGTCAGCGTCCTC
		ACCGTCCTGCACCAGGACTGGCTG
		AATGGCAAGGAGTACAAGTGCAAG
		GTGTCCAACAAAGCCCTCCCAGCCC
		CCATCGAGAAAACCATCTCCAAAG
		CCAAAGGGCAGCCCCGAGAACCAC
		AGGTGTACACCCTGCCCCCATCCCG
		GGAGGAGATGACCAAGAACCAGGT
		CAGCCTGACCTGCCTGGTCAAAGG
		CTTCTATCCCAGCGACATCGCCGTG
		GAGTGGGAGAGCAATGGGCAGCCG
		GAGAACAACTACAAGACCACGCCT
		CCCGTGCTGGACTCCGACGGCTCCT
		TCTTCCTCTATAGCAAGCTCACCGT
		GGACAAGAGCAGGTGGCAGCAGGG
		GAACGTCTTCTCATGCTCCGTGATG
		CATGAGGCTCTGCACAACCACTAC
		ACGCAGAAGAGCCTCTCCCTGTCTC
		CGGGCAAATAG
1225	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTATACTGGTCAT
		CTATAGGAATACCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGTCG
		GGGATGAGTCTGACTATTTCTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		ATTCGGCGGAGGGACCAAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1226	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGGTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGGAGCCTCTGGATT
		CACCTTCAGTGGCTATGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATATGATGGAAGTAATAAATACT
		ATGCAGACTCCGTGAAGGGCCGAT
		TCACCATCTCAAGAGACAATTCCAA
		GAACACGCTGTATCTGCAAATGAA
		CAGCCTGAGAGGTGAGGACACGGC
		GGTGTATTACTGTGCGAGAGTTTAT
		TATGGTTCGGGGATTTATTATAAAA
		ACCGCTACTACTACGGTATGGACGT
		CTGGGGCCAAGGGACCACGGTCGC
		CGTCTCCTCAGCCTCCACCAAGGGC
		CCATCGGTCTTCCCCCTGGCACCCT
		CCTCCAAGAGCACCTCTGGGGGCA
		CAGCGGCCCTGGGCTGCCTGGTCA
		AGGACTACTTCCCCGAACCGGTGA
		CGGTGTCGTGGAACTCAGGCGCCCT
		GACCAGCGGCGTGCACACCTTCCC
		GGCTGTCCTACAGTCCTCAGGACTC
		TACTCCCTCAGCAGCGTGGTGACCG
		TGCCCTCCAGCAGCTTGGGCACCCA
		GACCTACATCTGCAACGTGAATCAC
		AAGCCCAGCAACACCAAGGTGGAC
		AAGAAAGTTGAGCCCAAATCTTGT
		GACAAAACTCACACATGCCCACCG
		TGCCCAGCACCTGAACTCCTGGGG
		GGACCGTCAGTCTTCCTCTTCCCCC
		CAAAACCCAAGGACACCCTCATGA
		TCTCCCGGACCCCTGAGGTCACATG
		CGTGGTGGTGGACGTGAGCCACGA
		AGACCCTGAGGTCAAGTTCAACTG
		GTACGTGGACGGCGTGGAGGTGCA
		TAATGCCAAGACAAAGCCGCGGGA
		GGAGCAGTACAACAGCACGTACCG
		TGTGGTCAGCGTCCTCACCGTCCTG
		CACCAGGACTGGCTGAATGGCAAG
		GAGTACAAGTGCAAGGTGTCCAAC
		AAAGCCCTCCCAGCCCCCATCGAG
		AAAACCATCTCCAAAGCCAAAGGG
		CAGCCCCGAGAACCACAGGTGTAC
		ACCCTGCCCCCATCCCGGGAGGAG
		ATGACCAAGAACCAGGTCAGCCTG
		ACCTGCCTGGTCAAAGGCTTCTATC
		CCAGCGACATCGCCGTGGAGTGGG
		AGAGCAATGGGCAGCCGGAGAACA
		ACTACAAGACCACGCCTCCCGTGCT
		GGACTCCGACGGCTCCTTCTTCCTC
		TATAGCAAGCTCACCGTGGACAAG
		AGCAGGTGGCAGCAGGGGAACGTC
		TTCTCATGCTCCGTGATGCATGAGG
		CTCTGCACAACCACTACACGCAGA
		AGAGCCTCTCCCTGTCTCCGGGCAA
		ATAG
1227	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGACCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAGATAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGGAATAACGTCCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAACTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		TTTCGGCGGAGGGACCAAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1228	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAATCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGGCT
		CAACTTCAGTAACTTTGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGACTGGGTGGCAGTTATA
		TCATATGATGGAGGTAATAAATACT
		ATGCAGACTCCGTGAAGGGCCGAT
		TCACCGTCTCCAGAGACAATTCCAA
		GAACACGCTCTTTCTGCAAATGAAC
		AGCCTGAGAGCTGAGGACACGGCT
		CTGTATTACTGTGCGAAAGTTTACT
		ATGGCTCGGGCAGTTATTATAAAA
		AGAGGTACTACTACGGTATGGACG
		TCTGGGGCCAGGGGACCACGGTCA
		CCGTCTCCTCAGCCTCCACCAAGGG
		CCCATCGGTCTTCCCCCTGGCACCC
		TCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1229	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	ATGGCCTGGGCTCTGCTGCTCCTCA
	mAb_LC	CCCTCCTCACTCAGGGCACAGGGTC
		CTGGGCCTCCTATGAGCTGACTCAG
		CCACTCTCAGTGTCAGTGGCCCTGG
		GACAGACGGCCAGGATTACCTGTG
		GGGGAAACAACATTGGAAGTAAAA
		ATGTGCACTGGTACCAGCAGAAGC
		CAGGCCAGGCCCCTGTGCTGGTCAT
		CTATAGGGATAGCAACCGGCCCTCT
		GGGATCCCTGAGCGATTCTCTGGCT
		CCAAGTCGGGGAACACGGCCACCC
		TGACCATCAGCAGAGCCCAAGCCG
		GGGATGAGGCTGACTATTACTGTCA
		GGTGTGGGACAGCAGCACTGTGGT
		TTTCGGCGGAGGGGCCAAGCTGAC
		CGTCCTAGGTCAGCCCAAGGCTGC
		ACCCTCGGTCACTCTGTTCCCGCCC
		TCCTCTGAGGAGCTTCAAGCCAACA
		AGGCCACACTGGTGTGTCTCATCAG
		TGACTTCTACCCGGGAGCCGTGACA
		GTGGCCTGGAAGGCAGATAGCAGC
		CCCGTCAAGGCGGGAGTGGAAACC
		ACCACACCCTCCAAACAAAGCAAC
		AACAAGTACGCGGCCAGCAGCTAT
		CTGAGCCTGACGCCTGAGCAGTGG
		AAGTCCCACAGAAGCTACAGCTGC
		CAGGTCACGCATGAAGGGAGCACC
		GTGGAGAAGACAGTGGCCCCTACA
		GAATGTTCATAG
1230	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	ATGGACATGAGGGTGCCCGCTCAG
	mAb_HC	CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTCAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCG
		TGGTCCAGCCTGGGAGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		CAACTTCAGTAGCTGTGGCATGCAC
		TGGGTCCGCCAGGCTCCAGGCAAG
		GGGCTGGAGTGGGTGGCAGTTATA
		TCATATGATGGAACTAATAAATACT
		ATGCGGACTCCGTGAAGGGCCGAT
		TCACCATCTCCAGAGACAATTCCAA
		GAACACGCTGTATCTGCAAATGAA
		CAGCCTGAGAGCTGAGGACACGGC
		TGTGTATTACTGTGCGAAAGTTTAC
		TATGGTTCGGGTATTTATTATAAAA
		AGAACTACTACTACGGTATGGACG
		TCTGGGGCCAAGGGACCACGGTCA
		CCGTCTCCTCAGCCTCCACCAAGGG
		CCCATCGGTCTTCCCCCTGGCACCC
		TCCTCCAAGAGCACCTCTGGGGGC
		ACAGCGGCCCTGGGCTGCCTGGTC
		AAGGACTACTTCCCCGAACCGGTG
		ACGGTGTCGTGGAACTCAGGCGCC
		CTGACCAGCGGCGTGCACACCTTCC
		CGGCTGTCCTACAGTCCTCAGGACT
		CTACTCCCTCAGCAGCGTGGTGACC
		GTGCCCTCCAGCAGCTTGGGCACCC
		AGACCTACATCTGCAACGTGAATC
		ACAAGCCCAGCAACACCAAGGTGG
		ACAAGAAAGTTGAGCCCAAATCTT
		GTGACAAAACTCACACATGCCCAC
		CGTGCCCAGCACCTGAACTCCTGGG
		GGGACCGTCAGTCTTCCTCTTCCCC
		CCAAAACCCAAGGACACCCTCATG
		ATCTCCCGGACCCCTGAGGTCACAT
		GCGTGGTGGTGGACGTGAGCCACG
		AAGACCCTGAGGTCAAGTTCAACT
		GGTACGTGGACGGCGTGGAGGTGC
		ATAATGCCAAGACAAAGCCGCGGG
		AGGAGCAGTACAACAGCACGTACC
		GTGTGGTCAGCGTCCTCACCGTCCT
		GCACCAGGACTGGCTGAATGGCAA
		GGAGTACAAGTGCAAGGTGTCCAA
		CAAAGCCCTCCCAGCCCCCATCGA
		GAAAACCATCTCCAAAGCCAAAGG
		GCAGCCCCGAGAACCACAGGTGTA
		CACCCTGCCCCCATCCCGGGAGGA
		GATGACCAAGAACCAGGTCAGCCT
		GACCTGCCTGGTCAAAGGCTTCTAT
		CCCAGCGACATCGCCGTGGAGTGG
		GAGAGCAATGGGCAGCCGGAGAAC
		AACTACAAGACCACGCCTCCCGTG
		CTGGACTCCGACGGCTCCTTCTTCC
		TCTATAGCAAGCTCACCGTGGACA
		AGAGCAGGTGGCAGCAGGGGAACG
		TCTTCTCATGCTCCGTGATGCATGA
		GGCTCTGCACAACCACTACACGCA
		GAAGAGCCTCTCCCTGTCTCCGGGC
		AAATAG
1231	huCCR8_32360_huIgG1z mAb_HC	ATGGACATGAGGGTGCCCGCTCAG
		CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTGAGGTGC
		AGCTGGTGGAGTCTGGGGGAGGCT
		TGGTAAAGCCTGGGGGGTCCCTGA
		GACTCTCCTGTGCAGCCTCTGGATT
		TACTTTCAGTAACGCCCGGATGGGC
		TGGGTCCGCCAGGCTCCAGGGAAG
		GGGCTGGAGTGGGTTGGCCGTATT
		AAAAGCAAAACTGAAGGTGGGACA
		AGAGACTACGCTGCACCCGTGAAA
		GGCAGATTCACCATCTCAAGAGAT
		GATTCAAAAAACACGCTGTATCTGC
		AAATGAACAGCCTGAAAACCGAGG
		ACACAGCCGTGTATTATTGTACCTC
		GTATAGTGGGGTCTGGGGCCAAGG
		GACAATGGTCACCGTCTCTTCAGCC
		TCCACCAAGGGCCCATCGGTCTTCC
		CCCTGGCACCCTCCTCCAAGAGCAC
		CTCTGGGGGCACAGCGGCCCTGGG
		CTGCCTGGTCAAGGACTACTTCCCC
		GAACCGGTGACGGTGTCGTGGAAC
		TCAGGCGCCCTGACCAGCGGCGTG
		CACACCTTCCCGGCTGTCCTACAGT
		CCTCAGGACTCTACTCCCTCAGCAG
		CGTGGTGACCGTGCCCTCCAGCAGC
		TTGGGCACCCAGACCTACATCTGCA
		ACGTGAATCACAAGCCCAGCAACA
		CCAAGGTGGACAAGAAAGTTGAGC
		CCAAATCTTGTGACAAAACTCACAC
		ATGCCCACCGTGCCCAGCACCTGA
		ACTCCTGGGGGGACCGTCAGTCTTC
		CTCTTCCCCCCAAAACCCAAGGACA
		CCCTCATGATCTCCCGGACCCCTGA
		GGTCACATGCGTGGTGGTGGACGT
		GAGCCACGAAGACCCTGAGGTCAA
		GTTCAACTGGTACGTGGACGGCGT
		GGAGGTGCATAATGCCAAGACAAA
		GCCGCGGGAGGAGCAGTACAACAG
		CACGTACCGTGTGGTCAGCGTCCTC
		ACCGTCCTGCACCAGGACTGGCTG
		AATGGCAAGGAGTACAAGTGCAAG
		GTGTCCAACAAAGCCCTCCCAGCCC
		CCATCGAGAAAACCATCTCCAAAG
		CCAAAGGGCAGCCCCGAGAACCAC
		AGGTGTACACCCTGCCCCCATCCCG
		GGAGGAGATGACCAAGAACCAGGT
		CAGCCTGACCTGCCTGGTCAAAGG
		CTTCTATCCCAGCGACATCGCCGTG
		GAGTGGGAGAGCAATGGGCAGCCG
		GAGAACAACTACAAGACCACGCCT
		CCCGTGCTGGACTCCGACGGCTCCT
		TCTTCCTCTATAGCAAGCTCACCGT
		GGACAAGAGCAGGTGGCAGCAGGG
		GAACGTCTTCTCATGCTCCGTGATG
		CATGAGGCTCTGCACAACCACTAC
		ACGCAGAAGAGCCTCTCCCTGTCTC
		CGGGCAAATAG
1232	huCCR8_32360_huIgG1z mAb_LC	ATGGACATGAGGGTGCCCGCTCAG
		CTCCTGGGGCTCCTGCTGCTGTGGC
		TGAGAGGTGCGCGCTGTGACATCG
		TGATGACCCAGTCTCCAGACTCCCT
		GGCTGTGTCTCTGGGCGAGAGGGC
		CACCATCAACTGCAAGTCCAGCCA
		GAGTGTTTTATACAGTTCCAACAAT
		AAGAACTACTTAGCTTGGTACCATC
		AGAAACCAGGACAGTCTCCTAAGC
		TGCTCATTTCCTGGGCATCTACCCG
		GGAATCCGGGGTCCCTGACCGATTC
		AGTGGCAGCGGGTCTGGGACAGAT
		TTCACTCTCACCATCAACAGCCTGC
		AGGCTGAAGATGTGGCAGTTTATTA
		CTGTCAACAATATTATAGTATTCCG
		ATCACTTTCGGCGGAGGGACCAAG
		GTGGAGATCAAACGAACGGTGGCT
		GCACCATCTGTCTTCATCTTCCCGC
		CATCTGATGAGCAGTTGAAATCTGG
		AACTGCCTCTGTTGTGTGCCTGCTG
		AATAACTTCTATCCCAGAGAGGCC
		AAAGTACAGTGGAAGGTGGATAAC
		GCCCTCCAATCGGGTAACTCCCAGG
		AGAGTGTCACAGAGCAGGACAGCA
		AGGACAGCACCTACAGCCTCAGCA
		GCACCCTGACGCTGAGCAAAGCAG
		ACTACGAGAAACACAAAGTCTACG
		CCTGCGAAGTCACCCATCAGGGCCT
		GAGCTCGCCCGTCACAAAGAGCTT
		CAACAGGGGAGAGTGTTAG
1233	HCDR1 Consensus	X1X2GX4H
		X1 = N, S, D, G, T, or R, X2 = C, N, Y, S,
		or F, X4 = M or F
1234	LCDR2 Consensus	RX2X3X4RPS
		X2 = A, N, D, S, or Q, X3 = S, T, N, I, F,
		or A, and X4 = N or V
1235	LCDR1 consensus	KSSQSVLYSSNNX1NYLA; X1 is K or R
1236	LCVR consensus	DIVMTQSPDSLAVSLGERATINCKSS
		QSVLYSSNNX1NYLA
		WYX2QKPGQX3PKLLISWASTRESGV
		PDRFSGSGSGTDFTLTINSLQAEDVA
		VYYCQQYYSIPITFGGGTKVEIKR,
		wherein X1 is K or R, X2 is H or Q, and/or
		X3 is S or P
1237	huCCR8_32360_huIgG1z	EVQLVESGGGLVKPGGSLRLSCAAS
	mAb(LC:K38R)_HC_no Cterm K	GFTFSNARMGWVRQAPGKGLEWVG
		RIKSKTEGGTRDYAAPVKGRFTISRD
		DSKNTLYLQMNSLKTEDTAVYYCTS
		YSGVWGQGTMVTVSSASTKGPSVFP
		LAPSSKSTSGGTAALGCLVKDYFPEP
		VTVSWNSGALTSGVHTFPAVLQSSG
		LYSLSSVVTVPSSSLGTQTYICNVNH
		KPSNTKVDKKVEPKSCDKTHTCPPCP
		APELLGGPSVFLFPPKPKDTLMISRTP
		EVTCVVVDVSHEDPEVKFNWYVDG
		VEVHNAKTKPREEQYNSTYRVVSVL
		TVLHQDWLNGKEYKCKVSNKALPA
		PIEKTISKAKGQPREPQVYTLPPSREE
		MTKNQVSLTCLVKGFYPSDIAVEWE
		SNGQPENNYKTTPPVLDSDGSFFLYS
		KLTVDKSRWQQGNVFSCSVMHEAL
		HNHYTQKSLSLSPG
1238	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D72S, VL:N67A_S68A_	GFTFSNYGFHWVRQTPGKGLEWVA
	M99G_W109F_S111A)_huIgG1z	VISYDGSNRYYASSVKGRFTISRDNS
	(mAb)_HC_no Cterm K	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1239	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D61A_D72A, VL:N67Q_	GFTFSNYGFHWVRQTPGKGLEWVA
	M99E_W109F_S111A)_huIgG1z	VISYAGSNRYYAASVKGRFTISRDNS
	(mAb)_HC_no Cterm K	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1240	anti-	QVQLVESGGGVVQPGRSLRLSCAAS
	huCCR8_44379(VH:D61S, VL:N67Q_M99G_	GFTFSNYGFHWVRQTPGKGLEWVA
	W109F_S111A)_huIgG1z (mAb)_HC_no	VISYSGSNRYYADSVKGRFTISRDNS
	Cterm K	KNTLYLQMNSLRGEDTALYYCARV
		YYGSGTYYKNRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1241	Hu anti-huCCR8 LIBC315615-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFNFSNCGMHWVRQAPGKGLEWVA
		VISYDGGNKYHADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1242	Hu anti-huCCR8 LIBC317152-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFNFSNCGMHWVRQAPGKGLEWVA
		VISYDGGNKYYADSVKGRFTISRDDS
		KNTLYLQMDSLRTEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1243	Hu anti-huCCR8 LIBC317471-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCVVS
	mAb_HC_no Cterm K	GFNFSNNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYADSVRGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYSCAKV
		YYGSGIYYKNNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1244	Hu anti-huCCR8 LIBC317977-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFNFNTYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KSTLYLQMNSLRAEDTAVYYCARVY
		YGSGSYYKKNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1245	Hu anti-huCCR8 LIBC318774-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFTLSSYGFHWVRQTPGKGLEWVAV
		ISYDGSNKYYADSVKGRFTISRDNSK
		NTLYLQMNSLRGEDTAVYYCARVY
		YGSGTYYKNRYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1246	Hu anti-huCCR8 LIBC319840-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCVVS
	mAb_HC_no Cterm K	GFNFINNGMHWVRQAPGKGLDWVA
		VISNDGSNKYYPDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDSAVYYCAKV
		YYGSGNYYKNNYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1247	Hu anti-huCCR8 LIBC320212-1 HuIgG1z	QMQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFTFSSSGMHWVRQAPGKGLEWVA
		VISHDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLGGEDTAVYYCAKV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VIVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1248	Hu anti-huCCR8 LIBC320384-1 HuIgG1z	QVQLVESGGGVAQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFNFSDCGMHWVRQAPGKGLEWVA
		VISYDGGNKYYADSVKGRFTISRDDS
		KNTLYLQTDSLRTEDTAVYYCAKVY
		YGSGIYYKNRYYYGMDVWGQGTTV
		TVSSASTKGPSVFPLAPSSKSTSGGTA
		ALGCLVKDYFPEPVTVSWNSGALTS
		GVHTFPAVLQSSGLYSLSSVVTVPSS
		SLGTQTYICNVNHKPSNTKVDKKVE
		PKSCDKTHTCPPCPAPELLGGPSVFLF
		PPKPKDTLMISRTPEVTCVVVDVSHE
		DPEVKFNWYVDGVEVHNAKTKPRE
		EQYNSTYRVVSVLTVLHQDWLNGK
		EYKCKVSNKALPAPIEKTISKAKGQP
		REPQVYTLPPSREEMTKNQVSLTCLV
		KGFYPSDIAVEWESNGQPENNYKTTP
		PVLDSDGSFFLYSKLTVDKSRWQQG
		NVFSCSVMHEALHNHYTQKSLSLSP
		G
1249	Hu anti-huCCR8 LIBC320689-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFTFSSYGMHWVRQAPGKGLEWVA
		VISFDGNNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGSYYKNRYYYGMDVWGQGT
		TVTVSTASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1250	Hu anti-huCCR8 LIBC321408-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAVS
	mAb_HC_no Cterm K	GFTFSSNGMHWVRQAPGKGLEWVA
		VISNDGSNKYYGDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYRNNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1251	Hu anti-huCCR8 LIBC321824-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCGAS
	mAb_HC_no Cterm K	GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFPISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VAVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1252	Hu anti-huCCR8 LIBC321845-1 HuIgG1z	QVQVVESGGGVVQPGRSLRLSCGAS
	mAb_HC_no Cterm K	GFTFSGYGMHWVRQAPGKGLEWVA
		VISYDGSNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRGEDTAVYYCARV
		YYGSGIYYKNRYYYGMDVWGQGTT
		VAVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1253	Hu anti-huCCR8 LIBC322176-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GLNFSNFGMHWVRQAPGKGLDWVA
		VISYDGGNKYYADSVKGRFTVSRDN
		SKNTLFLQMNSLRAEDTALYYCAKV
		YYGSGSYYKKRYYYGMDVWGQGT
		TVTVSSASTKGPSVFPLAPSSKSTSGG
		TAALGCLVKDYFPEPVTVSWNSGAL
		TSGVHTFPAVLQSSGLYSLSSVVTVP
		SSSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG
1254	Hu anti-huCCR8 LIBC323412-1 HuIgG1z	QVQLVESGGGVVQPGRSLRLSCAAS
	mAb_HC_no Cterm K	GFNFSSCGMHWVRQAPGKGLEWVA
		VISYDGTNKYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKV
		YYGSGIYYKKNYYYGMDVWGQGTT
		VTVSSASTKGPSVFPLAPSSKSTSGGT
		AALGCLVKDYFPEPVTVSWNSGALT
		SGVHTFPAVLQSSGLYSLSSVVTVPS
		SSLGTQTYICNVNHKPSNTKVDKKV
		EPKSCDKTHTCPPCPAPELLGGPSVFL
		FPPKPKDTLMISRTPEVTCVVVDVSH
		EDPEVKFNWYVDGVEVHNAKTKPR
		EEQYNSTYRVVSVLTVLHQDWLNG
		KEYKCKVSNKALPAPIEKTISKAKGQ
		PREPQVYTLPPSREEMTKNQVSLTCL
		VKGFYPSDIAVEWESNGQPENNYKT
		TPPVLDSDGSFFLYSKLTVDKSRWQQ
		GNVFSCSVMHEALHNHYTQKSLSLS
		PG

Claims

1. An antibody that binds to human C—C chemokine receptor type 8 (CCR8), or an antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof comprises: (a) a heavy chain complementarity-determining region (HCDR) 1 amino acid sequence of SEQ ID NO: 839;(b) an HCDR2 amino acid sequence of SEQ ID NO: 840,(c) an HCDR3 amino acid sequence of SEQ ID NO: 841,(d) a light chain complementarity-determining region (LCDR) 1 amino acid sequence of KSSQSVLYSSNNX1NYLA (SEQ ID NO: 1235), wherein X1 is K or R,(e) an LCDR2 amino acid sequence of SEQ ID NO: 843, and(f) an LCDR3 amino acid sequence of SEQ ID NO: 844.

2. The antibody or antigen binding fragment of claim 1, which comprises an LCDR1 amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 842.

3. The antibody or antigen binding fragment of claim 1, which comprises a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 13, and a light chain variable region (LCVR) comprising the amino acid sequence: DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNX1NYLAWYX2QKPGQX3PKLLIS WASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYYSIPITFGGGTKVEIK R (SEQ ID NO: 1236), wherein X1 is K or R, X2 is H or Q, and/or X3 is S or P.

4. The antibody or antigen-binding fragment of claim 1, which comprises a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 1017 and a light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 1018.

5. The antibody or antigen-binding fragment of claim 1, which comprises a heavy chain (HC) amino acid sequence of SEQ ID NO: 1125 or SEQ ID NO: 1237 and a light chain (LC) amino acid sequence of SEQ ID NO: 1126.

6. The antibody or antigen-binding fragment of claim 1, which comprises two HCs and two LCs, wherein both HCs comprise an amino acid sequence of SEQ ID NO: 1125 or SEQ ID NO: 1237, and both LCs comprise an amino acid sequence of SEQ ID NO: 1126.

7. An antibody that binds to human CCR8, or an antigen-binding fragment thereof, wherein the antibody comprises: (a) an HCDR1 amino acid sequence of X1X2GX4H, (SEQ ID NO: 1233), wherein (i) X1 is N, S, D, G, T, or R, (ii) X2 is C, N, Y, S, or F, and (iii) X4 is M or F;(b) an HCDR2 amino acid sequence of SEQ ID NO: 648, 654, 660, 666, 672, 678, 684, 690, 696, 702, 708, 714, 720, 726, 732, 738, 744, 750, 756, 762, 768, 774, 780, 786, 792, 798, 804, 810, 816, 822, 828, 834, 840, 846, 852, 858, 867, 873, 879, 885, 891, 897, 903, 909, 915, 921, 927, 933, 939, or 945, or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any of the foregoing HCDR2 amino acid sequences;(c) an HCDR3 amino acid sequence of SEQ ID NO: 649, 655, 661, 667, 673, 679, 685, 691, 697, 703, 709, 715, 721, 727, 733, 739, 745, 751, 757, 763, 769, 775, 781, 787, 793, 799, 805, 811, 817, 823, 829, 835, 847, 853, 859, 868, 874, 880, 886, 892, 898, 904, 910, 916, 922, 928, 934, 940, or 946, or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any of the foregoing HCDR3 amino acid sequences;(d) an LCDR1 amino acid sequence of SEQ ID NO: 650, 656, 662, 668, 674, 680, 686, 692, 698, 704, 710, 716, 722, 728, 734, 740, 746, 752, 758, 764, 770, 776, 782, 788, 794, 800, 806, 812, 818, 824, 830, 836, 848, 854, 860, 863, 869, 875, 881, 887, 893, 899, 905, 911, 917, 923, 929, 935, or 941, or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any of the foregoing LCDR1 amino acid sequences;(e) an LCDR2 amino acid sequence of RX2X3X4RPS (SEQ ID NO: 1234), wherein (i) X2 is A, N, D, S, or Q, (ii) X3 is S, T, N, I, F, or A, and (iii) X4 is N or V; and(f) an LCDR3 amino acid sequence of SEQ ID NO: 652, 658, 664, 670, 676, 682, 688, 694, 700, 706, 712, 718, 724, 730, 736, 742, 748, 754, 760, 766, 772, 778, 784, 790, 796, 802, 808, 814, 820, 826, 832, 838, 850, 856, 862, 865, 871, 877, 883, 889, 895, 901, 907, 913, 919, 925, 931, 937, or 943, or a variant thereof that comprises 1-4 amino acid substitutions or is at least 90% identical to any of the foregoing LCDR3 amino acid sequences.

8. The antibody or antigen-binding fragment of claim 7, which comprises an HCDR1 amino acid sequence of SEQ ID NO: 647, 653, 659, 665, 671, 677, 683, 689, 695, 701, 707, 713, 719, 725, 731, 737, 743, 749, 755, 761, 767, 773, 779, 785, 791, 797, 803, 809, 815, 821, 827, 833, 845, 851, 857, 866, 872, 878, 884, 890, 896, 902, 908, 914, 920, 926, 932, 938, or 944.

9. The antibody or antigen-binding fragment of claim 7, which comprises an LCDR2 amino acid sequence of SEQ ID NO: 651, 657, 663, 669, 675, 681, 687, 693, 699, 705, 711, 717, 723, 729, 735, 741, 747, 753, 759, 765, 771, 777, 783, 789, 795, 801, 807, 813, 819, 825, 831, 837 849, 855, 861, 864, 870, 876, 882, 888, 894, 900, 906, 912, 918, 924, 930, 936, or 942.

10. The antibody or antigen-binding fragment of claim 7, which comprises a HCVR amino acid sequence comprising SEQ ID NO: 953, 955, 957, 959, 961, 963, 965, 967, 969, 971, 973, 975, 977, 979, 981, 983, 985, 987, 989, 991, 993, 995, 997, 999, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1019, 1021, 1023, 1026, 1028, 1030, 1032, 1034, 1036, 1038, 1040, 1042, 1044, 1046, 1048, 1050, or 1052, or an amino acid sequence that is at least 90% identical to any of the foregoing HCVR amino acid sequences.

11. The antibody or antigen-binding fragment of claim 7, which comprises a LCVR amino acid sequence comprising SEQ ID NO: 964, 966, 968, 970, 972, 974, 976, 978, 980, 982, 984, 986, 988, 990, 992, 994, 996, 998, 1000, 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1020, 1022, 1024, 1025, 1027, 1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043, 1045, 1047, 1049, or 1051, or an amino acid sequence that is at least 90% identical to any of the foregoing LCVR amino acid sequences.

12. The antibody of or antigen-binding fragment of claim 7, which comprises: (a) a HCVR comprising an amino acid sequence of SEQ ID NO: 1019 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1020;(b) a HCVR comprising an amino acid sequence of SEQ ID NO: 1021 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1022;(c) a HCVR comprising an amino acid sequence of SEQ ID NO: 1023 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1024;(d) a HCVR comprising an amino acid sequence of SEQ ID NO: 1026 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1025;(e) a HCVR comprising an amino acid sequence of SEQ ID NO: 1028 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1027;(f) a HCVR comprising an amino acid sequence of SEQ ID NO: 1030 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1029;(g) a HCVR comprising an amino acid sequence of SEQ ID NO: 1032 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1031;(h) a HCVR comprising an amino acid sequence of SEQ ID NO: 1034 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1033;(i) a HCVR comprising an amino acid sequence of SEQ ID NO: 1036 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1035;(j) a HCVR comprising an amino acid sequence of SEQ ID NO: 1038 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1037;(k) a HCVR comprising an amino acid sequence of SEQ ID NO: 1040 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1039;(l) a HCVR comprising an amino acid sequence of SEQ ID NO: 1042 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1041;(m) a HCVR comprising an amino acid sequence of SEQ ID NO: 1044 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1043;(n) a HCVR comprising an amino acid sequence of SEQ ID NO: 1046 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1045;(o) a HCVR comprising an amino acid sequence of SEQ ID NO: 1048 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1047;(p) a HCVR comprising an amino acid sequence of SEQ ID NO: 1050 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1049; or(q) a HCVR comprising an amino acid sequence of SEQ ID NO: 1052 and a LCVR comprising an amino acid sequence of SEQ ID NO: 1051.

13. The antibody or antigen-binding fragment of claim 7, which comprises a HC amino acid sequence of SEQ ID NO: 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, 1160, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, or 1254, or an amino acid sequence that is at least 90% identical to any of the foregoing HC amino acid sequences.

14. The antibody or antigen-binding fragment of claim 7, which comprises a LC amino acid sequence of SEQ ID NO: 1128, 1130, 1132, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, or 1159, or an amino acid sequence that is at least 90% identical to any of the foregoing LC amino acid sequences.

15. The antibody or antigen-binding fragment of claim 7, which comprises: (a) an HC amino acid sequence of SEQ ID NO: 1127 or SEQ ID NO: 1238 and a LC amino acid sequence of SEQ ID NO: 1128;(b) an HC amino acid sequence of SEQ ID NO: 1129 or SEQ ID NO: 1239 and a LC amino acid sequence of SEQ ID NO: 1130;(c) an HC amino acid sequence of SEQ ID NO: 1131 or SEQ ID NO: 1240 and a LC amino acid sequence of SEQ ID NO: 1132;(d) an HC amino acid sequence of SEQ ID NO: 1134 or SEQ ID NO: 1241 and a LC amino acid sequence of SEQ ID NO: 1133;(e) an HC amino acid sequence of SEQ ID NO: 1136 or SEQ ID NO: 1242 and a LC amino acid sequence of SEQ ID NO: 1135;(f) an HC amino acid sequence of SEQ ID NO: 1138 or SEQ ID NO: 1243 and a LC amino acid sequence of SEQ ID NO: 1137;(g) an HC amino acid sequence of SEQ ID NO: 1140 or SEQ ID NO: 1244 and a LC amino acid sequence of SEQ ID NO: 1139;(h) an HC amino acid sequence of SEQ ID NO: 1142 or SEQ ID NO: 1245 and a LC amino acid sequence of SEQ ID NO: 1141;(i) an HC amino acid sequence of SEQ ID NO: 1144 or SEQ ID NO: 1246 and a LC amino acid sequence of SEQ ID NO: 1143;(j) an HC amino acid sequence of SEQ ID NO: 1146 or SEQ ID NO: 1247 and a LC amino acid sequence of SEQ ID NO: 1145;(k) an HC amino acid sequence of SEQ ID NO: 1148 or SEQ ID NO: 1248 and a LC amino acid sequence of SEQ ID NO: 1147;(l) an HC amino acid sequence of SEQ ID NO: 1150 or SEQ ID NO: 1249 and a LC amino acid sequence of SEQ ID NO: 1149;(m) an HC amino acid sequence of SEQ ID NO: 1152 or SEQ ID NO: 1250 and a LC amino acid sequence of SEQ ID NO: 1151;(n) an HC amino acid sequence of SEQ ID NO: 1154 or SEQ ID NO: 1251 and a LC amino acid sequence of SEQ ID NO: 1153;(o) an HC amino acid sequence of SEQ ID NO: 1156 or SEQ ID NO: 1252 and a LC amino acid sequence of SEQ ID NO: 1155;(p) an HC amino acid sequence of SEQ ID NO: 1158 or SEQ ID NO: 1253 and a LC amino acid sequence of SEQ ID NO: 1157; or(q) an HC amino acid sequence of SEQ ID NO: 1160 or SEQ ID NO: 1254 and a LC amino acid sequence of SEQ ID NO: 1159.

16. The antibody of or antigen-binding fragment claim 7, which is a single chain variable fragment (scFv) comprising an amino acid sequence of SEQ ID NO: 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, or 1124.

17. The antibody of or antigen-binding fragment claim 7, which comprises an HCDR1 amino acid sequence of SEQ ID NO: 857, an HCDR2 amino acid sequence of SEQ ID NO: 858, an HCDR3 amino acid sequence of SEQ ID NO: 859, an LCDR1 amino acid sequence of SEQ ID NO: 860, an LCDR2 amino acid sequence of SEQ ID NO: 861, and an LCDR3 amino acid sequence of SEQ ID NO: 862.

18. The antibody or antigen-binding fragment of claim 1, which is an antibody.

19. The antibody or antigen-binding fragment of claim 7, which is an antibody.

20. The antibody or antigen-binding fragment of claim 1, which is an antigen-binding fragment of an antibody.

21. The antibody or antigen-binding fragment of claim 7, which is an antigen-binding fragment of an antibody.

22. The antibody or antigen-binding fragment of claim 1, which is an afucosylated antibody.

23. The antibody or antigen-binding fragment of claim 7, which is an afucosylated antibody.

24. A nucleic acid sequence encoding the antibody or antigen-binding fragment of claim 1.

25. A nucleic acid sequence encoding the antibody or antigen-binding fragment of claim 7.

26. A nucleic acid sequence encoding a heavy chain amino acid sequence of SEQ ID NO: 1125, 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, 1160, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, or 1254.

27. A nucleic acid sequence encoding a light chain amino acid sequence of SEQ ID NO: 1126, 1128, 1130, 1132, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, or 1159.

28. A vector comprising the nucleic acid sequence of claim 26.

29. A vector comprising the nucleic acid sequence of claim 27.

30. A mammalian cell comprising the vector of claim 28.

31. A mammalian cell comprising the vector of claim 29.

32. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 7 and a pharmaceutically acceptable carrier.

34. A method of treating cancer in a patient comprising administering an effective amount of the pharmaceutical composition of claim 32 to the patient.

35. The method of claim 34, wherein the cancer is a solid tumor.

36. The method of claim 34, wherein the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer, pancreatic cancer, or metastatic castrate-resistant prostate cancer.

37. The method of claim 34, which further comprises administering an effective amount of a PD-1 antagonist antibody to the patient.

38. The method of claim 37, wherein the PD-1 antagonist antibody is a monoclonal antibody.

39. A method of treating cancer in a patient comprising administering an effective amount of the pharmaceutical composition of claim 33 to the patient.

40. The method of claim 39, wherein the cancer is a solid tumor.

41. The method of claim 39, wherein the cancer is non-small cell lung cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer, pancreatic cancer, or metastatic castrate-resistant prostate cancer.

42. The method of claim 39, which further comprises administering an effective amount of a PD-1 antagonist antibody to the patient.

43. The method of claim 42, wherein the PD-1 antagonist antibody is a monoclonal antibody.

44. A process for producing an antibody comprising two HCs and two LCs, wherein the process comprises cultivating the mammalian cell of claim 30 under conditions such that the antibody is expressed and recovering the expressed antibody, and wherein: (a) both HCs comprise an amino acid sequence of SEQ ID NO: 1125 or 1237, or an amino acid sequence that is at least 90% identical to any of the foregoing HC amino acid sequences; and(b) both LCs comprise an amino acid sequence of SEQ ID NO: 1126, or an amino acid sequence that is at least 90% identical to any of the foregoing LC amino acid sequences.

45. An antibody obtainable by the process of claim 44.

46. A process for producing an antibody comprising two HCs and two LCs, wherein the process comprises cultivating the mammalian cell of claim 31 under conditions such that the antibody is expressed and recovering the expressed antibody, and wherein: (a) both HCs comprise an amino acid sequence of SEQ ID NO: 1127, 1129, 1131, 1134, 1136, 1138, 1140, 1142, 1144, 1146, 1148, 1150, 1152, 1154, 1156, 1158, 1160, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, or 1254, or an amino acid sequence that is at least 90% identical to any of the foregoing HC amino acid sequences; and(b) both LCs comprise an amino acid sequence of SEQ ID NO: 1128, 1130, 1132, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, or 1159, or an amino acid sequence that is at least 90% identical to any of the foregoing LC amino acid sequences.

47. An antibody obtainable by the process of claim 46.

48. A method of treating cancer in a patient, comprising administering to the patient an effective amount of a Treg depleting antibody and one or more of a bispecific T-cell engager molecule, an agonist of a T cell co-stimulatory receptor, and an antagonist of the PD-1/PD-L1 pathway.

49. The method of claim 48, comprising administering an effective amount of a Treg depleting antibody and a bispecific T-cell engager molecule.

50. The method of claim 49, further comprising administering an antagonist of the PD-1/PD-L1 pathway.

51. The method of claim 48, wherein the Treg depleting antibody is an anti-CCR8 antibody.

52. The method of claim 48, wherein the Treg depleting antibody is an anti-CTLA-4 antibody.

53. The method of claim 48, wherein the antagonist of the PD-1/PD-L1 pathway is a PD-1 antagonist antibody.

54. A method of treating cancer in a patient comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof that binds human CCR8 at an epitope, wherein the epitope comprises at least one residue of SEQ ID NO: 82.

55. The method of claim 54, wherein the antibody does not block ligand binding to CCR8.

56. The method of claim 54, wherein the epitope comprises a threonine at position 4 of SEQ ID NO: 82.

57. The method of claim 54, wherein the epitope is determined by anti-CCR8 antibody or antigen-binding fragment thereof binding to a T4R mutation in cynomolgus monkey CCR8.